Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
_ .
WO 2017/053748 PCT/US2016/053368
ANT1-TIGIT ANTIBODIES AND METHODS OF USE
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted
electronically
in ASCII format. Said ASCII copy, created on September 22, 2016, is named
50474-120W03_Sequence_Listing_9_22_16_ST25 and is 209,318 bytes in size.
FIELD OF THE INVENTION
The present invention relates to anti-TIGIT (T-cell immunoreceptor with Ig and
ITIM domains)
antibodies and methods of using the same.
BACKGROUND OF THE INVENTION
Immune-related diseases (e.g., cancer) are the manifestation or consequence of
complex
biological pathways, which in normal physiology are critical for responding to
insult or injury, initiating
repair from insult or injury, and mounting innate and acquired defenses.
Disease or pathology occurs
when these normal physiological pathways cause additional insult or injury
that is directly related to the
intensity of the response (e.g., as a consequence of abnormal regulation or
excessive stimulation) or as a
reaction to self.
Although the genesis of these diseases often involves multi-step pathways and
often multiple
different biological systems/pathways, intervention at critical points in one
or more of these pathways can
have an ameliorative or therapeutic effect. Therapeutic intervention can occur
by either antagonism of a
detrimental process/pathway or stimulation of a beneficial process/pathway.
Many immune-related diseases are known and have been extensively studied. Such
diseases
include cancer (neoplasia), immune-mediated inflammatory diseases, non-immune-
mediated
inflammatory diseases, infectious diseases, and immunodeficiency diseases.
T lymphocytes (T cells) are an important component of a mammalian immune
response. T cells
recognize antigens that are associated with a self-molecule encoded by genes
within the major
histocompatibility complex (MHC). The antigen may be displayed together with
MHC molecules on the
surface of antigen presenting cells (APCs), virus infected cells, cancer
cells, grafts, etc. The T cell
system eliminates these altered cells, which pose a health threat to the host
mammal. I cells include
helper T cells and cytotoxic T cells. Helper T cells proliferate extensively
following recognition of an
antigen-MHC complex on an APC. Helper T cells also secrete a variety of
cytokines (i.e., lymphokines),
which play a central role in the activation of B cells, cytotoxic T cells, and
a variety-of other cells that
participate in the immune response. =
Regulatory T cells (Treg) are a subset of helper T cells that play a critical
role in inhibition of self-
reactive immune responses and are Often found in sites of chronic inflammation
such as in tumor tissue.
Tregs are defined phenotypically by high cell surface expression of CD25,
CLTA4, GITR, and neuropilin-1
(NRP-1), and are under the control of the transcription factor FOXP3. Tregs
perform their suppressive
function on activated T cells through contact-dependent mechanisms and
cytokine production. Tregs
1
CA 2994858 2019-05-06
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
also modulate immune responses by direct interaction with ligands on dendritic
cells (DCs), such as
CD4OL ligation and CTLA4 interaction with B7 molecules on DCs that elicits the
induction of indoleamine
2,3-dioxygenase (IDO). DCs are professional APCs capable of inducing immunity
or tolerance against
self or non-self antigens. DC-expanded Tregs suppress alloreactivity responses
in vitro, and when
adoptively transferred, appropriate Tregs inhibited diabetes in NODscid mice
or experimentally induced
asthma. Specific interactions of ligands on DC with Tregs can also abrogate
their suppressive function,
such as engagement of GITR in mice, suggesting DC may have a pluralistic role
in modulating Treg
function.
The molecules CTLA4 and GITR are representative of ligands defined within the
CD28-B7 and
TNF-superfamilies of co-stimulatory/-inhibitory molecules, respectively. These
molecules are highly
expressed on Tregs but are typically upregulated on activated T cells. More
recently, a protein
designated TIGIT (for T-cell immunoreceptor with Ig and MM domains) was
identified as a cell surface-
bound protein specifically expressed in T cells that possessing an IgV domain,
a transmembrane domain,
and two putative immunoreceptor tyrosine inhibitory (MM) motifs. TIGIT was
shown to be particularly
expressed on Treg and memory T cell subsets, as well as NK cells. As there is
an unmet need for new
therapeutics and methods of treatment of immune-related disorders and
particularly cancers, described
herein are unexpectedly efficacious therapeutic compositions, such as the anti-
TIGIT antibodies and
compositions thereof, and methods of treatment of immune-related disorders and
cancers, which involve
modulating the interaction of TIGIT with its binding partners.
SUMMARY OF THE INVENTION
The present invention provides anti-TIGIT (T-cell immunoreceptor with Ig and
ITIM domains)
antibodies and variants thereof with improved properties, including, for
example, binding affinity, cross-
reactivity, pharmacokinetics, and/or expression. In particular, the present
invention provides anti-TIGIT
antibodies and variants thereof that possess, for example, high binding
affinity to human TIGIT; cross-
reactivity between human TIGIT. cynomolgus monkey (cyno) TIGIT, and/or rabbit
TIGIT; desirable
clearance properties in cyno; and biochemical and biophysical properties that
confer the antibodies and
variants thereof with high stability.
In one aspect, the invention features an antibody that specifically binds to
human TIGIT, wherein
the antibody binds to an epitope on human TIGIT comprising one or more of
amino acid residues Ser78,
Ser80, and Lys82 of human TIGIT. In one embodiment, the epitope comprises
amino acid residues
Ser80 and Lys82 of human TIGIT. In another embodiment, the epitope comprises
amino acid residues
Ser78, Ser80, and Lys82 of human TIGIT. In another embodiment, the epitope
further comprises amino
acid residue Ala67 of human TIGIT. In another embodiment, the epitope further
comprises one or more
additional amino acid residues selected from the group consisting of Glue ,
Leu65, and Ile68 of human
TIGIT. In another embodiment, the epitope further comprises one or more
additional amino acid residues
selected from the group consisting of Gin56, Asn70, Leu73, and His111 of human
TIGIT. In another
embodiment, the epitope further comprises one or more additional amino acid
residues selected from the
group consisting of Thr55, Asn58, Asp63, GIn64, His76, Ile77, and Pro79 of
human TIGIT. In another
embodiment, the epitope consists of amino acid residues Thr55, Gin56, Asn58,
Glue , Asp63, Gin64,
2
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
Leu65, Ala67, Ile68, Asn70, Leu73, His76, I1e77. Ser78, Pro79, Ser80, Lys82,
and His111 of human
TIGIT.
In another aspect, the invention features an antibody that specifically binds
to human TIGIT,
wherein the antibody binds to an epitope on human TIGIT comprising one or more
of amino acid residues
Thr55, Ser80, and Lys82 of human TIGIT. In one embodiment, the epitope
comprises amino acid residue
Lys82 of human TIGIT. In another embodiment, the epitope comprises amino acid
residues Thr55,
Ser80, and Lys82 of human TIGIT. In another embodiment, the epitope further
comprises amino acid
residue G1n56 of human TIGIT. In another embodiment, the epitope further
comprises amino acid
residue Ile77 or Pro79 of human TIGIT. In another embodiment, the epitope
further comprises amino
acid residues Ile77 and Pro79 of human TIGIT In another embodiment, the
epitope further comprises
amino acid residue Asn58 or Glu60 of human TIGIT. In another embodiment, the
epitope further
comprises amino acid residues Asn58 and Glu60 of human TIGIT. In another
embodiment, the epitope
further comprises one or more additional amino acid residues selected from the
group consisting of
Leu65, Ile68, Leu73, His76, Ser78, and His111 of human TIGIT. In another
embodiment, the epitope
further comprises amino acid residues Leu65, ile68, Leu73, His76, Ser78, and
Hisi 11 of human TIGIT.
In yet another embodiment, the epitope consists of Thr55, GIn56, Asn58, Glu60,
Leu65, 11e68, Leu73,
His76, 11e77, Ser78, Pro79, Sera(); Lys82, and His111 of human TIGIT.
In another aspect, the invention features an antibody that specifically binds
to human TIGIT.
wherein the antibody comprises a paratope comprising one or more amino acid
residues selected from
the group consisting of heavy chain variable region amino acid residues Asn32,
Tyr52, Arg52b, Phe53,
Lys54, Tyr56, Asp58, Tyr99, Asp100, Leu100a, Leu100b, and Ala100c and light
chain variable region
amino acid residues Tyr27d, Tyr92, Ser93, Thr94, and Phe96. In one embodiment,
the paratope consists
of heavy chain variable region amino acid residues Asn32, 1yr52, Arg52b,
Phe53, Lys54, Tyr56, Asp58,
Tyr99, Aspl 00, Leu100a, Leu100b, and Ala100c and light chain variable region
amino acid residues
Tyr27d, Tyr92, Ser93, Thr94, and Phe96. In any of the above aspects, the
antibody may be capable of
binding to rabbit TIGIT.
In another aspect, the invention features an antibody that specifically binds
to human TIGIT,
wherein the antibody binds to an epitope on human TIGIT comprising one or more
amino acid residues
selected from the group consisting of GIn53, His111, and Tyr113 of human
TIGIT. In some
embodiments, the epitope further comprises GIn56 of human TIGIT. In some
embodiments, the epitope
further comprises Glue , Leu65, Ile68, Asn70, Leu73, and His76 of human TIGIT.
In another aspect, the invention features an antibody that specifically binds
to human TIGIT,
wherein the antibody comprises the following six hypervariable regions (HVRs):
an HVR-H1 comprising
the amino acid sequence of SNSAAWN (SEQ ID NO: 1); an HVR-H2 comprising the
amino acid
sequence of KTYYRFKVVYSDYAVSVKG (SEQ ID NO: 2); an HVR-H3 comprising the amino
acid
sequence of ESTTYDLLAGPFDY (SEQ ID NO: 3); an HVR-L1 comprising the amino acid
sequence of
KSSQTVLYSSNNKKYLA (SEQ ID NO: 4); an HVR-L2 comprising the amino acid sequence
of
WASTRES (SEQ ID NO: 5); and an HVR-L3 comprising the amino acid sequence of
QQYYSTPFT (SEQ
ID NO: 6). In some embodiments, the antibody further comprises the following
light chain variable region
framework regions (FRs): an FR-L1 comprising the amino acid sequence of
3
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
DIVMTQSPDSLAVSLGERATINC (SEQ ID NO: 7); an FR-L2 comprising the amino acid
sequence of
VVYQQKPGQPPNLLIY (SEQ ID NO: 8); an FR-1.3 comprising the amino acid sequence
of
GVPDRFSGSGSGTDRITISSLQAEDVAVYYC (SEQ ID NO: 9); and an FR-1.4 comprising the
amino
acid sequence of FGPGTKVEIK (SEQ ID NO: 10). In some embodiments, the antibody
further comprises
the following heavy chain variable region FRs: an FR-H1 comprising the amino
acid sequence of
XIVOLQQSGPGLVKPSOTLSLICAISGDSVS (SEQ ID NO: 11), wherein Xi is Q or E; an FR-
H2
comprising the amino acid sequence of WIRQSPSRGLEWLG (SEQ ID NO: 12); an FR-H3
comprising the
amino acid sequence of RITINPDTSKNQFSLQLNSVTPEDTAVEYCIR (SEQ ID NO: 13); and
an FR-H4
comprising the amino acid sequence of WGOGTLVTVSS (SEQ ID NO: 14). In some
embodiments, the
antibody further comprises the following heavy chain variable region FRs: an
FR-H1 comprising the
amino acid sequence of EVQLQQSGPGLVKPSQTLSLTCAISGDSVS (SEQ ID NO: 15); an FR-
H2
comprising the amino acid sequence of WIRQSPSRGLEWLG (SEQ ID NO: 12); an FR-H3
comprising the
amino acid sequence of RITINPDTSKNQFSLOLNSVTPEDTAVFYCTR (SEQ ID NO: 13); and
an FR-H4
comprising the amino acid sequence of WG0GTLVTVSS (SEQ ID NO: 14). In some
embodiments, the
antibody further comprises the following heavy chain variable region FRs: an
FR-H1 comprising the
amino acid sequence of QVQLQQSGPGLVKPSQTLSLTCAISGDSVS (SEQ ID NO: 16); an FR-
H2
comprising the amino acid sequence of WIRQSPSRGLEWLG (SEQ ID NO: 12); an FR-H3
comprising the
amino acid sequence of RITINPDTSKNQFSLOLNSVTPEDTAVFYCIR (SEQ ID NO: 13); and
an FR-H4
comprising the amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 14). In some
embodiments, the
antibody is capable of binding to rabbit TIGIT.
In another aspect, the invention features an antibody that specifically binds
to human TIGIT,
wherein the antibody comprises the following six HVRs: an HVR-H1 comprising
the amino acid sequence
of SYPMN (SEQ ID NO: 17); an HVR-H2 comprising the amino acid sequence of
WINTNTGNPTYVQGFTG (SEQ ID NO: 18); an HVR-H3 comprising the amino acid
sequence of
TGGHTYDSYAFDV (SEQ ID NO: 19): an HVR-L1 comprising the amino acid sequence of
RASQVISSSLA (SEQ ID NO: 20); an HVR-L2 comprising the amino acid sequence of
AASTLQS (SEQ ID
NO: 21); and an HVR-L3 comprising the amino acid sequence of QHLHGYPXIN (SEQ
ID NO: 22),
wherein Xi is C or S. In some embodiments, the antibody comprises the
following six HVRs: an HVR-H1
comprising the amino acid sequence of SYPMN (SEQ ID NO: 17); an HVR-H2
comprising the amino acid
sequence of WINTNTGNPTYVQGFTG (SEQ ID NO: 18); an HVR-H3 comprising the amino
acid
sequence of TGGHTYDSYAFDV (SEQ ID NO: 19); an HVR-L1 comprising the amino acid
sequence of
RASQVISSSLA (SEQ ID NO: 20); an HVR-L2 comprising the amino acid sequence of
AASTLQS (SEQ ID
NO: 21); and an HVR-L3 comprising the amino acid sequence of QHLHGYPSN (SEQ ID
NO: 23). In
some embodiments, the antibody further comprises the following heavy chain
variable region FRs: an FR-
H1 comprising the amino acid sequence of EVOLVQSGSDLKKPGASVRVSCKASGYTFT (SEQ
ID NO:
24); an FR-H2 comprising the amino acid sequence of WVRQAPGHGLEWMG (SEQ ID NO:
25); an FR-
H3 comprising the amino acid sequence of RFVFSLDTSVNTAYLQISSLKAEDTAVYFCAR (SEQ
ID NO:
26); and an FR-H4 comprising the amino acid sequence of WGQGTMVTVSS (SEQ ID
NO: 27). In some
embodiments, antibody comprises the following six HVRs: an HVR-H1 comprising
the amino acid
sequence of SYPMN (SEQ ID NO: 17); an HVR-H2 comprising the amino acid
sequence of
4
CA 02994858 2018-02-05
WO 2017/053748
PCT/US2016/053368
WINTNTGNPTYVQGFTG (SEQ ID NO: 18); an HVR-H3 comprising the amino acid
sequence of
TGGHTYDSYAFDV (SEQ ID NO: 19); an HVR-Ll comprising the amino acid sequence of
RASQVISSSLA (SEQ ID NO: 20); an HVR-L2 comprising the amino acid sequence of
AASTLQS (SEQ ID
NO: 21): and an HVR-L3 comprising the amino acid sequence of QHLHGYPCN (SEQ ID
NO: 28). In
some embodiments, the antibody further comprises the following heavy chain
variable region FRs: an FR-
H1 comprising the amino acid sequence of QVQLVQSGSDLKKPGASVRVSCKASGYTFT (SEQ
ID NO:
29); an FR-H2 comprising the amino acid sequence of VVVRQAPGHGLEVVMG (SEQ ID
NO: 25); an FR-
H3 comprising the amino acid sequence of RFVFSLDTSVNTAYLQISSLKAEDTAVYFCAR (SEQ
ID NO:
26); and an FR-H4 comprising the amino acid sequence of WGQGTMVTVSS (SEQ ID
NO: 27). In some
embodiments, the antibody further comprises the following light chain variable
region FRs: an FR-L1
comprising the amino acid sequence of DIQLTQSPTFLSASVGDRVTITC (SEQ ID NO: 30);
an FR-L2
comprising the amino acid sequence of VVYQQNPGKAPKLLIY (SEQ ID NO: 31); an FR-
L3 comprising
the amino acid sequence of GVPSRFSGSGSGTEFTLTISSLOPEDFVTYYC (SEQ ID NO: 32);
and an
FR-L4 comprising the amino acid sequence of FGOGTKVEIK (5E0 ID NO: 33).
In another aspect, the invention features an antibody that specifically binds
to human TIGIT,
wherein the antibody comprises (a) a heavy chain variable region (VH) having
at least 95% sequence
identity to the amino acid sequence of SEQ ID NO: 34 or 35; (b) a light chain
variable region (VL) having
at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 36; or
(c) a heavy chain
variable region as in (a) and a light chain variable region as in (b). In some
embodiments, antibody
comprises (a) a heavy chain variable region (VII) having at least 95% sequence
identity to the amino acid
sequence of SEQ ID NO: 34; (b) a light chain variable region (VL) having at
least 95% sequence identity
to the amino acid sequence of SEQ ID NO: 36; or (c) a heavy chain variable
region as in (a) and a light
chain variable region as in (b). In some embodiments, the antibody comprises
(a) a heavy chain variable
region (VII) having at least 95% sequence identity to the amino acid sequence
of SEQ ID NO: 35; (b) a
light chain variable region (VL) having at least 95% sequence identity to the
amino acid sequence of SEQ
ID NO: 36; or (c) a heavy chain variable region as in (a) and a light chain
variable region as in (b). In
some embodiments, the antibody is capable of binding to rabbit TIGIT.
In another aspect, the invention features an antibody that specifically binds
to human TIGIT,
wherein the antibody comprises (a) a heavy chain variable region (VII) having
at least 95% sequence
.. identity to the amino acid sequence of SEQ ID NO: 37; (b) a light chain
variable region (VL) having at
least 95% sequence identity to the amino acid sequence of SEQ ID NO: 38; or
(c) a heavy chain variable
region as in (a) and a light chain variable region as in (b).
In yet another aspect, the invention features an antibody that specifically
binds to human TIGIT,
wherein the antibody comprises (a) a heavy chain variable region (VII) having
at least 95% sequence
.. identity to the amino acid sequence of SEQ ID NO: 39; (b) a light chain
variable region (VL) having at
least 95% sequence identity to the amino acid sequence of SEQ ID NO: 40; or
(c) a heavy chain variable
region as in (a) and a light chain variable region as in (b).
In any one of the aspects described above, the antibody may be capable of
binding to both
human TIGIT and cynomolgus monkey (cyno) TIGIT, but not murine TIGIT. In some
embodiments, the
antibody binds human TIGIT with a Kd of about 10 nM or lower and cyno TIGIT
with a Kd of about 10 nM
5
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
or lower. In some embodiments, the antibody binds human TIGIT with a Kd of
about 0.1 nM to about 1
nM and cyno TIGIT with a Kd of about 0.5 nM to about 1 nM. In some
embodiments, the antibody binds
human TIG1T with a Kd of about 0.1 nM or lower and cyno TIGIT with a Kd of
about 0.5 nM or lower.
In any one of the aspects described above, the antibody may be an antagonist
antibody or an
agonist antibody.
In some embodiments, the antagonist antibody specifically binds TIGIT and
inhibits or blocks
TIGIT interaction with poliovirus receptor (PVR). In some embodiments, the
antagonist antibody inhibits
intracellular signaling mediated by TIGIT binding to PVR. In some embodiments,
the antagonist antibody
inhibits or blocks binding of human TIGIT to human PVR with an IC50 value of
10 nM or lower. In some
embodiments, the antagonist antibody inhibits or blocks binding of human TIGIT
to human PVR with an
1050 value of 1 nM to about 10 nM. In some embodiments, the antagonist
antibody inhibits or blocks
binding of cyno TIG1T to cyno PVR with an 1050 value of 50 nM or lower. In
some embodiments, the
antagonist antibody inhibits or blocks binding of cyno TIGIT to cyno PVR with
an 1050 value of 1 nM to
about 50 nM. In some embodiments, the antagonist antibody inhibits or blocks
binding of cyno TIGIT to
cyno PVR with an 1050 value of 1 nM to about 5 nM.
In some embodiments, the agonist antibody specifically binds TIGIT and
stimulates the
interaction of PVR with CD226 or CD96. In some embodiments, the agonist
antibody specifically binds
TIGIT and stimulates the interaction of PVR with CD226 and CD96. In some
embodiments, the agonist
antibody specifically binds TIGIT and stimulates the interaction of human PVR
with human CD226 and
human CD96. In some embodiments, the agonist antibody specifically binds TIGIT
and stimulates the
interaction of cyno PVR with cyno CD226 and cyno CD96.
In another aspect, the invention features an isolated antibody that competes
for binding to TIGIT
with an antibody of any one of the above aspects.
In another aspect, the invention features an isolated antibody that binds to
the same epitope as
an antibody of any one of the above aspects.
In some embodiments of any one of the aspects described above, the antibody is
monoclonal. In
some embodiments, the antibody is human, humanized, or chimeric. In some
embodiments, the antibody
is a full-length antibody. In some embodiments, the antibody has a clearance
following administration
(e.g., injection, e.g.. intravenous injection) of less than about 10 ml/kg/day
(e.g., about 3 milkg/day to
about 10 ml/kg/day). In some embodiments, the antibody antibody has a
clearance of about 3 ml/kg/day
to about 8 nil/kg/day. In some embodiments, administration of the antibody is
to a mammal (e.g., a
monkey, such as a cynomolgus monkey, or a human). In some embodiments, the
antibody is an
antibody fragment that binds TIGIT. In some embodiments, the antibody fragment
is selected from the
group consisting of Fab, Fab', Fab'-SH, Fv, single chain variable fragment
(scFv), and (Fab)2 fragments.
In some embodiments, the antibody is an IgG class antibody. In some
embodiments, the IgG class
antibody is an IgG1 subclass antibody. In some embodiments, an antibody
described herein can be for
use as a medicament. In some embodiments, an antibody described herein may be
for use in treating or
delaying progression of a cancer in a subject in need thereof. In some
embodiments, the cancer is
selected from the group consisting of a non-small cell lung cancer, a small
cell lung cancer, a renal cell
cancer, a colorectal cancer, an ovarian cancer, a breast cancer, a pancreatic
cancer, a gastric carcinoma,
6
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
a bladder cancer, an esophageal cancer, a mesothelioma, a melanoma, a head and
neck cancer, a
thyroid cancer, a sarcoma, a prostate cancer, a glioblastoma, a cervical
cancer, a thymic carcinoma, a
leukemia, a lymphoma, a myeloma, mycoses fungoides, a merkel cell cancer, and
a hematologic
malignancy. In some embodiments, an antibody described herein may be for use
in treating or delaying
progression of multiple myeloma (MM). In some embodiments, an antibody
described herein may be for
use in treating or delaying progression of an immune-related disease in a
subject in need thereof. In
some embodiments, the immune-related disease is associated with a T cell
dysfunctional disorder. In
some embodiments, the T cell dysfunctional disorder is characterized by T cell
exhaustion. In some
embodiments, the immune-related disease is selected from the group consisting
of unresolved acute
infection, chronic infection, and tumor immunity. In some embodiments, an
antibody described herein
may be for use in increasing, enhancing, or stimulating an immune response or
function in a subject in
need thereof.
In another aspect, the invention features a polynucleotide (e.g., an isolated
polynucleotide)
encoding any of the antibodies described herein. In another aspect, the
invention features a vector (e.g.,
an expression vector) comprising the polynucleotide for expressing the
antibody. In another aspect, the
invention features host cells comprising the preceding polynucleotides and/or
vectors. In some
embodiments, the host cell is a eukaryotic (e.g., a mammalian cell). In some
embodiments, the
eukaryotic cell is a 293 cell, a Chinese hamster ovary (CHO) cell, a yeast
cell, or a plant cell. In some
embodiments, the host cell is a prokaryotic cell. In some embodiments, the
prokaryotic cell is E. coll.
In another aspect, the invention features a method of producing any of the
antibodies described
herein, the method comprising culturing a host cell that comprises any of the
preceding vectors (e.g.,
expression vectors) in a culture medium. In some embodiments, the method
further comprises
recovering the antibody from the host cell or the culture medium. In some
embodiments, the host cell is a
eukaryotic cell, for example, a mammalian cell, for example, a 293 cell, a
Chinese hamster ovary (CHO)
cell, a yeast cell, or a plant cell. In some embodiments, the host cell is a
prokaryotic cell. In some
embodiments, the prokaryotic cell is E. coll.
In another aspect, the invention features an immunoconjugate comprising any
one of the
antibodies described herein and an agent (e.g., a therapeutic agent, e.g., a
cytotoxic agent).
In another aspect, the invention features a composition comprising an antibody
described herein.
In some embodiments, the composition further comprises a pharmaceutically
acceptable carrier,
excipient, or diluent. In some embodiments, the composition is for diagnostic
use (e.g., to detect TIGIT
expression levels, e.g., TIGIT protein expression levels). In some
embodiments, the composition is a
pharmaceutical composition. In some embodiments, the composition further
comprises a PD-1 axis
binding antagonist or an additional therapeutic agent.
In another aspect, the invention features the use of an antibody described
herein in the
manufacture of a medicament for treating or delaying progression of a cancer
in a subject in need thereof.
In some embodiments, the cancer is selected from the group consisting of a non-
small cell lung cancer, a
small cell lung cancer, a renal cell cancer, a colorectal cancer, an ovarian
cancer, a breast cancer, a
pancreatic cancer, a gastric carcinoma, a bladder cancer, an esophageal
cancer, a mesothelioma, a
melanoma, a head and neck cancer, a thyroid cancer, a sarcoma, a prostate
cancer, a glioblastoma, a
7
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
cervical cancer, a thymic carcinoma, a leukemia, a lymphoma, a myeloma,
mycoses fungoides, a merkel
cell cancer, and a hematologic malignancy. In some embodiments, the myeloma is
MM. In some
embodiments, the medicament is formulated for administration subcutaneously,
intravenously,
intramuscularly, topically, orally, transderrnally, intraperitoneally,
intraorbitally, by implantation, by
inhalation, intrathecally, intraventricularly, or intranasally. In some
embodiments, the subject is a human.
In another aspect, the invention features the use of an antibody described
herein in the
manufacture of a medicament for treating or delaying progression of an immune-
related disease in a
subject in need thereof. In some embodiments, the immune-related disease is
associated with a T cell
dysfunctional disorder. In some embodiments, the T cell dysfunctional disorder
is characterized by T cell
exhaustion. In some embodiments, the immune-related disease is selected from
the group consisting of
unresolved acute infection, chronic infection, and tumor immunity. In some
embodiments, the
medicament is formulated for administration subcutaneously, intravenously,
intramuscularly, topically,
orally, transderrnally, intraperitoneally, intraorbitally, by implantation, by
inhalation, intrathecally,
intraventricularly, or intranasally. In some embodiments, the subject is a
human.
In another aspect, the invention features the use of an antibody described
herein in the
manufacture of a medicament for increasing, enhancing, or stimulating an
immune response or function
in a subject in need thereof. In some embodiments, the medicament is
formulated for administration
subcutaneously, intravenously, intramuscularly, topically, orally.
transderrnally, intraperitoneally,
intraorbitally, by implantation, by inhalation, intrathecally,
intraventricularly, or intranasally. In some
embodiments, the subject is a human.
In another aspect, the invention features a method for treating or delaying
progression of a
cancer in a subject, the method comprising administering to the subject an
effective amount of any one or
more (e.g., 1, 2, 3, 4, 5, or 6 or more) of the antibodies described herein,
thereby treating or delaying the
progression of the cancer in the subject. In some embodiments, the cancer is
selected from the group
consisting of a non-small cell lung cancer, a small cell lung cancer, a renal
cell cancer, a colorectal
cancer, an ovarian cancer, a breast cancer, a pancreatic cancer, a gastric
carcinoma, a bladder cancer,
an esophageal cancer, a mesothelioma, a melanoma, a head and neck cancer, a
thyroid cancer, a
sarcoma, a prostate cancer, a glioblastoma, a cervical cancer, a thymic
carcinoma, a leukemia, a
lymphoma, a myeloma, mycoses fungoides, a merkel cell cancer, and a
hematologic malignancy. In
some embodiments, the myeloma is MM.
In another aspect, the invention features a method for treating or delaying
progression of an
immune-related disease in a subject, the method comprising administering to
the subject an effective
amount of one or more (e.g., 1, 2, 3, 4, 5, or 6 or more) of the antibodies
described herein, thereby
treating or delaying the progression of the immune-related disease in the
subject. In some embodiments,
the immune-related disease is associated with a T cell dysfunctional disorder.
In some embodiments, the
T cell dysfunctional disorder is characterized by T cell exhaustion. In some
embodiments, the immune-
related disease is selected from the group consisting of unresolved acute
infection, chronic infection, and
tumor immunity.
In another aspect, the invention features a method of increasing, enhancing,
or stimulating an
immune response or function in a subject, the comprising administering to the
subject an effective amount
8
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
of one or more (e.g., 1, 2, 3, 4, 5, or 6 or more) of the antibodies described
herein, thereby increasing,
enhancing, or stimulating an immune response or function in the subject. In
some embodiments, the
method further comprises administering to the subject a PD-1 axis binding
antagonist. In some
embodiments, the PD-1 axis binding antagonist is administered prior to or
subsequent to the
administration of the antibody. In some embodiments, the PD-1 axis binding
antagonist is administered
concurrently with the antibody. In some embodiments, the PD-1 axis binding
antagonist is selected from
the group consisting of a PD-1 binding antagonist, a PD-L1 binding antagonist,
and a PD-L2 binding
antagonist. In some embodiments, the PD-1 axis binding antagonist is a PD-1
binding antagonist. In
some embodiments, the PD-1 binding antagonist inhibits the binding of PD-1 to
its ligand binding
partners. In some embodiments, the PD-1 binding antagonist inhibits the
binding of PD-1 to PD-L1. In
some embodiments, the PD-1 binding antagonist inhibits the binding of PD-1 to
PD-L2. In some
embodiments, the PD-1 binding antagonist is an anti-PD-1 antibody. In some
embodiments, the PD-1
binding antagonist is selected from the group consisting of MDX 1106
(nivolumab), MK-3475
(pembrolizumab), CT-011 (pidilizumab), MEDI-0680 (AMP-514), PDR001, REGN2810,
and BGB-108. In
some embodiments, the PD-1 axis binding antagonist is a PD-Ll binding
antagonist. In some
embodiments, the PD-Ll binding antagonist inhibits the binding of PD-L1 to PD-
1. In some
embodiments, the PD-L1 binding antagonist inhibits the binding of PD-L1 to 87-
1. In some embodiments,
the PD-Ll binding antagonist inhibits the binding of PD-Ll to both PD-1 and B7-
1. In some
embodiments, the PD-Ll binding antagonist is an anti-PD-L1 antibody. In some
embodiments, the anti-
PD-Ll antibody is selected from the group consisting of: MPDL3280A
(atezolizumab), YW243.55.S70,
MDX-1105, MEDI4736 (durvalumab), and MS80010718C (avelumab). In some
embodiments, the
antibody is MPDL3280A. In some embodiments, the PD-1 axis binding antagonist
is a PD-L2 binding
antagonist. In some embodiments, the PD-L2 binding antagonist is an anti-PD-L2
antibody. In some
embodiments, the PD-L2 binding antagonist is an immunoadhesin.
In some embodiments, any one of the methods of treatment described above may
further
comprise administering to the subject an 0X40 binding agonist. In some
embodiments, the 0X40 binding
agonist is administered prior to or subsequent to the administration of the
antibody and/or the PD-1 axis
binding antagonist. In some embodiments, the 0X40 binding agonist is
administered concurrently with
the antibody and/or the PD-1 axis binding antagonist. In some embodiments, the
0X40 binding agonist is
selected from the group consisting of an 0X40 agonist antibody, an OX4OL
agonist fragment. an 0X40
oligomeric receptor, and an 0X40 immunoadhesin. In some embodiments, the 0X40
agonist antibody
depletes cells that express human 0X40. In some embodiments, the cells that
express human 0X40 are
CD4+ effector T cells. In some embodiments, the cells that express human 0X40
are regulatory T (Treg)
cells. In some embodiments, the depleting is by ADCC and/or phagocytosis. In
some embodiments, the
0X40 agonist antibody binds human 0X40 with an affinity of less than or equal
to about 1 nM. In some
embodiments, the 0X40 agonist antibody binds human 0X40 with an affinity of
less than or equal to
about 0.45 nM. In some embodiments, the 0X40 agonist antibody binds human 0X40
with an affinity of
less than or equal to about 0.4 nM. In some embodiments, the 0X40 agonist
antibody binds human
0X40 with an EC50 of less than or equal to 0.3 pg/ml. In some embodiments, the
0X40 agonist antibody
binds human 0X40 with an EC50 of less than or equal to 0.2 pg/ml. In some
embodiments, the 0X40
9
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
agonist antibody increases CD4+ effector T cell proliferation and/or increases
cytokine production by the
CD4+ effector T cell as compared to proliferation and/or cytokine production
prior to treatment with the
0X40 agonist antibody. In some embodiments, the 0X40 agonist antibody
increases memory T cell
proliferation and/or cytokine production by a memory T cell. In some
embodiments, the cytokine
production is IFN-y production. In some embodiments, the 0X40 agonist antibody
inhibits Treg function.
In some embodiments, the 0X40 agonist antibody inhibits Treg suppression of
effector T cell function
(e.g., effector T cell proliferation and/or cytokine production). In some
embodiments, the effector T cell is
a CD4+ effector T cell. In some embodiments, the 0X40 agonist antibody
increases 0X40 signal
transduction in a target cell that expresses 0X40. In some embodiments, the
0X40 signal transduction is
detected by monitoring NFId3 downstream signaling In some embodiments, the the
0X40 agonist
antibody comprises a variant IgG1 Fe polypeptide comprising a mutation that
eliminates binding to human
effector cells and has diminished activity relative to the 0X40 agonist
antibody comprising a native
sequence IgG1 Fc portion. In some embodiments, the 0X40 agonist antibody
comprises a variant IgG1
Fc polypeptide comprising a DANA mutation. In some embodiments, the 0X40
agonist antibody
comprises (a) a VH domain comprising (i) a HVR-H1 comprising the amino acid
sequence of SEQ ID NO:
278, 279, or 280, (ii) a HVR-H2 comprising the amino acid sequence of SEQ ID
NO: 281, 282, 283, 284,
285, or 286, and (iii) a HVR-H3 comprising an amino acid sequence selected
from SEQ ID NO: 287, 288,
or 289; and (b) a VL domain comprising (i) a HVR-L1 comprising the amino acid
sequence of SEQ ID NO:
290, (ii) a HVR-L2 comprising the amino acid sequence of SEQ ID NO: 291, and
(iii) a FIVR-L3
comprising the amino acid sequence of SEQ ID NO: 292, 293, 294, 295, 296, 297,
298, or 299. In some
embodiments, the 0X40 agonist antibody comprises (a) HVR-I-11 comprising the
amino acid sequence of
SEQ ID NO: 278: (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:
281; (c) HVR-H3
comprising the amino acid sequence of SEQ ID NO: 287; (d) HVR-L1 comprising
the amino acid
sequence of SEQ ID NO: 290; (e) HVR-L2 comprising the amino acid sequence of
SEQ ID NO: 291; and
(f) HVR-L3 comprising an amino acid sequence selected from SEQ ID NO: 292. In
some embodiments,
the OX40 agonist antibody comprises (a) HVR-H1 comprising the amino acid
sequence of SEQ ID NO:
278; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 281; (c) HVR-
H3 comprising the
amino acid sequence of SEQ ID NO: 287; (d) HVR-Ll comprising the amino acid
sequence of SEQ ID
NO: 290; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 291; and
(1)1-11/R-1..3
comprising an amino acid sequence selected from SEQ ID NO: 297. In some
embodiments, the 0X40
agonist antibody comprises (a) HVR-H1 comprising the amino acid sequence of
SEQ ID NO: 278; (b)
HVR-H2 comprising the amino acid sequence of SEQ ID NO: 281; (c) HVR-I-13
comprising the amino acid
sequence of SEQ ID NO: 287; (d) HVR-Ll comprising the amino acid sequence of
SEQ ID NO: 290; (e)
HVR-L2 comprising the amino acid sequence of SEQ ID NO: 291; and (t) HVR-L3
comprising an amino
acid sequence selected from SEQ ID NO: 298. In some embodiments, the OX40
agonist antibody
comprises a VH sequence having at least 90% sequence identity to the amino
acid sequence of any one
of SEQ ID NOs: 300-325. In some embodiments, the 0X40 agonist antibody
comprises a VII sequence
having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:
300. In some
embodiments, a total of 1 to 10 amino acids have been substituted, inserted,
and/or deleted in SEQ ID
NO: 300. In some embodiments, the 0X40 agonist antibody comprises a VH
comprising one, two, or
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
three HVRs selected from: (a) HVR-H1 comprising the amino acid sequence of SEQ
ID NO: 278, (b)
FIVR-H2 comprising the amino acid sequence of SEQ ID NO: 281, and (c) FIVR-H3
comprising the amino
acid sequence of SEQ ID NO: 287. In some embodiments, the 0X40 agonist
antibody comprises a VL
sequence having at least 90% sequence identity to the amino acid sequence of
any one of SEQ ID NOs:
.. 326-351. In some embodiments, the 0X40 agonist antibody comprises a VL
having at least 90%
sequence identity to the amino acid sequence of SEQ ID NO: 326. In some
embodiments, a total of 1 to
amino acids have been substituted, inserted, and/or deleted in SEQ ID NO: 326.
In some
embodiments. the 0X40 agonist antibody comprises a VL comprising one, two, or
three HVRs selected
from (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 290; (b) HVR-
L2 comprising the
10 amino acid sequence of SEQ ID NO: 291; and (c) HVR-L3 comprising the
amino acid sequence of SEQ
ID NO: 292. In some embodiments, the 0X40 agonist antibody comprises (a) a VII
sequence of SEQ ID
NO: 300; (b) a VL sequence of SEQ ID NO: 326; or (c) a VII sequence as in (a)
and a VL sequence as in
(b). In some embodiments, the 0X40 agonist antibody comprises (a) a VII
sequence of SEQ ID NO: 319;
(b) a VL sequence of SEQ ID NO: 345; or (c) a VII sequence as in (a) and a VL
sequence as in (b). In
.. some embodiments, the 0X40 agonist antibody comprises (a) a VII sequence of
SEQ ID NO: 320; (b) a
VL sequence of SEQ ID NO: 346; or (c) a VII sequence as in (a) and a VL
sequence as in (b). In some
embodiments, the 0X40 agonist antibody is antibody L106, antibody ACT35,
MEDI6469, or MEDI0562.
In some embodiments, the 0X40 agonist antibody is a full-length IgG1 antibody.
In some embodiments.
the 0X40 immunoadhesin is a trimeric OX40-Fc protein.
In some embodiments, any one of the methods of treatment described above may
further
comprise administering to the subject an agent that decreases or inhibits one
or more additional immune
co-inhibitory receptors. In some embodiments, the one or more additional
immune co-inhibitory receptor
is selected from the group consisting of PD-1, CTLA-4, LAG3, TIM3, BTLA,
VISTA, B7H4, and CD96. In
some embodiments, any one of the methods of treatment described above may
further comprise
.. administering to the subject an additional therapeutic agent. In some
embodiments, the additional
therapeutic agent is a chemotherapeutic agent. In some embodiments, antibody
is administered
subcutaneously, intravenously, intramuscularly, topically, orally,
transdermally, intraperitoneally,
intraorbitally, by implantation, by inhalation, intrathecally,
intraventricularly, or intranasally. In some
embodiments, the subject is a human.
In another aspect, the invention features a kit comprising any one or more
(e.g., 1, 2, 3, 4, 5, or 6
or more) of the antibodies described herein and package insert comprising
instructions for using the
antibody for treating or delaying progression of a cancer in a subject. In
some embodiments, the cancer
is selected from the group consisting of a non-small cell lung cancer, a small
cell lung cancer, a renal cell
cancer, a colorectal cancer, an ovarian cancer, a breast cancer, a pancreatic
cancer, a gastric carcinoma,
a bladder cancer, an esophageal cancer, a mesothelioma, a melanoma, a head and
neck cancer, a
thyroid cancer, a sarcoma, a prostate cancer, a glioblastoma, a cervical
cancer, a thymic carcinoma, a
leukemia, a lymphoma, a myeloma, mycoses fungoides, a merkel cell cancer, and
a hematologic
malignancy. In some embodiments, the subject is a human. In some embodiments,
the myeloma is MM.
In another aspect, the invention features a kit comprising any one or more
(e.g., 1, 2, 3, 4, 5, or 6
.. or more) of the antibodies described herein and a package insert comprising
instructions for using the
11
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
antibody for treating or delaying progression of an immune-related disease in
a subject. In some
embodiments, the immune-related disease is associated with a T cell
dysfunctional disorder. In some
embodiments, the T cell dysfunctional disorder is characterized by T cell
exhaustion. In some
embodiments, the immune-related disease is selected from the group consisting
of unresolved acute
infection, chronic infection, and tumor immunity. In some embodiments, the
subject is a human.
In another aspect, the invention features a kit comprising any one or more
(e.g., 1, 2, 3, 4, 5, or 6
or more) of the antibodies described herein and a package insert comprising
instructions for increasing,
enhancing, or stimulating an immune response or function in a subject. In some
embodiments, the
subject is a human.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGURE 1A is a schematic diagram of a CHO-TIGIT binding assay.
FIGURE 18 is a graph showing the results of the CHO-TIGIT binding assay
depicted in Figure 1A
using human TIGIT-expressing CHO cells and the indicated OMT-derived anti-
TIGIT antibodies at varying
concentrations, as analyzed by FACS.
FIGURE 1C is a graph showing the results of the CHO-TIGIT binding assay
depicted in Figure 1A
using cynomolgus monkey (cyno) TIGIT-expressing CHO cells and the indicated
OMT-derived anti-TIGIT
antibodies at varying concentrations, as analyzed by FACS.
FIGURE 1D is a graph showing the results of the CHO-TIGIT binding assay
depicted in Figure 1A
using human TIGIT-expressing CHO cells and the indicated SD-derived anti-TIGIT
antibodies at varying
concentrations, as analyzed by FRCS.
FIGURE lE is a graph showing the results of the CHO-TIGIT binding assay
depicted in Figure 1A
using cyno TIGIT-expressing CHO cells and the indicated SD-derived anti-TIGIT
antibodies at varying
concentrations, as analyzed by FAGS.
FIGURE 2A is a graph showing the binding of the indicated OMT-derived anti-
TIGIT antibodies to
human CD4 T cells as a function of antibody concentration.
FIGURE 2B is a graph showing the binding of the indicated OMT-derived anti-
TIGIT antibodies to
human CD8 T cells as a function of antibody concentration.
FIGURE 2C is a graph showing the binding of the indicated SD-derived anti-
TIGIT antibodies to
human CD4 T cells as a function of antibody concentration.
FIGURE 2D is a graph showing the binding of the indicated SD-derived anti-
TIGIT antibodies to
human CD8 T cells as a function of antibody concentration.
FIGURE 3A is a graph showing the results of a blocking ELISA assay using human
PVR-Fc
fusion protein coated-plates, human TIGIT, and the indicated anti-TIGIT
antibodies (10A7 and 4.1D3.01E
in Fab or IgG format) or anti-CSF1 Fab control, as a function of antibody/Fab
concentration.
FIGURE 3B is a graph showing the results of a blocking ELISA assay using cyno
PVR-Fc fusion
protein coated-plates, cyno TIGIT, and the indicated anti-TIGIT antibodies
(10A7 and 4.1D3.01E in Fab
or IgG format) or anti-CSF1 Fab control, as a function of antibody/Fab
concentration.
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
FIGURE 3C is a graph showing the results of a blocking ELISA assay using
murine PVR-Fc
fusion protein coated-plates, murine TIGIT, and the indicated anti-TIGIT
antibodies (10A7 and 4.1D3.01E
in Fab or IgG format) or anti-CSF1 Fab control, as a function of antibody/Fab
concentration.
FIGURE 30 is a table showing the results of the blocking EUSA assays described
in Figures 3A-
3C.
FIGURE 4A is a schematic diagram of a CHO-TIGIT PVR blocking assay.
FIGURE 4B is a graph showing the results of the CHO-TIGIT PVR blocking assay
depicted in
Figure 4A using human TIGIT-expressing CHO cells and the indicated OMT-derived
anti-TIGIT antibodies
at varying concentrations, as analyzed by FAGS.
FIGURE 4C is a graph showing the results of the CHO-TIGIT PVR blocking assay
depicted in
Figure 4A using cyno TIGIT-expressing CHO cells and the indicated OMT-derived
anti-TIGIT antibodies
at varying concentrations, as analyzed by FACS.
FIGURE 4D is a graph showing the results of the CHO-TIGIT PVR blocking assay
depicted in
Figure 4A using human TIGIT-expressing CHO cells and the indicated SD-derived
anti-TIGIT antibodies
at varying concentrations, as analyzed by FACS.
FIGURE 4E is a graph showing the results of the CHO-TIGIT PVR blocking assay
depicted in
Figure 4A using cyno TIGIT-expressing CHO cells and the indicated SD-derived
anti-TIGIT antibodies at
varying concentrations, as analyzed by FACS.
FIGURE 5A is a graph showing the pharmacokinetic clearance of the indicated
anti-TIGIT
antibodies in cyno following 10 mg/kg intravenous administration as a function
of serum concentration
(pg/ml) over time (days).
FIGURE 5B is a table showing the calculated clearance values for each antibody
tested in the
pharmacokinetic clearance experiments in Figure 5A.
FIGURE 5C is a graph showing the pharmacokinetic clearance of anti-TIGIT
antibodies
h10A7.K4G3 and 4.1D3 in cyno following 10 mg/kg intravenous administration as
a function of serum
concentration (pg/m1) over time (days; do-d7).
FIGURE 5D is a table showing the calculated clearance values for the anti-
TIGIT antibodies
h 1 0A7.K4G3 and 4.1D3 tested in the pharmacokinetic clearance experiments in
Figure 5C.
FIGURE 6A is a rendering of the crystal structure of the 4.103 Fab bound to
human TIGIT, with
the 4.1 D3 heavy chain (I-IC) and light chain (LC) regions indicated and
distinguished by color.
FIGURE 6B is a rendering of the crystal structure of the 4.103 Fab bound to
human TIGIT,
superimposed with the known PVR-TIGIT structure (PDB 3UDW), showing that the
4.103 antibody and
PVR have overlapping binding sites for TIGIT.
FIGURE 6C is a rendering of the crystal structure of the 4.1D3 Fab bound to
human TIGIT, with
the relative location of the PVR binding site indicated. Also indicated is the
relative location of the 72-79
loop of TIGIT.
FIGURES 6D and SE are renderings of the crystal structure of the 4.1D3 Fab
bound to human
TIGIT from different views, identifying certain key contact residues 01 4.103
(paratope residues) and
TIGIT (epitope residues). The boxed residues indicated in Figure 6E were
identified as functionally
important epitopic residues by alanine scanning mutagenesis.
13
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
FIGURE 7A is a graph of showing the Ka values (nM) for each of the identified
anti-TIGIT
antibodies for the indicated human TIGIT alanine scanning mutant.
FIGURE 7B is a graph of showing the Ka values (nM) for each of the identified
anti-TIGIT
antibodies for the indicated human TIGIT alanine scanning mutant, normalized
against the wild-type
human TIGIT target. Alanine scanning mutants of TIGIT that resulted in a 1- to
10-fold or greater than
10-fold drop in binding affinity are indicated by light gray and dark gray
shading, respectively.
FIGURE 7C is a ribbon rendering of the human TIGIT structure with residues
identified as
important for 10A7 recognition by alanine scanning mutagenesis indicated and
represented as spheres.
FIGURE 7D is a ribbon rendering of the human TIGIT structure with residues
identified as
important for hl A5 recognition by alanine scanning mutagenesis indicated and
represented as spheres.
FIGURE 7E is a ribbon rendering of the human TIGIT structure with residues
identified as
important for 4.1D3 recognition by alanine scanning mutagenesis indicated and
represented as spheres.
FIGURE 7F is a ribbon rendering of the human TIGIT structure with residues
identified as
important for 7.4A3 recognition by alanine scanning mutagenesis indicated and
represented as spheres.
FIGURE 7G is a ribbon rendering of the human TIGIT structure with residues
identified as
important for 4.1A4 recognition by alanine scanning mutagenesis indicated and
represented as spheres.
FIGURE 7H is a ribbon rendering of the human TIGIT structure with residues
identified as
important for h662 recognition by alanine scanning mutagenesis indicated and
represented as spheres.
FIGURE 71 is a ribbon rendering of the human TIGIT structure with residues
identified as
important for h7E7 recognition by alanine scanning mutagenesis indicated and
represented as spheres.
FIGURE 8 is a rendering of the crystal structure of the 1A5 Fab bound to human
TIGIT, with the
1A5 heavy chain (HC) and light chain (LC) regions indicated and distinguished
by color.
FIGURE 9 is a rendering of the crystal structures of the 4.1D3-TIGIT, 1A5-
TIGIT, and 10A7-TIGIT
complexes: superimposed on one another with respect to TIGIT, showing that the
three anti-TIGIT
antibodies bind to human TIGIT at non-identical epitopes.
FIGURE 10A is a rendering of the crystal structure of the 10A7 Fab bound to
human TIGIT, with
the 10A7 heavy chain (HC) and light chain (LC) regions indicated and
distinguished by color.
FIGURE 10B is a rendering of the crystal structure of the 10A7 Fab bound to
human TIGIT, with
the relative location of the PVR binding site indicated. Also indicated is the
relative location of the 72-79
loop of TIGIT.
FIGURE 11 is a series of renderings of the 4.1 D3 (top left), 10A7 (center
middle), and 1A5
(bottom right) antibodies and the relative location of the Ser78, Ser80, and
Lys82 residues of human
TIGIT. The structures indicate that the Ser78, Sera , and Lys82 residues of
human TIGIT are key
epitopic residues for 4.1D3, but not for 10A7 or 1A5, where these three
residues are located at a distance
further from the antibody binding pocket.
FIGURE 12 is a series of graphs showing CD45, PD-1, TIGIT, and CD226
expression on CD4+
and CD8+ T cells isolated from the bone marrow of multiple myeloma (MM)
patients (top row) and PD-1,
TIGIT, and CD226 expression on CD4+ and CD8+ T cells isolated from the
peripheral blood of healthy
patients (bottom row), as assessed by multi-color flow cytometry.
14
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
FIGURE 13 is a series of flow cytometry graphs (left) and accompanying plots
(right) showing that
TIGIT and PD-1 are co-expressed on CD4+ and CD8+ T cells in bone marrow of MM
patients.
DETAILED DESCRIPTION OF THE INVENTION
I. General Techniques
The techniques and procedures described or referenced herein are generally
well understood
and commonly employed using conventional methodology by those skilled in the
art, such as, for
example, the widely utilized methodologies described in Sambrook et al.,
Molecular Cloning: A Laboratory
Manual 3d edition (2001) Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, N.Y.; Current
Protocols in Molecular Biology (F.M. Ausubel, et al. eds., (2003)): the series
Methods in Enzymology
(Academic Press, Inc.): PCR 2: A Practical Approach (M.J. MacPherson, B.D.
Hames and G.R. Taylor
eds. (1995)), Harlow and Lane, eds. (1988) Antibodies, A Laboratory Manual,
and Animal Cell Culture
(R.I. Freshney, ed. (1987)); Oligonucleo tide Synthesis (M.J. Gait, ed.,
1984); Methods in Molecular
Biology, Humana Press; Cell Biology: A Laboratory Notebook (J.E. Cellis, ed.,
1998) Academic Press;
Animal Cell Culture (R.I. Freshney), ed., 1987); introduction to Cell and
Tissue Culture (J.P. Mather and
P.E. Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory
Procedures (A. Doyle, J.B.
Griffiths, and D.G. Newell, eds., 1993-8) J. Wiley and Sons; Handbook of
Experimental Immunology (D.M.
Weir and C.C. Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells
(J.M. Miller and M.P. Cabs,
eds., 1987); PCR: The Polymerase Chain Reaction, (Mullis et al., eds., 1994);
Current Protocols in
Immunology (J.E. Coligan et al., eds., 1991); Short Protocols in Molecular
Biology (Wiley and Sons,
1999); Immunobiology (C.A. Janeway and P. Travers, 1997); Antibodies (P.
Finch, 1997); Antibodies: A
Practical Approach (D. Catty., ed., IRL Press, 1988-1989); Monoclonal
Antibodies: A Practical Approach
(P. Shepherd and C. Dean, eds., Oxford University Press, 2000); Using
Antibodies: A Laboratory Manual
(E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The
Antibodies (M. Zanetti and J.
D. Capra, eds., Harwood Academic Publishers, 1995); and Cancer Principles and
Practice of Oncology
(VT. DeVita et al., eds., J.B. Lippincott Company, 1993).
II. Definitions
The term "TIGIT" or VT-cell immunoreceptor with Ig and ITIM domains" as used
herein refers to
any native TIGIT from any vertebrate source, including mammals such as
primates (e.g., humans) and
rodents (e.g., mice and rats), unless otherwise indicated. TIGIT is also known
in the art as
DKFZp667A205, FU39873, V-set and immunoglobulin domain-containing protein 9, V-
set and
transmembrane domain-containing protein 3, VSIG9, VSTM3, and WUCAM. The term
encompasses
"full-length," unprocessed TIGIT (e.g., full-length human TIGIT having the
amino acid sequence of SEQ
ID NO: 352), as well as any form of TIGIT that results from processing in the
cell (e.g., processed human
TIGIT without a signal sequence, having the amino acid sequence of SEQ ID NO:
353). The term also
encompasses naturally occurring variants of TIGIT, e.g., splice variants or
allelic variants. The amino
acid sequence of an exemplary human TIGIT may be found under UniProt Accession
Number Q495A1.
The terms "anti-TIGIT antibody" and "an antibody that specifically binds to
TIGIT" refer to an
antibody that is capable of binding TIGIT with sufficient affinity such that
the antibody is useful as a
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
diagnostic and/or therapeutic agent in targeting TIGIT. In one embodiment, the
extent of binding of an
anti-TIGIT antibody to an unrelated, non-TIGIT protein is less than about 10%
of the binding of the
antibody to TIGIT as measured, e.g., by a radioimmunoassay (RIA). In certain
embodiments, an antibody
that binds to TIGIT has a dissociation constant (Kd) of S 1pM, S 100 nM, S 10
nM, 5 1 nM, 50.1 nM,
s 0.01 nM, or s 0.001 nM (e.g., 10-8M or less, e.g. from 10-8M to 10-13M,
e.g., from 104' M to 10-13 M). In
certain embodiments, an anti-TIGIT antibody binds to an epitope of TIGIT that
is conserved among TIGIT
from different species or an epitope on TIGIT that allows for cross-species
reactivity, such as an epitope
comprising amino acid residues Ser78, Ser80, and Lys82.
The term "antibody" includes monoclonal antibodies (including full length
antibodies which have
an immunoglobulin Fc region), antibody compositions with polyepitopic
specificity, multispecific antibodies
(e.g., bispecific antibodies, diabodies, and single-chain molecules, as well
as antibody fragments (e.g.,
Fab, F(ab)2, and Fv). The term "immunoglobulin" (1g) is used interchangeably
with "antibody" herein.
The term an "isolated antibody" when used to describe the various antibodies
disclosed herein,
means an antibody that has been identified and separated and/or recovered from
a cell or cell culture
from which it was expressed. Contaminant components of its natural environment
are materials that
would typically interfere with diagnostic or therapeutic uses for the
polypeptide, and can include enzymes,
hormones, and other proteinaceous or non-proteinaceous solutes. In some
embodiments, an antibody is
purified to greater than 95% or 99% purity as determined by, for example,
electrophoretic (e.g.. SDS-
PAGE. isoelectric focusing (1EF), capillary electrophoresis) or
chromatographic (e.g., ion exchange or
reverse phase HPLC). For a review of methods for assessment of antibody
purity, see, e.g.. Flatman et
al., J. Chromatogr. B 848:79-87 (2007). In preferred embodiments, the antibody
will be purified (1) to a
degree sufficient to obtain at least 15 residues of N-terminal or internal
amino acid sequence by use of a
spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing
or reducing conditions
using Coomassie blue or, preferably, silver stain. Isolated antibody includes
antibodies in situ within
recombinant cells, because at least one component of the polypeptide natural
environment will not be
present. Ordinarily, however, isolated polypeptide will be prepared by at
least one purification step.
The basic 4-chain antibody unit is a heterotetrameric glycoprotein composed of
two identical light
(L) chains and two identical heavy (H) chains. An IgM antibody consists of 5
of the basic heterotetramer
units along with an additional polypeptide called a .1 chain, and contains 10
antigen binding sites, while
IgA antibodies comprise from 2-5 of the basic 4-chain units which can
polymerize to form polyvalent
assemblages in combination with the J chain. In the case of igGs, the 4-chain
unit is generally about
150,000 gallons. Each L chain is linked to an H chain by one covalent
disulfide bond, while the two H
chains are linked to each other by one or more disulfide bonds depending on
the H chain isotype. Each
H and L chain also has regularly spaced intrachain disulfide bridges. Each H
chain has at the N-
terminus, a variable domain (VH) followed by three constant domains (CH) for
each of the a and y chains
and four CH domains for p and c isotypes. Each L chain has at the N-terminus,
a variable domain (VL)
followed by a constant domain at its other end. The VL is aligned with the VH
and the CL is aligned with
the first constant domain of the heavy chain (CH1). Particular amino acid
residues are believed to form an
interface between the light chain and heavy chain variable domains. The
pairing of a Vi-: and NA. together
forms a single antigen-binding site. For the structure and properties of the
different classes of antibodies,
16
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
see, e.g., Basic and Clinical Immunology, 8th Edition, Daniel P. Sties, Abba
I. Terr and Tristram G.
Parsolw (eds), Appleton & Lange, Norwalk, CT, 1994, page 71 and Chapter 6. The
L chain from any
vertebrate species can be assigned to one of two clearly distinct types,
called kappa and lambda, based
on the amino acid sequences of their constant domains. Depending on the amino
acid sequence of the
constant domain of their heavy chains (CH), immunoglobtilins can be assigned
to different classes or
isotypes. There are five classes of immunoglobulins: IgA, IgD, IgE, IgG and
IgM, having heavy chains
designated a, 6, E, y, and p, respectively. The y and a classes are further
divided into subclasses on the
basis of relatively minor differences in the CH sequence and function, e.g.,
humans express the following
subclasses: IgG1 , IgG2A, IgG2B, IgG3, IgG4, IgAl and IgA2.
The 'variable region' or "variable domain" of an antibody refers to the amino-
terminal domains of
the heavy or light chain of the antibody. The variable domains of the heavy
chain and light chain may be
referred to as "VH" and "Vt.", respectively. These domains are generally the
most variable parts of the
antibody (relative to other antibodies of the same class) and contain the
antigen binding sites.
The term "variable" refers to the fact that certain segments of the variable
domains differ
extensively in sequence among antibodies. The V domain mediates antigen
binding and defines the
specificity of a particular antibody for its particular antigen. However, the
variability is not evenly
distributed across the entire span of the variable domains. Instead, it is
concentrated in three segments
called hypervariable regions (HVRs) both in the light-chain and the heavy
chain variable domains. The
more highly conserved portions of variable domains are called the framework
regions (FR). The variable
domains of native heavy and light chains each comprise four FR regions,
largely adopting a beta-sheet
configuration, connected by three HVRs, which form loops connecting, and in
some cases forming part of,
the beta-sheet structure. The HVRs in each chain are held together in close
proximity by the FR regions
and, with the HVRs from the other chain, contribute to the formation of the
antigen binding site of
antibodies (see Kabat at al., Sequences of Immunological Interest, Fifth
Edition, National Institute of
Health, Bethesda, MD (1991)). The constant domains are not involved directly
in the binding of antibody
to an antigen, but exhibit various effector functions, such as participation
of the antibody in antibody-
dependent cellular toxicity.
A "blocking antibody" or an "antagonist antibody" is one that inhibits or
reduces a biological
activity of the antigen it binds. In some embodiments, blocking antibodies or
antagonist antibodies
substantially or completely inhibit the biological activity of the antigen.
The anti-TIGIT antibodies of the
invention may block signaling through PVR, PVRL2, and/or PVRL3 so as to
restore a functional response
by T-cells (e.g., proliferation, cytokine production, target cell killing)
from a dysfunctional state to antigen
stimulation.
An "agonist antibody" or "activating antibody" is one that enhances or
initiates signaling by the
antigen to which it binds. In some embodiments, agonist antibodies cause or
activate signaling without
the presence of the natural ligand. The 0X40 agonist antibodies of the
invention may increase memory T
cell proliferation, increase cytokine production by memory T cells, inhibit
Treg cell function, and/or inhibit
Treg cell suppression of effector T cell function, such as effector T cell
proliferation and/or cytokine
production.
17
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
An "epitope" is the portion of the antigen to which the antibody specifically
binds. For a
polypeptide antigen, the epitope is generally a peptide portion of about 4-15
amino acid residues, which
may be contiguous or non-contiguous.
An "antibody that binds to the same epitope" as a reference antibody refers to
an antibody that
blocks binding of the reference antibody to its antigen in a competition assay
by 50% or more, and
conversely, the reference antibody blocks binding of the antibody to its
antigen in a competition assay by
50% or more. An exemplary competition assay is provided herein.
By "paratope" is meant the part of an antibody which selectively binds the
epitope of an antigen.
The paratope typically includes amino acids from the antibody's VII and VL
chains, and, in particular,
from the antibody's HVR region(s).
The term "monoclonal antibody" as used herein refers to an antibody obtained
from a population
of substantially homogeneous antibodies, i.e., the individual antibodies
comprising the population are
identical except for possible naturally occurring mutations and/or post-
translation modifications (e.g.,
isomerizations: amidations) that may be present in minor amounts. Monoclonal
antibodies are highly
specific, being directed against a single antigenic site. In contrast to
polycional antibody preparations
which typically include different antibodies directed against different
determinants (epitopes), each
monoclonal antibody is directed against a single determinant on the antigen.
In addition to their
specificity, the monoclonal antibodies are advantageous in that they are
synthesized by the hybridoma
culture, uncontaminated by other immunoglobulins. The modifier "monoclonal"
indicates the character of
the antibody as being obtained from a substantially homogeneous population of
antibodies, and is not to
be construed as requiring production of the antibody by any particular method.
For example, the
monoclonal antibodies to be used in accordance with the present invention may
be made by a variety of
techniques, including, for example, the hybridoma method (e.g., Kohler and
Milstein., Nature, 256:495-97
(1975); Hongo at al., Hybridorna. 14 (3): 253-260 (1995), Harlow at al.,
Antibodies: A Laboratory Manual,
(Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling at al., in:
Monoclonal Antibodies and T-
Cell Hybridomas 563-681 (Elsevier, N.Y., 1981)), recombinant DNA methods (see,
e.g., U.S. Patent No.
4,816,567), phage-display technologies (see, e.g., Clackson etal., Nature,
352: 624-628 (1991); Marks et
al., J. Mot Biol. 222: 581-597 (1992); Sidhu at al., J. Mot Biol. 338(2): 299-
310 (2004); Lee at al., J. Mot
Biol. 340(5): 1073-1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34):
12467-12472 (2004); and
Lee etal., J. lmmunot Methods 284(1-2): 119-132 (2004), and technologies for
producing human or
human-like antibodies in animals that have parts or all of the human
immunoglobulin loci or genes
encoding human immunoglobulin sequences (see, e.g., WO 1998/24893; WO
1996/34096; WO
1996/33735; WO 1991/10741; Jalwbovits etal., 'oc. Natl. Acad. Sci. USA 90:
2551 (1993); Jakobovits
at al., Nature 362: 255-258 (1993); Bruggemann etal., Year in lmmunol. 7:33
(1993); U.S. Patent Nos.
5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; and 5,661,016; Marks at
al., Si/Technology 10:
779-783 (1992); Lonberg at al., Nature 368: 856-859 (1994); Morrison, Nature
368: 812-813 (1994);
Fishwild of al., Nature Biotechnot 14: 845-851 (1996); Neuberger, Nature
Biotechnot 14: 826 (1996); and
Lonberg and Huszar, intern. Rev. Immunot 13: 65-93 (1995).
The term "naked antibody' refers to an antibody that is not conjugated to a
cytotoxic moiety or
radiolabel.
18
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
The terms "full-length antibody," "intact antibody" or "whole antibody" are
used interchangeably to
refer to an antibody in its substantially intact form, as opposed to an
antibody fragment. Specifically
whole antibodies include those with heavy and light chains including an Fc
region. The constant domains
may be native sequence constant domains (e.g., human native sequence constant
domains) or amino
acid sequence variants thereof. In some eases, the intact antibody may have
one or more effector
functions.
An "antibody fragment" comprises a portion of an intact antibody, preferably
the antigen-binding
and/or the variable region of the intact antibody. Examples of antibody
fragments include Fab, Fab',
F(ab.)2 and Fv fragments; diabodies; linear antibodies (see U.S. Patent
5,641,870, Example 2; Zapata et
al., Protein Eng. 8(10): 1057-1062 [1995]); single-chain antibody molecules
and multispecific antibodies
formed from antibody fragments. Papain digestion of antibodies produced two
identical antigen-binding
fragments, called "Fab" fragments, and a residual "Fc" fragment, a designation
reflecting the ability to
crystallize readily. The Fab fragment consists of an entire L chain along with
the variable region domain
of the H chain (VH), and the first constant domain of one heavy chain (CHI).
Each Fab fragment is
monovalent with respect to antigen binding, i.e., it has a single antigen-
binding site. Pepsin treatment of
an antibody yields a single large F(ab,2 fragment which roughly corresponds to
two disulfide linked Fab
fragments having different antigen-binding activity and is still capable of
cross-linking antigen. Fab'
fragments differ from Fab fragments by having a few additional residues at the
carboxy terminus of the
CH1 domain including one or more cysteines from the antibody hinge region.
Fab`-SH is the designation
herein for Fab' in which the cysteine residue(s) of the constant domains bear
a free thiol group. F(ab)2
antibody fragments originally were produced as pairs of Fab' fragments which
have hinge cysteines
between them. Other chemical couplings of antibody fragments are also known.
The Fc fragment comprises the carboxy-terminal portions of both H chains held
together by
disulfides. The effector functions of antibodies are determined by sequences
in the Fe region, the region
which is also recognized by Fc receptors (FcR) found on certain types of
cells.
"Fv" is the minimum antibody fragment which contains a complete antigen-
recognition and -
binding site. This fragment consists of a dimer of one heavy- and one light-
chain variable region domain
in tight, non-covalent association. From the folding of these two domains
emanate six hypervariable
loops (3 loops each from the H and L chain) that contribute the amino acid
residues for antigen binding
and confer antigen binding specificity to the antibody. However, even a single
variable domain (or half of
an Fv comprising only three HVRs specific for an antigen) has the ability to
recognize and bind antigen,
although at a lower affinity than the entire binding site.
"Single-chain Fv" also abbreviated as "sFv" or "seFv" are antibody fragments
that comprise the VH
and Vi antibody domains connected into a single polypeptide chain. Preferably,
the sFy polypeptide
further comprises a polypeptide linker between the VI-c and Vi domains which
enables the sR/ to form the
desired structure for antigen binding. For a review of the sFv, see Pluckthun
in The Pharmacology of
Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag,
New York, pp. 269-315
(1994).
"Functional fragments" of the antibodies of the invention comprise a portion
of an intact antibody,
generally including the antigen binding or variable region of the intact
antibody or the Fc region of an
19
CA 02994858 2018-02-05
WO 2017/053748 PCT/U52016/053368
antibody which retains or has modified FcR binding capability. Examples of
antibody fragments include
linear antibody, single-chain antibody molecules and multispecific antibodies
formed from antibody
fragments.
The term "diabodies" refers to small antibody fragments prepared by
constructing sFy fragments
(see preceding paragraph) with short linkers (about 5-10) residues) between
the VH and VL domains such
that inter-chain but not intra-chain pairing of the V domains is achieved,
thereby resulting in a bivalent
fragment, i.e., a fragment having two antigen-binding sites. Bispecific
diabodies are heterodimers of two
"crossover" sFy fragments in which the VH and VL domains of the two antibodies
are present on different
polypeptide chains. Diabodies are described in greater detail in, for example,
EP 404,097: WO 93/11161;
Hollinger etal., Proc. Natl. Acad. Sc!. USA 90: 6444-6448 (1993).
The monoclonal antibodies herein specifically include 'chimeric" antibodies
(immunoglobulins) in
which a portion of the heavy and/or light chain is identical with or
homologous to corresponding
sequences in antibodies derived from a particular species or belonging to a
particular antibody class or
subclass, while the remainder of the chain(s) is(are) identical with or
homologous to corresponding
sequences in antibodies derived from another species or belonging to another
antibody class or subclass,
as well as fragments of such antibodies, so long as they exhibit the desired
biological activity (U.S. Patent
No. 4,816,567; Morrison etal., Proc. Natl. Acad. Sci. USA, 81:6851-6855
(1984)). Chimeric antibodies of
interest herein include PRIMATIZED0 antibodies wherein the antigen-binding
region of the antibody is
derived from an antibody produced by, e.g., immunizing macaque monkeys with an
antigen of interest.
As used herein, "humanized antibody" is used a subset of "chimeric
antibodies."
"Humanized" forms of non-human (e.g., murine) antibodies are chimeric
antibodies that contain
minimal sequence derived from non-human immunoglobulin. In one embodiment, a
humanized antibody
is a human immunoglobulin (recipient antibody) in which residues from an HVR
(hereinafter defined) of
the recipient are replaced by residues from an HVR of a non-human species
(donor antibody) such as
mouse, rat, rabbit or non-human primate having the desired specificity,
affinity, and/or capacity. In some
instances, framework ("FR") residues of the human immunoglobulin are replaced
by corresponding non-
human residues. Furthermore, humanized antibodies may comprise residues that
are not found in the
recipient antibody or in the donor antibody. These modifications may be made
to further refine antibody
performance, such as binding affinity. In general, a humanized antibody will
comprise substantially all of
at least one, and typically two, variable domains, in which all or
substantially all of the hypervariable loops
correspond to those of a non-human immunoglobulin sequence, and all or
substantially all of the FR
regions are those of a human immunoglobulin sequence, although the FR regions
may include one or
more individual FR residue substitutions that improve antibody performance,
such as binding affinity,
isomerization, immunogenicity, etc. The number of these amino acid
substitutions in the FR are typically
no more than 6 in the H chain, and in the L chain, no more than 3. The
humanized antibody optionally
will also comprise at least a portion of an immunoglobulin constant region
(Fc), typically that of a human
immunoglobulin. For further details, see, e.g., Jones etal., Nature 321:522-
525 (1986); Riechmann et al.,
Nature 332:323-329 (1988); and Presta, Cuir. Op. Struct. Biol. 2:593-
596(1992). See also, for example,
Vaswani and Hamilton, Ann. Allergy, Asthma & Immunol. 1:105-115 (1998);
Harris, Biochem. Soc.
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
Transactions 23:1035-1038 (1995); Hurle and Gross, Cuff. Op. Biotech. 5:428-
433 (1994); and U.S. Pat.
Nos. 6,982,321 and 7,087,409.
A 'human antibody" is an antibody that possesses an amino-acid sequence
corresponding to that
of an antibody produced by a human and/or has been made using any of the
techniques for making
human antibodies as disclosed herein. This definition of a human antibody
specifically excludes a
humanized antibody comprising non-human antigen-binding residues. Human
antibodies can be
produced using various techniques known in the art, including phage-display
libraries. Hoogenboom and
Winter, J. Moi. Biol., 227:381 (1991); Marks at al., J. Mot Biol., 222:581
(1991). Also available for the
preparation of human monoclonal antibodies are methods described in Cole at
al., Monoclonal Antibodies
and Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner etal., J. lminunol.,
147(1):86-95 (1991). See
also van Dijk and van de Winkel, Curr. Opin. Phannacol., 5: 368-74 (2001).
Human antibodies can be
prepared by administering the antigen to a transgenic animal that has been
modified to produce such
antibodies in response to antigenic challenge, but whose endogenous loci have
been disabled, e.g.,
immunized xenomice (see, e.g., U.S. Pat. Nos. 6,075,181 and 6,150,584
regarding XENOMOUSET"
technology). See also, for example, Li at al., Proc. Natl. Acad. Sci. USA,
103:3557-3562 (2006) regarding
human antibodies generated via a human B-cell hybridoma technology.
The term "hypervariable region," "HVR," or "HV," when used herein refers to
the regions of an
antibody variable domain which are hypervariable in sequence and/or form
structurally defined loops.
Generally, antibodies comprise six HVRs; three in the VH (HI, H2, H3), and
three in the VL (L1, L2, L3).
In native antibodies, H3 and L3 display the most diversity of the six HVRs,
and H3 in particular is believed
to play a unique role in conferring fine specificity to antibodies. See, e.g.,
Xu at al., immunity 13:37-45
(2000); Johnson and Wu, in Methods in Molecular Biology 248:1-25 (Lo, ed.,
Human Press, Totowa, NJ,
2003). Indeed, naturally occurring camelid antibodies consisting of a heavy
chain only are functional and
stable in the absence of light chain. See, e.g., Hamers-Casterman etal..
Nature 363:446-448 (1993);
Sheriff et al., Nature Struct Biol. 3:733-736 (1996).
A number of HVR delineations are in use and are encompassed herein. The Kabat
Complementarity Determining Regions (CDRs) are based on sequence variability
and are the most
commonly used (Kabat etal., Sequences of Proteins of Immunological interes(.
5th Ed. Public Health
Service, National Institutes of Health, Bethesda, MD. (1991)). Chothia refers
instead to the location of the
structural loops (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)). The AbM
HVRs represent a
compromise between the Kabat HVRs and Chothia structural loops, and are used
by Oxford Molecular's
AbM antibody modeling software. The "contact" HVRs are based on an analysis of
the available complex
crystal structures. The residues from each of these HVRs are noted below.
L000 Kabat AbM Chothia Contact
Ll L24-L34 L24-L34 L26-L32 L30-L36
L2 L50-L56 L50-L56 L50-L52 L46-L55
L3 L89-L97 L89-L97 L91-L96 L89-L96
H1 H31-H358 H26-H35B H26-H32 H30-H35B (Kabat numbering)
21
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
H1 H31-H35 H26-H35 H26-H32 H30-H35 (Chothia numbering)
H2 H50-H65 H50-H58 H53-H55 H47-H58
H3 H95-H102 H95-H102 H96-H101 H93-H101
HVRs may comprise 'extended HVRs" as follows: 24-36 or 24-34 (L1), 46-56 or 50-
56 (L2) and
89-97 or 89-96 (L3) in the VL and 26-35 (H1), 50-65 or 49-65 (112) and 93-102,
94-102, or 95-102 (H3) in
the VH. The variable domain residues are numbered according to Kabat at al.,
supra, for each of these
definitions.
The expression "variable-domain residue-numbering as in Kabat" or "amino-acid-
position
numbering as in Kabat," and variations thereof, refers to the numbering system
used for heavy-chain
variable domains or light-chain variable domains of the compilation of
antibodies in Kabat etal., supra.
Using this numbering system, the actual linear amino acid sequence may contain
fewer or additional
amino acids corresponding to a shortening of. or insertion into, a FR or HVR
of the variable domain. For
example, a heavy-chain variable domain may include a single amino acid insert
(residue 52a according to
Kabat) after residue 52 of H2 and inserted residues (e.g. residues 82a, 82b,
and 82c, etc. according to
Kabat) after heavy-chain FR residue 82. The Kabat numbering of residues may be
determined for a
given antibody by alignment at regions of homology of the sequence of the
antibody with a "standard"
Kabat numbered sequence.
"Framework" or "FR" residues are those variable-domain residues other than the
HVR residues
as herein defined.
A "human consensus framework" or 'acceptor human framework" is a framework
that represents
the most commonly occurring amino acid residues in a selection of human
immunoglobulin VL or VH
framework sequences. Generally, the selection of human immunoglobulin VL or VH
sequences is from a
subgroup of variable domain sequences. Generally, the subgroup of sequences is
a subgroup as in
Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public
Health Service, National
Institutes of Health, Bethesda, MD (1991). Examples include for the VL, the
subgroup may be subgroup
kappa I, kappa II, kappa III or kappa IV as in Kabat etal., supra.
Additionally, for the VH, the subgroup
may be subgroup I, subgroup II, or subgroup III as in Kabat etal.. supra.
Alternatively, a human
consensus framework can be derived from the above in which particular
residues, such as when a human
framework residue is selected based on its homology to the donor framework by
aligning the donor
framework sequence with a collection of various human framework sequences. An
acceptor human
framework "derived from" a human immunoglobulin framework or a human consensus
framework may
comprise the same amino acid sequence thereof, or it may contain pre-existing
amino acid sequence
changes. In some embodiments, the number of pre-existing amino acid changes
are 10 or less, 9 or less,
8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or
less.
A "VH subgroup III consensus framework" comprises the consensus sequence
obtained from the
amino acid sequences in variable heavy subgroup III of Kabat et al., supra. In
one embodiment, the VH
subgroup III consensus framework amino acid sequence comprises at least a
portion or all of each of the
following sequences: EVQLVESGGGLVQPGGSLRLSCAAS (HC-FR1) (SEQ ID NO: 229);
22
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
VVVRQAPGKGLEVVV (HC-FR2) (SEQ ID NO: 230); RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR
(HC-
FR3) (SEQ ID NO: 232); and WGQGTLVTVSA (HC-FR4) (SEQ ID NO: 232).
A uVL kappa I consensus framework" comprises the consensus sequence obtained
from the
amino acid sequences in variable light kappa subgroup I of Kabat etal., supra.
In one embodiment, the
VH subgroup I consensus framework amino acid sequence comprises at least a
portion or all of each of
the following sequences: DIQMTOSPSSLSASVGDRVTITC (LC-FR1) (SEQ ID NO: 233);
VVYQQKPGKAPKWY (LC-FR2) (SEQ ID NO: 234); GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (LC-
FR3) (SEQ ID NO: 235); and FGQGTKVEIKR (LC-FR4) (SEQ ID NO: 236).
An "amino-acid modification" at a specified position, for example, of the Fe
region, refers to the
substitution or deletion of the specified residue, or the insertion of at
least one amino acid residue
adjacent the specified residue. Insertion "adjacent" to a specified residue
means insertion within one to
two residues thereof. The insertion may be N-terminal or C-terminal to the
specified residue. The
preferred amino acid modification herein is a substitution.
"Affinity" refers to the strength of the sum total of non-covalent
interactions between a single
binding site of a molecule (e.g., an antibody) and its binding partner (e.g.,
an antigen, e.g., TIGIT).
Unless indicated otherwise, as used herein, "binding affinity" refers to
intrinsic binding affinity which
reflects a 1:1 interaction between members of a binding pair (e.g., antibody
and antigen). The affinity of a
molecule X for its partner Y can generally be represented by the dissociation
constant (Kd). Affinity can
be measured by common methods known in the art, including those described
herein. Specific illustrative
and exemplary embodiments for measuring binding affinity are described in the
following.
An "affinity-matured" antibody is one with one or more alterations in one or
more IIVRs thereof
that result in an improvement in the affinity of the antibody for antigen,
compared to a parent antibody that
does not possess those alteration(s). In one embodiment, an affinity-matured
antibody has nanomolar or
even picomolar affinities for the target antigen. Affinity-matured antibodies
are produced by procedures
.. known in the art. For example, Marks etal., Bioirechnology 10:779-783
(1992) describes affinity
maturation by VII- and VL-domain shuffling. Random mutagenesis of HVR and/or
framework residues is
described by, for example: Barbas etal. Proc Nat. Acad. Sci. USA 91:3809-3813
(1994): Sehier et al.
Gene 169:147-155 (1995); Yelton etal. J. ltnmunol. 155:1994-2004 (1995);
Jackson etal., J. Immunot
154(7):3310-9 (1995); and Hawkins et at J. Mot Biol. 226:889-896 (1992).
As used herein, the term "binds," "specifically binds to,' or is "specific
for' refers to measurable
and reproducible interactions such as binding between a target and an
antibody, which is determinative of
the presence of the target in the presence of a heterogeneous population of
molecules including
biological molecules. For example, an antibody that specifically binds to a
target (which can be an
epitope) is an antibody that binds this target with greater affinity, avidity,
more readily, and/or with greater
duration than it binds to other targets. In one embodiment, the extent of
binding of an antibody to an
unrelated target is less than about 10% of the binding of the antibody to the
target as measured, for
example, by a radioimmunoassay (RIA). In certain embodiments, an antibody that
specifically binds to a
target has a dissociation constant (Kd) of 5. 1pM, 5 100 nM, .5 10 nM, 5 1 nM,
or 5. 0.1 nM. In certain
embodiments, an antibody specifically binds to an epitope on a protein that is
conserved among the
protein from different species. In another embodiment, specific binding can
include, but does not require
23
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
exclusive binding. The term as used herein can be exhibited, for example, by a
molecule having a Kd for
the target of 104M or lower, alternatively 10.6M or lower, alternatively 10-6
M or lower, alternatively 10.7 to
or lower, alternatively 10-6 M or lower, alternatively 10-9 M or lower,
alternatively 10.10 M or lower,
alternatively 10-" M or lower, alternatively 10-12 M or lower or a Kd in the
range of10-4 M to 10-6 M or
10-6 M to 10-10 M or 10-7 M to 10-9 M. As will be appreciated by the skilled
artisan, affinity and Kd values
are inversely related. A high affinity for an antigen is measured by a low Kd
value. In one embodiment,
the term 'specific binding" refers to binding where a molecule binds to a
particular polypeptide or epitope
on a particular polypeptide without substantially binding to any other
polypeptide or polypeptide epitope.
As used herein, the term "immunoadhesin" designates antibody-like molecules
which combine
the binding specificity of a heterologous protein (an "adhesin") with the
effector functions of
immunoglobulin constant domains. Structurally, the immunoadhesins comprise a
fusion of an amino acid
sequence with the desired binding specificity which is other than the antigen
recognition and binding site
of an antibody (i.e., is "heterologous"), and an immunoglobulin constant
domain sequence. The adhesin
part of an immunoadhesin molecule typically is a contiguous amino acid
sequence comprising at least the
binding site of a receptor or a ligand. The immunoglobulin constant domain
sequence in the
immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2
(including IgG2A and
IgG2B), IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or
IgM. Thelg fusions
preferably include the substitution of a domain of a polypeptide or antibody
described herein in the place
of at least one variable region within an Ig molecule. In a particularly
preferred embodiment. the
immunoglobulin fusion includes the hinge, Cl-12 and C1-13, or the hinge, CH1,
CH2 and CH3 regions of an
IgG1 molecule. For the production of immunoglobulin fusions see also US Patent
No. 5,428,130 issued
June 27, 1995. For example, useful immunoadhesins for combination therapy
herein include
polypeptides that comprise the extracellular or 0X40 binding portions of
OX401. or the extracellular or
OX4OL binding portions of 0X40, fused to a constant domain of an
immunoglobulin sequence, such as a
0X40 ECD Fe or a OX4OL. ECD Fe. lmmunoadhesin combinations of 1g Fc and ECD of
cell surface
receptors are sometimes termed soluble receptors.
A "fusion protein' and a "fusion polypeptide" refer to a polypeptide having
two portions covalently
linked together, where each of the portions is a polypeptide having a
different property. The property may
be a biological property, such as activity in vitro or in vivo. The property
may also be simple chemical or
physical property, such as binding to a target molecule, catalysis of a
reaction, etc. The two portions may
be linked directly by a single peptide bond or through a peptide linker but
are in reading frame with each
other.
The term "Fe region" herein is used to define a C-terminal region of an
immunoglobulin heavy
chain, including native-sequence Fc regions and variant Fc regions. Although
the boundaries of the Fc
region of an immunoglobulin heavy chain might vary, the human IgG heavy-chain
Fc region is usually
defined to stretch from an amino acid residue at position Cys226, or from
Pro230, to the carboxyl-
terminus thereof. The C-terminal lysine (residue 447 according to the EU
numbering system) of the Fe
region may be removed, for example, during production or purification of the
antibody, or by
recombinantly engineering the nucleic acid encoding a heavy chain of the
antibody. Accordingly, a
composition of intact antibodies may comprise antibody populations with all
K447 residues removed,
24
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
antibody populations with no K447 residues removed, and antibody populations
having a mixture of
antibodies with and without the K447 residue. Suitable native-sequence Fc
regions for use in the
antibodies of the invention include human IgG1 , IgG2 (19G2A, IgG2B), IgG3 and
IgG4.
"Fe receptor" or "FcR" describes a receptor that binds to the Fe region of an
antibody. The
preferred FcR is a native sequence human FcR. Moreover, a preferred FcR is one
which binds an IgG
antibody (a gamma receptor) and includes receptors of the FcyRI, FcyRII, and
FcyRIII subclasses,
including allelic variants and alternatively spliced forms of these receptors,
FcyRII receptors include
FcyRIIA (an "activating receptor) and FcyRIIB (an "inhibiting receptor"),
which have similar amino acid
sequences that differ primarily in the cytoplasmic domains thereof. Activating
receptor FcyRIIA contains
an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic
domain. Inhibiting receptor
FcyRI113 contains an immunoreceptor tyrosine-based inhibition motif (MM) in
its cytoplasmic domain.
(see M. Daeron, Anna. Rev. Immunol. 15:203-234 (1997). FcRs are reviewed in
Ravetch and Kinet,
Annu. Rev. lmmunol. 9: 457-92 (1991); Capel et al., lmmunomethods 4: 25-34
(1994); and de Haas etal.,
J. Lab. Clin. Med. 126: 330-41 (1995). Other FcRs, including those to be
identified in the future, are
encompassed by the term "FcR" herein.
"Human effector cells" refer to leukocytes that express one or more FcRs and
perform effector
functions. In certain embodiments, the cells express at least FORM and perform
ADCC effector
function(s). Examples of human leukocytes which mediate ADCC include
peripheral blood mononuclear
cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells, and
neutrophils. The effector cells
may be isolated from a native source, e.g., from blood.
"Effector functions' refer to those biological activities attributable to the
Fe region of an antibody,
which vary with the antibody isotype. Examples of antibody effector functions
include: Clq binding and
complement dependent cytotoxicity (CDC); Fe receptor binding; antibody-
dependent cell-mediated
cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors
(e.g. B cell receptor); and B
cell activation.
The phrase "substantially reduced," or "substantially different," as used
herein, denotes a
sufficiently high degree of difference between two numeric values (generally
one associated with a
molecule and the other associated with a reference/comparator molecule) such
that one of skill in the art
would consider the difference between the two values to be of statistical
significance within the context of
the biological characteristic measured by said values (e.g., Kd values). The
difference between said two
values is, for example, greater than about 10%, greater than about 20%,
greater than about 30%, greater
than about 40%, and/or greater than about 50% as a function of the value for
the reference/comparator
molecule.
The term "substantially similar" or "substantially the same," as used herein,
denotes a sufficiently
high degree of similarity between two numeric values (for example, one
associated with an antibody of
the invention and the other associated with a reference/comparator antibody),
such that one of skill in the
art would consider the difference between the two values to be of little or no
biological and/or statistical
significance within the context of the biological characteristic measured by
said values (e.g., Kd values).
The difference between said two values is, for example, less than about 50%,
less than about 40%, less
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
than about 30%, less than about 20%, and/or less than about 10% as a function
of the
reference/comparator value.
The term "antagonist is used in the broadest sense, and includes any molecule
that partially or
fully blocks, inhibits, or neutralizes a biological activity of a native
polypeptide disclosed herein. In a
similar manner, the term "agonist" is used in the broadest sense and includes
any molecule that mimics a
biological activity of a native polypeptide disclosed herein. Suitable agonist
or antagonist molecules
specifically include agonist or antagonist antibodies or antibody fragments,
fragments or amino acid
sequence variants of native polypeptides, peptides, antisense
oligonucleotides, small organic molecules,
etc. Methods for identifying agonists or antagonists of a polypeptide may
comprise contacting a
polypeptide with a candidate agonist or antagonist molecule and measuring a
detectable change in one
or more biological activities normally associated with the polypeptide.
As used herein, an "antagonist antibody" of a target molecule refers to an
antibody that interferes
with the normal functioning of the target molecule, either by decreasing
transcription or translation of the
target molecule-encoding nucleic acid, or by inhibiting or blocking the target
molecule activity, or both.
For example, an antagonist antibody of TIGIT may be considered an antibody, or
anti-TIGIT binding
fragment thereof, that interferes with the normal functioning of TIGIT, either
by decreasing transcription or
translation of TIGIT-encoding nucleic acid, or by inhibiting or blocking TIGIT
polypeptide activity, or both.
It will be understood by one of ordinary skill in the art that in some
instances, an antagonist antibody of
TIGIT may antagonize one TIGIT activity without affecting another TIGIT
activity. For example, a
desirable antagonist antibody of TIGIT for use in certain methods herein is an
antagonist antibody of
TIGIT that antagonizes TIGIT activity in response to one of PVR interaction,
PVR1.3 interaction, or PVRL2
interaction, e.g., without affecting or minimally affecting any of the other
TIGIT interactions.
The terms "TIGIT antagonist' and "antagonist of TIGIT activity or TIGIT
expression" are used
interchangeably and refer to a compound that interferes with the normal
functioning of TIGIT, either by
decreasing transcription or translation of TIGIT-encoding nucleic acid, or by
inhibiting or blocking TIGIT
polypeptide activity, or both. Examples of TIGIT antagonists include, but are
not limited to, antisense
polynucleotides, interfering RNAs, catalytic RNAs, RNA-DNA chimeras, TIGIT-
specific aptamers, anti-
TIGIT antibodies, TIGIT-binding fragments of anti-TIGIT antibodies, TIGIT-
binding small molecules,
TIGIT-binding peptides, and other polypeptides that specifically bind TIGIT
(including, but not limited to,
TIGIT-binding fragments of one or more TIGIT ligands, optionally fused to one
or more additional
domains), such that the interaction between the TIGIT antagonist and TIGIT
results in a reduction or
cessation of TIGIT activity or expression. It will be understood by one of
ordinary skill in the art that in
some instances, a TIGIT antagonist may antagonize one TIGIT activity without
affecting another TIGIT
activity. For example, a desirable TIGIT antagonist for use in certain of the
methods herein is a TIGIT
antagonist that antagonizes TIGIT activity in response to one of PVR
interaction, PVRL3 interaction, or
PVRI.2 interaction, e.g., without affecting or minimally affecting any of the
other TIGIT interactions.
The terms "PVR antagonist" and "antagonist of PVR activity or PVR expression"
are used
interchangeably and refer to a compound that interferes with the normal
functioning of PVR, either by
decreasing transcription or translation of PVR-encoding nucleic acid, or by
inhibiting or blocking PVR
polypeptide activity, or both. Examples of PVR antagonists include, but are
not limited to, antisense
26
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
polynucleotides, interfering RNAs, catalytic RNAs, RNA-DNA chimeras, PVR-
specific aptamers, anti-PVR
antibodies, PVR-binding fragments of anti-PVR antibodies, PVR-binding small
molecules. PVR-binding
peptides, and other polypeptides that specifically bind PVR (including, but
not limited to, PVR-binding
fragments of one or more PVR ligands, optionally fused to one or more
additional domains), such that the
interaction between the PVR antagonist and PVR results in a reduction or
cessation of PVR activity or
expression. It will be understood by one of ordinary skill in the art that in
some instances, a PVR
antagonist may antagonize one PVR activity without affecting another PVR
activity. For example, a
desirable PVR antagonist for use in certain of the methods herein is a PVR
antagonist that antagonizes
PVR activity in response to TIGIT interaction without impacting the PVR-CD96
and/or PVR-CD226
interactions.
The term "PD-1 axis binding antagonist" refers to a molecule that inhibits the
interaction of a PD-1
axis binding partner with either one or more of its binding partner, so as to
remove T-cell dysfunction
resulting from signaling on the PD-1 signaling axis ¨ with a result being to
restore or enhance T-cell
function (e.g., proliferation, cytokine production, target cell killing). As
used herein, a PD-1 axis binding
antagonist includes a PD-1 binding antagonist, a PD-L1 binding antagonist and
a PD-L2 binding
antagonist.
The term "PD-1 binding antagonist" refers to a molecule that decreases,
blocks, inhibits,
abrogates or interferes with signal transduction resulting from the
interaction of PD-1 with one or more of
its binding partners, such as PD-L1, PD-L2. In some embodiments, the PD-1
binding antagonist is a
molecule that inhibits the binding of PD-1 to one or more of its binding
partners. In a specific aspect, the
PD-1 binding antagonist inhibits the binding of PD-1 to PD-L1 and/or PD-L2.
For example, PD-1 binding
antagonists include anti-PD-1 antibodies, antigen binding fragments thereof,
immunoadhesins, fusion
proteins, oligopeptides and other molecules that decrease, block, inhibit,
abrogate or interfere with signal
transduction resulting from the interaction of PD-1 with PD-L1 and/or PD-L2.
In one embodiment, a PD-1
binding antagonist reduces the negative co-stimulatory signal mediated by or
through cell surface
proteins expressed on T lymphocytes mediated signaling through PD-1 so as
render a dysfunctional T-
cell less dysfunctional (e.g., enhancing effector responses to antigen
recognition). In some embodiments,
the PD-1 binding antagonist is an anti-PD-1 antibody. In a specific aspect, a
PD-1 binding antagonist is
fv1DX-1106 (nivolumab) described herein. In another specific aspect, a PD-1
binding antagonist is MK-
3475 (lambrolizumab) described herein. In another specific aspect, a PD-1
binding antagonist is CT-011
(pidilizumab) described herein. In another specific aspect, a PD-1 binding
antagonist is MEDI-0680
(AMP-514) described herein. In another specific aspect, a PD-1 binding
antagonist is PDR001 described
herein. In another specific aspect, a PD-1 binding antagonist is REGN2810
described herein. In another
specific aspect, a PD-1 binding antagonist is 8GB-108 described herein.
The term "PD-L1 binding antagonist" refers to a molecule that decreases,
blocks, inhibits,
abrogates or interferes with signal transduction resulting from the
interaction of PD-L1 with either one or
more of its binding partners, such as PD-1, 87-1. In some embodiments, a PD-L1
binding antagonist is a
molecule that inhibits the binding of PD-L1 to its binding partners. In a
specific aspect, the PD-L1 binding
antagonist inhibits binding of PD-L1 to PD-1 and/or 137-1. In some
embodiments, the PD-L1 binding
antagonists include anti-PD-L1 antibodies, antigen binding fragments thereof,
immunoadhesins, fusion
27
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
proteins, oligopeptides and other molecules that decrease, block, inhibit,
abrogate or interfere with signal
transduction resulting from the interaction of PD-Ll with one or more of its
binding partners, such as PD-
1, B7-1. In one embodiment, a PD-L1 binding antagonist reduces the negative co-
stimulatory signal
mediated by or through cell surface proteins expressed on T lymphocytes
mediated signaling through PD-
Ll so as to render a dysfunctional 1-cell less dysfunctional (e.g., enhancing
effector responses to antigen
recognition). In some embodiments, a PD-L1 binding antagonist is an anti-PD-L1
antibody. In a specific
aspect, an anti-PD-L1 antibody is YVV243.55.S70 described herein. In another
specific aspect, an anti-
PD-L1 antibody is MDX-1105 described herein. In still another specific aspect,
an anti-PD-L1 antibody is
MPDL3280A (atezolizumab) described herein. In still another specific aspect,
an anti-PD-Ll antibody is
MEDI4736 (durvalumab) described herein. In still another specific aspect, an
anti-PD-L1 antibody is
YW243.55.570 described herein. In still another specific aspect, an anti-PD-L1
antibody is
MSB0010718C (avelumab) described herein.
The term "PD-L2 binding antagonist' refers to a molecule that decreases,
blocks, inhibits,
abrogates or interferes with signal transduction resulting from the
interaction of PD-L2 with either one or
more of its binding partners, such as PD-1. In some embodiments, a PD-L2
binding antagonist is a
molecule that inhibits the binding of PD-L2 to one or more of its binding
partners. In a specific aspect, the
PD-L2 binding antagonist inhibits binding of PD-L2 to PD-1. In some
embodiments, the PD-L2
antagonists include anti-PD-1.2 antibodies, antigen binding fragments thereof.
immunoadhesins, fusion
proteins, oligopeptides and other molecules that decrease, block, inhibit,
abrogate or interfere with signal
transduction resulting from the interaction of PD-L2 with either one or more
of its binding partners, such
as PD-1. In one embodiment, a PD-L2 binding antagonist reduces the negative co-
stimulatory signal
mediated by or through cell surface proteins expressed on T lymphocytes
mediated signaling through PD-
L2 so as render a dysfunctional 1-cell less dysfunctional (e.g., enhancing
effector responses to antigen
recognition). In some embodiments, a PD-L2 binding antagonist is an
immunoadhesin.
The term '0X40," as used herein, refers to any native 0X40 from any vertebrate
source,
including mammals such as primates (e.g., humans) and rodents (e.g., mice and
rats), unless otherwise
indicated. The term encompasses "full-length," unprocessed 0X40 as well as any
form of 0X40 that
results from processing in the cell. The term also encompasses naturally
occurring variants of 0X40, for
example, splice variants or allelic variants. The amino acid sequence of an
exemplary human 0X40 is
set forth in SEQ ID NO: 354.
"0X40 activation" refers to activation of the 0X40 receptor. Generally, 0X40
activation results in
signal transduction.
The term "aptamer' refers to a nucleic acid molecule that is capable of
binding to a target
molecule, such as a polypeptide. For example, an aptamer of the invention can
specifically bind to a
TIGIT polypeplide, or to a molecule in a signaling pathway that modulates the
expression of TIGIT. The
generation and therapeutic use of aptamers are well established in the art.
See, for example, U.S. Pat.
No. 5,475,096, and the therapeutic efficacy of MACUGENO (Eyetech, New York)
for treating age-related
macular degeneration.
The term "dysfunction," in the context of immune dysfunction, refers to a
state of reduced immune
responsiveness to antigenic stimulation.
28
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
The term "dysfunctional," as used herein, also includes refractory or
unresponsive to antigen
recognition, specifically, impaired capacity to translate antigen recognition
into downstream 1-cell effector
functions, such as proliferation, cytokine production (e.g., gamma interferon)
and/or target cell killing.
"Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of
cytotoxicity in which
secreted immunoglobulin bound onto Fc receptors (FoRs) present on certain
cytotoxic cells (e.g., NK
cells, neutrophils, and macrophages) enable these cytotoxic effector cells to
bind specifically to an
antigen-bearing target cell and subsequently kill the target cell with
cytotoxins. The primary cells for
mediating ADCC, NK cells, express FcyRIII only, whereas monocytes express
FcyRI, FcyRII, and FcyRIII.
FoR expression on hematopoietic cells is summarized in Table 3 on page 464 of
Ravetch and Kinet,
Anna. Rev. immunol 9:457-92 (1991). To assess ADCC activity of a molecule of
interest, an in vitro
ADCC assay, such as that described in US Patent No. 5,500,362 or 5,821,337 or
U.S. Patent No.
6,737,056 (Presta), may be performed. Useful effector cells for such assays
include PBMC and NK cells.
Alternatively, or additionally, ADCC activity of the molecule of interest may
be assessed in vivo, e.g., in an
animal model such as that disclosed in Clynes et al. PNAS (USA) 95:652-856
(1998). An exemplary
assay for assessing ADCC activity is provided in the examples herein.
The term "anergy" refers to the state of unresponsiveness to antigen
stimulation resulting from
incomplete or insufficient signals delivered through the T-cell receptor
(e.g., increase in intracellular Ca2+
in the absence of ras-activation). T cell anergy can also result upon
stimulation with antigen in the
absence of co-stimulation, resulting in the cell becoming refractory to
subsequent activation by the
antigen even in the context of costimulation. The unresponsive state can often
be overridden by the
presence of interleukin-2 (11.-2). Anergic 1-cells do not undergo clonal
expansion and/or acquire effector
functions.
"Enhancing T cell function" means to induce, cause or stimulate an effector or
memory T cell to
have a renewed, sustained or amplified biological function. Examples of
enhancing 1-cell function
include: increased secretion of y-interferon from CD8+ effector T cells,
increased secretion of y-interferon
from CD4+ memory and/or effector 1-cells, increased proliferation of CD4+
effector and/or memory T
cells, increased proliferation of CD8+ effector 1-cells, increased antigen
responsiveness (e.g., clearance),
relative to such levels before the intervention. In one embodiment, the level
of enhancement is at least
50%, alternatively 60%, 70%, 80%, 90%, 100%, 120%. 150%, 200%. The manner of
measuring this
enhancement is known to one of ordinary skill in the art.
The term "exhaustion" refers to T cell exhaustion as a state of T cell
dysfunction that arises from
sustained TCR signaling that occurs during many chronic infections and cancer.
It is distinguished from
anergy in that it arises not through incomplete or deficient signaling, but
from sustained signaling. It is
defined by poor effector function, sustained expression of inhibitory
receptors and a transcriptional state
distinct from that of functional effector or memory T cells. Exhaustion
prevents optimal control of infection
and tumors. Exhaustion can result from both extrinsic negative regulatory
pathways (e.g.,
immunoregulatory cytokines) as well as cell intrinsic negative regulatory
(costimulatory) pathways (PD-1,
87-113, 87-114, etc.).
"Enhancing 1-cell function" means to induce, cause or stimulate a 1-cell to
have a sustained or
amplified biological function, or renew or reactivate exhausted or inactive 1-
cells. Examples of enhancing
29
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
T-cell function include: increased secretion of y-interferon from CDS+ T-
cells, increased proliferation,
increased antigen responsiveness (e.g., viral, pathogen, or tumor clearance)
relative to such levels before
the intervention. In one embodiment, the level of enhancement is as least 50%,
alternatively 60%, 70%,
80%, 90%, 100%, 120%, 150%, 200%. The manner of measuring this enhancement is
known to one of
ordinary skill in the art.
A "T cell dysfunctional disorder" is a disorder or condition of T-cells
characterized by decreased
responsiveness to antigenic stimulation. In a particular embodiment, a T-cell
dysfunctional disorder is a
disorder that is specifically associated with inappropriate decreased
signaling through 0X40 and/or
OX401.. In another embodiment, a 1-cell dysfunctional disorder is one in which
T-cells are anergic or
have decreased ability to secrete cytokines, proliferate, or execute cytolytic
activity. In a specific aspect,
the decreased responsiveness results in ineffective control of a pathogen or
tumor expressing an
immunogen. Examples of T cell dysfunctional disorders characterized by 1-cell
dysfunction include
unresolved acute infection, chronic infection, and tumor immunity.
"Tumor immunity" refers to the process in which tumors evade immune
recognition and
clearance. Thus, as a therapeutic concept, tumor immunity is "treated" when
such evasion is attenuated,
and the tumors are recognized and attacked by the immune system. Examples of
tumor recognition
include tumor binding, tumor shrinkage, and tumor clearance.
"Immunogenicity" refers to the ability of a particular substance to provoke an
immune response.
Tumors are immunogenic and enhancing tumor immunogenicity aids in the
clearance of the tumor cells
by the immune response. Examples of enhancing tumor immunogenicity include but
are not limited to
treatment with an 0X40 binding agonist (e.g., anti-0X40 agonist antibodies)
and a TIGIT inhibitor (e.g.,
anti-TIGIT blocking antibodies).
"Sustained response" refers to the sustained effect on reducing tumor growth
after cessation of a
treatment. For example, the tumor size may remain to be the same or smaller as
compared to the size at
the beginning of the administration phase. In some embodiments, the sustained
response has a duration
at least the same as the treatment duration, at least 1.5X, 2.0X, 2.5X, or
3.0X length of the treatment
duration.
"Carriers" as used herein include pharmaceutically acceptable carriers,
excipients, or stabilizers
that are nontoxic to the cell or mammal being exposed thereto at the dosages
and concentrations
employed. Often the physiologically acceptable carrier is an aqueous pH
buffered solution. Examples of
physiologically acceptable carriers include buffers such as phosphate,
citrate, and other organic acids;
antioxidants including ascorbic acid; low molecular weight (less than about 10
residues) polypeptide;
proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic
polymers such as
polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine,
arginine or lysine;
monosaccharides, disacchandes, and other carbohydrates including glucose,
mannose, or dextrins;
chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol;
salt-forming counterions
such as sodium; and/or nonionic surfactants such as TVVEEN-rm, polyethylene
glycol (PEG), and
PLURONICSIm.
A "package insert' refers to instructions customarily included in commercial
packages of
medicaments that contain information about the indications customarily
included in commercial packages
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
of medicaments that contain information about the indications, usage, dosage,
administration,
contraindications, other medicaments to be combined with the packaged product,
and/or warnings
concerning the use of such medicaments.
As used herein, the term "treatment' refers to clinical intervention designed
to alter the natural
course of the individual or cell being treated during the course of clinical
pathology. Desirable effects of
treatment include decreasing the rate of disease progression, ameliorating or
palliating the disease state,
and remission or improved prognosis. For example, an individual is
successfully "treated" if one or more
symptoms associated with cancer are mitigated or eliminated, including, but
are not limited to, reducing
the proliferation of (or destroying) cancerous cells, decreasing symptoms
resulting from the disease,
increasing the quality of life of those suffering from the disease, decreasing
the dose of other medications
required to treat the disease, delaying the progression of the disease, and/or
prolonging survival of
individuals.
As used herein, 'delaying progression of a disease* means to defer, hinder,
slow, retard,
stabilize, and/or postpone development of the disease (such as cancer). This
delay can be of varying
lengths of time, depending on the history of the disease and/or individual
being treated. As is evident to
one skilled in the art, a sufficient or significant delay can, in effect,
encompass prevention, in that the
individual does not develop the disease. For example, a late stage cancer,
such as development of
metastasis, may be delayed.
As used herein, the term "reducing or inhibiting cancer relapse" means to
reduce or inhibit tumor
or cancer relapse or tumor or cancer progression.
As used herein, "cancer* and "cancerous" refer to or describe the
physiological condition in
mammals that is typically characterized by unregulated cell growth. Included
in this definition are benign
and malignant cancers as well as dormant tumors or micrometastatses. Examples
of cancer include but
are not limited to, carcinoma, myeloma, lymphoma, blastoma, sarcoma, and
leukemia. More particular
examples of such cancers include multiple myeloma (MM), squamous cell cancer,
lung cancer (including
small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the
lung, and squamous carcinoma
of the lung), cancer of the peritoneum, hepatocellular cancer, gastric or
stomach cancer (including
gastrointestinal cancer), pancreatic cancer, glioblastoma, cervical cancer,
ovarian cancer, liver cancer,
bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer,
endometrial or uterine
carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer,
prostate cancer, vulval cancer,
thyroid cancer, hepatic carcinoma, various types of head and neck cancer, as
well as B-cell lymphoma
(including low grade/follicular non-Hodgkin's lymphoma (NHL); small
lymphocytic (SL) NHL; intermediate
grade/follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic
NHL; high grade
lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL;
mantle cell lymphoma;
AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia), chronic
lymphocytic leukemia (CLL),
acute lymphoblastic leukemia (ALL), Hairy cell leukemia, chronic myeloblastic
leukemia, and post-
transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular
proliferation associated with
phakomatoses, edema (such as that associated with brain tumors), and Meigs'
syndrome.
31
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
The term "tumor" refers to all neoplastic cell growth and proliferation,
whether malignant or
benign, and all pre-cancerous and cancerous cells and tissues. The terms
"cancer," "cancerous," "cell
proliferative disorder," "proliferative disorder" and "tumor" are not mutually
exclusive as referred to herein.
As used herein, 'metastasis" is meant the spread of cancer from its primary
site to other places in
the body. Cancer cells can break away from a primary tumor, penetrate into
lymphatic and blood vessels,
circulate through the bloodstream, and grow in a distant focus (metastasize)
in normal tissues elsewhere
in the body. Metastasis can be local or distant. Metastasis is a sequential
process, contingent on tumor
cells breaking off from the primary tumor, traveling through the bloodstream,
and stopping at a distant
site. At the new site, the cells establish a blood supply and can grow to form
a life-threatening mass.
Both stimulatory and inhibitory molecular pathways within the tumor cell
regulate this behavior, and
interactions between the tumor cell and host cells in the distant site are
also significant.
An "effective amount" is at least the minimum concentration required to effect
a measurable
improvement or prevention of a particular disorder. An effective amount herein
may vary according to
factors such as the disease state, age, sex, and weight of the patient, and
the ability of the antibody to
elicit a desired response in the individual. An effective amount is also one
in which any toxic or
detrimental effects of the treatment are outweighed by the therapeutically
beneficial effects. For
prophylactic use, beneficial or desired results include results such as
eliminating or reducing the risk,
lessening the severity, or delaying the onset of the disease, including
biochemical, histological and/or
behavioral symptoms of the disease, its complications and intermediate
pathological phenotypes
presenting during development of the disease. For therapeutic use, beneficial
or desired results include
clinical results such as decreasing one or more symptoms resulting from the
disease, increasing the
quality of life of those suffering from the disease, decreasing the dose of
other medications required to
treat the disease, enhancing effect of another medication such as via
targeting, delaying the progression
of the disease, and/or prolonging survival. In the case of cancer or tumor, an
effective amount of the drug
may have the effect in reducing the number of cancer cells; reducing the tumor
size; inhibiting (i.e., slow
to some extent or desirably stop) cancer cell infiltration into peripheral
organs; inhibit (i.e., slow to some
extent and desirably stop) tumor metastasis; inhibiting to some extent tumor
growth; and/or relieving to
some extent one or more of the symptoms associated with the disorder. An
effective amount can be
administered in one or more administrations. For purposes of this invention,
an effective amount of drug,
compound, or pharmaceutical composition is an amount sufficient to accomplish
prophylactic or
therapeutic treatment either directly or indirectly. As is understood in the
clinical context, an effective
amount of a drug, compound, or pharmaceutical composition may or may not be
achieved in conjunction
with another drug, compound, or pharmaceutical composition. Thus, an
"effective amount" may be
considered in the context of administering one or more therapeutic agents, and
a single agent may be
considered to be given in an effective amount if, in conjunction with one or
more other agents, a desirable
result may be or is achieved.
As used herein, "in conjunction with" refers to administration of one
treatment modality in addition
to another treatment modality. As such, "in conjunction with" refers to
administration of one treatment
modality before, during, or after administration of the other treatment
modality to the individual.
32
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
As used herein, "subject" or Individual" is meant a mammal, including, but not
limited to, a human
or non-human mammal, such as a bovine, equine, canine, ovine, or feline.
Preferably, the subject is a
human. Patients are also subjects herein.
"Chemotherapeutic agent" includes chemical compounds useful in the treatment
of cancer.
Examples of chemotherapeutic agents include erlotinib (TARCEVAO, Genentech/OSI
Pharm.),
bortezomib (VELCADEOD, Millennium Pharm.), disulfiram, epigallocatechin
gallate salinosporamide A,
carfilzomib, 17-AAG (geldanamycin), radicicol, lactate dehydrogenase A (LDH-
A), fuivestrant
(FASLODEM AstraZeneca). sunitib (SUTENT , Pfizer/Sugen), letrozole (FEMARA ,
Novartis), imatinib
mesylate (GLEEVECO. Novartis), finasunate (VATALANIB , Novartis), oxaliplatin
(ELOXATINC, Sanofi).
5-FU (5-fiuorouracil), leucovorin, Raparnycin (Sirolirnus, RAPAMUNEO, Wyeth),
Lapatinib (TYKERBS,
GSK572016, Glaxo Smith Kline), Lonafamib (SCH 66336), sorafenib (NEXAVARO,
Bayer Labs), gefitinib
(IRESSAQD, AstraZeneca), AG1478, alkylating agents such as thiotepa and
CYTOXANO
cyclosphospharnide; alkyl sulfonates such as busulfan, improsulfan and
piposulfan; aziridines such as
benzodopa, carboquone, rneturedopa, and uredopa; ethyienimines and
methylamelamines including
altretamine, triethylenemelamine, triethylenephosphoramide,
triethylenethiophosphoramide and
trimethylomelamine; acetogenins (especially bullatacin and bullatacinone); a
camptothecin (including
topotecan and irinotecan); bryostatin; callystatin; CC-1065 (including its
adozelesin, carzelesin and
bizelesin synthetic analogs); cryptophycins (particularly cryptophycin 1 and
cryptophycin 8);
adrenocorticosteroids (including prednisone and prednisolone); cyproterone
acetate; 5a-reductases
including finasteride and dutasteride); vorinostat, romidepsin, panobinostat,
valproic acid, mocetinostat
dolastatin; aldesieukin, talc duocarmycin (including the synthetic analogs. KW-
2189 and CB1-TM1);
eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards
such as chlorambucil,
chlomaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine,
mechlorethamine oxide
hydrochloride, melphalan, novembichin, phenesterine, prednimustine,
trofosfamide, uracil mustard;
nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine,
nimustine, and ranimnustine;
antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially
calicheamicin yll and
calicheamicin w1I(Angew Chem. Intl. Ed. Engl. 1994 33:183-186), dynemicin,
including dynemicin A;
bisphosphonates, such as clodronate; an esperamicin; as well as
neocarzinostatin chromophore and
related chromoprotein enediyne antibiotic chromophores), aclacinomysins,
actinomycin, authramycin,
azaserine, bleomycins, cactinornycin, carabicin, caminomycin, carzinophilin,
chromomycinis,
dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norieucine,
ADRIAMYCINO (doxorubicin),
morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin
and deoxydoxorubicin),
epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as
mitomycin C, mycophenolic acid,
nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin,
rodorubicin, streptonigrin,
streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites
such as methotrexate and 5-
fiuorouracil (5-FU); folic acid analogs such as denopterin, methotrexate,
pteropterin, trimetrexate; purine
analogs such as fiudarabine, 6-mercaptopurine, thiamiprine, thioguanine;
pyrimidine analogs such as
ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine,
doxilluridine, enocitabine,
fioxuridine; androgens such as calusterone, dromostanolone propionate,
epitiostanol, mepitiostane,
testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane;
folic acid replenisher such as
33
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
frolinic acid; aceglatone; aldophospharnide glycoside; aminolevulinic acid;
eniluracil; amsacrine;
bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone;
elfomithine; elliptinium acetate;
an epothilone: etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine;
maytansinoids such as
maytansine and ansamitocins; mitoguazone: mitoxantrone; mopidamnol;
nitraerine; pentostatin;
phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide;
procarbazine; PSKI
polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane;
rhizoxin; sizofuran;
spirogemianium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine;
trichothecenes (especially T-
2 toxin. verracurin A. roridin A and anguidine); urethan; vindesine;
dacarbazine; mannomustine;
mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C");
cyclophosphamide; thiotepa;
taxoids, e.g., TAXOL (paclitaxel; Bristol-Myers Squibb Oncology, Princeton, N
J.), ABRAXANE
(Cremophor-free), albumin-engineered nanoparticle formulations of pacIdaxel
(American Pharmaceutical
Partners, Schaumberg, Ill.), and TAXOTERE (docetaxel, doxetaxel; Sanofi-
Aventis); chloranmbucil;
GEMZAR (gemcitabine); 6-thioguanine; mercaptopurine; methotrexate; platinum
analogs such as
cisplatin and carboplatin; vinblastine: etoposide (VP-16); ifosfamide;
mitoxantrone; vincristine;
NAVELBINEID (vinorelbine); novantrone; teniposide; edatrexate; daunomycin;
aminopterin; capecitabine
(XELODA0); ibandronate; CPT-11; topoisomerase inhibitor RFS 2000;
difluoromethylomithine (DMF0);
retinoids such as retinoic acid; and pharmaceutically acceptable salts, acids
and derivatives of any of the
above.
Chemotherapeutic agent also includes (i) anti-hormonal agents that act to
regulate or inhibit
hormone action on tumors such as anti-estrogens and selective estrogen
receptor modulators (SERMs),
including, for example, tamoxifen (including NOLVADEXO; tamoxifen citrate),
raloxifene, droloxifene,
iodoxyfene , 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone.
and FARESTON
(toremifine citrate); (ii) aromatase inhibitors that inhibit the enzyme
aromatase, which regulates estrogen
production in the adrenal glands, such as, for example, 4(5)-imidazoles,
aminoglutethimide, MEGASE
(megestrol acetate), AROMASIN (exemestane; Pfizer), formestanie, fadrozole,
RIVISOR (vorozole),
FEMARA (letrozole; Novarlis), and ARIMIDEXO (anastrozole; AstraZeneca); (iii)
anti-androgens such
as fiutamide, nilutamide, bicalutamide, leuprolide and goserelin; buserelin,
tripterelin,
medroxyprogesterone acetate, diethylstilbestrol, premarin, fiuoxymesterone,
all transretionic acid,
fenretinide, as well as troxacitabine (a 1,3-dioxolane nucleoside cytosine
analog); (iv) protein kinase
inhibitors; (v) lipid kinase inhibitors; (vi) antisense oligonucleotides,
particularly those which inhibit
expression of genes in signaling pathways implicated in aberrant cell
proliferation, such as, for example,
PKC-alpha, Ralf and H-Ras; (vii) ribozymes such as VEGF expression inhibitors
(e.g.. ANGIOZYMEO)
and HER2 expression inhibitors; (viii) vaccines such as gene therapy vaccines,
for example,
ALLOVECTIN , LEUVECTINSI, and VAXIDO; PROLEUKINO, rIL-2; a topoisomerase 1
inhibitor such as
LURTOTECANS; ABARELIXO nTIRH; and (ix) pharmaceutically acceptable salts,
acids and derivatives of
any of the above.
Chemotherapeutic agent also includes antibodies such as alemtuzumab (Campath),
bevacizumab (AVASTIN , Genentech); cetuximab (ERBITUX , Imclone); panitumumab
(VECTIBIXO,
Amgen), rituximab (RITUXANO, GenentechiBiogen !deo), pertuzumab (OMNITARGO,
2C4, Genentech),
trastuzumab (HERCEPTINO, Genentech), tositumomab (Bexxar, Corixia), and the
antibody drug
34
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
conjugate, gemtuzumab ozogamicin (MYLOTARGO, Wyeth). Additional humanized
monoclonal
antibodies with therapeutic potential as agents in combination with the
compounds of the invention
include: apolizumab, aselizumab, atlizumab, bapineuzumab, bivatuzumab
mertansine, cantuzumab
mertansine, cedelizumab, certolizumab pegol, cidfusituzumab, cidtuzumab,
daclizumab, eculizumab,
efalizumab, epratuzumab, erlizumab, felvizumab, fontolizumab, gemtuzumab
ozogamicin, inotuzumab
ozogamicin, ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab,
motavizumab,
motovizumab, natalizumab, nimotuzumab, nolovizumab, numavizumab, ocrelizumab,
omalizumab,
palivizumab, pascolizumab, pecfusituzumab. pectuzumab, pexelizumab,
ralivizumab, ranibizumab,
reslivizumab, reslizumab, resyvizumab, rovelizumab, ruplizumab, sibrotuzumab,
siplizumab, sontuzumab,
.. lacatuzurnab tetraxelan, tadocizumab, talizumab, tefibazumab, tocilizurnab,
toralizumab, tucoluzumab
celmoleukin, tucusituzumab, umavizumab, urtoxazumab, ustekinumab, visilizumab,
and the anti¨
interleukin-12 (ABT-874/J695, Wyeth Research and Abbott Laboratories) which is
a recombinant
exclusively human-sequence, full-length IgG1 A antibody genetically modified
to recognize interleukin-12
p40 protein.
Chemotherapeutic agent also includes "EGFR inhibitors,' which refers to
compounds that bind to
or otherwise interact directly with EGFR and prevent or reduce its signaling
activity, and is alternatively
referred to as an "EGFR antagonist." Examples of such agents include
antibodies and small molecules
that bind to EGFR. Examples of antibodies which bind to EGFR include MAb 579
(ATCC CRL HG 8506),
MAb 455 (ATCC CRL 1168507), MAb 225 (ATCC CRL 8508), MAb 528 (ATCC CRL 8509)
(see, US
Patent No. 4,943, 533, Mendelsohn et al.) and variants thereof, such as
chimerized 225 (C225 or
Cetuximab; ERBUTIXO) and reshaped human 225 (11225) (see, WO 96/40210, ImoIone
Systems Inc.);
IMC-11F8, a fully human. EGFR-targeted antibody (Imolone); antibodies that
bind type II mutant EGFR
(US Patent No. 5,212,290); humanized and chimeric antibodies that bind EGFR as
described in US
Patent No. 5,891,996; and human antibodies that bind EGFR, such as ABX-EGF or
Panitumumab (see
W098/50433, Abgenix/Amgen): EMD 55900 (Stragliotto et al. Eur. J. Cancer
32A:636-640 (1996)):
EMD7200 (matuzumab) a humanized EGFR antibody directed against EGFR that
competes with both
EGF and TGF-alpha for EGFR binding (EMD/Merck), human EGFR antibody, HuMax-
EGFR (GenMab):
fully human antibodies known as E1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6. 3 and
E7.6. 3 and described in
US 6,235,883; MDX-447 (Medarex Inc): and mAb 806 or humanized mAb 806 (Johns
et al., J. Biol.
Chem. 279(29):30375-30384 (2004)). The anti-EGFR antibody may be conjugated
with a cytotoxic agent,
thus generating an immunoconjugate (see, e.g., EP659,439A2, Merck Patent
GmbH). EGFR antagonists
include small molecules such as compounds described in US Patent Nos:
5,616,582, 5,457,105,
5,475,001, 5,654,307, 5,679,683, 6,084,095, 6,265,410, 6,455,534, 6,521,620,
6,596,726, 6,713,484,
5,770,599, 6,140,332, 5,866,572, 6,399,602, 6,344,459. 6,602,863, 6,391,874,
6,344,455, 5,760,041,
6,002,008, and 5,747,498, as well as the following PCT publications:
W098/14451, W098/50038,
W099/09016, and W099/24037. Particular small molecule EGFR antagonists include
OSI-774 (CP-
358774, erlotinib, TARCEVAO Genentech/OSI Pharmaceuticals); PD 183805 (Cl
1033, 2-propenamide,
N-E4-[(3-chloro-4-fluorophenyl)amino1-743-(4-morpholinyl)propoxy1-6-
qUinazolinyll-, dihydrochloride,
Pfizer Inc.): ZD1839, gefitinib (IRESSAID) 4-(3'-Chloro-4'-fluoroanilino)-7-
methoxy-6-(3-
morpholinopropoxy)quinazoline, AstraZeneca); ZM 105180 ((6-amino-4-(3-
rnethylphenyl-amino)-
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
quinazoline, Zeneca); BIBX-1382 (N8-(3-chloro-4-fluoro-pheny1)-N2-(1-methyl-
piperidin-4-y1)-pyrimido[5,4-
d]pyrimidine-2,8-diamine, Boehringer Ingelheim); PKI-166 OR)-444-[(1-
phenylethyl)arninol-lH-pyrrolo[2,3-
d]pyrimidin-6-y11-phenol); (R)-6-(4-hydroxypheny1)-4-[(1-phenylethyl)amino]-7H-
pyrrolo[2,3-dipyrimidine);
CL-387785 (N14-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide); EKB-569
(N-F44(3-chloro-4-
fluorophenyl)aminol-3-cyano-7-ethoxy-6-quinolinyll-4-(dimethylamino)-2-
butenamide) (Wyeth); AG1478
(Pfizer); AG1571 (SU 5271; Pfizer); dual EGFR/HER2 tyrosine kinase inhibitors
such as lapatinib
(TYKERBO, G5K572016 or N[3-chloro-4-[(3 fiuorophenyl)methoxy]pheny1]-
6[51[[2methylsulfonyl)ethyllamina]methyll-2-furanyl]-4-quinazolinamine).
Chemotherapeutic agents also include "tyrosine kinase inhibitors" including
the EGFR-targeted
drugs noted in the preceding paragraph; small molecule HER2 tyrosine kinase
inhibitor such as 1AK165
available from Takeda; CP-724,714, an oral selective inhibitor of the ErbB2
receptor tyrosine kinase
(Pfizer and OSI): dual-HER inhibitors such as EKB-569 (available from Wyeth)
which preferentially binds
EGFR but inhibits both HER2 and EGFR-overexpressing cells; lapatinib
(GSK572016; available from
Glaxo-SmithKline), an oral HER2 and EGFR tyrosine kinase inhibitor; PKI-166
(available from Novartis);
pan-HER inhibitors such as canertinib (C1-1033; Pharmacia); Raf-1 inhibitors
such as antisense agent
IS1S-5132 available from ISIS Pharmaceuticals which inhibit Rat-1 signaling;
non-HER targeted TK
inhibitors such as imatinib mesylate (GLEEVECS, available from Glaxo
SmithKline); multi-targeted
tyrosine kinase inhibitors such as sunitinib (SUTENTO, available from Pfizer);
VEGF receptor tyrosine
kinase inhibitors such as vatalanib (PTK787/ZK222584, available from
Novartis/Schering AG); MAPK
extracellular regulated kinase I inhibitor C1-1040 (available from Pharmacia);
quinazolines, such as PD
153035,4-(3-chloroanilino) quinazoline; pyridopyrimidines;
pyrimidopyrimidines; pyrrolopyrimidines, such
as CGP 59326, CGP 60261 and CGP 62706; pyrazolopyrimidines, 4-(phenylamino)-7H-
pyrrolo[2,3-d]
pyrimidines; curcumin (diferuloyl methane, 4,5-bis (4-
fluoroanilino)phthalimide); tyrphostines containing
nitrothiophene moieties; PD-0183805 (Warner-Lamber); antisense molecules (e.g.
those that bind to
HER-encoding nucleic acid); quinoxalines (US Patent No. 5,804,396);
tryphostins (US Patent No.
5,804,396); ZD6474 (Astra Zeneca); PIK-787 (Novartis/Schering AG); pan-HER
inhibitors such as Cl-
1033 (Pfizer); Affinitac (ISIS 3521; Isis/Lilly); imatinib mesylate
(GLEEVECe); PKI 166 (Novartis);
GW2016 (Glaxo SmithKline); CI-1033 (Pfizer); EKB-569 (Wyeth); Semaxinib
(Pfizer); ZD6474
(AstraZeneca); PIK-787 (Novartis/Schering AG); INC-1C11 (ImcIone), rapamycin
(sirolimus,
RAPAMUNEV); or as described in any of the following patent publications: US
Patent No. 5,804,396; WO
1999/09016 (American Cyanamid); WO 1998/43960 (American Cyanamid); WO
1997/38983 (Warner
Lambert); WO 1999/06378 (Warner Lambert); WO 1999/06396 (Warner Lambert); WO
1996/30347
(Pfizer, Inc); WO 1996/33978 (Zeneca); WO 1996/3397 (Zeneca) and WO
.1996/33980 (Zeneca).
Chemotherapeutic agents also include dexamethasone, interferons, colchicine,
metoprine,
cyclosporine. amphotericin, metronidazole, alemtuzumab, alitretinoin,
allopurinol, amffostine, arsenic
trioxide, asparaginase, BCG live, bevacuzimab, bexarotene, cladribine,
clofarabine, darbepoetin alfa,
denileukin, dexrazoxane, epoetin alfa, elotinib, filgrastim, histrelin
acetate, ibritumomab, interferon alfa-
2a, interferon alfa-2b, lenalidomide, levamisole, mesna, methoxsalen,
nandrolone, nelarabine,
nofetumomab, oprelvekin, palifermin, pamidronate, pegademase, pegaspargase,
pegfilgrastim,
pemetrexed disodium, plicamycin, porfimer sodium, quinacrine, rasburicase,
sargramostim,
36
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
temozolomide, VM-26, 6-TG, toremifene, tretinoin, ATRA, vairubicin,
zoiedronate, and zoledronic acid,
and pharmaceutically acceptable salts thereof.
Chemotherapeutic agents also include hydrocortisone, hydrocortisone acetate,
cortisone acetate,
tixocortol pivalate, triamcinolone acetonide, triamcinolone alcohol,
mometasone, amcinonide,
budesonide, desonide, fluocinonide, fluocinolone acetonide, betamethasone,
betamethasone sodium
phosphate, dexamethasone, dexamethasone sodium phosphate, fluocortolone,
hydrocortisone-17-
butyrate, hydrocortisone-17-valerate, aclometasone dipropionate, betamethasone
valerate,
betamethasone dipropionate, prednicarbate, clobetasone-17-butyrate, clobetasol-
17-propionate,
fluocortolone caproate, fluocortolone pivalate and fluprednidene acetate;
immune selective anti-
inflammatory peptides (1mSAIDs) such as phenylalanine-glutamine-glycine (FEG)
and its D-isomeric form
(feG) (INIULAN BioTherapeutics, LLC); anti-rheumatic drugs such as
azathioprine, ciclosporin
(cyclosporine A), D-penicillamine, gold salts, hydroxychloroquine,
leflunomideminocycline, sullasalazine,
tumor necrosis factor alpha (TNFa) blockers such as etanercept (Enbrel),
infliximab (Remicade),
adalimumab (Humira), certolizumab pegol (Cimzia), golimumab (Simponi).
Interleukin 1 (IL-1) blockers
such as anakinra (Kineret), T cell costimulation blockers such as abatacept
(Orencia), Interleukin 6 (1L-6)
blockers such as tocilizumab (ACTEMERA0); Interleukin 13 (1L-13) blockers such
as lebrikizumab;
Interferon alpha (1FN) blockers such as Rontalizumab; Beta 7 integrin blockers
such as rhuMAb Beta7;
IgE pathway blockers such as Anti-M1 prime; Secreted homotrimeric LTa3 and
membrane bound
heterotrimer LTalip2 blockers such as Anti-lymphotoxin alpha (LTa);
radioactive isotopes (e.g., At211,
1131, 1125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212 and radioactive
isotopes of Lu);
miscellaneous investigational agents such as thioplatin, PS-341,
phenylbutyrate, ET-18- OCH3, or
farnesyl transferase inhibitors (L-739749, L-744832); polyphenols such as
quercetin, resveratrol,
piceatannol, epigallocatechine gallate, theaflavins, flavanols, procyanidins,
betulinic acid and derivatives
thereof; autophagy inhibitors such as chloroquine; delta-9-
tetrahydrocannabinol (dronabinol,
MAR1NOLOD); beta-lapachone; lapachol; colchicines: betulinic acid;
acetylcamptothecin, scopolectin, and
9-aminocamptothecin); podophyllotoxin; tegafur (UFTORAL6); bexarotene
(TARGRETINO);
bisphosphonates such as clodronate (for example, BONEFOS410 or OSTACO),
etidronate (DIDROCAL6),
NE-58095, zoledronic acidizoledmnate (ZOMETA0), alendronate (FOSAMAX0),
pamidronate
(AREDIA0), tiludronate (SKELIDO), or risedronate (ACTONELe); and epidermal
growth factor receptor
(EGF-R); vaccines such as THERATOPEO vaccine; perifosine, COX-2 inhibitor
(e.g. celecoxib or
etoricoxib), proteosome inhibitor (e.g. PS341); CC1-779; tipifarnib (R11577);
orafenib, ABT5l 0; BcI-2
inhibitor such as oblimersen sodium (GENASENSE0); pixantrone;
famesyltransferase inhibitors such as
lonafarnib (SCH 6636, SARASARTM); and pharmaceutically acceptable salts, acids
or derivatives of any
of the above; as well as combinations of two or more of the above such as
CHOP, an abbreviation for a
combined therapy of cyclophosphamide, doxorubicin, vincristine, and
prednisolone; and FOLFOX, an
abbreviation for a treatment regimen with oxaliplatin (ELOXATINTM) combined
with 5-FU and leucovorin.
Chemotherapeutic agents also include non-steroidal anti-inflammatory drugswith
analgesic,
antipyretic and anti-inflammatory effects. NSA1Ds include non-selective
inhibitors of the enzyme
cyclooxygenase. Specific examples of NSA1Ds include aspirin, propionic acid
derivatives such as
ibuprofen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin and naproxen,
acetic acid derivatives such as
37
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
indomethacin, sulindac, etodolac, diclofenac, enolic acid derivatives such as
piroxicam, meloxicam,
tenoxicam, droxicam, lornoxicam and isoxicam, fenamic acid derivatives such as
mefenamic acid,
meclofenamic acid, flufenamic acid, tolfenamic acid, and COX-2 inhibitors such
as celecoxib, etoricoxib,
lumiracoxib, parecoxib, rofecoxib, rofecoxib, and valdecoxib. NSAIDs can be
indicated for the
symptomatic relief of conditions such as rheumatoid arthritis, osteoarthritis,
inflammatory arthropathies,
ankylosing spondylitis, psoriatic arthritis, Reiter's syndrome, acute gout,
dysmenorrhoea, metastatic bone
pain, headache and migraine, postoperative pain, mild-to-moderate pain due to
inflammation and tissue
injury, pyrexia, ileus, and renal colic.
As used herein, the term "cytokine" refers generically to proteins released by
one cell population
that act on another cell as intercellular mediators or have an autocrine
effect on the cells producing the
proteins. Examples of such cytokines include lymphokines. monokines;
interleukins ("ILs") such as IL-1,
IL-la, IL-2, IL-3, 1L-4, 1L-5, IL-6,1L-7,1L-8, 1L-9, IL10, IL-11, 1L-12, IL-
13, 1L-15, IL-17A-F,IL-18 to 1L-29
(such as 1L-23), 1L-31, including PROLEUKIIV rIL-2; a tumor-necrosis factor
such as TNF-a or INF-13,
TGF-61-3; and other polypeptide factors including leukemia inhibitory factor
("LIF"), ciliary neurotrophic
factor ('CNTF"), CNTF-like cytokine ("CLC"), cardiotrophin ("CT"), and kit
ligand ("KL").
As used herein, the term "chemokine" refers to soluble factors (e.g.,
cytokines) that have the
ability to selectively induce chemotaxis and activation of leukocytes. They
also trigger processes of
angiogenesis, inflammation, wound healing, and tumorigenesis. Example
chemokines include 1L-8, a
human homolog of murine keratinocyte chemoattractant (KC).
"Percent (%) amino acid sequence identity" with respect to a reference
polypeptide sequence is
defined as the percentage of amino acid residues in a candidate sequence that
are identical with the
amino acid residues in the reference polypeptide sequence, after aligning the
sequences and introducing
gaps, if necessary, to achieve the maximum percent sequence identity, and not
considering any
conservative substitutions as part of the sequence identity. Alignment for
purposes of determining
percent amino acid sequence identity can be achieved in various ways that are
within the skill in the art,
for instance, using publicly available computer software such as BLAST, BLAST-
2, ALIGN or Megalign
(DNASTAR) software. Those skilled in the art can determine appropriate
parameters for aligning
sequences, including any algorithms needed to achieve maximal alignment over
the full length of the
sequences being compared. For purposes herein, however, % amino acid sequence
identity values are
generated using the sequence comparison computer program ALIGN-2. The ALIGN-2
sequence
comparison computer program was authored by Genentech, Inc., and the source
code has been filed with
user documentation in the U.S. Copyright Office, Washington D.C., 20559, where
it is registered under
U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly
available from
Genentech, Inc., South San Francisco, California, or may be compiled from the
source code. The ALIGN-
2 program should be compiled for use on a UNIX operating system, including
digital UNIX V4.0D. All
sequence comparison parameters are set by the ALIGN-2 program and do not vary.
In situations where ALIGN-2 is employed for amino acid sequence comparisons,
the % amino
acid sequence identity of a given amino acid sequence A to, with, or against a
given amino acid
sequence B (which can alternatively be phrased as a given amino acid sequence
A that has or comprises
38
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
a certain % amino acid sequence identity to, with, or against a given amino
acid sequence B) is
calculated as follows:
100 times the fraction WY
where X is the number of amino acid residues scored as identical matches by
the sequence alignment
program ALIGN-2 in that program's alignment of A and B, and where Y is the
total number of amino acid
residues in B. It will be appreciated that where the length of amino acid
sequence A is not equal to the
length of amino acid sequence B. the % amino acid sequence identity of A to B
will not equal the %
amino acid sequence identity of B to A. Unless specifically stated otherwise,
all % amino acid sequence
identity values used herein are obtained as described in the immediately
preceding paragraph using the
ALIGN-2 computer program.
The phrase "pharmaceutically acceptable" indicates that the substance or
composition must be
compatible chemically and/or toxicologically, with the other ingredients
comprising a formulation, and/or
the mammal being treated therewith.
As used herein, 'administering" is meant a method of giving a dosage of a
compound (e.g., an
anti-T1GIT antibody of the invention or a nucleic acid encoding an anti-T1GIT
antibody of the invention) or
a composition (e.g., a pharmaceutical composition, e.g., a pharmaceutical
composition including an anti-
TIGIT antibody of the invention) to a subject. The compositions utilized in
the methods described herein
can be administered, for example, intravenously, intramuscularly,
intravitreally (e.g., by intravitreal
injection), by eye drop, intradermally, percutaneously, intraarterially,
intraperitoneally, intralesionally,
intracranially, intraarticularly, intraprostatically, intrapleurally,
intratracheally, intrathecally, intranasally,
intravaginally, intrarectally, topically, intraturnorally, peritoneally,
subcutaneously, subconjunctivally,
intravesicularly, mucosally, intrapericardially, intraumbilically,
intraocularly, intraorbitally, orally, topically,
transdermally, by inhalation, by injection, by implantation, by infusion, by
continuous infusion, by localized
perfusion bathing target cells directly, by catheter, by lavage, in cremes, or
in lipid compositions. The
compositions utilized in the methods described herein can also be administered
systemically or locally.
The method of administration can vary depending on various factors (e.g., the
compound or composition
being administered and the severity of the condition, disease, or disorder
being treated).
The term "vector." as used herein, is intended to refer to a nucleic acid
molecule capable of
transporting another nucleic acid to which it has been linked. One type of
vector is a "plasmid", which
refers to a circular double stranded DNA loop into which additional DNA
segments may be ligated.
Another type of vector is a phage vector. Another type of vector is a viral
vector, wherein additional DNA
segments may be ligated into the viral genome. Certain vectors are capable of
autonomous replication in
a host cell into which they are introduced (e.g., bacterial vectors having a
bacterial origin of replication
and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian
vectors) can be
integrated into the genome of a host cell upon introduction into the host
cell, and thereby are replicated
along with the host genome. Moreover, certain vectors are capable of directing
the expression of genes
to which they are operatively linked. Such vectors are referred to herein as
"recombinant expression
vectors" (or simply, "recombinant vectors" or "expression vectors"). In
general, expression vectors of
39
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
utility in recombinant DNA techniques are often in the form of plasmids. In
the present specification,
"plasmid" and 'vector" may be used interchangeably.
The term "about" as used herein refers to the usual error range for the
respective value readily
known to the skilled person in this technical field. Reference to "about' a
value or parameter herein
includes (and describes) embodiments that are directed to that value or
parameter per se.
Ill. Exemplary anti-TIGIT antibodies
The invention provides anti-TIGIT antibodies useful for treating or delaying
the progression of
cancer or an immune-related disease (e.g., a T cell dysfunctional disorder) in
a subject (e.g., a human).
In one example, the anti-TIGIT antibodies bind to an epitope on human TIGIT
including one or
more amino acid residues (e.g., 1, 2, or 3 amino acid residues) selected from
the group consisting of
Ser78, Ser80, and Lys82 of human TIGIT. For example, in some instances, the
anti-TIGIT antibodies
bind to an epitope on human TIGIT including amino acid residues Ser80 and
Lys82. In some instances,
the anti-TIGIT antibodies bind to an epitope on human TIGIT including amino
acid residues Ser78 and
Ser80. In some instances, the anti-TIGIT antibodies bind to an epitope on
human TIGIT including amino
acid residues Ser78 and Lys82. In some instances, the anti-TIGIT antibodies
bind to an epitope on
human TIGIT including amino acid residues Ser78, Ser80, and Lys82.
In some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
that includes, in
addition to Ser78, Ser80, and/or Lys82, residue Ala67 of human TIGIT. In some
instances, the anti-T1GIT
antibodies bind to an epitope on human TIGIT including Ser78 and Ala67; Ser80
and Ala67; Lys82 and
Ala67; Ser78, Ser80, and Ala67; 6er78, Lys82, and Ala67; Ser80, Lys82, and
Ala67; or Ser78, Ser80,
Lys82, and Ala67.
In some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
that includes, in
addition to Ser78, Ser80, and/or Lys82, one or more additional amino acid
residues (e.g., 1, 2, or 3 amino
acid residues) selected from the group consisting of Glu60, Leu65, and Ile68
of human TIGIT. In some
instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT that
includes Ser78 and Glu60:
Ser80 and Glu60; Lys82 and Glu60; Ser78 and Leu65; Ser80 and Leu65; Lys82 and
Leu65; Ser78 and
Ile68; Ser80 and I1e68; Lys82 and Ile68. In some instances, the anti-TIGIT
antibodies bind to an epitope
on human TIGIT that includes Ser78. Ser80, and Glu60; Ser78, Ser80, and Leu65;
Ser78, Ser80, and
Ile68; Ser80, Lys82, and Glu60: Ser80, Lys82, and Leu65; Ser80, Lys82, and
11e68; Ser78, Lys82, and
Glu60; Ser78, Lys82, and Leu65; Ser78, Lys82, and 11e68. In some instances,
the anti-TIG1T antibodies
bind to an epitope on human TIGIT that includes Ser78, Ser80, Lys82, and
Glu60; Ser78, Ser80, Lys82,
and Leu65; Ser78, Ser80, Lys82, and I1e68. In some instances, the anti-TIGIT
antibodies bind to an
epitope on human TIGIT that includes Glu60, Leu65, and Ser78; Glu60, Leu65,
and Ser80; Glu60, Leu65,
and Lys82; Leu65, Ile68, and Ser78; Leu65, Ile68, and Ser80; Leu65, I1e68, and
Lys82; Glu60, Ile68, and
Ser78; Glu60, Ile68, and Ser80: Glu60, Ile68, and Lys82. In some instances,
the anti-TIGIT antibodies
bind to an epitope on human TIGIT that includes Glu60, Leu65, Ile68, and
Ser78. Glu60, Leu65, Ile68,
and Ser80; Glu60, Leu65, Ile68, and Lys82. In some instances, the anti-TIGIT
antibodies bind to an
epitope on human TIGIT that includes Glue , Leu65, Ser78, and Ser80; Glu60,
Leu65, Ser78, and Lys82;
Glu60, Leu65, Sera , and Lys82; Le65, I1e68, Ser78, and Ser80; Leu65, I1e68,
Ser78, and Lys82;
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
Leu65, Ile68, Ser80, and Lys82; Leu65, Glu60, Ser78, and Ser80; Leu65, Glu60,
Ser78, and Lys82;
Leu65, Glu60, Ser80, and Lys82. In some instances, the anti-TIGIT antibodies
bind to an epitope on
human TIGIT that includes Glu60, Leu65, Ser78, Ser80, and Lys82; Leu65, 11e68,
Ser78, Ser80, and
14582; Glu60, Leu65, Ser78, Ser80, and Lys82. In some instances, the anti-
TIGIT antibodies bind to an
epitope on human TIGIT that includes Ser78, Ser80, Glu60, Leu65, and Ile68;
Ser78, Lys82, Glu60,
Leu65, and 11e68; Ser80, and Lys82, Glu60, Leu65, and 11e68. In some
instances, the anti-TIGIT
antibodies bind to an epitope on human TIGIT that includes Ser78, Ser80,
Lys82, Glu60, Leu65, and
0e68.
In some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
that includes, in
addition to Ser78. Ser80, and Lys82, one or more additional amino acid
residues (e.g., 1, 2, 3, or 4 amino
acid residues) selected from the group consisting of GIn56, Asn70, Leu73, and
His111 of human TIGIT.
In some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
that includes Ser78,
Ser80, Lys82, and Gin56; Ser78, Sere , Lys82, and Asn70; Ser78, Ser80, Lys82,
and Leu73; Ser78,
Ser80, Lys82, and His111. In some instances, the anti-TIGIT antibodies bind to
an epitope on human
TIGIT that includes Ser78, Ser80, Lys82, GIn56, and Asn70; Ser78, Ser80,
Lys82, Gln56, and Leu73;
Ser78, Ser80, Lys82, G(156, and His111; Ser78, Ser80, Lys82, Asn70. and Leu73;
Ser78, Ser80, Lys82,
Asn70, and His111; Ser78, Ser80, Lys82, Leu73, and His111. In some instances,
the anti-TIGIT
antibodies bind to an epitope on human TIGIT that includes Ser78, Ser80,
Lys82. GIn56, Asn70, and
Leu73; Ser78, Ser80, Lys82, Gin56, Asn70, and Hisl 11; Ser78, Ser80, Lys82,
GIn56, Leu73, and
His111; Ser78, Ser80, Lys82, Asn70, Leu73, and His111. In some instances, the
anti-TIGIT antibodies
bind to an epitope on human TIGIT that includes Ser78, Ser80, Lys82, GIn56,
Asn70, Leu73, and
His111.In some instances, the anti-TIGIT antibodies bind to an epitope on
human TIGIT that includes, in
addition to Ser78, Ser80, and/or Lys82, one or more additional amino acid
residues (e.g., 1, 2, or 3 amino
acid residues) selected from the group consisting of Thr55, Asn58, Asp63,
Gin64, His76, Ile77, and Pro79
of human TIGIT.
In some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
that includes
amino acid residues Thr55, GIn56, Asn58, Glu60, Asp63, GIn64, Leu65, Ala67,
Ile68, Asn70, Leu73,
His76, 11e77, Ser78, Pro79. Ser80, Lys82, and His111 of human TIGIT. In some
instances, the anti-TIGIT
antibodies bind to an epitope on human TIGIT that consists of amino acid
residues Thr55, Gln56, Asn58,
Glu60. Asp63, GIn64, Leu65, Ala67, I1e68, Asn70, Leu73, His76, I1e77, Ser78,
Pro79, Ser80, Lys82, and
His111 of human TIGIT.
In another example, the anti-TIGIT antibodies bind to an epitope on human
TIGIT including one
or more amino acid residues (e.g., 1, 2, or 3 amino acid residues) selected
from the group consisting of
Thr55, Ser80, and Lys82 of human TIGIT. For example, in some instances, the
anti-TIGIT antibodies
bind to an epitope on human TIGIT including amino acid residue Lys82. In some
instances, the anti-
TIGIT antibodies bind to an epitope on human TIGIT including amino acid
residues Ser80 and Lys82. In
some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
including amino acid
residues Thr55 and Ser80. In some instances, the anti-T1GIT antibodies bind to
an epitope on human
TIGIT including amino acid residues Thr55 and Lys82. In some instances, the
anti-TIGIT antibodies bind
to an epitope on human TIGIT including amino acid residues Thr55, Ser80, and
Lys82.
41
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
In some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
that includes, in
addition to Thr55, Ser80, and/or Lys82, residue G1n56 of human TIGIT. In some
instances, the anti-TIGIT
antibodies bind to an epitope on human TIGIT including Thr55 and Gin56; Ser80
and Gln56; Lys82 and
Gln56; Thr55, Ser80, and Gln56; Thr55, Lys82, and GIn56; Ser80, 14582, and
Gln56; or 1hr55, Ser80,
Lys82, and Gln56.
In some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
that includes, in
addition to Thr55, Ser80, and/or Lys82, one or more additional amino acid
residues (e.g., 1, 2, or 3 amino
acid residues) selected from the group consisting of Asn58. Glu60, 11e77, and
Pro79 of human TIGIT. In
some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
that includes Thr55 and
Asn58; Thr55 and Glue(); Ser80 and Asn58; Ser80 and Glu60; Lys82 and Asn58;
Lys82 and Glue();
Thr55 and Ile77; Ser80 and Ile77; Lys82 and Ile77; Thr55 and Pro79; Ser80 and
Pro79; Lys82 and
Pro79. In some instances, the anti-TIGIT antibodies bind to an epitope on
human TIGIT that includes
Thr55, Ser80, and Asn58; Thr55, 8er80, and Glu60; Thr55, Ser80, and 11e77;
1hr55, Ser80, and Pro79;
Ser80, Lys82, and Asn58; Ser80, Lys82, and Glu60; Ser80, Lys82, and Ile77;
Ser80, Lys82, and Pro79;
Thr55, Lys82, and Asn58; Thr55, Lys82, and Glu60; Thr55, Lys82, and 11e77;
1hr55, Lys82, and Pro79.
In some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
that includes Thr55,
Ser80, Lys82, and Asn58; Thr55, Ser80, Lys82, and Glu60; Thr55, Ser80, Lys82,
and Ile77; Thr55,
Ser80, Lys82, and Pro79. In some instances, the anti-TIGIT antibodies bind to
an epitope on human
TIGIT that includes Asn58, Ile77, and Thr55; Glu60, Ile77, and Thr55; Asn58,
Ile77, and Ser80; Glu60,
Ile77, and Ser80; Asn58, Ile77, and Lys82; Glu60, Ile77, and Lys82; I1e77,
Pro79, and Thr55; I1e77,
Pro79, and Ser80; Ile77, Pro79, and Lys82; Glu60, Pro79, and Thr55; Asn58,
Pro79, and Ser80; Glu60,
Pro79, and Ser80; Asn58. Pro79, and Lys82; Glu60. Pro79. and Lys82. In some
instances, the anti-
TIGIT antibodies bind to an epitope on human TIGIT that includes Asn58, Ile77,
Pro79, and Thr55; Glu60,
Ile77, Pro79, and Thr55: Asn58, Ile77, Pro79, and Ser80; Glu60, I1e77, Pro79,
and Ser80; Asn58, Ile77,
Pro79, and Lys82; Glu60, Ile77, Pro79, and Lys82. In some instances, the anti-
TIGIT antibodies bind to
an epitope on human TIGIT that includes Asn58, I1e77, Thr55, and 8er80; Glu60,
11e77, Thr55, and
Ser80; Asn58, Ile77, Thr55, and Lys82; Glu60, I1e77, 1hr55, and Lys82; Asn58,
Ile77, Ser80, and Lys82;
Glu60. Ile77, Ser80, and Lys82, Ile77, Pro79, Thr55, and Ser80; Ile77, Pro79,
Thr55, and Lys82; Ile77,
Pro79. Ser80, and Lys82; 11e77, Asn58, Thr55, and Ser80; 11e77, Glu60, Thr55,
and Ser80; Ile77, Asn58,
Thr55, and Lys82; Ile77, Asn58, Thr55. and Lys82; 11877, Glu60, Thr55, and
Lys82; Ile77, Asn58, Ser80,
and Lys82; Ile77, Glu60, Ser80. and Lys82. In some instances, the anti-TIGIT
antibodies bind to an
epitope on human TIGIT that includes Asn58, Ile77, Thr55, Ser80, and Lys82;
Glu60, Ile77, Thr55, Ser80,
and Lys82; Ile77, Pro79, Thr55, Ser80, and Lys82; Asn58, Ile77, Thr55, Ser80,
and Lys82; Glu60, Ile77,
Thr55, Ser80, and Lys82. In some instances, the anti-TIGIT antibodies bind to
an epitope on human
TIGIT that includes Thr55, Ser80. Asn58, 11077, and Pro79; Thr55, Ser80,
Glu60, Ile77, and Pro79;
Thr55, Lys82, Asn58, 11e77, and Pro79; Thr55, Lys82, Glu60, Ile77, and Pro79;
Ser80, Lys82, Asn58,
Ile77, and Pro79; and Ser80, Lys82, Glu60, 11877, and Pro79. In some
instances, the anti-TIGIT
antibodies bind to an epitope on human TIGIT that includes Thr55, Ser80,
Lys82, Glu60.1Ie77, and
Pro79. In some instances, the anti-TIGIT antibodies bind to an epitope on
human TIGIT that includes
42
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
Thr55, Ser80, Lys82, Asn58, I1e77, and Pro79. In some instances, the anti-
TIGIT antibodies bind to an
epitope on human TIGIT that includes 1hr55, Asn58, Glu60, Ile77, Pro79, Ser80,
and Lys82.
In some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
that includes, in
addition to Thr55, Ser80, and Lys82, one or more additional amino acid
residues (e.g., 1, 2, 3, 4, 5, or 6
amino acid residues) selected from the group consisting of Leu65, I1e68,
Leu73, His76, Ser78, and
His111 of further comprises amino acid residues Leu65, Ile68, Leu73, His76,
Ser78, and His111 of
human TIGIT.
In some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
that includes
amino acid residues Thr55, GIn56, Asn58, Glu60, Leu65, I1e68, Leu73, His76,
11e77, Ser78, Pro79,
Ser80, Lys82, and His111 of human TIGIT In some instances, the anti-TIGIT
antibodies bind to an
epitope on human TIGIT that consists of amino acid residues Thr55, Gln56,
Asn58, Glue , Leu65, Ile68,
Leu73, His76, I1e77, Ser78, Pro79, Ser80, Lys82, and His111 of human TIGIT.
In some instances, any of the anti-TIGIT antibodies described above may
include a paratope that
includes one or more amino acid residues (e.g., 1, 2, 3,4, 5,6, 7, 8, 9, 10,
11, or 12 amino acid residues)
selected from the group consisting of heavy chain variable region amino acid
residues Asn32, Tyr52,
Arg52b, Phe53, Lys54, Tyr56, Asp58, Tyr99. Asp100, Leu100a, Leu100b, and
Ala100c and/or one or
more amino acid residues (e.g., 1, 2, 3, 4, or 5 amino acid residues) selected
from the group consisting of
light chain variable region amino acid residues Tyr27d, Tyr92, 8er93, Thr94,
and Phe96.
In some instances, the anti-TIGIT antibodies may include a paratope that
consists of heavy chain
variable region amino acid residues Asn32, Tyr52, Arg52b, Phe53, Lys54, Tyr56,
Asp58, Tyr99, Asp100,
Leu100a, Leu100b, and Ala100c and light chain variable region amino acid
residues Tyr27d, Tyr92,
Ser93, Thr94, and Phe96.
In certain embodiments, the anti-TIGIT antibody of the invention makes unique
contacts with
amino acids of human TIGIT at a distance of 4.5 Angstroms, 3.7 Angstroms, 3.5
Angstroms, 3.25
Angstroms, 3.00 Angstroms, 2.75 Angstroms, or less. In certain embodiments, an
antibody is provided
that binds to an epitope consisting of one, two, three, four, or five amino
acids of human TIGIT at a
distance of 4.5 Angstroms, 3.7 Angstroms, 3.5 Angstroms, 3.25 Angstroms, 3.00
Angstroms, 2.75
Angstroms or less. In one embodiment, the anti-TIGIT antibody of the invention
makes unique contacts
with amino acids of human TIGIT at a distance of 3.7 Angstroms or less. In
certain embodiments, an
antibody is provided that binds to an epitope consisting of one, two, three,
four, or five amino acids of
human TIGIT at a distance of 3.7 Angstroms or less.
In some instances, any of the above anti-TIGIT antibodies includes at least
one, two, three, four,
five, or six HVRs selected from (a) an HVR-H1 comprising the amino acid
sequence of SNSAAWN (SEQ
ID NO: 1); (b) an HVR-H2 comprising the amino acid sequence of
KTYYRFKWYSDYAVSVKG (SEQ ID
NO: 2); (c) an HVR-H3 comprising the amino acid sequence of ESTTYDLLAGPFDY
(SEQ ID NO: 3); (d)
an HVR-L1 comprising the amino acid sequence of KSSQ1VLYSSNNKKYLA (SEQ ID NO:
4); (e) an
HVR-L2 comprising the amino acid sequence of WASTRES (SEQ ID NO: 5); and/or
(f) an HVR-L3
comprising the amino acid sequence of QQYYSTPFT (SEQ ID NO: 6), or a
combination of one or more of
the above HVRs and one or more variants thereof having at least about 90%
sequence identity (e.g.,
90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of
SEQ ID NOs: 1-6. In
43
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
some instances, any of the above anti-TIGIT antibodies includes (a) an HVR-H1
comprising the amino
acid sequence of SNSAAVVN (SEQ ID NO: 1); (b) an HVR-H2 comprising the amino
acid sequence of
KTYYRFKWYSDYAVSVKG (SEQ ID NO: 2); (c) an HVR-H3 comprising the amino acid
sequence of
ESTTYDLLAGPFDY (SEQ ID NO: 3); (d) an HVR-L1 comprising the amino acid
sequence of
KSSQTVLYSSNNKKYLA (SEQ ID NO: 4); (e) an HVR-1.2 comprising the amino acid
sequence of
WASTRES (SEQ ID NO: 5); and (f) an HVR-L3 comprising the amino acid sequence
of QQYYSTPFT
(SEQ ID NO: 6), such as possessed by the anti-TIGIT antibody 4.103 and
derivatives thereof (e.g.,
4.103.Q1E). In some instances, the anti-TIGIT antibody may have a VH domain
comprising an amino
acid sequence having at least at least 90% sequence identity (e.g., at least
91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 34
or 35 and/or a VL
domain comprising an amino acid sequence having at least 90% sequence identity
(e.g., at least 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the
sequence of, SEQ ID
NO: 36. In some instances, the anti-TIGIT antibody may have a VH domain
comprising an amino acid
sequence having at least at least 90% sequence identity (e.g., at least 91%,
92%, 93%, 94%, 95%, 96%,
.. 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 34
and/or a VL domain
comprising an amino acid sequence having at least 90% sequence identity (e.g.,
at least 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ
ID NO: 36. In a
particular instance, the anti-TIGIT antibody can be 4.1D3.01E, or a derivative
or clonal relative thereof.
In some instances, the anti-TIGIT antibody may have a VH domain comprising an
amino acid sequence
having at least at least 90% sequence identity (e.g., at least 91%, 92%, 93%,
94%, 95%, 96%, 97%,
98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 35 and/or a
VL domain comprising
an amino acid sequence having at least 90% sequence identity (e.g., at least
91%, 92%, 93%, 94%, 95%,
96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO:
36. In a particular
instance, the anti-TIGIT antibody can be 4.1D3, or a derivative or clonal
relative thereof.
In some instances, the antibody further comprises at least one, two, three, or
four of the following
light chain variable region framework regions (FRs): an FR-L1 comprising the
amino acid sequence of
DIVMTQSPDSLAVSLGERATINC (SEQ ID NO: 7); an FR-1.2 comprising the amino acid
sequence of
WYQQKPGQPPNLLIY (SEQ ID NO: 8); an FR-L3 comprising the amino acid sequence of
GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC (SEQ ID NO: 9); and/or an FR-L4 comprising
the amino
.. acid sequence of FGPGTKVEIK (SEQ ID NO: 10), or a combination of one or
more of the above FRs and
one or more variants thereof having at least about 90% sequence identity
(e.g., 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 7-10. In
some instances, for
example, the antibody further comprises an FR-L1 comprising the amino acid
sequence of
DIVMTQSPDSLAVSLGERATINC (SEQ ID NO: 7); an FR-1.2 comprising the amino acid
sequence of
VVYQQKPGQFPNLLIY (SEQ ID NO: 8); an FR-L.3 comprising the amino acid sequence
of
GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC (SEQ ID NO: 9); and an FR-L4 comprising the
amino
acid sequence of FGPGTKVEIK (SEQ ID NO: 10), such as possessed by the anti-
TIGIT antibodies
4.1D3.01E and 4.1D3.
In some instances, the antibody further comprises at least one, two, three, or
four of the following
.. heavy chain variable region FRs: an FR-H1 comprising the amino acid
sequence of
44
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
XIVOLQQSGPGLVKPSQTLSLICAISGDSVS (SEQ ID NO: 11), wherein Xi is Q or E; an FR-
H2
comprising the amino acid sequence of WIRQSPSRGLEWLG (SEQ ID NO: 12); an FR-H3
comprising the
amino acid sequence of RITINPDTSKNQFSLQLNSVTPEDTAVFYCTR (SEQ ID NO: 13):
and/or an FR-
H4 comprising the amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 14), or a
combination of one
or more of the above FRs and one or more variants thereof having at least
about 90% sequence identity
(e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any
one of SEQ ID NOs: 11-
14. The anti-TIGIT antibody may further include, for example, at least one,
two, three, or four of the
following heavy chain variable region FRs: an FR-H1 comprising the amino acid
sequence of
EVQLQQSGPGLVKPSQTLSLTCAISGDSVS (SEQ ID NO: 15); an FR-H2 comprising the amino
acid
sequence of WIRQSPSRGLEWLG (SEQ ID NO: 12); an FR-H3 comprising the amino acid
sequence of
RITINPDTSKNQFSLQLNSVTPEDTAVFYCTR (SEQ ID NO: 13); and/or an FR-H4 comprising
the amino
acid sequence of WGQGTLVTVSS (SEQ ID NO: 14), or a combination of one or more
of the above FRs
and one or more variants thereof having at least about 90% sequence identity
(e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs. 12-
15. In some instances,
the anti-TIGIT antibody includes an FR-H1 comprising the amino acid sequence
of
EVQLQQSGPGLVKPSQTLSLTCAISGOSVS (SEQ ID NO: 15); an FR-H2 comprising the amino
acid
sequence of WIRQSPSRGLEWLG (SEQ ID NO: 12): an FR-H3 comprising the amino acid
sequence of
RITINPDTSKNQFSLQLNSVTPEDTAVFYCTR (SEQ ID NO: 13); and an FR-H4 comprising the
amino
acid sequence of WGQGTLVTVSS (SEQ ID NO: 14), such as possessed by the
4.1D3.01E antibody. In
another instance, for example, the anti-TIGIT antibody may further include at
least one, two, three, or four
of the following heavy chain variable region FRs: an FR-H1 comprising the
amino acid sequence of
QVQLQQSGPGLVKPSQTLSLICAISGDSVS (SEQ ID NO: 16); an FR-H2 comprising the amino
acid
sequence of WIRQSPSRGLEWLG (SEQ ID NO: 12); an FR-H3 comprising the amino acid
sequence of
RITINPDTSKNQFSLQLNSVTPEDTAVFYCTR (SEQ ID NO: 13); and/or an FR-H4 comprising
the amino
acid sequence of WGQGTLVTVSS (SEQ ID NO: 14), or a combination of one or more
of the above FRs
and one or more variants thereof having at least about 90% sequence identity
(e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 12-14
and 16. In some
instances, the anti-TIGIT antibody includes an FR-H1 comprising the amino acid
sequence of
QVQLQQSGPGLVKPSQTLSLTCAISGDSVS (SEQ ID NO: 16); an FR-H2 comprising the amino
acid
sequence of WIRQSPSRGLEWLG (SEQ ID NO: 12); an FR-H3 comprising the amino acid
sequence of
RITINPDTSKNQFSLQLNSVTPEDTAVFYCTR (SEQ ID NO: 13); and an FR-H4 comprising the
amino
acid sequence of WGQGTLVTVSS (SEQ ID NO: 14), such as possessed by the 4.1D3
antibody.
In another example, the invention provides anti-TIGIT antibodies that bind to
an epitope on
human TIGIT including one or more amino acid residues (e.g., 1,2, or 3 amino
add residues) selected
from the group consisting of GIn53, His111, and Tyr113 of human TIGIT. For
example, in some
instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
including amino acid residues
Hisl 11 and Tyr113. In some instances, the anti-TIGIT antibodies bind to an
epitope on human TIGIT
including amino acid residues GIn53 and His111. In some instances, the anti-
TIGIT antibodies bind to an
epitope on human TIGIT including amino acid residues Gin53 and Tyr113. In some
instances, the anti-
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
TIGIT antibodies bind to an epitope on human TIGIT including amino acid
residues Gin53, His111, and
Tyr113.
In some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
that includes, in
addition to GIn53, His111, and/or Tyr113, residue GIn56 of human TIGIT. In
some instances, the anti-
TIGIT antibodies bind to an epitope on human TIGIT including GIn53 and GIn56;
His111 and GIn56;
Tyr113 and GIn56; GIn53, His111, and GIn56; GIn53, Tyr113, and Gln56; His111,
Tyr113, and GIn56; or
GIn53, Hisl11, Tyr113, and GIn56.
In some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
that includes, in
addition GIn53, Hisi 11, Tyr113, and/or GIn56, and one or more additional
amino acid residues (e.g., 1, 2,
3, 4, 5, or 6 amino acid residues) selected from the group consisting of
Glu60, Leu65, 11e68, Asn70,
Leu73, and His76 of human TIGIT. For example, in some instances, the anti-
TIGIT antibodies bind to an
epitope on human TIGIT including GIn53, His111, Tyr113, Gln56, and Glu60;
GIn53, His111, Tyr113,
GIn56, and Leu65; Gln53, His111, Tyr113, Gln56, and 11e68; Gln53, His111,
Tyr113, Gln56, and Asn70;
GIn53, His111, Tyr113, GIn56, and Leu73; Gln53, His111, Tyr113, Gln56, and
His76. In some instances,
the anti-TIGIT antibodies bind to an epitope on human TIGIT including GIn53,
His111, Tyr113, Gln56,
Glu60, and Leu65; GIn53, His111, Tyr113, GIn56, Glu60, and Ile68; GIn53,
His111, Tyr113, GIn56,
Glu60, and Asn70; GIn53, His111, Tyr113, GIn56, Glu60, and Leu73; GIn53,
His111, Tyr113, Gln56,
Glu60, and His76. In some instances, the anti-TIGIT antibodies bind to an
epitope on human TIGIT
including Gln53, His111, Tyr113, GIn56. Glu60, Leu65, and 11e68; Gln53,
His111, Tyr113, Gln56, Glu60,
Leu65, and Asn70; Gln53, 1-lis111, Tyr113, Gln56, Glu60, Leu65, and Leu73;
Gln53, His111, Tyr113,
GIn56, Glu60, Leu65, and His76. In some instances, the anti-TIG1T antibodies
bind to an epitope on
human TIGIT including Gln53, His111, Tyr113, Gln56, Glu60, Ile68, and Asn70;
GIn53, His111 , Tyr113,
GIn56, Glu60, 11e68, and Leu73; Gln53, His111, Tyr113, GIn56, Glu60, Ile68,
and His76. In some
instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
including GIn53, His111, Tyr113,
GIn56, Glu60, Asn70, and Leu73; Gln53, His111, Tyr113, GIn56, Glu60, Asn70,
and His76. In some
instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
including GIn53, His111, Tyr113,
GIn56, Glu60, Leu73, and His76. In some instances, the anti-TIGIT antibodies
bind to an epitope on
human TIGIT including GIn53, His111, Tyr113, GIn56, Glu60, Leu65, Ile68, and
Asn70; GIn53, His111,
Tyr113, GIn56, GIu60, Leu65, I1e68, and Leu73; GIn53, His111, Tyr113, GIn56,
Glu60, Leu65, 11e68, and
His76. In some instances, the anti-TIGIT antibodies bind to an epitope on
human TIGIT including Gln53,
His111, Tyr113, GIn56, Glu60, I1e68, Asn70, and Leu73; GIn53, His111, Tyr113,
GIn56, Glu60, 11e68,
Asn70, and His76. In some instances, the anti-TIGIT antibodies bind to an
epitope on human TIGIT
including GIn53, His111, Tyr113, GIn56. Glu60, Leu65, Ile68, Asn70, and Leu73;
GIn53, His111, Tyr113,
GIn56, Glu60, Leu65, 11e68, Asn70, and His76; GIn53. His111, Tyr113, Gln56,
Glu60, Ile68, Asn70,
Leu73 and His76. In some instances, the anti-TIGIT antibodies bind to an
epitope on human TIGIT
including GIn53, His111, Tyr113, GIn56, Glue , Leu65, Ile68, Asn70, Leu73, and
His76.
In some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
including Gln53,
His111, Tyr113, GIn56, Leu65, and 11e68; GIn53, His111, Tyr113, GIn56, Leu65,
and Asn70; Gln53,
His111, Tyr113, Gln56, Leu65, and Leu73; Gln53, His111, Tyr113, Gln56, Leu65,
and His76. In some
instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
including GIn53, His111, Tyr113,
46
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
GIn56, Leu65, I1e68, and Asn70; GIn53, His111, Tyr113, GIn56, Leu65, Ile68,
and Leu73; GIn53, Hisl 11,
Tyr113, Gin56, Leu65, Ile68, and Asn70: GIn53, Hisl 1 1, Tyr113, GIn56, Leu65,
Ile68, and His76. In
some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
including GIn53, His111,
Tyr113, Gin56, Leu65. Asn70, and Leu73; GIn53, His111, Tyr113, Gln56, Leu65,
Asn70, and His76. In
some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
including GIn53, His111,
Tyr113, Gin56, Leu65, Leu73, and His76. In some instances, the anti-TIGIT
antibodies bind to an epitope
on human TIGIT including GIn53, His111, Tyr113, Gin56, Leu65, Ile68, Asn70,
and Leu73; Gin53,
His111, Tyr113. Gin56, Leu65, 11e68, Asn70, and His76. In some instances, the
anti-TIGIT antibodies
bind to an epitope on human MIT including Gin53, His111, Tyr113, GIn56, Leu65,
Asn70, Leu73, and
His76. In some instances, the anti-TIGIT antibodies bind to an epitope on
human TIGIT including GIn53,
His111, Tyr113, Gin56, Leu65, Ile68, Asn70, Leu73, and His76.
In some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
including GIn53,
His111, Tyr113, GIn56, Ile68, and Asn70; GIn53, Hisl 11, Tyr113, Gin56,11e68,
and Leu73; GIn53,
His111 , Tyr113, GIn56, Ile68, and His76. In some instances, the anti-TIGIT
antibodies bind to an epitope
on human TIGIT including GIn53, His111, Tyr113, Gln56, I1e68. Asn70, and
Leu73; GIn53, His111,
Tyr113, GIn56, Ile68, Asn70, and His76; GIn53, His111, Tyr113, GIn56, Ile68,
Leu73, and His76. In
some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
including GIn53, His111,
Tyr113, GIn56,11e68, Asn70, Leu73, and His76.
In some instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
including Gin53,
His111, Tyr113, GIn56, Asn70, and Leu73; GIn53, His111, Tyr113, Gin56, Asn70,
and His76. In some
instances, the anti-TIGIT antibodies bind to an epitope on human TIGIT
including GIn53, His111, Tyr113,
Gin56, Asn70. Leu73, and His76. In some instances, the anti-TIGIT antibodies
bind to an epitope on
human TIGIT including GIn53, His111, Tyr113, Gin56, Leu73, and His76.
In some instances, any of the anti-TIGIT antibodies of the preceding example
includes at least
one, two, three, four, five, or six HVRs selected from (a) an HVR-H1
comprising the amino acid sequence
of SYPMN (SEQ ID NO: 17); (b) an HVR-H2 comprising the amino acid sequence of
WINTNTGNPTYVQGFTG (SEQ ID NO: 18); (c) an HVR-H3 comprising the amino acid
sequence of
TGGHTYDSYAFDV (SEQ ID NO: 19): (d) an HVR-L1 comprising the amino acid
sequence of
RASQVISSSLA (SEQ ID NO: 20); (e) an HVR-L2 comprising the amino acid sequence
of AASTLQS
(SEQ ID NO: 21); and/or (f) an HVR-L3 comprising the amino acid sequence of
QHLHGYPX,N (SEQ ID
NO: 22), wherein X1 is C or S, or a combination of one or more of the above
HVRs and one or more
variants thereof having at least about 90% sequence identity (e.g.. 90%, 91%,
92%, 93%, 94%, 95%,
98%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 17-22. In some
instances, any of the above
anti-TIGIT antibodies of the preceding example may include, for example, (a)
an HVR-H1 comprising the
.. amino acid sequence of SYPMN (SEQ ID NO: 17); (b) an HVR-H2 comprising the
amino acid sequence
of WINTNTGNPTYVQGFTG (SEQ ID NO: 18); (c) an HVR-H3 comprising the amino acid
sequence of
TGGHTYDSYAFDV (SEQ ID NO: 19); (d) an HVR-Ll comprising the amino acid
sequence of
RASQVISSSLA (SEQ ID NO: 20); (e) an HVR-L2 comprising the amino acid sequence
of AASTLQS
(SEQ ID NO: 21); and (f) an HVR-L3 comprising the amino acid sequence of
QHLHGYPX1N (SEQ ID NO:
22), such as possessed by the anti-TIGIT antibody 7.4A3 and derivatives
thereof (e.g., 7.4A3.C96S.Q1E).
47
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
In some instances, the anti-TIGIT antibody may include (a) an HVR-H1
comprising the amino acid
sequence of SYPMN (SEQ ID NO: 17); (b) an HVR-H2 comprising the amino acid
sequence of
WINTNTGNPTYVQGFTG (SEQ ID NO: 18); (c) an HVR-H3 comprising the amino acid
sequence of
TGGHTYDSYAFDV (SEQ ID NO: 19); (d) an HVR-L1 comprising the amino acid
sequence of
RASQVISSSLA (SEQ ID NO: 20); (e) an HVR-L2 comprising the amino acid sequence
of AASTLQS
(SEQ ID NO: 21); and (f) an HVR-L3 comprising the amino acid sequence of
QHLHGYPSN (SEQ ID NO:
23), such as possessed by the anti-TIGIT antibody 7.4A3.C968.Q1E. In other
instances, the anti-TIGIT
antibody may include (a) an HVR-H1 comprising the amino acid sequence of SYPMN
(SEQ ID NO: 17);
(b) an HVR-H2 comprising the amino acid sequence of WINTNTGNPTYVQGFTG (SEQ ID
NO: 18); (c)
an HVR-H3 comprising the amino acid sequence of TGGHTYDSYAFDV (SEQ ID NO: 19):
(d) an HVR-Ll
comprising the amino acid sequence of RASQVISSSLA (SEQ ID NO: 20); (e) an HVR-
L2 comprising the
amino acid sequence of AASTLQS (SEQ ID NO: 21); and (f) an FIVR-L3 comprising
the amino acid
sequence of QHLHGYPCN (SEQ ID NO: 28), such as possessed by the anti-TIGIT
antibody 7.4A3.
In some instances, the anti-TIGIT antibody may have a VH domain comprising an
amino acid
sequence having at least at least 90% sequence identity (e.g., at least 91%,
92%, 93%, 94%, 95%, 96%,
97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 37
and/or a VL domain
comprising an amino acid sequence having at least 90% sequence identity (e.g.,
at least 91%, 92%, 93%,
94%. 95%, 96%, 97%, 98%, or 99% sequence identity) to. or the sequence of. SEQ
ID NO: 38. In a
particular instance, the anti-TIGIT antibody can be 7.4A3.C96S.Q1E, or a
derivative or clonal relative
thereof. In some instances, the anti-TIGIT antibody may have a VI-I domain
comprising an amino acid
sequence having at least at least 90% sequence identity (e.g., at least 91%,
92%, 93%, 94%, 95%, 96%,
97%. 98%, or 99% sequence identity) to, or the sequence of, SEQ ID NO: 39
and/or a VL domain
comprising an amino acid sequence having at least 90% sequence identity (e.g.,
at least 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98%, or 99% sequence identity) to, or the sequence of, SEQ
ID NO: 40. In a
particular instance, the anti-TIGIT antibody can be 7.4A3, or a derivative or
clonal relative thereof.
In some instances, the antibody further comprises at least one, two, three, or
four of the following
light chain variable region framework regions (FRs): an
DIQLTQSPTFLSASVGDRVTITC (SEQ ID NO:
30); an FR-L2 comprising the amino acid sequence of WYQQNPGKAPKLLIY (SEQ ID
NO: 31); an FR-L3
comprising the amino acid sequence of GVPSRFSGSGSGTEFTLTISSLQPEDFVTYYC (SEQ ID
NO: 32);
and/or an FR-L4 comprising the amino acid sequence of FGQGTKVEIK (SEQ ID NO:
33), or a
combination of one or more of the above FRs and one or more variants thereof
having at least about 90%
sequence identity (e.g., 90%, 91%, 92%, 93%, 94%. 95%, 96%, 97%, 98%, or 99%
identity) to any one of
SEQ ID NOs: 30-33, such as possessed by the anti-TIGIT antibody 7.4A3 and
derivatives thereof (e.g.,
7.4A3.C96S.Q1E).
In some instances, the antibody further comprises at least one, two, three, or
four of the following
heavy chain variable region FRs: an FR-H1 comprising the amino acid sequence
of
EVOLVQSGSDLKKPGASVRVSCKASGYTFT (SEQ ID NO: 24) or the amino acid sequence of
QVQLVQSGSDLKKPGASVRVSCKASGYTFT (SEQ ID NO: 29); an FR-H2 comprising the amino
acid
sequence of \WRQAPGHGLEWMG (SEQ ID NO: 25); an FR-H3 comprising the amino acid
sequence of
RFVFSLDTSVNTAYLQISSLKAEDTAVYFCAR (SEQ ID NO: 26); and/or an FR-H4 comprising
the amino
48
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
acid sequence of WGQGTMVTVSS (SEQ ID NO: 27), or a combination of one or more
of the above FRs
and one or more variants thereof having at least about 90% sequence identity
(e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%. 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 24-27
and 29. The anti-
TIGIT antibody may further include, for example, at least one, two, three, or
four of the following heavy
chain variable region FRs: an FR-I-11 comprising the amino acid sequence of
EVQLVQSGSDLKKPGASVRVSCKASGYTFT (SEQ ID NO: 24); an FR-H2 comprising the amino
acid
sequence of WVRQAPGHGLEWMG (SEQ ID NO: 25); an FR-H3 comprising the amino acid
sequence of
RFVFSLDTSVNTAYLQISSLKAEDTAVYFCAR (SEQ ID NO: 26): and/or an FR-H4 comprising
the amino
acid sequence of WGQGTMVTVSS (SEQ ID NO: 27), or a combination of one or more
of the above FRs
.. and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%. 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 24-
27. In some instances,
the anti-TIGIT antibody includes an FR-H1 comprising the amino acid sequence
of
EVOLVQSGSDLKKPGASVRVSCKASGYTFT (SEQ ID NO: 24); an FR-H2 comprising the amino
acid
sequence of WVROAPGHGLEWMG (SEC) ID NO: 25); an FR-H3 comprising the amino
acid sequence of
RFVFSLDTSVNTAYLQISSLKAEDTAVYFCAR (SEQ ID NO: 26); and an FR-H4 comprising the
amino
acid sequence of WGQGTMVTVSS (SEQ ID NO: 27), such as possessed by the
7.4A3.C965.Q1E
antibody. In another instance, for example, the anti-TIGIT antibody may
further include at least one, two,
three, or four of the following heavy chain variable region FRs: an FR-H1
comprising the amino acid
sequence of QVQLVQSGSDLKKPGASVRVSCKASGYTFT (SEQ ID NO: 29); an FR-H2
comprising the
amino acid sequence of VVVRQAPGHGLEWMG (SEQ ID NO: 25); an FR-H3 comprising
the amino acid
sequence of RFVFSLDTSVNTAYLQISSLKAEDTAVYFCAR (SEQ ID NO: 26); and/or an FR-H4
comprising the amino acid sequence of WGQGTMVTVSS (SEQ ID NO: 27), or a
combination of one or
more of the above FRs and one or more variants thereof having at least about
90% sequence identity
(e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any
one of SEQ ID NOs: 25-
27 and 29. In some instances, the anti-TIGIT antibody includes an FR-H1
comprising the amino acid
sequence of QVQLVQSGSDLKKPGASVRVSCKASGYTFT (SEQ ID NO: 29); an FR-H2
comprising the
amino acid sequence of VVVRQAPGHGLEWMG (SEQ ID NO: 25); an FR-H3 comprising
the amino acid
sequence of RFVFSLDTSVNTAYLQISSLKAEDTAVYFCAR (SEQ ID NO: 26); and an FR-H4
comprising
the amino acid sequence of WGQGTMVTVSS (SEQ ID NO: 27), such as possessed by
the 7.4A3 anti-
.. TIGIT antibody.
In another example, the invention provides anti-TIGIT antibodies that include
at least one, two,
three, four, five, or six HVRs selected from (a) an HVR-H1 comprising the
amino acid sequence of
NYPMN (SEQ ID NO: 41); (b) an HVR-H2 comprising the amino acid sequence of
WINTNTGSPAYAQDFTE (SEQ ID NO: 42); (c) an HVR-H3 comprising the amino acid
sequence of
TAITSVYHFDY (SEQ ID NO: 43); (d) an HVR-L1 comprising the amino acid sequence
of RASQGISSYLA
(SEQ ID NO: 44); (e) an HVR-L2 comprising the amino acid sequence of GATTLQS
(SEQ ID NO: 45);
and/or (f) an HVR-L3 comprising the amino acid sequence of QKLNSHPXIS (SEQ ID
NO: 46), wherein Xi
is C, S, or Y, or a combination of one or more of the above HVRs and one or
more variants thereof having
at least about 90% sequence identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98%, or 99%
identity) to any one of SEQ ID NOs: 41-46. In some instances, any of the above
anti-TIGIT antibodies of
49
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
the preceding example may include, for example, (a) an HVR-H1 comprising the
amino acid sequence of
NYPMN (SEQ ID NO: 41); (b) an HVR-H2 comprising the amino acid sequence of
WINTNTGSPAYAQDFTE (SEQ ID NO: 42); (c) an HVR-H3 comprising the amino acid
sequence of
TAITSVYHFDY (SEQ ID NO: 43); (d) an HVR-Ll comprising the amino acid sequence
of RASQGISSYLA
(SEQ ID NO: 44); (e) an HVR-1.2 comprising the amino acid sequence of GATTLQS
(SEQ ID NO: 45);
and (f) an HVR-1.3 comprising the amino acid sequence of QKLNSHPX1S (SEQ ID
NO: 46), wherein Xi is
C, S, or Y, such as possessed by the anti-TIGIT antibody 4.1A4 and derivatives
thereof (e.g.,
4.1A4.C968.Q1E and 4.1A4.C96Y.Q1E). In some instances, the anti-TIGIT antibody
may include (a) an
HVR-H1 comprising the amino acid sequence of NYPMN (SEQ ID NO: 41); (b) an HVR-
H2 comprising
the amino acid sequence of WINTNTGSPAYAQDFTE (SEQ ID NO: 42); (c) an HVR-H3
comprising the
amino acid sequence of TAITSVYHFDY (SEQ ID NO: 43); (d) an HVR-L1 comprising
the amino acid
sequence of RASQGISSYLA (SEQ ID NO: 44); (e) an HVR-L2 comprising the amino
acid sequence of
GATTLQS (SEQ ID NO: 45); and (f) an HVR-L3 comprising the amino acid sequence
of QKLNSHPCS
(SEQ ID NO: 47), such as possessed by the anti-TIGIT antibody 4.1A4. In other
instances, the anti-TIGIT
antibody may include (a) an HVR-H1 comprising the amino acid sequence of NYPMN
(SEQ ID NO: 41):
(b) an HVR-H2 comprising the amino acid sequence of WINTNTGSPAYAQDFTE (SEQ ID
NO: 42); (c) an
HVR-H3 comprising the amino acid sequence of TAITSVYHFDY (SEQ ID NO: 43); (d)
an HVR-L1
comprising the amino acid sequence of RASQGISSYLA (SEQ ID NO: 44); (e) an HVR-
L2 comprising the
amino acid sequence of GATTLQS (SEQ ID NO: 45); and (f) an FIVR-L3 comprising
the amino acid
sequence of QKLNSHPSS (SEQ ID NO: 48), such as possessed by the anti-TIGIT
antibody
4.1A4.C96S.Q1E. In other instances, the anti-TIGIT antibody may include (a) an
HVR-H1 comprising the
amino acid sequence of NYPMN (SEQ ID NO: 41); (b) an HVR-H2 comprising the
amino acid sequence
of WINTNTGSPAYAQDFTE (SEQ ID NO: 42); (c) an HVR-H3 comprising the amino acid
sequence of
TAITSVYHFDY (SEQ ID NO: 43); (d) an HVR-Ll comprising the amino acid sequence
of RASQGISSYLA
(SEQ ID NO: 44); (e) an HVR-L2 comprising the amino acid sequence of GATTLQS
(SEQ ID NO: 45);
and (f) an HVR-L3 comprising the amino acid sequence of QKLNSHPYS (SEQ ID NO:
49), such as
possessed by the anti-TIGIT antibody 4.1A4 C96Y.Q1E.
In some instances, the antibody further comprises at least one, two, three, or
four of the following
light chain variable region framework regions (FRs): an FR-L1 comprising the
amino acid sequence of
DIQLTOSPSFLSASVGDRVTITC (SEQ ID NO: 56): an FR-L2 comprising the amino acid
sequence of
WYQQKPGKAPRVLIY (SEQ ID NO: 57); an FR-L3 comprising the amino acid sequence
of
GVPSRFSGSESGTEFTLTISSLQPEDLATYYC (SEQ ID NO: 58); and/or an FR-L4 comprising
the amino
acid sequence of FGQGTKVEIK (SEQ ID NO: 59), or a combination of one or more
of the above FRs and
one or more variants thereof having at least about 90% sequence identity
(e.g., 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 56-59,
such as possessed by
the anti-TIGIT antibody 4.1A4 and derivatives thereof (e.g., 1A4.C96S.Q1E and
1A4.C96Y.Q1E).
In some instances, the antibody further comprises at least one, two, three, or
four of the following
heavy chain variable region FRs: an FR-H1 comprising the amino acid sequence
of
XIVQLVQSGSELKKPGASVKVSCKASGYTLT (SEQ ID NO: 50), wherein Xi is E or Q; an FR-
H2
comprising the amino acid sequence of VVVRQAPGRGLEWMG (SEQ ID NO: 51); an FR-
H3 comprising
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
the amino acid sequence of RFVFSLDTSVTTAYLQISSLKAEDTAVYYCAR (SEQ ID NO: 52);
and/or an
FR-H4 comprising the amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 53), or a
combination of
one or more of the above FRs and one or more variants thereof having at least
about 90% sequence
identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity)
to any one of SEQ ID
NOs: 50-53. The anti-TIGIT antibody may further include, for example, at least
one, two, three, or four of
the following heavy chain variable region FRs: an FR-H1 comprising the amino
acid sequence of
QVQLVQSGSELKKPGASVKVSCKASGYTLT (SEQ ID NO: 54); an FR-H2 comprising the amino
acid
sequence of WVRQAPGRGLEWMG (SEQ ID NO: 51); an FR-H3 comprising the amino acid
sequence of
RFVFSLDTSVrTAYWISSLKAEDTAVYYCAR (SEQ ID NO: 52); and/or an FR-H4 comprising
the amino
acid sequence of WGQGTLVIVSS (SEQ ID NO: 53), or a combination of one or more
of the above FRs
and one or more variants thereof having at least about 90% sequence identity
(e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 51-
54, such as possessed
by the anti-TIGIT antibody 4.1A4. In some instances, the anti-TIGIT antibody
includes an FR-H1
comprising the amino acid sequence of EVOLVQSGSELKKPGASVKVSCKASGYILT (SEQ ID
NO: 55);
an FR-H2 comprising the amino acid sequence of VVVRQAPGRGLEWMG (SEQ ID NO:
51); an FR-H3
comprising the amino acid sequence of RFVFSLOTSVTTAYLQISSLKAEDTAVYYCAR (SEQ ID
NO: 52);
and/or an FR-H4 comprising the amino acid sequence of WGQGTLVTVSS (SEQ ID NO:
53), or a
combination of one or more of the above FRs and one or more variants thereof
having at least about 90%
sequence identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
identity) to any one of
SEQ ID NOs: 51-53 and 55, such as possessed by the anti-TIGIT antibody
1A4.C96S.Q1E or
1A4.C96Y.Q1E.
In another example, the invention provides anti-TIGIT antibodies that include
at least one, two,
three, four, five, or six HVRs selected from (a) an HVR-H1 comprising the
amino acid sequence of
TYGMGVS (SEQ ID NO: 68); (b) an HVR-H2 comprising the amino acid sequence of
SIVVWNGNTYYNPSLKS (SEQ ID NO: 69); (c) an HVR-H3 comprising the amino acid
sequence of
TGGAVITWFAY (SEQ ID NO: 70); (d) an HVR-Ll comprising the amino acid sequence
of
KASQSVGKNIA (SEQ ID NO: 71); (e) an HVR-L2 comprising the amino acid sequence
of YASNRYT
(SEQ ID NO: 72); and/or (f) an HVR-L3 comprising the amino acid sequence of
QHIYNSPYP (SEQ ID
NO: 73), or a combination of one or more of the above HVRs and one or more
variants thereof having at
least about 90% sequence identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98%. or 99%
identity) to any one of SEQ ID NOs: 68-73. In some instances, any of the above
anti-TIGIT antibodies of
the preceding example may include, for example, (a) an HVR-H1 comprising the
amino acid sequence of
TYGMGVS (SEQ ID NO: 68); (b) an HVR-H2 comprising the amino acid sequence of
SI1MNNGNTYYNPSLKS (SEQ ID NO: 69); (c) an HVR-H3 comprising the amino acid
sequence of
TGGAVITWFAY (SEQ ID NO: 70); (d) an HVR-L1 comprising the amino add sequence
of
KASQSVGKNIA (SEQ ID NO: 71); (e) an HVR-L2 comprising the amino acid sequence
of YASNRYT
(SEQ ID NO: 72); and (f) an HVR-L3 comprising the amino acid sequence of
QHIYNSPYP (SEQ ID NO:
73), such as possessed by the anti-TIGIT antibody rat6132 and derivatives
thereof (e.g., h68211 H1,
h6B2.1.2H1, h6B2.1.1 H2, h6B2.1.1H3, h6B211H4, h6B211H5, and h6B212H5).
51
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
In some instances, the antibody further comprises at least one, two, three, or
four of the following
light chain variable region framework regions (FRs): an FR-11 comprising the
amino acid sequence of
Xi IX2MTQSPX3SX4SX5SVGDRVIX6X7C (SEQ ID NO: 88), wherein X, is D or N; X2 is Q
or V; X3 is K or
S; X4 is L or M; X5 is A or I; Xs is I or M; and X7 is N or T; an FR-12
comprising the amino acid sequence
of WYQQKPGX,X2PKLLIY (SEQ ID NO: 89), wherein Xi is K or 0 and X2 is A or S;
an FR-L3 comprising
the amino acid sequence of GVPX1RFX2GX3GSGIDFTX4T1XsXsX7QX8EDXsAXioXitYC (SEQ
ID NO: 90),
wherein Xi is D or S; X2 is S or T; X3 is G or S; X4 is F or L; Xs is N or S;
X9 is S or T; X7 is L or V; X9 is A
or P; X9 is A or I; X=ic is F or T; and Xii is F or Y; and/or an FR-L4
comprising the amino acid sequence of
FGX1GTKX2EIK (SEQ ID NO: 91), wherein Xi is Q or T and X2 is L or V, or a
combination of one or more
of the above FRs and one or more variants thereof having at least about 90%
sequence identity (e g.,
90%, 91%, 92%, 93%. 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of
SEQ ID NOs: 88-91,
such as possessed by the anti-TIGIT antibody rat6B2 and derivatives thereof
(e.g., h682.1.1 I-11,
h6B2.1.2H1, h68211H2, h68211 H3, h613211 H4, h6B21.1H5, and h6B2.1.2H5). The
anti-TIGIT antibody
may further include, for example, at least one, two, three, or four of the
following light chain variable
region FRs: an FR-11 comprising the amino acid sequence of
NIVMTOSPKSMSISVGDRVIMNC (SEQ
ID NO: 92); an FR-1.2 comprising the amino acid sequence of WYQQKPGQSPKLLIY
(SEQ ID NO: 93);
an FR-L3 comprising the amino acid sequence of
GVPDRFTGGGSGTDFTLTINTVQAEDAAFFYC (SEQ
ID NO: 94); and/or an FR-L4 comprising the amino acid sequence of FGTGTKLEIK
(SEQ ID NO: 95), or a
combination of one or more of the above FRs and one or more variants thereof
having at least about 90%
sequence identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
identity) to any one of
SEQ ID NOs: 92-65, such as possessed by the anti-TIGIT antibody rat6B2. In
some instances, the anti-
TIGIT antibody includes an FR-11 comprising the amino acid sequence of
DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 96); an FR-12 comprising the amino acid
sequence of
WYQQKPGKSPKLLIY (SEQ ID NO: 97); an FR-L3 comprising the amino acid sequence
of
GVPSRFSGSGSGTOFTFTISSLOPEDIATYYC (SEQ ID NO: 99); and/or an FR-14 comprising
the amino
acid sequence of FGQGTKVEIK (SEQ ID NO: 100), or a combination of one or more
of the above FRs
and one or more variants thereof having at least about 90% sequence identity
(e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 96-97
and 99-100, such as
possessed by the anti-TIGIT antibodies h6B2.11 H1, h682.11 H2, h68211 H3,
h613211 H4, and
h6B2.11115. In some instances, the anti-TIGIT antibody includes an FR-11
comprising the amino acid
sequence of DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 96); an FR-L2 comprising the
amino acid
sequence of WYQQKPGKAPKLLIY (SEQ ID NO: 98); an FR-L3 comprising the amino
acid sequence of
GVPSRFSGSGSGTDFTFTISSLOPEDIATYYC (SEQ ID NO: 99): and/or an FR-L4 comprising
the amino
acid sequence of FGQGTKVEIK (SEQ ID NO: 100), or a combination of one or more
of the above FRs
and one or more variants thereof having at least about 90% sequence identity
(e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 96
and 98-100, such as
possessed by the anti-TIGIT antibodies h6B212H1 and h6B212H5.
In some instances, the antibody further comprises at least one, two, three, or
four of the following
heavy chain variable region FRs: an FR-H1 comprising the amino acid sequence
of
XIVX2LKESGPX3X4X5X3PX7XellX9LTCX10FSGFSLS (SEQ ID NO: 74), wherein XI is E or
Q; X2 is S or T;
52
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
X3 is A or G; X4 is I or L.; Xs is L or V; Xs is K or Q; X7 is S or T; Xs is H
or 0: Xo is S or T; and Xio is S or T;
an FR-H2 comprising the amino acid sequence of WIRQPX1X2KX3LEWLA (SEQ ID NO:
75), wherein Xi
is P or S; X2 is E or G; and X3 is A or G; an FR-H3 comprising the amino acid
sequence of
RLD(1)(2KDX3SX4X5QX8X71)(8X9TkokiDX12X13DTATYYCAH (SEQ ID NO: 76), wherein Xi
is I or V; X2
.. is S or T; X3 is A or T; X4 is K or N; Xs is D or N; Xs is A or V; X7 is F
or V; Xs is N or T; X9 is M or V; Xio is
N or S; Xii is M or V; X12 is P or T; and X13 is T or V; and/or an FR-H4
comprising the amino acid
sequence of WGQGTLVTVSS (SEQ ID NO: 77), or a combination of one or more of
the above FRs and
one or more variants thereof having at least about 90% sequence identity
(e.g., 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%. 98%, or 99% identity) to any one of SEQ ID NOs: 74-77,
such as possessed by
the anti-TIGIT antibody rat682 and derivatives thereof (e.g., h6B21.1 H1, h682
L21-11 , h6B2 Ll H2,
h6B2.1..1H3, h6B2.1..1H4, h6B211H5, and h68212H5). The anti-TIGIT antibody may
further include, for
example, at least one, two, three, or four of the following heavy chain
variable region FRs: an FR-H1
comprising the amino acid sequence of QVSLKESGPGILQPSHTLSLTCSFSGFSLS (SEQ ID
NO: 78); an
FR-H2 comprising the amino acid sequence of WIRQPSEKGLEWLA (SEQ ID NO: 79); an
FR-H3
.. comprising the amino acid sequence of RLTVSKDASNDQAFLNVISVDTTDTATYYCAH (SEQ
ID NO:
80); and/or an FR-H4 comprising the amino acid sequence of WGQGTLVTVSS (SEQ ID
NO: 77), or a
combination of one or more of the above FRs and one or more variants thereof
having at least about 90%
sequence identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
identity) to any one of
SEQ ID NOs: 77-80, such as possessed by the anti-TIGIT antibody rat6B2. In
some instances, the anti-
TIGIT antibody includes an FR-H1 comprising the amino acid sequence of
EVILKESGPALVKPTQTLTLICTFSGFSLS (SEQ ID NO: 81); an FR-H2 comprising the amino
acid
sequence of WIRQPPGKALEWLA (SEQ ID NO: 82); an FR-H3 comprising the amino acid
sequence of
RLTVTKDASKNQAVLTMTNMDPVDTATYYCAH (SEQ ID NO: 83); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 77), or a combination of one or
more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 77 and 81-83,
such as possessed by the anli-TIGIT antibodies h6B2.1.1H1 and h6132.1.2H1. In
some instances, the anti-
TIGIT antibody includes an FR-H1 comprising the amino acid sequence of
EVTLKESGPALVKPIQTLTLICTFSGFSLS (SEQ ID NO: 81); an FR-H2 comprising the amino
acid
sequence of WIRQPPGKALEWLA (SEQ ID NO: 82); an FR-H3 comprising the amino acid
sequence of
RLTITKDASKNQAVLIMINMDPVDTATYYCAH (SEQ ID NO: 84); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 77), or a combination of one or
more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g.. 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 77, 81-82, and
.. 84, such as possessed by the anti-TIGIT antibody h6B2.1.1H2. in some
instances, the anti-TIGIT
antibody includes an FR-H1 comprising the amino acid sequence of
EVILKESGPALVKPTOTLTLICTFSGFSLS (SEQ ID NO: 81); an FR-H2 comprising the amino
acid
sequence of WIRQPPGKALEWLA (SEQ ID NO: 82); an FR-H3 comprising the amino acid
sequence of
RLTVTKDTSKNQAVLTMTNMDPVDTATYYCAH (SEQ ID NO: 85); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 77), or a combination of one or
more of the
53
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 77, 81-82, and
85, such as possessed by the anti-TIGIT antibody h6B211H3. In some instances,
the anti-TIGIT
antibody includes an FR-H1 comprising the amino acid sequence of
EVTLKESGPALVKPTQTLTLICTFSGFSLS (SEQ ID NO: 81); an FR-H2 comprising the amino
acid
sequence of WIROPPGKALEWLA (SEQ ID NO: 82); an FR-H3 comprising the amino acid
sequence of
RLTVIKDASKNQVVLIMTNMDPVDTATYYCAH (SEQ ID NO: 86); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVIVSS (SEQ ID NO: 77), or a combination of one or
more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%. 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 77, 81-82, and
85, such as possessed by the anti-TIGIT antibody h6B211H4. In some instances,
the anti-TIGIT
antibody includes an FR-I-11 comprising the amino acid sequence of
EVTLKESGPALVKFTQTLTLICTFSGFSLS (SEQ ID NO: 81); an FR-H2 comprising the amino
acid
sequence of WIROPPGKALEWLA (SEQ ID NO: 82); an FR-H3 comprising the amino acid
sequence of
RLTITKDTSKNOVVLTMTNMDPVDTATYYCAH (SEQ ID NO: 87); and/or an FR-H4 comprising
the amino
acid sequence of WGQGTLVTVSS (SEQ ID NO: 77), or a combination of one or more
of the above FRs
and one or more variants thereof having at least about 90% sequence identity
(e.g., 90%, 91%, 92%,
93%. 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 77,
81-82, and 87, such as
possessed by the anti-TIGIT antibodies h6B2.1...1H5 and h6B212H5.
In another example, the invention provides anti-TIGIT antibodies that include
at least one, two,
three, four, five, or six HVRs selected from (a) an HVR-H1 comprising the
amino acid sequence of
TYGMGVS (SEQ ID NO: 110): (b) an HVR-H2 comprising the amino acid sequence of
SIWWNGNTYYNPSLRS (SEQ ID NO: 111); (c) an HVR-H3 comprising the amino acid
sequence of
TGGAVITWFAY (SEQ ID NO: 112); (d) an FIVR-1.1 comprising the amino acid
sequence of
KASQSVGKNIA (SEQ ID NO: 113); (e) an HVR-L2 comprising the amino acid sequence
of YASNRYT
(SEQ ID NO: 114); and/or (f) an HVR-L3 comprising the amino acid sequence of
QHIYNSPYP (SEQ ID
NO: 115), or a combination of one or more of the above HVRs and one or more
variants thereof having at
least about 90% sequence identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98%. or 99%
identity) to any one of SEQ ID NOs: 110-115. In some instances, any of the
above anti-TIGIT antibodies
of the preceding example may include, for example, (a) an HVR-H1 comprising
the amino acid sequence
of TYGMGVS (SEQ ID NO: 110); (b) an HVR-H2 comprising the amino acid sequence
of
SIVVWNGNTYYNPSLRS (SEQ ID NO: 111); (c) an HVR-H3 comprising the amino acid
sequence of
TGGAVITWFAY (SEQ ID NO: 112); (d) an HVR-L1 comprising the amino acid sequence
of
KASQSVGKNIA (SEQ ID NO: 113); (e) an HVR-L2 comprising the amino acid sequence
of YASNRYT
(SEQ ID NO: 114); and (f) an HVR-L3 comprising the amino acid sequence of
QHIYNSPYP (SEQ ID NO:
115), such as possessed by the anti-TIGIT antibody rat10A5 and derivatives
thereof (e.g., hi 0A511H1;
hi 0A512H1; h10A513H1; h10A5.L4H1; h10A511H2; hl 0A5.1.1 H3; hi 0A5.1..1H4;
and hi 0A514H4).
In some instances, the antibody further comprises at least one, two, three, or
four of the following
light chain variable region framework regions (FRs): an FR-Li comprising the
amino acid sequence of
Xi IVMTQSPX2X3X4SX5SX6GX7RX8TX9XioC (SEQ ID NO: 129), wherein Xi is E or N; X2
is A or K; X3 is S
54
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
or T: X4 is L or M; Xs is I or V; Xs is I or P; X7 is D or E; Xe is A or V; Xs
is L or M; and Xio is N or S; an FR-
L2 comprising the amino acid sequence of VVYQQKX1GQX2PX3LLIY (SEQ ID NO: 130),
wherein Xi is P
or T: X2 is A or S; and X3 is Q or R; an FR-L3 comprising the amino acid
sequence of
GX1PX2RFX3GX4GSGTX5FILTIX6SX7QX8EDX9AXIAI1YC (SEQ ID NO: 131), wherein Xi is I
or V; X2 is
A or D; X3 is S or T; X4 is G or S; Xs is D or E; Xs is N or S; X7 is L or V;
X8 is A or S; X9 is A or F: Xio is F
or V; and Xii is F or Y; and/or an FR-L4 comprising the amino acid sequence of
FGXIGTKX2EIK (SEQ ID
NO: 132), or a combination of one or more of the above FRs and one or more
variants thereof having at
least about 90% sequence identity (e.g., 90%. 91%, 92%, 93%, 940/0, 95%, 96%,
97%, 98%, or 99%
identity) to any one of SEQ ID NOs: 129-132, such as possessed by the anti-
TIGIT antibody rail 0A5 and
derivatives thereof (e.g.: hi 0A5.L1 Fil ; hi 0A5.1.2H1; h10A5.L3H1 ;
h10A514F11; h10A511 H2;
hi 0A51.1H3; h10A5.L1 H4; and h10A5.L4H4). The anti-TIGIT antibody may further
include, for example,
at least one, two, three, or four of the following light chain variable region
FRs: an FR-L1 comprising the
amino acid sequence of NIVMTOSPKSMSISIGDRVTMNC (SEQ ID NO: 133); an FR-L2
comprising the
amino acid sequence of VVY0OKTGCISPQLLIY (SEQ ID NO: 134); an FR-L3 comprising
the amino acid
sequence of GVPDRFTGGGSGTDFTLTINSVQAEDAAFFYC (SEQ ID NO: 135); and/or an FR-L4
comprising the amino acid sequence of FGTGTKLEIK (SEQ ID NO: 136), or a
combination of one or
more of the above FRs and one or more variants thereof having at least about
90% sequence identity
(e.g.. 90%, 91%, 92%, 93%, 94%, 95%, 96%. 97%, 98%, or 99% identity) to any
one of SEQ ID NOs:
133-136, such as possessed by the anti-TIGIT antibody rail 0A5. In some
instances, the anti-TIGIT
antibody includes an FR-L1 comprising the amino acid sequence of
EIVMTQSPATLSVSPGERATLSC
(SEQ ID NO: 137); an FR-L2 comprising the amino acid sequence of
WYQQKPGQSPRLLIY (SEQ ID
NO: 138); an FR-L3 comprising the amino acid sequence of
GVPARFSGSGSGTEFILTISSLOSEDFAVYYC (SEQ ID NO: 140); and/or an FR-L4 comprising
the
amino acid sequence of FGQGTKVEIK (SEQ ID NO: 142), or a combination of one or
more of the above
FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 137-
138, 140, and 142,
such as possessed by the anii-TIGIT antibodies h10A511 Hi hi 0A5. L1 H2, hi
0A5.1-1 H3, and
h 1 0A511H4. In some instances, the anti-TIGIT antibody includes an FR-L1
comprising the amino acid
sequence of EIVMTQSPATLSVSPGERATLSC (SEQ ID NO: 137); an FR-L2 comprising the
amino acid
sequence of WYQQKPGQAPRLLIY (SEQ ID NO: 139); an FR-L3 comprising the amino
acid sequence of
GVPARFSGSGSGTEFTLTISSLQSEDFAVYYC (SEQ ID NO: 140); and/or an FR-L4 comprising
the
amino acid sequence of FGQGTKVEIK (SEQ ID NO: 142), or a combination of one or
more of the above
FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 137,
139-140, and 142,
such as possessed by the anti-TIGIT antibody h10A5.L2H1. In some instances,
the anti-TIGIT antibody
includes an FR-L1 comprising the amino acid sequence of
EIVMTQSPATLSVSPGERATLSC (SEQ ID
NO. 137); an FR-L2 comprising the amino acid sequence of VVYQQKPGQSPRLLIY (SEQ
ID NO: 138);
an FR-L3 comprising the amino acid sequence of
GIPARFSGSGSGTEFTLTISSLQSEDFAVYYC (SEQ ID
NO: 141); and/or an FR-L4 comprising the amino acid sequence of FGQGTKVEIK
(SEQ ID NO: 142), or
a combination of one or more of the above FRs and one or more variants thereof
having at least about
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
90% sequence identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%. 97%, 98%, or
99% identity) to any
one of SEQ ID NOs: 137-138 and 141-142, such as possessed by the anti-TIGIT
antibodies h10A513H1
In some instances, the anti-TIGIT antibody includes an FR-L1 comprising the
amino acid sequence of
EIVMTQSPATLSVSPGERATLSC (SEQ ID NO: 137); an FR-L2 comprising the amino acid
sequence of
VVYQQKPGQAPRLLIY (SEQ ID NO: 139); an FR-L3 comprising the amino acid sequence
of
GIPARFSGSGSGTEFILTISSLQSEDFAVYYC (SEQ ID NO: 141); and/or an FR-L4 comprising
the amino
acid sequence of FGQGTKVEIK (SEQ ID NO: 142), or a combination of one or more
of the above FRs
and one or more variants thereof having at least about 90% sequence identity
(e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%. 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 137,
139, and 141-142,
such as possessed by the anti-TIGIT antibodies h10A514H1 and hi 0A5 L4H4.
In some instances, the antibody further comprises at least one, two, three, or
four of the following
heavy chain variable region FRs: FR-I-11 comprising the amino acid sequence of
X;VX2.LKESGPX3X4X5XePX7X6TLX9L-TCXioFSGFSLT (SEQ ID NO: 116), wherein X1 is E
or Q; X2 is S or
T: X3 is A or G; X4 is I or L; Xs is L or V; Xe is K or 0; X7 is S or T; X8 is
H or 0; X9 is S or T; and Xto is S or
T: an FR-H2 comprising the amino acid sequence of WIRQPX1)(2KX3LEWLA (SEQ ID
NO: 117), wherein
Xi is P or S; X2 is E or G; and X3 is A or G; an FR-H3 comprising the amino
acid sequence of
RI-TX1X2KDISX3X4QX5X6LX7XoTX9X ;oDX iXizDTATYYCAH (SEQ ID NO: 118), wherein X1
is I or V; X2 is
S or T; X3 is K or N; X4 is D or N; Xs is A or V; ki is F or V; X is N or T;
Xs is M or V; X9 is N or S; Xio is M
or V; Xii is P or T; and X12 is T or V; and/or an FR-H4 comprising the amino
acid sequence of
WGQGTLVTVSS (SEQ ID NO: 119), or a combination of one or more of the above FRs
and one or more
variants thereof having at least about 90% sequence identity (e.g., 90%, 91%,
92%, 93%, 94%, 95%,
96%. 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 116-119. such as
possessed by the anti-
TIGIT antibody rail 0A5 and derivatives thereof (e.g., hi 0A511 HI; h10A512H1;
hi 0A5.1.3H1;
h 1 0A5.1.4H1; hl ASIA H2; h10A511H3; h10A511H4; and h10A514H4). The anti-
TIGIT antibody may
further include, for example, at least one, two, three, or four of the
following heavy chain variable region
FRs: an FR-H1 comprising the amino acid sequence of
QVSLKESGPGILQPSHTLSLTCSFSGFSLT
(SEQ ID NO: 120); an FR-H2 comprising the amino acid sequence of
WIRQPSEKGLEWLA (SEQ ID NO:
121); an FR-H3 comprising the amino acid sequence of
RITVSKDTSNDQAFLNVTSVDTTDTATYYCAH
(SEQ ID NO: 122); and/or an FR-H4 comprising the amino acid sequence of
WGQGTLVTVSS (SEQ ID
NO: 119), or a combination of one or more of the above FRs and one or more
variants thereof having at
least about 90% sequence identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98%, or 99%
identity) to any one of SEQ ID NOs: 119-122, such as possessed by the anti-
TIGIT antibody rail 0A5. In
some instances, the anti-TIGIT antibody includes an FR-H1 comprising the amino
acid sequence of
EVILKESGPALVKPTQTLTLTCTFSGESLT (SEQ ID NO: 123); an FR-H2 comprising the amino
acid
sequence of WIRQPPGKALEWLA (SEQ ID NO: 124): an FR-H3 comprising the amino
acid sequence of
RLTVIKDISKNQAVLTMTNMDPVDTATYYDAH (SEQ ID NO: 125); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 119). or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g.. 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 119 and 123-
125, such as possessed by the anti-TIGIT antibodies h10A511H1, h10A512H1, hi
0A513H1, and
56
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
h10A5.L4H1. In some instances, the anti-TIGIT antibody includes an FR-H1
comprising the amino acid
sequence of EVTLKESGPALVKFTQTLTLTCTFSGFSLT (SEQ ID NO: 123); an FR-H2
comprising the
amino acid sequence of WIRQPPGKALEWLA (SEQ ID NO: 124); an FR-H3 comprising
the amino acid
sequence of RLTITKDTSKNQAVLTMTNMDPVDTATYYCAH (SEQ ID NO: 126); and/or an FR-H4
comprising the amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 119), or a
combination of one or
more of the above FRs and one or more variants thereof having at least about
90% sequence identity
(e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any
one of SEQ ID NOs:
119, 123-124, and 126, such as possessed by the anti-TIGIT antibody h 1
0A511H2. In some instances,
the anti-TIGIT antibody includes an FR-H1 comprising the amino acid sequence
of
EVTLKESGPALVKPTQTLTLTCTFSGFSLT (SEQ ID NO: 123); an FR-H2 comprising the amino
acid
sequence of WIRQPPGKALEWLA (SEQ ID NO: 124); an FR-H3 comprising the amino
acid sequence of
RLTVTKDISKNQVVLIMTNMDPVDTATYYCAH (SEQ ID NO: 127); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 119), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 119, 123-124,
and 127, such as possessed by the anti-TIG1T antibody h10A5.L1H3. In some
instances, the anti-TIG1T
antibody includes an FR-H1 comprising the amino acid sequence of
EVTLKESGPALVKPTQTLTLICTFSGFSLT (SEQ ID NO: 123); an FR-H2 comprising the amino
acid
sequence of WIRQPPGKALEWLA (SEQ ID NO: 124); an FR-H3 comprising the amino
acid sequence of
RLTITKDTSKNOVVLTMTNMDPVDTATYYCAH (SEQ ID NO: 128); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 119), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 119, 123-124,
and 128, such as possessed by the anti-T1GIT antibodies Ill 0A511H4 and
h10A5.L4H4.
In another example, the invention provides anti-TIGIT antibodies that include
at least one, two,
three, four, five, or six HVRs selected from (a) an HVR-H1 comprising the
amino acid sequence of EYSIY
(SEQ ID NO: 153); (b) an HVR-H2 comprising the amino acid sequence of
RIDPKNGRTYYVDKFKN
(SEQ ID NO: 154); (c) an HVR-H3 comprising the amino acid sequence of 1YGFYFDF
(SEQ ID NO: 155);
(d) an HVR-L1 comprising the amino acid sequence of KGSQNVNKYLV (SEQ ID NO:
156): (e) an HVR-
L2 comprising the amino acid sequence of NTDNLQS (SEQ ID NO: 157); and/or (f)
an HVR-L3
comprising the amino acid sequence of YQYNNGFT (SEQ ID NO: 158), or a
combination of one or more
of the above HVRs and one or more variants thereof having at least about 90%
sequence identity (e.g.,
90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of
SEQ ID NOs: 153-.158.
In some instances, any of the above anti-T1GIT antibodies of the preceding
example may include, for
example, (a) an HVR-H1 comprising the amino acid sequence of EYSIY (SEQ ID NO:
153); (b) an HVR-
H2 comprising the amino acid sequence of RIDPKNGRTYYVDKFKN (SEQ ID NO: 154);
(c) an HVR-H3
comprising the amino acid sequence of IYGFYFDF (SEQ ID NO: 155); (d) an HVR-Ll
comprising the
amino acid sequence of KGSQNVNKYLV (SEQ ID NO: 156); (e) an HVR-L2 comprising
the amino acid
sequence of NTDNLQS (SEQ ID NO: 157); and (f) an HVR-L3 comprising the amino
acid sequence of
YQYNNGFT (SEQ ID NO: 158) such as possessed by the anti-T1GIT antibody rat7E7
and derivatives
57
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
thereof (e.g., h7E7.L1H1, h7E7.L2H1, h7E7.L3H1 , h7E7.L4H1, h7E7.L5H1, h7E7.L1
H2, h7E7.L1H3,
h7E7.L1H4, h7E7.L1H5, h7E7.L1H6, h7E7.L1H7, h7E7.L1H8, h7E7.L1H9, h7E7.L5H9,
and
7E7.L5aH9a).
In some instances, the antibody further comprises at least one, two, three, or
four of the following
light chain variable region framework regions (FRs): an FR-L1 comprising the
amino acid sequence of
IX2LTOSPSX3LSASVGDRVI-X4X5C (SEQ ID NO: 180), wherein Xi is D or N; X2 is H or
Q; X3 is F or L:
X4 is I or L; and X5 is S or T; an FR-L2 comprising the amino acid sequence of
WYQQKXiGX2APKLLIY
(SEQ ID NO: 181), wherein X1 is L or P; and X2 is E or K; an FR-L3 comprising
the amino acid sequence
of GX=IPSRFSGSGSGTX2X3TLTISSLQPEDX4ATYX5C (SEQ ID NO: 182), wherein Xi is I or
V; X2 is D or
E; X3 is F or Y; X4 is A or F; and Xs is F or Y and/or an FR-L4 comprising the
amino acid sequence of
FGX1GTKX2EIK (SEQ ID NO: 183),wherein Xi is Q or S; and X2 is L or V or a
combination of one or more
of the above FRs and one or more variants thereof having at least about 90%
sequence identity (e.g.,
90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of
SEQ ID NOs: 180-183,
such as possessed by the anti-TIGIT antibody rat7E7 and derivatives thereof
(e.g., h7E7.L1H1,
h7E7.L2H1, 117E71.3H1, h7E7.L4H1, h7E71.5H1 h7E7.1.1 H2, h7E71.1H3, h7E7.L1
H4, h7E7.1.1 H5,
h7E7.L1H6,h7E71.1H7, h7E7.L1H8, h7E7.L1H9, h7E7.L5H9, and 7E7.L5aH9a). The
anti-TIGIT
antibody may further include, for example, at least one, two, three, or four
of the following light chain
variable region FRs: an FR-L1 comprising the amino acid sequence of
NIHLTQSPSLLSASVGDRVTLSC
(SEQ ID NO: 184); an FR-L2 comprising the amino acid sequence of
WYQQKLGEAPKLLIY (SEQ ID NO:
185); an FR-L3 comprising the amino acid sequence of
GIPSRFSGSGSGTDYILTISSLOPEDAA'TYFC
(SEQ ID NO: 186); and/or an FR-L4 comprising the amino acid sequence of
FGSGTKLEIK (SEQ ID NO:
187). or a combination of one or more of the above FRs and one or more
variants thereof having at least
about 90% sequence identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, or 99% identity) to
any one of SEQ ID NOs: 184-187, such as possessed by the anti-TIGIT antibody
rat7E7. In some
instances, the anti-TIGIT antibody includes an FR-L1 comprising the amino acid
sequence of
DIQLTQSPSFLSASVGDRVTITC (SEQ ID NO: 188); an FR-L2 comprising the amino acid
sequence of
VVYQQKPGKAPKLLIY (SEQ ID NO: 189); an FR-L3 comprising the amino acid sequence
of
GIPSRFSGSGSGTEYTLTISSLQPEDFATYFC (SEQ ID NO: 190); and/or an FR-L4 comprising
the amino
acid sequence of FGQGTKVEIK (SEQ ID NO: 196), or a combination of one or more
of the above FRs
and one or more variants thereof having at least about 90% sequence identity
(e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 188-
190 and 196, such as
possessed by the anti-TIGIT antibodies h7E7.L1H1, h7E7.L1H2, h7E7.L1H3,
h7E7.L1H4, h7E7.L1H5,
h7E7111-16, h7E7.L11-17, h7E7.L1H8, and h7E7.L1I-19. In some instances, the
anti-TIGIT antibody
includes an FR-L1 comprising the amino acid sequence of
DIQLTQSPSFLSASVGDRVTITC (SEQ ID NO:
188); an FR-L2 comprising the amino acid sequence of WYQQKPGKAPKLLIY (SEQ ID
NO: 189); an FR-
n comprising the amino acid sequence of GVPSRFSGSGSGTEYTLTISSLOPEDFATYFC (SEQ
ID NO:
191); and/or an FR-L4 comprising the amino acid sequence of FGQGTKVEIK (SEQ ID
NO: 196), or a
combination of one or more of the above FRs and one or more variants thereof
having at least about 90%
sequence identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
identity) to any one of
SEQ ID NOs: 188-189, 191 and 196, such as possessed by the anti-TIGIT antibody
h7E7.L21-I1. In some
58
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
instances, the anti-TIGIT antibody includes an FR-L1 comprising the amino acid
sequence of
DIQLTQSPSFLSASVGDRVTITC (SEQ ID NO: 188); an FR-1.2 comprising the amino acid
sequence of
WYQQKPGKAPKLLIY (SEQ ID NO: 189); an FR-L3 comprising the amino acid sequence
of
GIPSRFSGSGSGTEFTLTISSLQPEDFATYFC (SEQ ID NO: 192); and/or an FR-L4 comprising
the amino
acid sequence of FGQGTKVEIK (SEQ ID NO: 196), or a combination of one or more
of the above FRs
and one or more variants thereof having at least about 90% sequence identity
(e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%. 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 188-
189, 192 and 196,
such as possessed by the anii-TIGIT antibodies h7E713H1. In some instances,
the anti-TIGIT antibody
includes an FR-L1 comprising the amino acid sequence of
DIQLTQSPSFLSASVGDRVTITC (SEQ ID NO:
188); an FR-L2 comprising the amino acid sequence of WYQQKPGKAPKLLIY (SEQ ID
NO: 189): an FR-
1.3 comprising the amino acid sequence of GIPSRFSGSGSGTEYTLTISSLQPEDFATYYC
(SEQ ID NO:
193); and/or an FR-L4 comprising the amino acid sequence of FGQGTKVEIK (SEQ ID
NO: 196), or a
combination of one or more of the above FRs and one or more variants thereof
having at least about 90%
sequence identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
identity) to any one of
SEQ ID NOs: 188-189, 193 and 196, such as possessed by the anti-TIGIT
antibodies h7E7.1.4-11. In
some instances, the anti-TIGIT antibody includes an FR-L.1 comprising the
amino acid sequence of
DIQLTQSPSFLSASVGDRVTITC (SEQ ID NO: 188); an FR-L2 comprising the amino acid
sequence of
WYQQKPGKAPKLLIY (SEQ ID NO: 189); an FR-L3 comprising the amino acid sequence
of
GVPSRFSGSGSGTEFTLTISSLOPEDFATYYC (SEQ ID NO: 194); and/or an FR-L4 comprising
the
amino acid sequence of FGQGTKVEIK (SEQ ID NO: 196), or a combination of one or
more of the above
FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 188-
189, 194 and 196,
such as possessed by the anii-TIGIT antibodies h7E7.L5H1 and h7E7.L5H9. In
some instances, the anti-
TIGIT antibody includes an FR-L1 comprising the amino acid sequence of
DIQLTQSPSFLSASVGDRVTITC (SEQ ID NO: 188); an FR-L2 comprising the amino acid
sequence of
WYQQKPGKAPKLLIY (SEQ ID NO: 189); an FR-L3 comprising the amino acid sequence
of
GVPSRFSGSGSGTEYILTISSLOPEDFATYYC (SEQ ID NO: 195); and/or an FR-L4 comprising
the
amino acid sequence of FGQGTKVEIK (SEQ ID NO: 196), or a combination of one or
more of the above
FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 188-
189 and 195-196,
such as possessed by the anii-TIGIT antibodies 7E7.L5aH9a.
In some instances, the antibody further comprises at least one, two, three, or
four of the following
heavy chain variable region FRs: an FR-H1 comprising the amino add sequence of
EVOLX1QSGX2EX3X4X5PGASVKX8SCKAX7GYTFT (SEQ ID NO: 159), wherein X1 is Q or V;
X2 is A or P;
Xs is L or V; X4 is K or 0: X5 is K or R; Xe is L or V; and X7 is S or T; an
FR-H2 comprising the amino acid
sequence of WVXI0X2PX3QX4LEX5X6G (SEQ ID NO: 160), wherein XI is K or R; X2 is
A or R; X3 is G or
K; X4 is R or S: Xs is I or W; and Xe is I or M; an FR-H3 comprising the amino
acid sequence of
RX11)(2TX3DTSX4XsTAYMX61-SSLX7SEDTAX8YX9CX1oR (SEQ ID NO: 161), wherein Xi is
A or V; X2 is I
or L.; Xs is A or R; X4 is A or S; X5 is N or S; Xs is E or Q; X7 is R or T;
Xe is T or V; X9 is F or Y; and Xie is
A or T; and/or an FR-H4 comprising the amino acid sequence of WGQGX1X2VTX3SS
(SEQ ID NO: 162),
59
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
wherein Xi is T or V; X2 is L or M; and X3 is A or V, or a combination of one
or more of the above FRs and
one or more variants thereof having at least about 90% sequence identity
(e.g., 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%. 98%, or 99% identity) to any one of SEQ ID NOs: 159-162.
such as possessed by
the anti-TIGIT antibody rat7E7 and derivatives thereof (e.g., h7E711H1,
h7E712H1, h7E713H1,
h7E714H1, h7E7.1.5H1, h7E711 H2, h7E7.1.1H3, h7E711H4, h7E7.1.1H5, h7E711H6,
h7E711H7,
h7E7.1..1H8, h7E7.1_1 H9, h7E715H9, and 7E7.1.5aH9a). The anti-TIGIT antibody
may further include, for
example, at least one, two, three, or four of the following heavy chain
variable region FRs: an FR-H1
comprising the amino acid sequence of EVQLQQSGPELQRPGASVKLSCKATGYTFT (SEQ ID
NO: 163):
an FR-H2 comprising the amino acid sequence of WVKORPKQSLEIIG (SEQ ID NO:
164): an FR-H3
comprising the amino acid sequence of RATUTADTSSNTAYMOLSSLTSEDTATYFCTR (SEQ ID
NO:
165); and/or an FR-H4 comprising the amino acid sequence of WGQGVMVTASS (SEQ
ID NO: 166), or a
combination of one or more of the above FRs and one or more variants thereof
having at least about 90%
sequence identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
identity) to any one of
SEQ ID NOs: 163-166, such as possessed by the anti-TIG1T antibody rat7E7. In
some instances, the
anti-TIGIT antibody includes an FR-H1 comprising the amino acid sequence of
EVOLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 167); an FR-H2 comprising the amino
acid
sequence of WVRQAPGQRLEIIG (SEQ ID NO: 168); an FR-H3 comprising the amino
acid sequence of
RATLTADTSASTAYMELSSLRSEDTAVYFCTR (SEQ ID NO: 172); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 179), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 167-138, 172,
and 179, such as possessed by the anti-TIGIT antibodies h7E711H1, h7E7.L2H1,
h7E713H1,
h7E714H1, and h7E7.L5H1. In some instances, the anti-TIGIT antibody includes
an FR-H1 comprising
the amino acid sequence of EVOLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 167); an
FR-H2
comprising the amino acid sequence of WVRQAPGQRLEWIG (SEQ ID NO: 169); an FR-
H3 comprising
the amino acid sequence of RATLTADTSASTAYMELSSLRSEDTAVYFCTR (SEQ ID NO: 172);
and/or an
FR-H4 comprising the amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 179), or a
combination of
one or more of the above FRs and one or more variants thereof having at least
about 90% sequence
identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity)
to any one of SEQ ID
NOs: 167, 169, 172, and 179, such as possessed by the anti-TIGIT antibody
h7E7.L1H2. In some
instances, the anti-TIGIT antibody includes an FR-H1 comprising the amino acid
sequence of
EVOLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 167); an FR-H2 comprising the amino
acid
sequence of 1NVRQAPGQRLEIMG (SEQ ID NO: 170); an FR-H3 comprising the amino
acid sequence of
RATLTADTSASTAYMELSSLRSEDTAVYFCTR (SEQ ID NO: 172); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 179), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g.. 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 167, 170, 172,
and 179, such as possessed by the anti-TIGIT antibody h7E7.L1H3. In some
instances, the anti-TIGIT
antibody includes an FR-H1 comprising the amino acid sequence of
EVOLVQSGAEVKKPGASVIWSCKASGYTFT (SEQ ID NO: 167); an FR-H2 comprising the amino
acid
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
sequence of WVRQAPGQRLEIIG (SEQ ID NO: 168); an FR-H3 comprising the amino
acid sequence of
RVTLTADTSASTAYMELSSLRSEDTAVYFCTR (SEQ ID NO: 173); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 179), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 167-168, 173,
and 179, such as possessed by the anti-TIGIT antibody h7E711H4. In some
instances, the anti-TIGIT
antibody includes an FR-H1 comprising the amino acid sequence of
EVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 167); an FR-H2 comprising the amino
acid
sequence of WVRQAPGQRLEIIG (SEQ ID NO: 168); an FR-H3 comprising the amino
acid sequence of
RATITADTSASTAYMELSSLRSEDTAVYFCTR (SEQ ID NO: 174); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 179), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 167-168, 174,
and 179, such as possessed by the anti-TIGIT antibody h7E711H5. In some
instances, the anti-TIGIT
.. antibody includes an FR-H1 comprising the amino acid sequence of
EVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 167); an FR-H2 comprising the amino
acid
sequence of WVRQAPGQRLEIIG (SEQ ID NO: 168); an FR-H3 comprising the amino
acid sequence of
RATLTRDTSASTAYMELSSLRSEDTAVYFCTR (SEQ ID NO: 175): and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 179), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 167-168, 175,
and 179, such as possessed by the anti-TIGIT antibody h7E711H6. In some
instances, the anti-TIGIT
antibody includes an FR-H1 comprising the amino acid sequence of
EVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 167); an FR-H2 comprising the amino
acid
sequence of WVRQAPGQRLEIIG (SEQ ID NO: 168); an FR-H3 comprising the amino
acid sequence of
RATLTADTSASTAYMELSSLRSEDTAVYYCTR (SEQ ID NO: 176); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 179), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 167-168, 176,
and 179, such as possessed by the anti-TIGIT antibody h7E711H7. In some
instances, the anti-TIGIT
antibody includes an FR-H1 comprising the amino acid sequence of
EVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 167); an FR-H2 comprising the amino
acid
sequence of WVRQAPGQRLEIIG (SEQ ID NO: 168); an FR-H3 comprising the amino
acid sequence of
RATLTADTSASTAYMELSSLRSEDTAVYFCAR (SEQ ID NO: 177); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 179), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g.. 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 167-168, 177,
and 179, such as possessed by the anti-TIGIT antibody h7E7.1.1H8. In some
instances, the anti-TIGIT
antibody includes an FR-H1 comprising the amino acid sequence of
.. EVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 167); an FR-H2 comprising the
amino acid
61
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
sequence of WVRQAPGQRLEWMG (SEQ ID NO: 171); an FR-113 comprising the amino
acid sequence
of RVTITRDTSASTAYMELSSLRSEDTAVYYCAR (SEQ ID NO: 178); and/or an FR-114
comprising the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 179), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 167, 171, and
178-179, such as possessed by the anti-TIGIT antibodies h7E7.L1119 and
h7E7.L5119. In some
instances, the anti-TIGIT antibody includes an FR-H1 comprising the amino acid
sequence of
EVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 167); an FR-H2 comprising the amino
acid
sequence of WVRQAPGQRLEIMG (SEQ ID NO: 170); an FR-H3 comprising the amino
acid sequence of
RVTITRDTSASTAYMELSSLRSEDTAVYYCAR (SEQ ID NO: 178); and/or an FR-I14 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 179), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 167, 170, and
178-179, such as possessed by the anti-TIGIT antibody 7E7.L5aH9a.
In another example, the invention provides anti-TIGIT antibodies that include
at least one, two,
three, four, five, or six HVRs selected from (a) an HVR-H1 comprising the
amino acid sequence of EHSIY
(SEQ ID NO: 215); (b) an HVR-112 comprising the amino acid sequence of
RIDPKNGRTYFVDKFKN
(SEQ ID NO: 216); (c) an HVR-I13 comprising the amino acid sequence of
IDGFYFDF (SEQ ID NO: 217);
(d) an HVR-Ll comprising the amino acid sequence of KGSONVNKYLV (SEQ ID NO:
218); (e) an HVR-
L2 comprising the amino acid sequence of STDNLQS (SEQ ID NO: 219); and/or (f)
an HVR-L3
comprising the amino acid sequence of YQYNNGFT (SEQ ID NO: 220), or a
combination of one or more
of the above HVRs and one or more variants thereof having at least about 90%
sequence identity (e.g.,
90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of
SEQ ID NOs: 215-220
In some instances, any of the above anti-TIGIT antibodies of the preceding
example may include, for
example, (a) an HVR-H1 comprising the amino acid sequence of EHSIY (SEQ ID NO:
215); (b) an HVR-
112 comprising the amino acid sequence of RIDPKNGRTYFVDKFKN (SEQ ID NO: 216);
(c) an HVR-113
comprising the amino acid sequence of IDGFYFDF (SEQ ID NO: 217); (d) an HVR-L1
comprising the
amino acid sequence of KGSQNVNKYLV (SEQ ID NO: 218); (e) an HVR-L2 comprising
the amino acid
sequence of STDNLQS (SEQ ID NO: 219); and (f) an HVR-L3 comprising the amino
acid sequence of
YQYNNGFT (SEQ ID NO: 220), such as possessed by the anti-TIGIT antibody ratl
5C8 and derivatives
thereof (e.g., hl 5C8.L1 H1, h 1 5C8.L2H1, h 1 5C8.L3H1, h15C8.L4H1,
h15C8.L5H1, h15C8.L1H2,
h 1 5C8.L1H3, h 1 5C8.1...1 H4, hi 5C8.1..1H5, hl 5C8.L1H6, hi 5C8111-17, hl
5C8.L1H8, hi 5C811H9,
h15C8.L5119, and 5C815aH9a).
In some instances, the antibody further comprises at least one, two, three, or
four of the following
light chain variable region framework regions (FRs): an FR-L1 comprising the
amino acid sequence of
X11X2LTQSPSX3LSASVGDRVTX4X5C (SEQ ID NO: 243), wherein X1 is D or N; X2 is H
or Q; X3 is F or L;
X4 is I or L; and X5 is S or T; an FR-L2 comprising the amino acid sequence of
WYQQKX,GX2APKWY
(SEQ ID NO: 244), wherein X1 is L or P and X2 is E or K; an FR-L3 comprising
the amino acid sequence
of GX,PSRFSGSGSGTX2X3TLTISSLQPEDX4ATYX5C (SEQ ID NO: 245), wherein XI is I or
V; X2 is D or
E; X3 is F or Y; X4 is A or F; and X5 is F or Y; and/or an FR-L4 comprising
the amino acid sequence of
62
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
FGX,GTKX2EIK (SEQ ID NO: 246), wherein Xi is Q or S and X2 is L or V, or a
combination of one or
more of the above FRs and one or more variants thereof having at least about
90% sequence identity
(e.g., 90%, 91%, 92%. 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any
one of SEQ ID NOs:
243-246, such as possessed by the anti-TIGIT antibody ratl 5C8 and derivatives
thereof (e.g.,
hl5C811Fil hl5C812111, hl5C813111, h15C814111, h15C8.L5111, h15C8.L1H2,
hl5C811F13,
hi 5C811F14, hi 5C811115, h1508111-16, hi 5C8.1.1117, hi 5C8.1.1118, hl
5C8.1.1fri9, hi 5C815119, and
5C815aH9a). The anti-TIGIT antibody may further include, for example, at least
one, two, three, or four
of the following light chain variable region FRs: an FR-L1 comprising the
amino acid sequence of
NIFILTQSPSLLSASVGDRVILSC (SEQ ID NO: 247); an FR-L2 comprising the amino acid
sequence of
WYQQKLGEAPKWY (SEQ ID NO: 248); an FR-L3 comprising the amino acid sequence of
GIPSRFSGSGSGTDYTLTISSLQPEDAATYFC (SEQ ID NO: 249); and/or an FR-L4 comprising
the amino
acid sequence of FGSGTKLEIK (SEQ ID NO: 250), or a combination of one or more
of the above FRs
and one or more variants thereof having at least about 90% sequence identity
(e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs. 247-
250, such as
possessed by the anti-TIGIT antibody ratl 5C8. In some instances, the anti-
TIGIT antibody includes an
FR-L1 comprising the amino acid sequence of DIQLTQSPSFLSASVGDRVTITC (SEQ ID
NO: 251); an
FR-12 comprising the amino acid sequence of VVYQQKPGKAPKWY (SEQ ID NO: 252);
an FR-L3
comprising the amino acid sequence of GIPSRFSGSGSGTEYILTISSLOPEDFATYFC (SEQ ID
NO:
253); and/or an FR-L4 comprising the amino acid sequence of FGQGTKVEIK (SEQ ID
NO: 259), or a
combination of one or more of the above FRs and one or more variants thereof
having at least about 90%
sequence identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
identity) to any one of
SEQ ID NOs: 251-253 and 259, such as possessed by the anti-TIGIT antibodies hi
5C811h11 ,
h15C8.1.1H2, hl 5C8.1.1F13, h15C8.LIH4, h15C8111-15, hl 5C811F16, hl 5C811F17,
h15C811 H8, and
h15C811F19. In some instances, the anti-TIGIT antibody includes an FR-L1
comprising the amino acid
sequence of DIQLTQSPSFLSASVGDRVTITC (SEQ ID NO: 251); an FR-L2 comprising the
amino acid
sequence of WYQQKPGKAPKWY (SEQ ID NO: 252); an FR-L3 comprising the amino acid
sequence of
GVPSRFSGSGSGTEYILTISSLOPEDFATYFC (SEQ ID NO: 254); and/or an FR-1.4 comprising
the
amino acid sequence of FGQGTKVEIK (SEQ ID NO: 259), or a combination of one or
more of the above
FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 251-
252, 254, and 259,
such as possessed by the anti-TIGIT antibody h15C812Fil. In some instances,
the anti-TIGIT antibody
includes an FR-L1 comprising the amino acid sequence of
DIQLTQSPSFLSASVGDRVTITC (SEQ ID NO:
251); an FR-L2 comprising the amino acid sequence of WYQQKPGKAPKLLIY (SEQ ID
NO: 252); an FR-
L3 comprising the amino acid sequence of GIPSRFSGSGSGTEFTLTISSLOPEDFATYFC (SEQ
ID NO:
255); and/or an FR-L4 comprising the amino acid sequence of FGQGTKVEIK (SEQ ID
NO: 259), or a
combination of one or more of the above FRs and one or more variants thereof
having at least about 90%
sequence identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
identity) to any one of
SEQ ID NOs: 251-252, 255, and 259, such as possessed by the anti-TIGIT
antibodies h15C8.1.3H1. In
some instances, the anti-TIGIT antibody includes an FR-L1 comprising the amino
acid sequence of
DIQLTQSPSFLSASVGDRVTITC (SEQ ID NO: 251); an FR-12 comprising the amino acid
sequence of
63
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
VVYQQKPGKAPKWY (SEQ ID NO: 252); an FR-L3 comprising the amino acid sequence
of
GIPSRFSGSGSGTEYILTISSLOPEDFATYYC (SEQ ID NO: 256); and/or an FR-L4 comprising
the amino
acid sequence of FGQGTKVEIK (SEQ ID NO: 259), or a combination of one or more
of the above FRs
and one or more variants thereof having at least about 90% sequence identity
(e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 251-
252, 256, and 259,
such as possessed by the anii-TIGIT antibodies hl5C8.L4H1. In some instances,
the anti-TIGIT antibody
includes an FR-L1 comprising the amino acid sequence of DIQLTQSPSFLSASVGDRVI-
ITC (SEQ ID NO:
251); an FR-L2 comprising the amino acid sequence of WYQQKPGKAPKLUY (SEQ ID
NO: 252); an FR-
L3 comprising the amino acid sequence of GVPSRFSGSGSGTEFTLTISSLQPEDFATYYC (SEQ
ID NO:
257); and/or an FR-L4 comprising the amino acid sequence of FGQGTKVEIK (SEQ ID
NO: 259), or a
combination of one or more of the above FRs and one or more variants thereof
having at least about 90%
sequence identity (e.g.. 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
identity) to any one of
SEQ ID NOs: 251-252, 257, and 259, such as possessed by the anti-TIGIT
antibodies h15C815H1 and
hi 5C8.1...5H9. In some instances, the anti-TIGIT antibody includes an FR-L1
comprising the amino acid
sequence of DIOLTQSPSFLSASVGDRVTITC (SEQ ID NO: 251); an FR-L2 comprising the
amino acid
sequence of WYQQKPGKAPKLLIY (SEQ ID NO: 252): an FR-L3 comprising the amino
acid sequence of
GVPSRFSGSGSGTEYTLTISSLQPEDFATYYC (SEQ ID NO: 258); and/or an FR-L4 comprising
the
amino acid sequence of FGQGTKVEIK (SEQ ID NO: 259), or a combination of one or
more of the above
FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID NOs: 251-
252, and 258-259,
such as possessed by the anti-TIGIT antibodies 5C8.L5aH9a.
In some instances, the antibody further comprises at least one, two, three, or
four of the following heavy
chain variable region FRs: FR-H1 comprising the amino acid sequence of
EVQL.X10SGX2EX3X4X5PGA5V10:6SCKA5GY1FT (SEQ ID NO: 221), wherein Xi is Q or V;
X2 is A or P;
X3 is L or V; X4 is K or Q; Xs is K or R; and Xs is L or V; an FR-H2
comprising the amino acid sequence of
VVX1X2QX3PX4QX5LEXeX7G (SEQ ID NO: 222), wherein Xi is L or V; X2 is K or R:
X3 is A or R; X4 is G or
K; X5 is R or S; X6 is I or W; and X7 is I or M; an FR-H3 comprising the amino
acid sequence of
RX11X21X3X4TSX5X6TAYMX7LSSLX8SEDTAX9YX10CAR (SEQ ID NO: 223), wherein Xi is A
or V; X2 is I
or L; X3 is R or T; X4 is D or N; Xs is A or S; Xs is N or S; X7 is E or Q; X8
is R or T; X6 is I or V; and Xr0 is
F or Y; and/or an FR-H4 comprising the amino acid sequence of WGQGX1X2VTX3SS
(SEQ ID NO: 224),
or a combination of one or more of the above FRs and one or more variants
thereof having at least about
90% sequence identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or
99% identity) to any
one of SEQ ID NOs: 221-224, such as possessed by the anti-TIGIT antibody
ratl5C8 and derivatives
thereof (e.g., hi 5C8.L1H1, hi 5C812H1, hi 5C813H1, hi 5C8.1.4H1, hi
5C8.1.5H1, hi 5C811H2,
hl 5C8.L1H3, hl 5C8.L1H4, hi 5C811H5, hl 5C8.L1H6, h15C8.L1H7, hi 5C8111-18,
h15C8.L1H9,
hl5C8.L5H9, and 5C8.L5aH9a). The anti-TIGIT antibody may further include, for
example, at least one,
two, three, or four of the following heavy chain variable region FRs: an FR-H1
comprising the amino acid
sequence of EVQLQQSGPELORPGASVKLSCKASGYTFT (SEQ ID NO: 225); an FR-H2
comprising the
amino acid sequence of WLKORPKQSLEIIG (SEQ ID NO: 226); an FR-H3 comprising
the amino acid
sequence of RATLTTNTSSNTAYMQLSSLTSEDTAIYFCAR (SEQ ID NO: 227); and/or an FR-H4
64
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
comprising the amino acid sequence of WGQGVMVTASS (SEQ ID NO: 228), or a
combination of one or
more of the above FRs and one or more variants thereof having at least about
90% sequence identity
(e.g., 90%, 91%, 92%. 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any
one of SEQ ID NOs:
225-228, such as possessed by the anti-TIGIT antibody rail 5C8. In some
instances, the anti-TIGIT
antibody includes an FR-H1 comprising the amino acid sequence of
EVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 229); an FR-H2 comprising the amino
acid
sequence of WLRQAPGQRLEIIG (SEQ ID NO: 230); an FR-H3 comprising the amino
acid sequence of
RATLTTDTSASTAYMELSSLRSEDTAVYFCAR (SEQ ID NO: 235); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 242), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%. 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 229-230, 235,
and 242, such as possessed by the anti-TIGIT antibodies h15C8.1.1H1,
h15C81.2H1, h15C813H1,
hi 5C814H1, and 1115C815H1. In some instances, the anti-TIGIT antibody
includes an FR-H1
comprising the amino acid sequence of EVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID
NO: 229);
an FR-H2 comprising the amino acid sequence of VVVRQAPGQRLEIIG (SEQ ID NO:
231); an FR-H3
comprising the amino acid sequence of RATLTTDTSASTAYMELSSLRSEDTAVYFCAR (SEQ ID
NO:
235); and/or an FR-H4 comprising the amino acid sequence of WGQGTLVTVSS (SEQ
ID NO: 242), or a
combination of one or more of the above FRs and one or more variants thereof
having at least about 90%
sequence identity (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%
identity) to any one of
SEQ ID NOs: 229, 231, 235, and 242, such as possessed by the anti-TIGIT
antibody hi 5C811 H2. In
some instances, the anti-TIGIT antibody includes an FR-H1 comprising the amino
acid sequence of
EVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 229); an FR-H2 comprising the amino
acid
sequence of WLRQAPGQRLEWIG (SEQ ID NO: 232); an FR-H3 comprising the amino
acid sequence of
RATLTTDTSASTAYMELSSLRSEDTAVYFCAR (SEQ ID NO: 235); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 242), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g.. 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 229, 232, 235,
and 242, such as possessed by the anti-TIGIT antibody h15C8.1..1H3. In some
instances, the anti-TIGIT
antibody includes an FR-H1 comprising the amino acid sequence of
EVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 229); an FR-H2 comprising the amino
acid
sequence of WLRQAPGQRLEIMG (SEQ ID NO: 233); an FR-H3 comprising the amino
acid sequence of
RATLTTDTSASTAYMELSSLRSEDTAVYFCAR (SEQ ID NO: 235); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 242). or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 229, 233, 235,
and 242, such as possessed by the anti-TIGIT antibody h15C811H4. In some
instances, the anti-TIGIT
antibody includes an FR-H1 comprising the amino acid sequence of
EVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 229); an FR-H2 comprising the amino
acid
sequence of WLRQAPGQRLEIIG (SEQ ID NO: 230); an FR-H3 comprising the amino
acid sequence of
RVILTTDTSASTAYMELSSLRSEDTAVYFCAR (SEQ ID NO: 236); and/or an FR-H4 comprising
the
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 242), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%. 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 229-230, 236,
and 242, such as possessed by the anti-TIGIT antibody hi 5C811 H5. In some
instances, the anti-TIGIT
antibody includes an FR-H1 comprising the amino acid sequence of
EVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 229); an FR-H2 comprising the amino
acid
sequence of WLRQAPGQRLEIIG (SEQ ID NO: 230); an FR-H3 comprising the amino
acid sequence of
RATITTDTSASTAYMELSSLRSEDTAVYFCAR (SEQ ID NO: 237); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 242), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%. 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 229-230, 237,
and 242, such as possessed by the anti-TIGIT antibody h15C811H6. In some
instances, the anti-TIGIT
antibody includes an FR-H1 comprising the amino acid sequence of
EVOLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 229); an FR-H2 comprising the amino
acid
sequence of WLRQAPGQRLEIIG (SEQ ID NO: 230); an FR-H3 comprising the amino
acid sequence of
RATLTRDTSASTAYMELSSLRSEDTAVYFCAR (SEQ ID NO: 238); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 242), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 229-230, 238,
and 242, such as possessed by the anti-TIGIT antibody hi 5C811 H7. In some
instances, the anti-TIGIT
antibody includes an FR-H1 comprising the amino acid sequence of
EVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 229); an FR-H2 comprising the amino
acid
sequence of WLRQAPGQRLEIIG (SEQ ID NO: 230); an FR-H3 comprising the amino
acid sequence of
RATLTTDTSASTAYMELSSLRSEDTAVYYCAR (SEQ ID NO: 239); and/or an FR-H4 comprising
the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 242), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 229-230, 239,
and 242, such as possessed by the anti-TIGIT antibody h15C811H8. In some
instances, the anti-TIGIT
antibody includes an FR-H1 comprising the amino acid sequence of
EVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 229); an FR-H2 comprising the amino
acid
sequence of WVRQAPGQRLEWMG (SEQ ID NO: 234); an FR-H3 comprising the amino
acid sequence
of RVTITRDTSASTAYMELSSLRSEDTAVYYCAR (SEQ ID NO: 240); and/or an FR-H4
comprising the
amino acid sequence of WGQGTLVTVSS (SEQ ID NO: 242). or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 229, 234, 240,
and 242, such as possessed by the anti-TIGIT antibodies h15C8.1.1H9 and hl
5C8.1.5H9. In some
instances, the anti-TIGIT antibody includes an FR-H1 comprising the amino acid
sequence of
EVQLVQSGAEVKKPGASVKVSCKASGYTFT (SEQ ID NO: 229); an FR-H2 comprising the amino
acid
sequence of WLRQAPGQRLEIMG (SEQ ID NO: 233); an FR-H3 comprising the amino
acid sequence of
.. RATITTDTSASTAYMELSSLRSEDTAVYYCAR (SEQ ID NO: 241); and/or an FR-H4
comprising the
66
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
amino acid sequence of WGQGTINTVSS (SEQ ID NO: 242), or a combination of one
or more of the
above FRs and one or more variants thereof having at least about 90% sequence
identity (e.g., 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to any one of SEQ ID
NOs: 229, 233, and
241-242, such as possessed by the anti-TIGIT antibody 5C81.5aH9a.
Anti-TIGIT antibodies are also provided that include a heavy chain variable
region having at least
90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or
99%) sequence identity to,
or the sequence of, SEQ ID NO: 60, 62, 66, 101, 103, 104, 105, 106, 107, 145,
146. 147, 148, 197, 199,
200, 201. 202, 203, 204, 205, 206, 207, 213, 260, 262, 263, 264, 265, 266,
267, 268, 269, 270, or 276.
Also provided are anti-TIGIT antibodies that include a light chain variable
region having at least 90%
(e.g., 91%, 92%, 93%. or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%)
sequence identity to, or
the sequence of, SEQ ID NO: 61, 63,64, 67, 102, 108, 109, 144, 149, 150, 151,
152, 198, 208, 209, 210,
211, 212, 214, 261, 271, 272, 273, 274, 275, or 277.
In some instances, the anti-TIGIT antibody includes a heavy chain variable
region having at least
90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or
99%) sequence identity to,
or the sequence of, SEQ ID NO: 60, and a light chain variable region having at
least 90% (e.g., 91%,
92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 61. In some instances, the anti-TIGIT antibody includes a heavy
chain variable region
having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%,
97%, 98%, or 99%)
sequence identity to. or the sequence of, SEC) ID NO: 62, and a light chain
variable region having at least
90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or
99%) sequence identity to,
or the sequence of, SEQ ID NO: 63. In some instances, the anti-TIGIT antibody
includes a heavy chain
variable region having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least
95% (e.g., 96%. 97%,
98%, or 99%) sequence identity to, or the sequence of, SEQ ID NO: 62, and a
light chain variable region
having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%,
97%, 98%, or 99%)
sequence identity to, or the sequence of, SEQ ID NO: 64. In some instances,
the anti-TIGIT antibody
includes a heavy chain variable region having at least 90% (e.g., 91%, 92%,
93%, or 94%), or at least
95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the sequence of,
SEQ ID NO: 66, and a light
chain variable region having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at
least 95% (e.g., 96%,
97%, 98%, or 99%) sequence identity to, or the sequence of, SEQ ID NO: 67. In
some instances, the
anti-TIGIT antibody includes a heavy chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or
94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or
the sequence of, SEQ ID
NO: 101, and a light chain variable region having at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least
95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the sequence of,
SEQ ID NO: 102. In some
instances, the anti-TIGIT antibody includes a heavy chain variable region
having at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 103, and a light chain variable region having at least 90%
(e.g.. 91%, 92%, 93%, or 94%),
or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the
sequence of, SEQ ID NO:
108. In some instances, the anti-TIGIT antibody includes a heavy chain
variable region having at least
90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or
99%) sequence identity to,
or the sequence of, SEQ ID NO: 104, and a light chain variable region having
at least 90% (e.g., 91%,
67
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 108. In some instances, the anti-TIGIT antibody includes a
heavy chain variable region
having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%,
97%, 98%, or 99%)
sequence identity to, or the sequence of, SEQ ID NO: 105, and a light chain
variable region having at
least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%,
or 99%) sequence
identity to, or the sequence of, SEQ ID NO: 108. In some instances, the anti-
TIGIT antibody includes a
heavy chain variable region having at least 90% (e.g., 91%. 92%, 93%, or 94%),
or at least 95% (e.g.,
96%, 97%, 98%, or 99%) sequence identity to, or the sequence of, SEQ ID NO:
106, and a light chain
variable region having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least
95% (e.g., 96%, 97%,
98%, or 99%) sequence identity to, or the sequence of. SEQ ID NO 108. In some
instances, the anti-
TIGIT antibody includes a heavy chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or
94%), or at least 95% (e.g., 96%, 97%, 98%. or 99%) sequence identity to, or
the sequence of, SEQ ID
NO: 107, and a light chain variable region having at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least
95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the sequence of,
SEQ ID NO: 109. In some
instances, the anti-TIGIT antibody includes a heavy chain variable region
having at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 143, and a light chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or 94%),
or at least 95% (e.g., 96%, 97%, 98%. or 99%) sequence identity to, or the
sequence of, SEQ ID NO:
144. In some instances, the anti-TIGIT antibody includes a heavy chain
variable region having at least
90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or
99%) sequence identity to,
or the sequence of, SEQ ID NO: 145, and a light chain variable region having
at least 90% (e.g., 91%,
92%. 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 149. In some instances, the anti-TIGIT antibody includes a
heavy chain variable region
having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%,
97%, 98%, or 99%)
sequence identity to, or the sequence of, SEQ ID NO: 145, and a light chain
variable region having at
least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%,
or 99%) sequence
identity to, or the sequence of, SEQ ID NO: 150. In some instances, the anti-
TIGIT antibody includes a
heavy chain variable region having at least 90% (e.g., 91%, 92%, 93%, or 94%),
or at least 95% (e.g.,
96%, 97%, 98%, or 99%) sequence identity to, or the sequence of, SEQ ID NO:
145, and a light chain
variable region having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least
95% (e.g., 96%, 97%,
98%, or 99%) sequence identity to, or the sequence of, SEQ ID NO: 151. In some
instances, the anti-
TIGIT antibody includes a heavy chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or
94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or
the sequence of, SEQ ID
NO: 145, and a light chain variable region having at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least
95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the sequence of,
SEQ ID NO: 152. In some
instances, the anti-TIGIT antibody includes a heavy chain variable region
having at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 147, and a light chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or 94%),
or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the
sequence of, SEQ ID NO:
149. In some instances, the anti-TIGIT antibody includes a heavy chain
variable region having at least
68
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or
99%) sequence identity to,
or the sequence of, SEQ ID NO: 148, and a light chain variable region having
at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 149. In some instances, the anti-TIGIT antibody includes a
heavy chain variable region
having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%,
97%, 98%, or 99%)
sequence identity to, or the sequence of, SEQ ID NO: 148, and a light chain
variable region having at
least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%,
or 99%) sequence
identity to, or the sequence of, SEQ ID NO: 152. In some instances, the anti-
TIGIT antibody includes a
heavy chain variable region having at least 90% (e.g., 91%, 92%, 93%, or 94%),
or at least 95% (e.g.,
96%, 97%, 98%, or 99%) sequence identity to, or the sequence of, SEQ ID NO:
197, and a light chain
variable region having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least
95% (e.g., 96%, 97%,
98%, or 99%) sequence identity to, or the sequence of, SEQ ID NO: 198. In some
instances, the anti-
TIGIT antibody includes a heavy chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or
94%), or at least 95% (e.g., 96%, 97%, 98%. or 99%) sequence identity to, or
the sequence of, SEQ ID
NO: 199, and a light chain variable region having at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least
95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the sequence of,
SEQ ID NO: 208. In some
instances, the anti-TIGIT antibody includes a heavy chain variable region
having at least 90% (e.g., 91%,
92%. 93%, or 94%), or at least 95% (e.g., 96%. 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 200, and a light chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or 94%),
or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the
sequence of, SEQ ID NO:
208. In some instances, the anti-TIGIT antibody includes a heavy chain
variable region having at least
90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, 01
99%) sequence identity to,
or the sequence of, SEQ ID NO: 201, and a light chain variable region having
at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 208. In some instances, the anti-TIGIT antibody includes a
heavy chain variable region
having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%,
97%, 98%, or 99%)
sequence identity to, or the sequence of, SEQ ID NO: 202, and a light chain
variable region having at
least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%,
or 99%) sequence
identity to, or the sequence of, SEQ ID NO: 208. In some instances, the anti-
TIGIT antibody includes a
heavy chain variable region having at least 90% (e.g., 91%, 92%, 93%, or 94%),
or at least 95% (e.g.,
96%, 97%, 98%, or 99%) sequence identity to, or the sequence of, SEQ ID NO:
203, and a light chain
variable region having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least
95% (e.g., 96%, 97%,
98%, or 99%) sequence identity to, or the sequence of, SEQ ID NO: 208. In some
instances, the anti-
TIGIT antibody includes a heavy chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or
94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or
the sequence of, SEQ ID
NO: 204, and a light chain variable region having at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least
95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the sequence of,
SEQ ID NO: 208. In some
instances, the anti-TIGIT antibody includes a heavy chain variable region
having at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 205, and a light chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or 94%),
69
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the
sequence of, SEQ ID NO:
208. In some instances, the anti-TIGIT antibody includes a heavy chain
variable region having at least
90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or
99%) sequence identity to,
or the sequence of, SEQ ID NO: 206, and a light chain variable region having
at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 208. In some instances, the anti-TIGIT antibody includes a
heavy chain variable region
having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%,
97%, 98%, or 99%)
sequence identity to, or the sequence of, SEQ ID NO: 207, and a light chain
variable region having at
least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%,
or 99%) sequence
identity to, or the sequence of, SEQ ID NO: 208. In some instances, the anti-
TIGIT antibody includes a
heavy chain variable region having at least 90% (e.g., 91%. 92%, 93%, or 94%),
or at least 95% (e.g.,
96%, 97%, 98%, or 99%) sequence identity to, or the sequence of, SEQ ID NO:
207, and a light chain
variable region having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least
95% (e.g., 96%, 97%,
98%, or 99%) sequence identity to, or the sequence of, SEQ ID NO: 212. In some
instances, the anti-
TIGIT antibody includes a heavy chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or
94%), or at least 95% (e.g., 96%, 97%, 98%. or 99%) sequence identity to, or
the sequence of, SEQ ID
NO: 199, and a light chain variable region having at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least
95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the sequence of,
SEQ ID NO: 209. In some
instances, the anti-TIGIT antibody includes a heavy chain variable region
having at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 199, and a light chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or 94%),
or at least 95% (e.g., 96%, 97%, 98%. or 99%) sequence identity to, or the
sequence of, SEQ ID NO:
210. In some instances, the anti-TIGIT antibody includes a heavy chain
variable region having at least
90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, 01
99%) sequence identity to,
or the sequence of, SEQ ID NO: 199, and a light chain variable region having
at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%. 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 211. In some instances, the anti-TIGIT antibody includes a
heavy chain variable region
having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%,
97%, 98%, or 99%)
sequence identity to, or the sequence of, SEQ ID NO: 190, and a light chain
variable region having at
least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%,
or 99%) sequence
identity to, or the sequence of, SEQ ID NO: 212. In some instances, the anti-
TIGIT antibody includes a
heavy chain variable region having at least 90% (e.g., 91%, 92%, 93%, or 94%),
oral least 95% (e.g.,
96%, 97%, 98%, or 99%) sequence identity to, or the sequence of, SEQ ID NO:
213, and a light chain
variable region having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least
95% (e.g., 96%, 97%,
98%, or 99%) sequence identity to, or the sequence of, SEQ ID NO: 214. In some
instances, the anti-
TIGIT antibody includes a heavy chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or
94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or
the sequence of, SEQ ID
NO: 260, and a light chain variable region having at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least
95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the sequence of,
SEQ ID NO: 261. In some
instances, the anti-TIGIT antibody includes a heavy chain variable region
having at least 90% (e.g., 91%,
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 262, and a light chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or 94%),
or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the
sequence of, SEQ ID NO:
271. In some instances, the anti-TIGIT antibody includes a heavy chain
variable region having at least
90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or
99%) sequence identity to,
or the sequence of, SEQ ID NO: 263, and a light chain variable region having
at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 271. In some instances, the anti-TIGIT antibody includes a
heavy chain variable region
having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%,
97%, 98%, or 99%)
sequence identity to, or the sequence of, SEQ ID NO: 264, and a light chain
variable region having at
least 90% (e.g., 91%, 92%, 93%, 01 94%), or at least 95% (e.g., 96%, 97%, 98%,
or 99%) sequence
identity to, or the sequence of, SEQ ID NO: 271. In some instances, the anti-
TIGIT antibody includes a
heavy chain variable region having at least 90% (e.g., 91%. 92%, 93%, or 94%),
or at least 95% (e.g.,
96%, 97%, 98%, or 99%) sequence identity to, or the sequence of, SEQ ID NO:
265, and a light chain
variable region having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least
95% (e.g., 96%, 97%,
98%, or 99%) sequence identity to, or the sequence of, SEQ ID NO: 271. In some
instances, the anti-
TIGIT antibody includes a heavy chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or
94%), or at least 95% (e.g., 96%, 97%, 98%. or 99%) sequence identity to, or
the sequence of, SEC) ID
NO: 266, and a light chain variable region having at least 90% (e.g., 91%,
92%, 93%, 01 94%). or at least
95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the sequence of,
SEQ ID NO: 271. In some
instances, the anti-TIGIT antibody includes a heavy chain variable region
having at least 90% (e.g., 91%,
92%. 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 267, and a light chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or 94%),
or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the
sequence of, SEQ ID NO:
271. In some instances, the anti-TIGIT antibody includes a heavy chain
variable region having at least
90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or
99%) sequence identity to,
or the sequence of, SEQ ID NO: 268, and a light chain variable region having
at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 271. In some instances, the anti-TIGIT antibody includes a
heavy chain variable region
having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%,
97%, 98%, or 99%)
sequence identity to, or the sequence of, SEQ ID NO: 269, and a light chain
variable region having at
least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%,
or 99%) sequence
identity to, or the sequence of, SEQ ID NO: 271. In some instances, the anti-
TIGIT antibody includes a
heavy chain variable region having at least 90% (e.g., 91%, 92%, 93%, or 94%),
or at least 95% (e.g.,
96%, 97%, 98%, or 99%) sequence identity to. or the sequence of, SEQ ID NO:
270, and a light chain
variable region having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least
95% (e.g., 96%, 97%,
98%, or 99%) sequence identity to, or the sequence of, SEQ ID NO. 271. In some
instances, the anti-
TIGIT antibody includes a heavy chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or
94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or
the sequence of, SEQ ID
NO: 270, and a light chain variable region having at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least
71
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the sequence of,
SEQ ID NO: 275. In some
instances, the anti-TIGIT antibody includes a heavy chain variable region
having at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 262, and a light chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or 94%),
or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the
sequence of, SEQ ID NO:
272. In some instances, the anti-TIGIT antibody includes a heavy chain
variable region having at least
90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or
99%) sequence identity to,
or the sequence of, SEQ ID NO: 262, and a light chain variable region having
at least 90% (e.g.. 91%,
92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence
identity to, or the sequence
of, SEQ ID NO: 273. In some instances, the anti-TIGIT antibody includes a
heavy chain variable region
having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%,
97%, 98%, or 99%)
sequence identity to, or the sequence of, SEQ ID NO: 262, and a light chain
variable region having at
least 90% (e.g., 91%, 92%, 93%, or 94%), or at least 95% (e.g., 96%, 97%, 98%,
or 99%) sequence
identity to, or the sequence of, SEQ ID NO: 274. In some instances, the anti-
TIGIT antibody includes a
heavy chain variable region having at least 90% (e.g., 91%, 92%, 93%, or 94%),
or at least 95% (e.g.,
96%, 97%, 98%, or 99%) sequence identity to, or the sequence of, SEQ ID NO:
262, and a light chain
variable region having at least 90% (e.g., 91%, 92%, 93%, or 94%), or at least
95% (e.g., 96%, 97%,
98%. or 99%) sequence identity to, or the sequence of. SEQ ID NO: 275. In some
instances, the anti-
TIGIT antibody includes a heavy chain variable region having at least 90%
(e.g., 91%, 92%, 93%, or
94%), or at least 95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or
the sequence of, SEQ ID
NO: 276, and a light chain variable region having at least 90% (e.g., 91%,
92%, 93%, or 94%), or at least
95% (e.g., 96%, 97%, 98%, or 99%) sequence identity to, or the sequence of,
SEQ ID NO: 277.
In another aspect, an anti-TIGIT antibody is provided, wherein the antibody
comprises a VH as in
any of the embodiments provided above, and a VL as in any of the embodiments
provided above,
wherein one or both of the variable domain sequences include post-
translational modifications.
In some instances, any one of the anti-TIGIT antibodies described above may be
capable of
binding to rabbit TIGIT, in addition to human TIGIT. In some instances, any
one of the anti-TIGIT
antibodies described above may be capable of binding to both human TIGIT and
cynomolgus monkey
(cyno) TIGIT. In some instances, any one of the anti-TIGIT antibodies
described above may be capable
of binding to human TIGIT, cyno TIGIT, and rabbit TIGIT. In some instances,
any one of the anti-TIGIT
antibodies described above (e.g., 4.1D3 or a derivative thereof) may be
capable of binding to human
TIGIT, cyno TIGIT, and rabbit TIGIT, but not murine TIGIT.
In some instances, the anti-TIGIT antibody binds human TIGIT with a Kd of
about 10 nM or lower
and cyno TIGIT with a Kd of about 10 nM or lower (e.g., binds human TIGIT with
a Kd of about 0.1 nM to
about 1 nM and cyno TIGIT with a Kd of about 0.5 nM to about 1 nM, e.g., binds
human TIGIT with a Kd
of about 0.1 nM or lower and cyno TIGIT with a Kd of about 0.5 nM or lower).
In some embodiments, the anti-TIGIT antibody is an antagonist antibody. The
antagonist
antibody may specifically bind TIGIT and inhibit or block TIGIT interaction
with poliovirus receptor (PVR)
(e.g., the antagonist antibody inhibits intracellular signaling mediated by
TIGIT binding to PVR). In some
.. instances, the antagonist antibody inhibits or blocks binding of human
TIGIT to human PVR with an IC50
72
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
value of 10 nM or lower (e.g., 1 nM to about 10 nM). In some instances, the
antagonist antibody inhibits
or blocks binding of cyno TIGIT to cyno PVR with an 1050 value of 50 nM or
lower (e.g., 1 nM to about 50
nM, e.g., 1 nM to about 5 nM).
In other embodiments, the anti-TIGIT antibody can be an agonist antibody. The
agonist antibody
can specifically bind TIGIT and stimulate the interaction of PVR with CD226 or
CD96. For example, the
agonist antibody can specifically bind TIGIT and stimulate the interaction of
PVR with CD226 and CD96
(e.g., binds human TIGIT and stimulates the interaction of human PVR with
human CD226 and human
CD96 and/or binds cyno TIGIT and stimulates the interaction of cyno PVR with
cyno CD226 and cyno
CD96).
In a further aspect, the invention provides an isolated antibody that competes
for binding to TIGIT
with any of the anti-TIGIT antibodies described above. In yet a further
aspect, the invention provides an
isolated antibody that binds to the same epitope as an anti-TIGIT antibody
described above.
An anti-T1GIT antibody according to any of the above embodiments is a
monoclonal antibody,
comprising a chimeric, humanized, or human antibody. In one embodiment, an
anti-TIGIT antibody is an
antibody fragment, for example, a Fv, Fab, Fab', scFv, diabody, or F(at:02
fragment. In another
embodiment, the antibody is a full-length antibody, e.g., an intact IgG
antibody (e.g., an intact IgG1
antibody) or other antibody class or isotype as defined herein.
In a further aspect, an anti-T1GIT antibody according to any of the above
embodiments may
incorporate any of the features, singly or in combination, as described in
Sections 1-7 below.
1. Antibody Affinity
In certain embodiments, an antibody (e.g.. an anti-TIGIT antibody) provided
herein has a
dissociation constant (Kd) of s 1pM, 5. 100 nM, 5. 10 nM, 5. 1 nM, 5. 0.1 nM,
5. 0.01 nM, or .5. 0.001 nM
(e.g., 10-,3M or less, e.g., from 1043M to 10-13M, e.g., from 10.9m to 10.13
M).
In one embodiment, Kd is measured by a radiolabeled antigen binding assay
(R1A). In one
embodiment, an R1A is performed with the Fab version of an antibody of
interest and its antigen. For
example, solution binding affinity of Fabs for antigen is measured by
equilibrating Fab with a minimal
concentration of (1281)-labeled antigen in the presence of a titration series
of unlabeled antigen, then
capturing bound antigen with an anti-Fab antibody-coated plate (see, e.g.,
Chen et al., J. Mot Biol.
293:865-881(1999)). To establish conditions for the assay, M1CROTITEfr multi-
well plates (Thermo
Scientific) are coated overnight with 5 pg/ml of a capturing anti-Fab antibody
(Cappel Labs) in 50 mM
sodium carbonate (pH 9.6), and subsequently blocked with 2% (w/v) bovine serum
albumin in PBS for
two to five hours at room temperature (approximately 23 C). In a non-adsorbent
plate (Nunc #269620),
100 pM or 26 pM [1251]-antigen are mixed with serial dilutions of a Fab of
interest (e.g., consistent with
assessment of the anti-VEGF antibody, Fab-12, in Presta et al., Cancer Res.
57:4593-4599 (1997)). The
Fab of interest is then incubated overnight; however, the incubation may
continue for a longer period
(e.g., about 65 hours) to ensure that equilibrium is reached. Thereafter, the
mixtures are transferred to
the capture plate for incubation at room temperature (e.g., for one hour). The
solution is then removed
and the plate washed eight times with 0.1% polysorbate 20 (TWEEN-200) in PBS.
When the plates have
dried, 150 p1/well of scintillant (MICROSCINT-20 TM; Packard) is added, and
the plates are counted on a
73
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
TOPCOUNT TM gamma counter (Packard) for ten minutes. Concentrations of each
Fab that give less
than or equal to 20% of maximal binding are chosen for use in competitive
binding assays.
According to another embodiment, Kd is measured using a BIACORE' surface
plasmon
resonance assay. For example, an assay using a BIACORE-2000 or a BIACORE-3000
(BlAcore, Inc.,
Piscataway, NJ) is performed at 25 C with immobilized antigen CM5 chips at ¨10
response units (RU). In
one embodiment, carboxymethylated dextran biosensor chips (CM5, BIACORE, Inc.)
are activated with
N-ethyl-Ar- (3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-
hydroxysuccinimide (NHS)
according to the supplier's instructions. Antigen is diluted with 10 mM sodium
acetate, pH 4.8, to 5 pg/ml
(-0.2 pM) before injection at a flow rate of 5 p1/minute to achieve
approximately 10 response units (RU) of
coupled protein. Following the injection of antigen, 1 M ethanolarnine is
injected to block unreacted
groups. For kinetics measurements, two-fold serial dilutions of Fab (0.78 nM
to 500 nM) are injected in
PBS with 0.05% polysorbate 20 (IA/VEEN-20m) surfactant (PBST) at 25 C at a
flow rate of approximately
25 pl/min. Association rates (kon) and dissociation rates (ko) are calculated
using a simple one-to-one
Langmuir binding model (BIACORE Evaluation Software version 3.2) by
simultaneously fitting the
association and dissociation sensorgrams. The equilibrium dissociation
constant (Kd) is calculated as the
ratio kodkon. See, for example. Chen et al., J. MoL Biol. 293:865-881 (1999).
If the on-rate exceeds
106M-1s-1 by the surface plasmon resonance assay above, then the on-rate can
be determined by using a
fluorescent quenching technique that measures the increase or decrease in
fluorescence emission
intensity (excitation = 295 nm; emission = 340 nm, 16 nm band-pass) at 25 C of
a 20 nM anti-antigen
antibody (Fab form) in PBS, pH 7.2, in the presence of increasing
concentrations of antigen as measured
in a spectrometer, such as a stop-flow equipped spectrophome.ter (Aviv
Instalments) or a 8000-series
SLM-AMINCO TM spectrophotometer (ThennoSpectronic) with a stirred cuvette.
2. Antibody Fragments
In certain embodiments, an antibody provided herein is an antibody fragment.
Antibody
fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(a13)2, Fv,
and scFv fragments, and other
fragments described below. For a review of certain antibody fragments, see
Hudson et al. Nat. Med.
9:129-134 (2003). For a review of scFv fragments, see, e.g., Pluckth0n, in The
Pharmacology of
Monoclonal Antibodies. vol. 113, Rosenburg and Moore eds., (Springer-Verlag,
New York), pp. 269-315
(1994); see also WO 93/16185; and U.S. Patent Nos. 5,571,894 and 5,587,458.
For discussion of Fab
and F(a1312 fragments comprising salvage receptor binding epitope residues and
having increased in viva
half-life, see U.S. Patent No. 5,869,046.
Diabodies are antibody fragments with two antigen-binding sites that may be
bivalent or
bispecific. See, for example, EP 404,097; WO 1993/01161; Hudson et al. Nat.
Med. 9:129-134 (2003);
and Hollinger et al. Proc. Na!!. Acad. Sci. USA 90: 6444-6448 (1993).
Triabodies and tetrabodies are
also described in Hudson et al. Nat. Med. 9:129-134 (2003).
Single-domain antibodies are antibody fragments comprising all or a portion of
the heavy chain
variable domain or all or a portion of the light chain variable domain of an
antibody. In certain
74
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
embodiments, a single-domain antibody is a human single-domain antibody
(Domantis, Inc., Waltham,
MA; see, e.g., U.S. Patent No. 6,248,516 B1).
Antibody fragments can be made by various techniques, including but not
limited to proteolytic
digestion of an intact antibody as well as production by recombinant host
cells (e.g. E. a* or phage), as
described herein.
3. Chimeric and Humanized Antibodies
In certain embodiments, an antibody provided herein is a chimeric antibody.
Certain chimeric
antibodies are described, e.g., in U.S. Patent No. 4,816,567: and Morrison at
al. Proc. Natl. Acad. Sc!.
USA, 81:6851-6855 (1984)). In one example, a chimeric antibody comprises a non-
human variable
region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or
non-human primate, such as
a monkey) and a human constant region. In a further example, a chimeric
antibody is a 'class switched"
antibody in which the class or subclass has been changed from that of the
parent antibody. Chimeric
antibodies include antigen-binding fragments thereof.
In certain embodiments, a chimeric antibody is a humanized antibody.
Typically, a non-human
antibody is humanized to reduce immunogenicity to humans, while retaining the
specificity and affinity of
the parental non-human antibody. Generally, a humanized antibody comprises one
or more variable
domains in which HVRs, e.g., CDRs, (or portions thereof) are derived from a
non-human antibody. and
FRs (or portions thereof) are derived from human antibody sequences. A
humanized antibody optionally
will also comprise at least a portion of a human constant region. In some
embodiments, some FR
residues in a humanized antibody are substituted with corresponding residues
from a non-human
antibody (e.g., the antibody from which the HVR residues are derived), e.g.,
to restore or improve
antibody specificity or affinity.
Humanized antibodies and methods of making them are reviewed, e.g., in Almagro
and
Fransson, Front. Biosci. 13:1619-1633 (2008), and are further described, e.g.,
in Riechmann et al.,
Nature 332:323-329 (1988): Queen et al., Proc. Nat'l Acad. Sci. USA 86:10029-
10033 (1989): US Patent
Nos. 5, 821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., Methods
36:25-34 (2005)
(describing specificity determining region (SDR) grafting); Padlan, Mot
Immunol. 28:489-498 (1991)
(describing "resurfacing"); Dall'Acqua et al., Methods 36:43-60 (2005)
(describing "FR shuffling"); and
Osbourn et al., Methods 36:61-68 (2005) and Klimka et al.. Br. J. Cancer,
83:252-260(2000) (describing
the "guided selection" approach to FR shuffling).
Human framework regions that may be used for humanization include but are not
limited to:
framework regions selected using the "best-fit" method (see, e.g., Sims et
al¨J. ltnrnunol. 151:2296
(1993)); framework regions derived from the consensus sequence of human
antibodies of a particular
subgroup of light or heavy chain variable regions (see, e.g., Carter et al.
Proc. Natl. Acad. Sc!. USA,
89:4285 (1992): and Presta at al. J. Immunolõ 151:2623 (1993)): human mature
(somatically mutated)
framework regions or human germline framework regions (see, e.g.. Almagro and
Fransson, Front.
Biosci. 13:1619-1633 (2008)); and framework regions derived from screening FR
libraries (see, e.g., Baca
et al., J. Biol. Chem. 272:10678-10684 (1997) and Rosok et al., J. Biol. Chem.
271:22611-22618 (1996)).
75
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
4. Human Antibodies
In certain embodiments, an antibody provided herein is a human antibody. Human
antibodies
can be produced using various techniques known in the art. Human antibodies
are described generally in
van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 368-74 (2001) and
Lonberg, Curr. Opin. Immunol.
20:450-459 (2008).
Human antibodies may be prepared by administering an immunogen to a transgenic
animal that
has been modified to produce intact human antibodies or intact antibodies with
human variable regions in
response to antigenic challenge. Such animals typically contain all or a
portion of the human
immunoglobulin loci, which replace the endogenous immunoglobulin loci, or
which are present
.. extrachromosomally or integrated randomly into the animal's chromosomes. In
such transgenic mice, the
endogenous immunoglobulin loci have generally been inactivated. For review of
methods for obtaining
human antibodies from transgenic animals, see Lonberg, Nat. Biotech. 23:1117-
1125 (2005). See also,
e.g., U.S. Patent Nos. 6,075,181 and 6,150,584 describing XENOMOUSETm
technology; U.S. Patent No.
5,770,429 describing HUMAN technology; U.S. Patent No. 7,041,870 describing K-
M MOUSEet
.. technology, and U.S. Patent Application Publication No. US 2007/0061900,
describing VELociMousEe
technology). Human variable regions from intact antibodies generated by such
animals may be further
modified, e.g., by combining with a different human constant region.
Human antibodies can also be made by hybridoma-based methods. Human myeloma
and
mouse-human heteromyeloma cell lines for the production of human monoclonal
antibodies have been
.. described. (See, e.g., Kozbor J. Immunot, 133: 3001 (1984); Brodeur et al.,
Monoclonal Antibody
Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New
York, 1987); and Boerner
et al., J. lmmunol., 147: 86 (1991).) Human antibodies generated via human B-
cell hybridoma technology
are also described in Li et al., Proc. Nat!. Acad. Sci. USA, 103:3557-3562
(2006). Additional methods
include those described, for example, in U.S. Patent No. 7,189,826 (describing
production of monoclonal
human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue,
26(4):265-268 (2006)
(describing human-human hybridomas). Human hybridoma technology (Trioma
technology) is also
described in Vollmers and Brandlein, Histology and Histopathology, 20(3):927-
937 (2005) and Vollmers
and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology,
27(3):185-91 (2005).
Human antibodies may also be generated by isolating FN./ clone variable domain
sequences
selected from human-derived phage display libraries. Such variable domain
sequences may then be
combined with a desired human constant domain. Techniques for selecting human
antibodies from
antibody libraries are described below.
5. Library-Derived Antibodies
Antibodies of the invention may be isolated by screening combinatorial
libraries for antibodies
with the desired activity or activities. For example, a variety of methods are
known in the art for
generating phage display libraries and screening such libraries for antibodies
possessing the desired
binding characteristics. Such methods are reviewed, e.g., in Hoogenboom et al.
in Methods in Molecular
Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001) and
further described, e.g., in the
.. McCafferty et al., Nature 348:552-554; Clackson et al, Nature 352: 624-628
(1991); Marks et al., J. Mot
76
CA 02994858 2018-02-05
WO 2017/053748
PCT/US2016/053368
Biot 222: 581-597 (1992); Marks and Bradbury, in Methods in Molecular Biology
248:161-175 (Lo, ed.,
Human Press, Totowa, NJ, 2003); Sidhu et at., J. Mot Biol. 338(2): 299-310
(2004); Lee et al., J. Mot
Biol. 340(5): 1073-1093 (2004); Fe!louse, Proc. Natl. Acad. Sc!. USA 101(34):
12467-12472 (2004); and
Lee et at., J. Immunot Methods 284(1-2): 119-132(2004).
In certain phage display methods, repertoires of VH and VL genes are
separately cloned by
polymerase chain reaction (PCR) and recombined randomly in phage libraries,
which can then be
screened for antigen-binding phage as described in Winter et at., Ann. Rev.
Immunot, 12: 433-455
(1994). Phage typically display antibody fragments, either as single-chain Fv
(scFv) fragments or as Fab
fragments. Libraries from immunized sources provide high-affinity antibodies
to the immunogen without
the requirement of constructing hybridomas. Alternatively, the naive
repertoire can be cloned (e.g., from
human) to provide a single source of antibodies to a wide range of non-self
and also self antigens without
any immunization as described by Griffiths et at., EMBO J, 12: 725-734 (1993).
Finally, naive libraries
can also be made synthetically by cloning unrearranged V-gene segments from
stem cells, and using
PCR primers containing random sequence to encode the highly variable CDR3
regions and to accomplish
rearrangement in vitro, as described by Hoogenboorn and Winter, J. Mot Biol.,
227: 381-388 (1992).
Patent publications describing human antibody phage libraries include, for
example: US Patent No.
5,750,373, and US Patent Publication Nos. 2005/0079574, 2005/0119455,
2005/0266000,
2007/0117126, 2007/0160598, 2007/0237764, 2007/0292936, and 2009/0002360.
Antibodies or antibody fragments isolated from human antibody libraries are
considered human
antibodies or human antibody fragments herein.
6. Multispecific Antibodies
In any one of the above aspects, the anti-TIGIT antibodies (e.g., 4 1D3 or a
variant thereof, e.g.,
4.1D3.01E) provided herein can be multispecific antibodies, for example,
bispecific antibodies.
Multispecific antibodies can be monoclonal antibodies that have binding
specificities for at least two
different sites. In certain embodiments, bispecific antibodies may bind to two
different epitopes on TIGIT.
In certain embodiments, one of the binding specificities is for TIGIT and the
other is for any other antigen
(e.g., a second biological molecule, e.g., a cell surface antigen, e.g., a
tumor antigen). Accordingly, a
bispecific anti-TIGIT antibody may have binding specificities for TIGIT and a
second biological molecule,
such as a PD-1, PD-L1, PD-U, 0X40, PD-1, CTLA-4, LAG3, TIM3, BTLA, VISTA,
B7H4, or CD96.
Bispecific antibodies can also be prepared as full-length antibodies or
antibody fragments.
In other embodiments, bispecific antibodies may bind to two different epitopes
of TIGIT, 0X40,
PD-1, PD-Ll , PD-L2. In certain embodiments, one of the binding specificities
is for TIGIT and the other is
for any other antigen (e.g., a second biological molecule, such as 0X40). In
other embodiments, the
bispecific antibody may have binding specificity for TIGIT and PD-L1; TIGIT
and PD-L2; TIGIT and PD-1;
TIGIT and CTLA-4: TIGIT and LAG3; TIGIT and TIM3; TIGIT and BTLA; TIGIT and
VISTA; TIGIT and
87H4; or TIGIT and CD96, wherein the bispecific antibody is preferably an
antagonist antibody for TIGIT
and an antagonist antibody for its second target. In other embodiments, the
bispecific antibody may have
binding specificity for TIGIT and CD226; TIGIT and CD28; TIGIT and CD27; TIGIT
and CD137; TIGIT and
HVEM; TIGIT and GITR; TIGIT and MICA; TIGIT and ICOS; TIGIT and NKG2D; or
TIGIT and 2B4,
77
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
wherein the bispecific antibody is preferably an antagonist antibody for TIGIT
and for its second target. In
other embodiments, the bispecific antibody may have binding specificity for
TIGIT that is not antagonistic
in nature (i.e., the bispecific antibody does not have act as a TIGIT
antagonist).
Techniques for making multispecific antibodies include, but are not limited
to, recombinant co-
expression of two immunoglobulin heavy chain-light chain pairs having
different specificities (see Milstein
and Cuello, Nature 305: 537 (1983)), WO 93/08829, and Traunecker et al., EMBO
J. 10: 3655 (1991)),
and "knob-in-hole" engineering (see. e.g., U.S. Patent No. 5,731,168). "Knob-
in-hole" engineering of
multispecific antibodies may be utilized to generate a first arm containing a
knob and a second arm
containing the hole into which the knob of the first arm may bind. The knob of
the multispecific antibodies
of the invention may be an anti-TIGIT arm in one embodiment Alternatively, the
knob of the multispecific
antibodies of the invention may be an anti-TIGIT arm in one embodiment.
Multispecific antibodies may
also be engineered using immunoglobulin crossover (also known as Fab domain
exchange or CrossMab
format) technology (see e.g., W02009/080253; Schaefer et al., Proc. Nat!.
Acad. Sci. USA, 108:11187-
11192 (2011)). Multispecific antibodies may also be made by engineering
electrostatic steering effects
for making antibody Fc-heterodimeric molecules (WO 2009/089004A1); cross-
linking two or more
antibodies or fragments (see, e.g., US Patent No. 4,676,980, and Brennan et
al., Science, 229: 81
(1985)); using leucine zippers to produce bi-specific antibodies (see, e.g.,
Kostelny et al., J. linmunol.,
148(5):1547-1553 (1992)); using "diabody" technology for making bispecific
antibody fragments (see,
e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and
using single-chain Fv (sFv)
dimers (see,e.g. Gruber et al., J. Immunoi., 152:5368 (1994)); and preparing
trispecific antibodies as
described, e.g., in Tutt et al. J. immunot 147: 60 (1991).
Engineered antibodies with three or more functional antigen binding sites,
including 'Octopus
antibodies," are also included herein (see, e.g. US 2006/0025576A1).
The antibodies, or antibody fragments thereof, may also include a "Dual Acting
FAb" or "DAF"
comprising an antigen binding site that binds to TIGIT as well as another,
different antigen (e.g., a second
biological molecule) (see, e.g., US 2008/0069820).
7. Antibody Variants
In certain embodiments, amino acid sequence variants of the anti-TIGIT
antibodies of the
invention are contemplated. As described in detail herein, anti-TIGIT
antibodies may be optimized based
on desired structural and functional properties. For example, it may be
desirable to improve the binding
affinity and/or other biological properties of the antibody. Amino acid
sequence variants of an antibody
may be prepared by introducing appropriate modifications into the nucleotide
sequence encoding the
antibody, or by peptide synthesis. Such modifications include, for example,
deletions from, and/or
insertions into and/or substitutions of residues within the amino acid
sequences of the antibody. Any
combination of deletion, insertion, and substitution can be made to arrive at
the final construct, provided
that the final construct possesses the desired characteristics, for example,
antigen-binding.
78
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
I. Substitution, insertion, and Deletion Variants
In certain embodiments, antibody variants having one or more amino acid
substitutions are
provided. Sites of interest for substitutional mutagenesis include the HVRs
and FRs. Conservative
substitutions are shown in Table 1 under the heading of 'preferred
substitutions." More substantial
changes are provided in Table I under the heading of "exemplary
substitutions," and as further described
below in reference to amino acid side chain classes. Amino acid substitutions
may be introduced into an
antibody of interest and the products screened for a desired activity, for
example, retained/improved
antigen binding, decreased immunogenicity, or improved ADCC or CDC.
Table 1. Exemplary and Preferred Amino Acid Substitutions
Original Exemplary Preferred
Residue Substitutions Substitutions
Ala (A) Val; Leo; Ile Val
Arg (R) Lys; Gin; Asn Lys
Asn (N) Gin; His; Asp, Lys; Arg Gin
Asp (D) Glu; Asn Giu
Cys (C) Ser; Ala Ser
Gin (0) Asa; Giu Asn
Giu (E) Asp; Gin Asp
Gly (G) Ala Ala
His (H) Asn: Gin; Lys; Arg Arg
Ile (I) Lou; Val; Met; Ala; Phe; Norleucine Leu
Lou (L) Norleucine; Ile; Val; Met; Ala; Phe lie
Lys (K) Arg; Gin; Asn Arg
Met (M) Leo; Phe; Ile Leu
Phe (F) Trp; Leu: Val; Ile; Ala; Tyr Tyr
Pro (P) Ala Ala
Ser (S) Thr Thr
Thr (T) Val; Ser Ser
Trp (W) Tyr; Phe Tyr
Tyr (Y) Trp; Phe; Thr; Ser Phe
Val (V) lie; Lou; Met; Phe; Ala; Norleucine Leu
Amino acids may be grouped according to common side-chain properties:
(1) hydrophobic. Norleucine, Met, Ala, Val, Leu, Ile;
(2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gin:
79
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
(3) acidic: Asp, Glu;
(4) basic: His, Lys, Arg;
(5) residues that influence chain orientation: Gly, Pro;
(6) aromatic: Trp, Tyr, Phe.
Non-conservative substitutions will entail exchanging a member of one of these
classes for
another class.
One type of substitutional variant involves substituting one or more
hypervariable region residues
of a parent antibody (e.g. a humanized or human antibody). Generally, the
resulting variant(s) selected
for further study will have modifications (e.g., improvements) in certain
biological properties (e.g.,
increased affinity, reduced irnmunogenicity) relative to the parent antibody
and/or will have substantially
retained certain biological properties of the parent antibody. An exemplary
substitutional variant is an
affinity matured antibody, which may be conveniently generated, e.g., using
phage display-based affinity
maturation techniques such as those described herein. Briefly, one or more HVR
residues are mutated
and the variant antibodies displayed on phage and screened for a particular
biological activity (e.g.
binding affinity).
Alterations (e.g., substitutions) may be made in HVRs, e.g., to improve
antibody affinity. Such
alterations may be made in HVR ¶hotspots,÷ i.e., residues encoded by codons
that undergo mutation at
high frequency during the somatic maturation process (see, e.g., Chowdhury,
Methods Mot Biol.
207:179-196 (2008)), and/or residues that contact antigen, with the resulting
variant VH or VL being
tested for binding affinity. Affinity maturation by constructing and
reselecting from secondary libraries has
been described, e.g., in Hoogenboom et at. in Methods in Molecular Biology
178:1-37 (O'Brien et al., ed.,
Human Press, Totowa, NJ, (2001).) In some embodiments of affinity maturation,
diversity is introduced
into the variable genes chosen for maturation by any of a variety of methods
(e.g., error-prone PCR,
chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library
is then created. The library
is then screened to identify any antibody variants with the desired affinity.
Another method to introduce
diversity involves HVR-directed approaches, in which several HVR residues
(e.g., 4-6 residues at a time)
are randomized. HVR residues involved in antigen binding may be specifically
identified, e.g., using
alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are
often targeted.
In certain embodiments, substitutions, insertions, or deletions may occur
within one or more
HVRs so long as such alterations do not substantially reduce the ability of
the antibody to bind antigen.
For example, conservative alterations (e.g., conservative substitutions as
provided herein) that do not
substantially reduce binding affinity may be made in HVRs. Such alterations
may, for example, be
outside of antigen contacting residues in the HVRs. In certain embodiments of
the variant VH and VL
sequences provided above, each HVR either is unaltered, or contains no more
than one, two or three
amino acid substitutions.
A useful method for identification of residues or regions of an antibody that
may be targeted for
mutagenesis is called "alanine scanning mutagenesis' as described by
Cunningham and Wells (1989)
Science, 244:1081-1085. In this method, a residue or group of target residues
(e.g., charged residues
such as ars asp, his, lys, and glu) are identified and replaced by a neutral
or negatively charged amino
acid (e.g., alanine or polyalanine) to determine whether the interaction of
the antibody with antigen is
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
affected. Further substitutions may be introduced at the amino acid locations
demonstrating functional
sensitivity to the initial substitutions. Alternatively, or additionally, a
crystal structure of an antigen-
antibody complex to identify contact points between the antibody and antigen.
Such contact residues and
neighboring residues may be targeted or eliminated as candidates for
substitution. Variants may be
screened to determine whether they contain the desired properties.
Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions
ranging in length
from one residue to polypeptides containing a hundred or more residues, as
well as intrasequence
insertions of single or multiple amino acid residues. Examples of terminal
insertions include an antibody
with an N-terminal methionyl residue. Other insertional variants of the
antibody molecule include the
fusion to the N- or C-terminus of the antibody to an enzyme (e.g. for ADEPT)
or a polypeptide which
increases the serum half-life of the antibody.
11. Glycosy1ation variants
In certain embodiments, anti-TIGIT antibodies of the invention (e.g., 4.1D3 or
a variant thereof,
e.g., 4.1 D3.01 E) can be altered to increase or decrease the extent to which
the antibody is glycosylated.
Addition or deletion of glycosylation sites to anti-TIGIT antibody of the
invention may be conveniently
accomplished by altering the amino acid sequence such that one or more
glycosylation sites is created or
removed.
Where the antibody comprises an Fe region, the carbohydrate attached thereto
may be altered.
Native antibodies produced by mammalian cells typically comprise a branched,
biantennary
oligosaccharide that is generally attached by an N-linkage to Asn297 of the Cl-
12 domain of the Fc region.
See, e.g., Wright et al. TIB TECH 15:26-32 (1997). The oligosaccharide may
include various
carbohydrates, e.g., mannose, N-acetyl glucosamine (GIcNAc), galactose, and
sialic acid, as well as a
fucose attached to a GIcNAc in the "stem of the biantennary oligosaccharide
structure. In some
embodiments, modifications of the oligosaccharide in an antibody of the
invention may be made in order
to create antibody variants with certain improved properties.
In one embodiment, anti-TIGIT antibody variants are provided having a
carbohydrate structure
that lacks fucose attached (directly or indirectly) to an Fc region. For
example, the amount of fucose in
such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65% or from
20% to 40%. The
amount of fucose is determined by calculating the average amount of fucose
within the sugar chain at
Asn297, relative to the sum of all glycostructures attached to Asn 297 (e, g.
complex, hybrid and high
mannose structures) as measured by MALDI-TOF mass spectrometry, as described
in WO 2008/077546,
for example. Asn297 refers to the asparagine residue located at about position
297 in the Fe region (EU
numbering of Fc region residues); however, Asn297 may also be located about
3 amino acids upstream
or downstream of position 297, i.e., between positions 294 and 300, due to
minor sequence variations in
antibodies. Such fucosylation variants may have improved ADCC function. See,
e.g., US Patent
Publication Nos. US 2003/0157108 (Presta, L.); US 2004/0093621 (Kyowa Hakko
Kogyo Co., Ltd).
Examples of publications related to ¶defucosylated" or "fucose-deficient"
antibody variants include: US
2003/0157108: WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328;
US
2004/0093621: US 2004/0132140; US 200410110704; US 2004/0110282; US
2004/0109865; WO
81
CA 02994858 2018-02-05
WO 2017/053748 PCT/U52016/053368
2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778; W02005/053742;
W02002/031140; Okazaki et al. J. Mot Biol. 336:1239-1249 (2004); Yamane-
Ohntiki et al. Biotech.
Bioeng. 87: 614 (2004). Examples of cell lines capable of producing
defucosylated antibodies include
Lec13 CHO cells deficient in protein fucosylation (Ripka et al. Arch. Biochem.
Biophys. 249:533-545
(1986); US Pat Appl No US 2003/0157108 Al, Presta, L; and WO 2004/056312 Al,
Adams et al.,
especially at Example 11), and knockout cell lines, such as alpha-1,6-
fucosyltransferase gene, FUT8,
knockout CHO cells (see, e.g., Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614
(2004); Kanda, Y. et al.,
Bioteohnol. Bioeng., 94(4):680-688 (2006); and W02003/085107).
Anti-TIGIT antibodies variants are further provided with bisected
oligosaccharides, for example, in
which a biantermary oligosaccharide attached to the Fc region of the antibody
is bisected by GIcNAc.
Such antibody variants may have reduced fucosylation and/or improved ADCC
function. Examples of
such antibody variants are described, e.g., in WO 2003/011878 (Jean-Mairet et
al.); US Patent No.
6,602,684 (Umana et al.); and US 2005/0123546 (Umana etal.). Antibody variants
with at least one
galactose residue in the oligosaccharide attached to the Fc region are also
provided. Such antibody
variants may have improved CDC function. Such antibody variants are described,
e.g., in WO
1997/30087 (Patel et al.); WO 1998/58964 (Rajti, S.); and WO 1999/22764 (Raju,
S.).
Fc region variants
In certain embodiments, one or more amino acid modifications may be introduced
into the Fc
region of an anti-TIGIT antibody of the invention (e.g., 4.1D3 or a valiant
thereof, e.g., 4.1D3.Q1E),
thereby generating an Fc region variant (see e.g., US 2012/0251531). The Fc
region variant may
comprise a human Fc region sequence (e.g., a human IgG1 , IgG2, lgG3 or IgG4
Fc region) comprising
an amino acid modification (e.g., a substitution) at one or more amino acid
positions.
In certain embodiments, the invention contemplates an anti-TIGIT antibody
variant that
possesses some but not all effector functions, which make it a desirable
candidate for applications in
which the half life of the antibody in vivo is important yet certain effector
functions (such as complement
and ADCC) are unnecessary or deleterious. In vitro and/or in vivo cytotoxicity
assays can be conducted
to confirm the reduction/depletion of CDC and/or ADCC activities. For example,
Fc receptor (FcR)
binding assays can be conducted to ensure that the antibody lacks Fc-1R
binding (hence likely lacking
ADCC activity), but retains FcRn binding ability. The primary cells for
mediating ADCC, NK cells. express
FcyRIII only, whereas monocytes express FcyRI, FcyRil and FcyRill. FcR
expression on hematopoietic
cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev.
Immunot 9:457-492
(1991). Non-limiting examples of in vitro assays to assess ADCC activity of a
molecule of interest is
described in U.S. Patent No. 5,500,362 (see, e.g. Hellstrom, I. et al. Proc.
Nat'l Acad. Sci. USA 83:7059-
7063 (1986)) and Hellstrom, I et al., Proc. Nat'l Acad. Sci. USA 82:1499-1502
(1985); 5,821,337 (see
Bruggernann, M. et al., J. Exp. Med. 166:1351-1361(1987)). Alternatively, non-
radioactive assays
methods may be employed (see, for example, ACTI TM non-radioactive
cytotoxicity assay for flow
cytometry (CellTechnology, Inc. Mountain View, CA; and CytoTox 96 non-
radioactive cytotoxicity assay
(Promega, Madison, WI). Useful effector cells for such assays include
peripheral blood mononuclear
cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally,
ADCC activity of the molecule of
82
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
interest may be assessed in vivo, e.g., in a animal model such as that
disclosed in Clynes et al. Proc.
Nat? Acad. Sci USA 95:652-656 (1998). Clq binding assays may also be carried
out to confirm that the
antibody is unable to bind Clq and hence lacks CDC activity. See, e.g., Clq
and C3c binding ELISA in
WO 2006/029879 and WO 2005/100402. To assess complement activation, a CDC
assay may be
performed (see, for example. Gazzano-Santoro etal. J. Immunol. Methods 202:163
(1996); Gregg, M.S.
et al. Blood. 101:1045-1052 (2003); and Cragg, M.S. and M.J. Glennie Blood.
103:2738-2743 (2004)).
FoRn binding and in vivo clearance/half life determinations can also be
performed using methods known
in the art (see, e.g., Petkova, S.B. et al. Intl Immunol. 18(12):1759-1769
(2006)).
Antibodies with reduced effector function include those with substitution of
one or more of Fc
region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Patent Nos.
6,737,056 and 8,219,149). Such
Fe mutants include Fe mutants with substitutions at two or more of amino acid
positions 265, 269, 270,
297 and 327, including the so-called "DANA' Fe mutant with substitution of
residues 265 and 297 to
alanine (US Patent No. 7,332,581 and 8,219,149).
In certain embodiments, the proline at position 329 of a wild-type human Fc
region in the antibody
is substituted with glycine or arginine or an amino acid residue large enough
to destroy the proline
sandwich within the Fc/Fc.gamma. receptor interface that is formed between the
proline 329 of the Fc
and tryptophan residues lip 87 and Trp 110 of FegRIII (Sondermann et al.:
Nature 406,267-273 (20 Jul.
2000)). In certain embodiments, the antibody comprises at least one further
amino acid substitution. In
one embodiment, the further amino acid substitution is S228P, E233P, L234A,
L235A, L235E, N297A,
N297D, or P331S, and still in another embodiment the at least one further
amino acid substitution is
L234A and L235A of the human IgG1 Fc region or S228P and L235E of the human
IgG4 Fc region (see
e.g., US 2012/0251531), and still in another embodiment the at least one
further amino acid substitution
is L234A and L235A and P329G of the human IgG1 Fc region.
Certain antibody variants with improved or diminished binding to FcRs are
described. (See, e.g.,
U.S. Patent No. 6,737,056; WO 2004/056312, and Shields et al., J. Biol. Chern.
9(2): 6591-6604 (2001))
In certain embodiments, an antibody variant comprises an Fc region with one or
more amino acid
substitutions which improve ADCC, e.g., substitutions at positions 298, 333,
and/or 334 of the Fe region
(EU numbering of residues).
In some embodiments, alterations are made in the Fe region that result in
altered (i.e.. either
improved or diminished) Clq binding and/or Complement Dependent Cytotoxicity
(CDC), e.g., as
described in US Patent No. 6,194,551, WO 99/51642, and ldusogie et al. J.
lmmunol. 164: 4178-4184
(2000).
Antibodies with increased half lives and improved binding to the neonatal Fc
receptor (FeRn),
which is responsible for the transfer of maternal IgGs to the fetus (Guyer et
al., J. Immunol. 117:587
(1976) and Kim et al., J. lmmunot 24:249(1994)), are described in
U52005/0014934A1 (Hinton et al.).
Those antibodies comprise an Fc region with one or more substitutions therein
which improve binding of
the Fe region to FeRn. Such Fe variants include those with substitutions at
one or more of Fc region
residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356.
360, 362, 376, 378, 380, 382,
413, 424 or 434, e.g., substitution of Fc region residue 434 (US Patent No.
7,371,826).
83
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
See also Duncan & Winter, Nature 322:738-40 (1988); U.S. Patent No. 5,648,260;
U.S. Patent
No. 5,624,821; and WO 94/29351 concerning other examples of Fe region
variants.
In some aspects the anti-TIGIT antibody (e.g., 4.103 or a variant thereof,
e.g., 4.1D3.Q1E)
comprises an Fc region comprising an N297G mutation.
In some embodiments, the anti-TIGIT antibody (e.g., 4.103 or a variant
thereof, e.g., 4.1D3.01E)
comprises one or more heavy chain constant domains, wherein the one or more
heavy chain constant
domains are selected from a first CH1 (CHI 1) domain, a first CH2 (CI-12/)
domain, a first CH3 (CH3/)
domain, a second CH1 (CH12) domain, second CH2 (CH22) domain, and a second CH3
(CH32) domain.
In some instances, at least one of the one or more heavy chain constant
domains is paired with another
heavy chain constant domain In some instances, the CH31 and CH32 domains each
comprise a
protuberance or cavity, and wherein the protuberance or cavity in the CH3/
domain is positionable in the
cavity or protuberance, respectively, in the CH32 domain. In some instances,
the CH3/ and CH32
domains meet at an interface between said protuberance and cavity. In some
instances, the CH21 and
CH22 domains each comprise a protuberance or cavity, and wherein the
protuberance or cavity in the
Cl-121 domain is positionable in the cavity or protuberance, respectively, in
the CH22 domain. In other
instances, the 0H2/ and CH22 domains meet at an interface between said
protuberance and cavity. in
some instances, the anti-TIGIT antibody is an IgG1 antibody.
IV. Cysteine engineered antibody variants
In certain embodiments, it may be desirable to create cysteine engineered
antibodies, e.g.,
"thioMAbs," in which one or more residues of an antibody are substituted with
cysteine residues. In
particular embodiments, the substituted residues occur at accessible sites of
the antibody. By
substituting those residues with cysteine, reactive thiol groups are thereby
positioned at accessible sites
of the antibody and may be used to conjugate the antibody to other moieties,
such as drug moieties or
linker-drug moieties, to create an immunoconjugate, as described further
herein. In certain embodiments,
any one or more of the following residues may be substituted with cysteine:
V205 (Kabat numbering) of
the light chain; A118 (EU numbering) of the heavy chain; and 6400 (EU
numbering) of the heavy chain Fc
region. Cysteine engineered antibodies may be generated as described, for
example, in U.S. Patent No.
7,521,541.
V. Antibody derivatives
In certain embodiments, an anti-TIGIT antibody of the invention (e.g., 4.103
or a variant thereof,
e.g., 4.103.Q1E) provided herein may be further modified to contain additional
nonproteinaceous
moieties that are known in the art and readily available. The moieties
suitable for derivatization of the
antibody include but are not limited to water soluble polymers. Non-limiting
examples of water soluble
polymers include, but are not limited to, polyethylene glycol (PEG),
copolymers of ethylene
glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol,
polyvinyl pyrrolidone, poly-1,
3-dioxolane, poly-1,3,6-trioxane, ethyiene/maleic anhydride copolymer,
poiyaminoacids (either
homopolymers or random copolymers), and dextran or poly(n-vinyl
pyrrolidone)polyethylene glycol,
propropylene glycol homopolymers, prolypropylene oxide/ethylene oxide co-
polymers, polyoxyethylated
84
WO 2017/053748 PCT/US2016/053368
polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof.
Polyethylene glycol propionaldehyde may
have advantages in manufacturing due to its stability in water. The polymer
may be of any molecular
weight, and may be branched or unbranched. The number of polymers attached to
the antibody may
vary, and if more than one polymer are attached, they can be the same or
different molecules. in
general, the number and/or type of polymers used for derivatization can be
determined based on
considerations including, but not limited to, the particular properties or
functions of the antibody to be
improved, whether the antibody derivative will be used in a therapy under
defined conditions, etc.
in another embodiment, conjugates of an antibody and nonproteinaceous moiety
that may be
selectively heated by exposure to radiation are provided. in one embodiment,
the nonproteinaceous
moiety is a carbon nanotube (Kam et al., Proc. Nat!. Acad. Sci. USA 102: 11600-
11605 (2005)). The
radiation may be of any wavelength, and includes, but is not limited to,
wavelengths that do not harm
ordinary cells, but which heat the nonproteinaceous moiety to a temperature at
which cells proximal to the
antibody-nonproteinaceous moiety are killed.
W. Recombinant Methods and Compositions
Anti-TIGIT antibodies of the invention (e.g., 4.1D3 or a variant thereof,
e.g., 4.103.01E) may be
produced using recombinant methods and compositions, for example, as described
in U.S. Patent No.
4,816,567. In one embodiment, isolated nucleic acid encoding an anti-TIGIT
antibody described herein is
provided. Such nucleic acid may encode an amino acid sequence comprising the
VL and/or an amino
acid sequence comprising the VH of the antibody (e.g., the light and/or heavy
chains of the antibody). In a
further embodiment, one or more vectors (e.g., expression vectors) comprising
such nucleic acid are
provided. in a further embodiment, a host cell comprising such nucleic acid is
provided. In one such
embodiment, a host cell comprises (e.g., has been transformed with): (1) a
vector comprising a nucleic
acid that encodes an amino acid sequence comprising the VL of the antibody and
an amino acid
sequence comprising the VH of the antibody, or (2) a first vector comprising a
nucleic acid that encodes
an amino acid sequence comprising the VL of the antibody and a second vector
comprising a nucleic acid
that encodes an amino acid sequence comprising the VH of the antibody. In one
embodiment, the host
cell is eukaryotic, e.g, a Chinese Hamster Ovary
(CHO) cell or lymphoid cell (e.g., YO, NSO, Sp20 cell). In one embodiment, a
method of making an anti-
TIGIT antibody is provided, wherein the method comprises culturing a host cell
comprising a nucleic acid
encoding the antibody, as provided above, under conditions suitable for
expression of the antibody, and
optionally recovering the antibody from the host cell (or host cell culture
medium).
For recombinant production of an anti-TIGIT antibody, nucleic acid encoding an
antibody, e.g,, as
described above, is isolated and inserted into one or more vectors for further
cloning and/or expression in
a host cell. Such nucleic acid may be readily isolated and sequenced using
conventional procedures
(e.g., by using oligonucleotide probes that are capable of binding
specifically to genes encoding the
heavy and light chains of the antibody).
Suitable host cells for cloning or expression of antibody-encoding vectors
include prokaryotic or
eukaryotic cells described herein. For example, antibodies may be produced in
bacteria, in particular
when glycosylation and Fc effector function are not needed. For expression of
antibody fragments and
Date Recue/Date Received 2021-04-08
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
polypeptides in bacteria, see, e.g., U.S. Patent Nos. 5,648,237, 5,789,199,
and 5,840,523. (See also
Charlton, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana
Press, Totowa, NJ, 2003), pp.
245-254, describing expression of antibody fragments in E co/i.) After
expression, the antibody may be
isolated from the bacterial cell paste in a soluble fraction and can be
further purified.
In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or
yeast are suitable
cloning or expression hosts for antibody-encoding vectors, including fungi and
yeast strains whose
glycosylation pathways have been "humanized," resulting in the production of
an antibody with a partially
or fully human glycosylation pattern. See Gerngross, Nat. Biotech. 22:1409-
1414 (2004), and Li et al.,
Nat. Biotech. 24:210-215 (2006).
Suitable host cells for the expression of glycosylated antibody are also
derived from multicellular
organisms (invertebrates and vertebrates). Examples of invertebrate cells
include plant and insect cells.
Numerous baculoviral strains have been identified which may be used in
conjunction with insect cells,
particularly for transfection of Spodoptera frugiperda cells.
Plant cell cultures can also be utilized as hosts. See. e.g., US Patent Nos.
5,959,177, 6,040,498,
6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIESTm technology for
producing antibodies
in transgenic plants).
Vertebrate cells may also be used as hosts. For example, mammalian cell lines
that are adapted
to grow in suspension may be useful. Other examples of useful mammalian host
cell lines are monkey
kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293
or 293 cells as
described, e.g., in Graham et al., J. Gen Virot 36:59 (1977)); baby hamster
kidney cells (BHK); mouse
sertoli cells (TM4 cells as described, e.g., in Mather, Biol. Reprod. 23:243-
251 (1980)); monkey kidney
cells (CV1): African green monkey kidney cells (VER0-76); human cervical
carcinoma cells (HELA);
canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A): human lung cells
(W138); human liver cells
(Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in
Mather et al., Annals
N.Y. Acad. Sci. 383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful
mammalian host cell lines
include Chinese hamster ovary (CHO) cells, including DHFR- CHO cells (Urlaub
et al., Proc. NatL Acad.
ScL USA 77:4216 (1980)); and myeloma cell lines such as YO, NSO and Sp2/0. For
a review of certain
mammalian host cell lines suitable for antibody production, see, e.g., Yazaki
and Wu, Methods in
Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ), pp.
255-268 (2003).
V. Immunoconjugates
The invention also provides immunoconjugates comprising an anti-TIGIT antibody
of the
invention (e.g., 4.1D3 or a variant thereof, e.g., 4.1D3.Q1E) conjugated to
one or more cytotoxic agents,
such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins
(e.g., protein toxins,
enzymatically active toxins of bacterial, fungal, plant, or animal origin, or
fragments thereof), or radioactive
isotopes.
In one embodiment, an immunoconjugate is an antibody-drug conjugate (ADC) in
which an
antibody is conjugated to one or more drugs, including but not limited to a
maytansinoid (see U.S. Patent
Nos. 5,208,020, 5,416,064 and European Patent EP 0 425 235 B1); an auristatin
such as
monomethylauristatin drug moieties DE and DF (MMAE and MMAF) (see U.S. Patent
Nos. 5,635,483 and
86
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
5,780,588, and 7,498,298); a dolastatin; a calicheamicin or derivative thereof
(see U.S. Patent Nos.
5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001,
and 5,877,296; Hinman et
al., Cancer Res. 53:3336-3342 (1993); and Lode et al., Cancer Res. 58:2925-
2928 (1998)); an
anthracycline such as daunomycin or doxorubicin (see Kratz et al., Current
Med. Chem. 13:477-523
(2006); Jeffrey et al., Bioorganic & Med. Chem. Letters 16:358-362 (2006);
Torgov et at. Bioconj. Chem.
16:717-721 (2005); Nagy et at., Proc. Natl. Acad. Sci. USA 97:829-834 (2000);
Dubowchik et al., Bioorg.
& Med. Chem. Letters 12:1529-1532 (2002); King et al, J. Med. Chem. 45:4336-
4343 (2002); and U.S.
Patent No. 6,630,579); methotrexate; vindesine; a taxane such as clocetaxel,
paclitaxel, larotaxel,
tesetaxel, and ortataxel; a trithothecene; and CC1065.
In another embodiment, an immunoconjugate comprises an anti-TIGIT antibody as
described
herein (e.g., 4.1D3 or a variant thereof, e.g., 4.1D3.Q1E) conjugated to an
enzymatically active toxin or
fragment thereof, including but not limited to diphtheria A chain, nonbinding
active fragments of diphtheria
toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A
chain, modeccin A chain,
alpha-sarcin, Aleurites fordii proteins, dianthin proteins. Phytolaca
americana proteins (PAPI, PAPII, and
PAP-S), momoriclica charantia inhibitor, curcin, cretin, sapaonaria
officinalis inhibitor, gelonin, mitogellin,
restrictodn, phenomycin, enomycin, and the tricothecenes.
In another embodiment, an immunoconjugate comprises an anti-TIGIT antibody as
described
herein (e.g., 4.1D3 or a variant thereof, e.g., 4.1D3.01E) conjugated to a
radioactive atom to form a
radioconjugate. A variety of radioactive isotopes are available for the
production of radioconjugates.
Examples include At211,1131, 1125, yso, Relee, Re'08, smi53, Bi212, P32, pb212
and radioactive isotopes of Lu.
When the radioconjugate is used for detection, it may comprise a radioactive
atom for scintigraphic
studies, for example tc99m or 1123, or a spin label for nuclear magnetic
resonance (NMR) imaging (also
known as magnetic resonance imaging, mri), such as iodine-123 again, iodine-
131, indium-111, fluorine-
19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.
Conjugates of an antibody and cytotoxic agent may be made using a variety of
bifunctional
protein coupling agents such as N-succinimidy1-3-(2-pyridyldithio) propionate
(SPDP), succinimidy1-4-(N-
maleimidomethyl) cyclohexane-l-carboxylate (SMCC), iminothiolane (IT),
bifunctional derivatives of
imidoesters (such as dimethyl adipimidate HCI), active esters (such as
disuccinimidyl suberate),
aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-
azidobenzoyl) hexanediamine),
bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyI)-ethylenediamine),
diisocyanates (such as
toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-
difluoro-2,4-dinitrobenzene).
For example. a dcin immunotoxin can be prepared as described in Vitetta et
al., Science 238:1098
(1987). Carbon-14-labeled 1-isothiocyartatobenzy1-3-methyldiethylene
triaminepentaacetic acid (MX-
DTPA) is an exemplary chelating agent for conjugation of radionucleotide to
the antibody. See
W094/11026. The linker may be a "cleavable linker" facilitating release of a
cytotoxic drug in the cell.
For example, an acid-labile linker, peptidase-sensitive linker, photolabile
linker, dimethyl linker or
disulfide-containing linker (Chad et al., Cancer Res. 52:127-131 (1992); U.S.
Patent No. 5,208,020) may
be used.
The immunuoconjugates or ADCs herein expressly contemplate, but are not
limited to such
conjugates prepared with cross-linker reagents including, but not limited to,
BMPS, EMCS, GMBS, HBVS,
87
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS,
sulfo-
KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and stilfo-SMPB, and SVSB
(succinimidy1-(4-
vinylsulfone)benzoate) which are commercially available (e.g., from Pierce
Biotechnology, Inc., Rockford,
IL., U.S.A).
VI. Methods and Compositions for Diagnostics and Detection
In certain embodiments, any of the anti-TIGIT antibodies of the invention
(e.g., 4.1D3 or a variant
thereof, e.g., 4.1 D3.Q1E) is useful for detecting the presence of TIG1T in a
biological sample. The term
"detecting" as used herein encompasses quantitative or qualitative detection.
In certain embodiments, a
biological sample comprises a cell or tissue.
In one embodiment, an anti-TIGIT antibody for use in a method of diagnosis or
detection is
provided. In a further aspect, a method of detecting the presence of TIGIT in
a biological sample is
provided. In certain embodiments, the method comprises contacting the
biological sample with an anti-
TIGIT antibody as described herein under conditions permissive for binding of
the anti-TIGIT antibody to
TIG1T, and detecting whether a complex is formed between the anti-TIGIT
antibody and TIGIT. Such
method may be an in vitro or in vivo method.
In certain embodiments, labeled anti-TIGIT antibodies are provided. Labels
include, but are not
limited to, labels or moieties that are detected directly (such as
fluorescent, chromophoric, electron-
dense, chemiluminescent: and radioactive labels), as well as moieties, such as
enzymes or ligands, that
are detected indirectly, e.g., through an enzymatic reaction or molecular
interaction. Exemplary labels
include, but are not limited to, the radioisotopes 32P, 14C, 125i, 31-1, and
13,1, fluorophores such as rare earth
chelates or fluorescein and its derivatives, rhodamine and its derivatives,
dansyl, umbelliferone,
luceriferases, e.g., firefly luciferase and bacterial luciferase (U.S. Patent
No. 4,737,456), luciferin, 2,3-
dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase,
p-galactosidase,
glucoamylase, lysozyme, saccharide oxidases, e.g., glucose oxidase, galactose
oxidase, and glucose-6-
phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine
oxidase, coupled with an
enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP,
lactoperoxidase, or
microperoxidase, biotin/avidin, spin labels, bacteriophage labels, stable free
radicals, and the like.
VII. Pharmaceutical Compositions
Pharmaceutical compositions of an anti-TIGIT antibody of the invention (e.g.,
4.1D3 or a variant
thereof, e.g., 4.1D3.01E) are prepared by mixing such an antibody having the
desired degree of purity
with one or more optional pharmaceutically acceptable can (Remington's
Pharmaceutical Sciences
16th edition, ()sot, A. Ed. (1980)), in the form of lyophilized compositions
or aqueous solutions.
Pharmaceutically acceptable carriers are generally nontoxic to recipients at
the dosages and
concentrations employed, and include, but are not limited to: buffers such as
phosphate, citrate, and other
organic acids; antioxidants including ascorbic acid and methionine;
preservatives (such as
octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride;
benzalkonium chloride;
benzethonium chloride; phenol, butyl or benzyl alcohol: alkyl parabens such as
methyl or propyl paraben;
catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular
weight (less than about 10
88
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
residues) polypeptides; proteins, such as serum albumin, gelatin, or
immunoglobulins; hydrophilic
polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine,
asparagine, histidine,
arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates
including glucose,
mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose,
mannitol, trehalose or
sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-
protein complexes); and/or
non-ionic surfactants such as polyethylene glycol (PEG). Exemplary
pharmaceutically acceptable carriers
herein further include insterstitial drug dispersion agents such as soluble
neutral-active hyaluronidase
glycoproteins (sHASEGP), for example, human soluble P11-20 hyaluronidase
glycoproteins, such as
rHuPH20 (HYLENEX*, Baxter International, Inc.). Certain exemplary sHASEGPs and
methods of use,
including rHuPH20, are described in US Patent Publication Nos. 2005/0260186
and 2006/0104968 In
one aspect, a sHASEGP is combined with one or more additional
glycosaminoglycanases such as
chondroitinases.
In some instances, a pharmaceutical composition including an anti-TIGIT
antibody provided
herein may further include a PD-1 axis binding antagonist, such as a PD-1
binding antagonist, a PD-L1
binding antagonist, and a PD-L2 binding antagonist.
In some instances, a pharmaceutical composition including an anti-TIGIT
antibody provided
herein may further include an 0X40 binding agonist, such as an 0X40 agonist
antibody, an OX4OL
agonist fragment, an 0X40 oligomeric receptor, and an 0X40 immunoadhesin.
In some instances, a pharmaceutical composition including an anti-TIGIT
antibody provided
herein may further include an additional therapeutic agent, such as a
chemotherapeutic agent or an agent
that decreases or inhibits one or more additional immune co-inhibitory
receptors (e.g., PD-1, CTLA-4,
LAG3, TIM3, BTLA, VISTA, 87H4, and/or CD96).
In other embodiments, a pharmaceutical composition including an anti-TIGIT
antibody may
further include (a) a PD-1 axis binding antagonist and an 0X40 binding
agonist; (b) a PD-1 axis binding
antagonist and an additional therapeutic agent (e.g., a chemotherapeutic
agent); (c) a PD-1 axis binding
antagonist and an agent that decreases or inhibits one or more additional
immune co-inhibitory receptors
(e.g., PD-1, CTLA-4, LAG3, TIM3, BTLA, VISTA, 87114, and/or CD96); (d) an 0X40
binding agonist and
an additional therapeutic agent (e.g., a chemotherapeutic agent); (e) an 0X40
binding agonist and an
agent that decreases or inhibits one or more additional immune co-inhibitory
receptors (e.g., PD-1, CTLA-
4, LAG3, TIM3, BTLA, VISTA, B7114, and/or CD96); (1) an additional therapeutic
agent (e.g., a
chemotherapeutic agent) and an agent that decreases or inhibits one or more
additional immune co-
inhibitory receptors (e.g., PD-1, CTLA-4, LAG3, TIM3, BTLA, VISTA, 87114,
and/or CD96); or (g) a PD-1
axis binding antagonist, an 0X40 binding agonist, and an agent that decreases
or inhibits one or more
additional immune co-inhibitory receptors (e.g., PD-1, CTLA-4, LAG3, TIM3,
BTLA, VISTA, 87114, and/or
CD96). Optionally, the pharmaceutical composition will include one or more
pharmaceutically acceptable
carriers, excipients, or diluent.
Exemplary lyophilized antibody compositions are described in US Patent No.
6,267,958.
Aqueous antibody compositions include those described in US Patent No.
6,171,586 and
W02006/044908, the latter compositions including a histidine-acetate buffer.
89
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
The composition herein may also contain more than one active ingredients as
necessary for the
particular indication being treated, preferably those with complementary
activities that do not adversely
affect each other. For example, it may be desirable to further provide an
additional therapeutic agent
(e.g., a chemotherapeutic agent, a cytotoxic agent, a growth inhibitory agent,
and/or an anti-hormonal
agent, such as those recited herein above). Such active ingredients are
suitably present in combination
in amounts that are effective for the purpose intended.
Active ingredients may be entrapped in microcapsules prepared, for example, by
coacervation
techniques or by interfacial polymerization, for example,
hydroxymethylcellulose or gelatin-microcapsules
and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug
delivery systems (for
example, liposomes, albumin microspheres, microemulsions, nano-particles and
nanocapsules) or in
macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical
Sciences 16th edition,
Osol, A. Ed. (1980).
Sustained-release preparations may be prepared. Suitable examples of sustained-
release
preparations include semipermeable matrices of solid hydrophobic polymers
containing the antibody,
which matrices are in the form of shaped articles, for example, films, or
microcapsules.
The compositions to be used for in vivo administration are generally sterile.
Sterility may be
readily accomplished, e.g., by filtration through sterile filtration
membranes.
VIII. Therapeutic Methods
Any of the anti-TIGIT antibodies of the invention (e.g., 4.1D3 or a variant
thereof, e.g.,
4.1D3.01E) may be used in therapeutic methods.
In one aspect, an anti-TIGIT antibody for use as a medicament is provided. In
further aspects, an
anti-TIGIT antibody described herein (e.g., 4.1D3 or a variant thereof, e.g.,
4.1D3.01E) for use in treating
or delaying progression of an immune-related disease in a subject is provided.
In certain embodiments,
the invention provides an anti-TIGIT antibody for use in a method of treating
a subject having an immune-
related disease that is associated with a T cell dysfunctional disorder. In
other embodiments, the
immune-related disease is a viral infection. In certain embodiments, the viral
infection is a chronic viral
infection. In some embodiments, T cell dysfunctional disorder is characterized
by decreased
responsiveness to antigenic stimulation. In some embodiments, the T cell
dysfunctional disorder is
characterized by T cell anergy or decreased ability to secrete cytokines,
proliferate or execute cytolytic
activity. In some embodiments, the T cell dysfunctional disorder is
characterized by T cell exhaustion. In
some embodiments, the T cells are CD4+ and CD8+ T cells. In some embodiments,
the T cell
dysfunctional disorder includes unresolved acute infection, chronic infection
and tumor immunity.
In another aspect, an anti-TIGIT antibody described herein (e.g., 4.1D3 or a
variant thereof, e.g.,
4.1D3.01E) for treating or delaying progression of a cancer in a subject is
provided. In certain
embodiments, the cancer is selected from the group consisting of a non-small
cell lung cancer, a small
cell lung cancer, a renal cell cancer, a colorectal cancer, an ovarian cancer,
a breast cancer, a pancreatic
cancer, a gastric carcinoma, a bladder cancer, an esophageal cancer, a
mesotheliorna, a melanoma, a
head and neck cancer, a thyroid cancer, a sarcoma, a prostate cancer, a
glioblastoma, a cervical cancer,
a thymic carcinoma, a leukemia, a lymphomas, a myeloma (e.g., multiple myeloma
(MM)), mycoses
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
fungoides, a merkel cell cancer, and a hematologic malignancy. Thus, a variety
of cancers may be
treated, or their progression may be delayed. In some embodiments, the
individual may have breast
cancer (e.g., triple-negative breast cancer). In other embodiments, the
individual may have pancreatic
cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)). In some embodiments,
the individual has non-
small cell lung cancer. The non-small cell lung cancer may be at early stage
or at late stage. In some
embodiments, the individual has small cell lung cancer. The small cell lung
cancer may be at early stage
or at late stage. In some embodiments, the individual has renal cell cancer.
The renal cell cancer may
be at early stage or at late stage. In some embodiments, the individual has
colorectal cancer. The
colorectal cancer may be at early stage or late stage. In some embodiments,
the individual has ovarian
cancer. The ovarian cancer may be at early stage or at late stage. In some
embodiments, the individual
has breast cancer. The breast cancer may be at early stage or at late stage.
In some embodiments, the
individual has pancreatic cancer. The pancreatic cancer may be at early stage
or at late stage. In some
embodiments, the individual has gastric carcinoma. The gastric carcinoma may
be at early stage or at
late stage. In some embodiments, the individual has bladder cancer. The
bladder cancer may be at early
.. stage or at late stage. In some embodiments, the individual has esophageal
cancer. The esophageal
cancer may be at early stage or at late stage. In some embodiments, the
individual has mesothelioma.
The mesothelioma may be at early stage or at late stage. In some embodiments,
the individual has
melanoma. The melanoma may be at early stage or at late stage. In some
embodiments, the individual
has head and neck cancer. The head and neck cancer may be at early stage or at
late stage. In some
embodiments, the individual has thyroid cancer. The thyroid cancer may be at
early stage or at late
stage. In some embodiments, the individual has sarcoma. The sarcoma may be at
early stage or late
stage. In some embodiments, the individual has prostate cancer. The prostate
cancer may be at early
stage or at late stage. In some embodiments, the individual has glioblastoma.
The glioblastoma may be
at early stage or at late stage. In some embodiments, the individual has
cervical cancer. The cervical
cancer may be at early stage or at late stage. In some embodiments, the
individual has thymic
carcinoma. The thymic carcinoma may be at early stage or at late stage. In
some embodiments, the
individual has leukemia. The leukemia may be at early stage or at late stage.
In some embodiments, the
individual has lymphomas. The lymphoma may be at early stage or at late stage.
In some embodiments,
the individual has a myeloma (e.g., MM). The myeloma (e.g., MM) may be at
early stage or at late stage.
In some embodiments, the individual has mycoses fungoides. The mycoses
fungoides may be at early
stage or at late stage. In some embodiments, the individual has merkel cell
cancer. The merkel cell
cancer may be at early stage or at late stage. In some embodiments, the
individual has hematologic
malignancies. The hematological malignancies may be early stage or late stage.
In another aspect, an anti-TIGIT antibody described herein (e.g., 4.1D3 or a
variant thereof, e.g.,
4.1D3.01E) for use in increasing, enhancing, or stimulating an immune response
or function in a subject
in need thereof is provided. In some embodiments, the immune response or
function is increased,
enhanced, and/or stimulated by activating effector cells (e.g., T cells, e.g..
CD8+ and/or CD4+ T cells),
expanding (increasing) an effector cell population, and/or killing target
cells (e.g., target tumor cells) in the
subject. In some embodiments, the CD4 and/or CD8 T cells in the individual
have increased or enhanced
.. priming, activation, proliferation, cytokine release and/or cytolytic
activity relative to prior to the
91
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
administration of the combination. In some embodiments, the number of CD4
and/or CD8 T cells is
elevated relative to prior to administration of the combination. In some
embodiments, the number of
activated CD4 and/or C08 T cells is elevated relative to prior to
administration of the combination. In
some embodiments, the activated CD4 and/or CD8 T cells is characterized by y-
IFN+ producing CD4
and/or CD8 T cells and/or enhanced cytolytic activity relative to prior to the
administration of the
combination. In some embodiments, the CD4 and/or CD8 T cells exhibit increased
release of cytokines
selected from the group consisting of IFN-y. TNF-a and interleukins. In some
embodiments of the
methods of this invention, the CD4 and/or CD8 T cell is an effector memory T
cell. In some
embodiments, the CD4 and/or CD8 effector memory T cell is characterized by y-
IFIsl+ producing CD4
and/or CD8 T cells and/or enhanced cytolytic activity. In some embodiments,
the CD4 and/or COB
effector memory T cell is characterized by having the expression of CD44high
CD62t..10". In some
embodiments, the cancer has elevated levels of T cell infiltration.
In any of the above aspects, the anti-TIGIT antibody may be for use in
combination with a
different TIGIT antagonist, a PD-1 axis binding antagonist, a 0X40 binding
agonist, an agent that
decreases or inhibits one or more additional immune co-inhibitory receptors,
and/or an additional
therapeutic agent, such as a chemotherapeutic agent, as described in detail
herein.
In another aspect, the invention provides for the use of an anti-TIGIT
antibody described herein
(e.g.. 4.1D3 or a variant thereof, e.g., 4.1D3.01E) in the manufacture or
preparation of a medicament. In
one embodiment, the medicament is for treating or delaying progression of a
cancer. In a further
embodiment, the medicament is for treating or delaying progression of a non-
small cell lung cancer, a
small cell lung cancer, a renal cell cancer, a colorectal cancer, an ovarian
cancer, a breast cancer, a
pancreatic cancer, a gastric carcinoma, a bladder cancer, an esophageal
cancer, a mesothelioma, a
melanoma, a head and neck cancer, a thyroid cancer, a sarcoma, a prostate
cancer, a glioblastoma, a
cervical cancer, a thymic carcinoma, a leukemia, a lymphoma, a myeloma,
mycoses fungoides, a merkel
cell cancer, or a hematologic malignancy. Thus, a variety of cancers may be
treated, or their progression
may be delayed. In some embodiments, the individual may have breast cancer
(e.g., triple-negative
breast cancer). In other embodiments, the individual may have pancreatic
cancer (e.g., pancreatic ductal
adenocarcinoma (PDAC)). In some embodiments, the individual has non-small cell
lung cancer. The
non-small cell lung cancer may be at early stage or at late stage. In some
embodiments, the individual
has small cell lung cancer. The small cell lung cancer may be at early stage
or at late stage. In some
embodiments, the individual has renal cell cancer. The renal cell cancer may
be at early stage or at late
stage. In some embodiments, the individual has colorectal cancer. The
colorectal cancer may be at early
stage or late stage. In some embodiments, the individual has ovarian cancer.
The ovarian cancer may
be at early stage or at late stage. In some embodiments, the individual has
breast cancer. The breast
cancer may be at early stage or at late stage. In some embodiments, the
individual has pancreatic
cancer. The pancreatic cancer may be at early stage or at late stage. In some
embodiments, the
individual has gastric carcinoma. The gastric carcinoma may be at early stage
or at late stage. In some
embodiments, the individual has bladder cancer. The bladder cancer may be at
early stage or at late
stage. In some embodiments, the individual has esophageal cancer. The
esophageal cancer may be at
early stage or at late stage. In some embodiments, the individual has
mesothelioma. The mesothelioma
92
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
may be at early stage or at late stage. In some embodiments, the individual
has melanoma. The
melanoma may be at early stage or at late stage. In some embodiments, the
individual has head and
neck cancer. The head and neck cancer may be at early stage or at late stage.
In some embodiments,
the individual has thyroid cancer. The thyroid cancer may be at early stage or
at late stage. In some
embodiments, the individual has sarcoma. The sarcoma may be at early stage or
late stage. In some
embodiments, the individual has prostate cancer. The prostate cancer may be at
early stage or at late
stage. In some embodiments, the individual has glioblastoma. The glioblastoma
may be at early stage or
at late stage. In some embodiments, the individual has cervical cancer. The
cervical cancer may be at
early stage or at late stage. In some embodiments, the individual has thymic
carcinoma. The thymic
carcinoma may be at early stage or at late stage. In some embodiments, the
individual has leukemia
The leukemia may be at early stage or at late stage. In some embodiments, the
individual has
lymphomas. The lymphoma may be at early stage or at late stage. In some
embodiments, the individual
has a myeloma (e.g., MM). The myeloma (e.g., MM) may be at early stage or at
late stage. In some
embodiments, the individual has mycoses fungoides. The mycoses fungoides may
be at early stage or at
late stage. In some embodiments, the individual has merkel cell cancer. The
rnerkel cell cancer may be
at early stage or at late stage. In some embodiments, the individual has
hematologic malignancies. The
hematological malignancies may be early stage or late stage.
In another aspect, the invention provides for the use of an anti-TIGIT
antibody described herein
(e.g., 4.1D3 or a variant thereof, e.g., 4.1D3.01E) in the manufacture of a
medicament for treating or
delaying progression of an immune-related disease. In some embodiments, the
immune-related disease
is associated with T cell dysfunctional disorder. In some embodiments, the
immune-related disease is a
viral infection. In certain embodiments, the viral infection is a chronic
viral infection. In some
embodiments, T cell dysfunctional disorder is characterized by decreased
responsiveness to antigenic
stimulation. In some embodiments, the T cell dysfunctional disorder is
characterized by T cell anergy or
decreased ability to secrete cytokines, proliferate or execute cytolytic
activity. In some embodiments, the
T cell dysfunctional disorder is characterized by T cell exhaustion. In some
embodiments, the T cells are
CD4+ and CD8+ T cells. In some embodiments, the T cell dysfunctional disorder
includes unresolved
acute infection, chronic infection and tumor immunity.
In another aspect, an anti-TIGIT antibody described herein (e.g., 4.103 or a
variant thereof, e.g.,
4.1D3.Q1E) in the manufacture of a medicament for use in increasing,
enhancing, or stimulating an
immune response or function in a subject in need thereof is provided. In some
embodiments, the immune
response or function is increased, enhanced, and/or stimulated by activating
effector cells (e.g., T cells,
e.g., CD8+ and/or CD4+ T cells), expanding (increasing) an effector cell
population, and/or killing target
cells (e.g., target tumor cells) in the subject. In some embodiments, the CD4
and/or CD8 T cells in the
individual have increased or enhanced priming, activation, proliferation,
cytokine release and/or cytolytic
activity relative to prior to the administration of the combination. In some
embodiments, the number of
CD4 and/or CD8 T cells is elevated relative to prior to administration of the
combination. In some
embodiments, the number of activated CD4 and/or CD8 T cells is elevated
relative to prior to
administration of the combination. In some embodiments, the activated CD4
and/or CD8 T cells is
characterized by y-IFN+ producing CD4 and/or CD8 T cells and/or enhanced
cytolytic activity relative to
93
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
prior to the administration of the combination. In some embodiments, the CD4
and/or CD8 T cells exhibit
increased release of cytokines selected from the group consisting of IFN-y,
TNF-a and interleukins. In
some embodiments of the methods of this invention, the CD4 and/or CD8 T cell
is an effector memory T
cell. In some embodiments, the CD4 and/or CD8 effector memory T cell is
characterized by y-IFN`
producing CD4 and/or CD8 T cells and/or enhanced cytolytic activity. In some
embodiments, the CD4
and/or CD8 effector memory T cell is characterized by having the expression of
CD44"i9" CD621.1. In
some embodiments, the cancer has elevated levels of T cell infiltration.
In any of the above aspects. the medicament may be formulated for use in
combination with a
different TIGIT antagonist, a PD-1 axis binding antagonist, an 0X40 binding
agonist, an agent that
decreases or inhibits one or more additional immune co-inhibitory receptors,
and/or an additional
therapeutic agent, such as a chemotherapeutic agent, as described in detail
herein.
In another aspect, the invention provides a method for treating or delaying
progression of a
cancer in a subject, the method comprising administering to the subject an
effective amount of an anti-
TIGIT antibody described herein (e.g., 4.1D3 or a variant thereof, e.g.,
4.1D3.01E), thereby treating or
delaying the progression of the cancer in the subject. In certain embodiments,
the cancer is selected
from the group consisting of a non-small cell lung cancer, a small cell lung
cancer, a renal cell cancer, a
colorectal cancer, an ovarian cancer, a breast cancer, a pancreatic cancer, a
gastric carcinoma, a bladder
cancer, an esophageal cancer, a mesothelioma. a melanoma, a head and neck
cancer, a thyroid cancer,
a sarcoma, a prostate cancer, a glioblastoma, a cervical cancer, a thymic
carcinoma, a leukemia, a
lymphoma, a myeloma, mycoses fungoides, a merkel cell cancer, and a
hematologic malignancy. Thus,
a variety of cancers may be treated, or their progression may be delayed. In
some embodiments, the
individual may have breast cancer (e.g., triple-negative breast cancer). In
other embodiments, the
individual may have pancreatic cancer (e.g., pancreatic ductal adenocarcinoma
(PDAC)). In some
embodiments, the individual has non-small cell lung cancer. The non-small cell
lung cancer may be at
early stage or at late stage. In some embodiments, the individual has small
cell lung cancer. The small
cell lung cancer may be at early stage or at late stage. In some embodiments,
the individual has renal
cell cancer. The renal cell cancer may be at early stage or at late stage. In
some embodiments, the
individual has colorectal cancer. The colorectal cancer may be at early stage
or late stage. In some
embodiments, the individual has ovarian cancer. The ovarian cancer may be at
early stage or at late
stage. In some embodiments, the individual has breast cancer. The breast
cancer may be at early stage
or at late stage. In some embodiments, the individual has pancreatic cancer.
The pancreatic cancer may
be at early stage or at late stage. In some embodiments, the individual has
gastric carcinoma. The
gastric carcinoma may be at early stage or at late stage. In some embodiments,
the individual has
bladder cancer. The bladder cancer may be at early stage or at late stage. In
some embodiments, the
individual has esophageal cancer. The esophageal cancer may be at early stage
or at late stage. In
some embodiments, the individual has mesothelioma. The mesothelioma may be at
early stage or at late
stage. In some embodiments, the individual has melanoma. The melanoma may be
at early stage or at
late stage. In some embodiments, the individual has head and neck cancer. The
head and neck cancer
may be at early stage or at late stage. In some embodiments, the individual
has thyroid cancer. The
thyroid cancer may be at early stage or at late stage. In some embodiments,
the individual has sarcoma.
94
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
The sarcoma may be at early stage or late stage. In some embodiments, the
individual has prostate
cancer. The prostate cancer may be at early stage or at late stage. In some
embodiments, the individual
has glioblastoma. The glioblastoma may be at early stage or at late stage. In
some embodiments, the
individual has cervical cancer. The cervical cancer may be at early stage or
at late stage. In some
embodiments, the individual has thymic carcinoma. The thymic carcinoma may be
at early stage or at
late stage. In some embodiments, the individual has leukemia. The leukemia may
be at early stage or at
late stage. In some embodiments, the individual has lymphomas. The lymphoma
may be at early stage
or at late stage. In some embodiments, the individual has a myeloma (e.g.,
MM). The myeloma (e.g.,
MM) may be at early stage or at late stage. In some embodiments, the
individual has mycoses
fungoides. The mycoses fungoides may be at early stage or at late stage. In
some embodiments, the
individual has merkel cell cancer. The merkel cell cancer may be at early
stage or at late stage. In some
embodiments, the individual has hematologic malignancies. The hematological
malignancies may be
early stage or late stage.
In another aspect, the invention provides a method for treating or delaying
progression of an
immune-related disease in a subject, the method comprising administering to
the subject an effective
amount of an anti-TIGIT antibody described herein (e.g., 4.1D3 or a variant
thereof, e.g., 4.1D3.Q1E),
thereby treating or delaying the progression of the immune-related disease in
the subject. In some
embodiments, the immune-related disease is associated with T cell
dysfunctional disorder. In some
embodiments, the immune-related disease is a viral infection. In certain
embodiments, the viral infection
is a chronic viral infection. In some embodiments, T cell dysfunctional
disorder is characterized by
decreased responsiveness to antigenic stimulation. In some embodiments, the T
cell dysfunctional
disorder is characterized by T cell anergy or decreased ability to secrete
cytokines, proliferate or execute
cytolytic activity. In some embodiments, the T cell dysfunctional disorder is
characterized by T cell
exhaustion. In some embodiments, the T cells are CD4+ and CD8+ T cells. In
some embodiments, the T
cell dysfunctional disorder includes unresolved acute infection, chronic
infection and tumor immunity.
In another aspect, the invention provides a method of increasing, enhancing,
or stimulating an
immune response or function in a subject, the comprising administering to the
subject an effective amount
of an anti-TIGIT antibody described herein (e.g., 4.1D3 or a variant thereof,
e.g.. 4.1D3.01E), thereby
increasing, enhancing, or stimulating an immune response or function in the
subject. In some
embodiments, the immune response or function is increased, enhanced, and/or
stimulated by activating
effector cells (e.g., T cells, e.g., CD8+ and/or CD4+ T cells), expanding
(increasing) an effector cell
population, and/or killing target cells (e.g., target tumor cells) in the
subject. In some embodiments of the
methods of this invention, the CD4 and/or CD8 T cells in the individual have
increased or enhanced
priming, activation, proliferation, cytokine release and/or cytolytic activity
relative to prior to the
administration of the combination. In some embodiments of the methods of this
invention, the number of
CD4 and/or CD8 T cells is elevated relative to prior to administration of the
combination. In some
embodiments of the methods of this invention, the number of activated CD4
and/or C08 T cells is
elevated relative to prior to administration of the combination. In some
embodiments of the methods of
this invention, the activated CD4 and/or CD8 T cells is characterized by y-
IFN+ producing CD4 and/or
CD8 T cells and/or enhanced cytolytic activity relative to prior to the
administration of the combination. In
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
some embodiments of the methods of this invention, the CD4 and/or CD8 T cells
exhibit increased
release of cytokines selected from the group consisting of IFN-y, TNF-a and
interleukins. In some
embodiments of the methods of this invention, the CD4 and/or CD8 T cell is an
effector memory T cell. In
some embodiments of the methods of this invention, the CD4 and/or CD8 effector
memory T cell is
characterized by y-IFN producing CD4 and/or CD8 T cells and/or enhanced
cytolytic activity. In some
embodiments of the methods of this invention, the CD4 and/or CD8 effector
memory T cell is
characterized by having the expression of CD44ho CD62L'ow. In some embodiments
of the methods of
this invention, the cancer has elevated levels of T cell infiltration.
In any of the above aspects, the anti-TIGIT antibody may be for administration
in combination
with a different TIGIT antagonist, a PD-1 axis binding antagonist, an 0X40
binding agonist, an agent that
decreases or inhibits one or more additional immune co-inhibitory receptors,
and/or an additional
therapeutic agent, such as a chemotherapeutic agent, as described in detail
herein.
In some embodiments, the different (second) TIGIT antagonist can be an
antagonist of TIGIT
expression and/or activity, such as a small molecule inhibitor, an inhibitory
antibody or antigen-binding
fragment thereof, an aptarner. an inhibitory nucleic acid, and an inhibitory
polypeptide. In some
embodiments, the TIGIT antagonist is a different anti-TIGIT antibody or
antigen-binding fragment thereof
(e.g., one that binds to a different epitope on TIGIT that is either non-
overlapping or only partially
overlapping with the epitope recognized by the anti-TIGIT antibody of the
invention that is used). In some
embodiments, the TIGIT antagonist is an inhibitory nucleic acid selected from
an antisense
polynucleotide, an interfering RNA, a catalytic RNA, and an RNA-DNA chimera.
In some embodiments, TIGIT antagonist can be an agent that modulates the CO226
expression
and/or activity. For example, an agent that modulates the CD226 expression
and/or activity that is
capable of increasing and/or stimulating CD226 expression and/or activity:
increasing and/or stimulating
the interaction of CD226 with PVR, PVRL2, and/or PVR1_3: and increasing and/or
stimulating the
intracellular signaling mediated by CD226 binding to PVR, PVRL2, and/or
PVRE.3. As used herein, an
agent that is capable of increasing and/or stimulating CO226 expression and/or
activity includes, without
limitation, agents that increase and/or stimulate CD226 expression and/or
activity. As used herein, an
agent that is capable of increasing and/or stimulating the interaction of
CD226 with PVR, PVRL2, and/or
PVRI.3 includes, without limitation, agents that increase and/or stimulate the
interaction of CD226 with
PVR, PVRL2, and/or PVRI.3. As used herein, an agent that is capable of
increasing and/or stimulating
the intracellular signaling mediated by CD226 binding to PVR, PVRL2, and/or
PVRL3 includes, without
limitation, agents that increase and/or stimulate the intracellular signaling
mediated by CD226 binding to
PVR, PVRL2, and/or PVRI.3.
In some embodiments, the agent that modulates the CD226 expression and/or
activity is selected
from an agent that inhibits and/or blocks the interaction of CD226 with TIGIT,
an antagonist of PVR
expression and/or activity, an agent that inhibits and/or blocks the
interaction of TIGIT with PVR, an agent
that inhibits and/or blocks the interaction of TIGIT with PVRI..2, an agent
that inhibits and/or blocks the
interaction of TIGIT with PVR1.3, an agent that inhibits and/or blocks the
intracellular signaling mediated
by TIGIT binding to PVR, an agent that inhibits and/or blocks the
intracellular signaling mediated by TIGIT
96
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
binding to PVRL2, an agent that inhibits and/or blocks the intracellular
signaling mediated by TIGIT
binding to PVRI.3, and combinations thereof.
In some embodiments, the agent that inhibits and/or blocks the interaction of
CD226 with TIGIT is
a small molecule inhibitor, an inhibitory antibody or antigen-binding fragment
thereof, an aptamer, an
inhibitory nucleic acid, and an inhibitory polypeptide. In some embodiments,
the agent that inhibits and/or
blocks the interaction of CD226 with TIGIT is an anti-TIGIT antibody or
antigen-binding fragment thereof
(e.g., one that binds to a different epftope on TIGIT that is either non-
overlapping or only partially
overlapping with the epitope recognized by the anti-TIGIT antibody of the
invention that is used). In some
embodiments, the agent that inhibits and/or blocks the interaction of CD226
with TIGIT is an inhibitory
nucleic acid selected from an antisense polynucleotide, an interfering RNA, a
catalytic RNA, and an RNA.
DNA chimera.
In some embodiments, the antagonist of PVR expression and/or activity is a
small molecule
inhibitor, an inhibitory antibody or antigen-binding fragment thereof, an
aptamer, an inhibitory nucleic acid,
and an inhibitory polypeptide. In some embodiments, the antagonist of PVR
expression and/or activity is
selected from a small molecule inhibitor, an inhibitory antibody or antigen-
binding fragment thereof, an
aptamer, an inhibitory nucleic acid, and an inhibitory polypeptide.
In some embodiments, the agent that inhibits and/or blocks the interaction of
TIGIT with PVR is a
small molecule inhibitor, an inhibitory antibody or antigen-binding fragment
thereof, an aptamer, an
inhibitory nucleic acid, and an inhibitory polypeptide. In some embodiments,
the agent that inhibits and/or
blocks the interaction of TIGIT with PVR is selected from a small molecule
inhibitor, an inhibitory antibody
or antigen-binding fragment thereof, an aptamer, an inhibitory nucleic acid,
and an inhibitory polypeptide.
In some embodiments, the agent that inhibits and/or blocks the interaction of
TIGIT with PVRL2 is
selected from a small molecule inhibitor, an inhibitory antibody or antigen-
binding fragment thereof, an
aptamer, an inhibitory nucleic acid, and an inhibitory polypeptide. In some
embodiments, the agent that
inhibits and/or blocks the interaction of TIGIT with PVRL3 is selected from a
small molecule inhibitor, an
inhibitory antibody or antigen-binding fragment thereof, an aptamer, an
inhibitory nucleic acid, and an
inhibitory polypeptide.
In some embodiments, the agent that inhibits and/or blocks the intracellular
signaling mediated by
TIGIT binding to PVR is a small molecule inhibitor, an inhibitory antibody or
antigen-binding fragment
thereof, an aptamer, an inhibitory nucleic acid, and an inhibitory
polypeptide. In some embodiments, the
agent that inhibits and/or blocks the intracellular signaling mediated by
TIGIT binding to PVR is selected
from a small molecule inhibitor, an inhibitory antibody or antigen-binding
fragment thereof, an aptamer, an
inhibitory nucleic acid, and an inhibitory polypeptide. In some embodiments,
the agent that inhibits and/or
blocks the intracellular signaling mediated by TIGIT binding to PVRL2 is
selected from a small molecule
inhibitor, an inhibitory antibody or antigen-binding fragment thereof, an
aptamer, an inhibitory nucleic acid,
and an inhibitory polypeptide. In some embodiments, the agent that inhibits
and/or blocks the intracellular
signaling mediated by TIGIT binding to PVRI.3 is selected from a small
molecule inhibitor, an inhibitory
antibody or antigen-binding fragment thereof, an aptamer, an inhibitory
nucleic acid, and an inhibitory
polypeptide.
97
WO 2017/053748 PCT/US2016/053368
Other TIGIT antagonists that can be used in combination with the anti-TIGIT
antibodies of the
invention include the anti-TIGIT antibodies and compositions containing such
antibodies described in WO
2009/126688,
In some instances, the methods provided herein include administration of an
effective amount of
a PD-1 axis binding antagonist, prior to, subsequent to, or concurrently with
an anti-TIGIT antibody of the
invention (and, optionally, one or more additional agents, such as a second,
different TIGIT antagonist, an
0X40 binding agonist, a chemotherapeutic agent, etc.), The PD-1 axis bidning
antagonist can be
selected from the group consisting of a PD-1 binding antagonist, a PD-L1
binding antagonist, and a PD
L2 binding antagonist.
In some embodiments of the above aspect, the PD-1 axis binding antagonist is a
PD-1 binding
antagonist. In some embodiments, the PD-1 binding antagonist inhibits the
binding of PD-1 to its ligand
binding partners. In some embodiments, the PD-1 binding antagonist inhibits
the binding of PD-1 to PD
Li. In some embodiments, the PD-1 binding antagonist inhibits the binding of
PD-1 to PD-L2. In some
embodiments, the PD-1 binding antagonist inhibits the binding of PD-1 to both
PD-L.1 and PD-L2. In
some embodiments, the PD-1 binding antagonist is an antibody. In some
embodiments, the PD-1 binding
antagonists selected from the group consisting of MDX 1106 (nivolumab), MK-
3475 (pembrolizumab);
CT-011 (pidzumab), MEDI-0680 (AMP-514), PDR001, REGN2810, and BGB-108.
In other embodiments of the above aspect, the PD-1 axis binding antagonist is
a PD-L1 binding
antagonist. In some embodiments, the PD-L1 binding antagonist inhibits the
binding of PD-L1 to PD-1.
In some embodiments, the PD-L1 binding antagonist inhibits the binding of PD-
L1 to B7-1. In some
embodiments, the PD-L1 binding antagonist inhibits the binding of PD-L1 to
both PD-1 and B7-1. In
some embodiments, the PD-L1 binding antagonist is an antibody. In some
embodiments, the antibody is
selected from the group consisting of: MPDL3280A (atezolizumab), YW243.55.670,
MDX-1105,
MEDI4736 (durvalumab), and MSB0010718C (avelumab),
In other embodiments of the above aspect, the PD-1 axis binding antagonist is
a PD-L2 binding
antagonist. In some embodiments, the PD-L2 binding antagonist is an antibody.
In some embodiments,
the PD-L2 binding antagonist is an immunoadhesin.
As a general proposition, the therapeutically effective amount of a PD-1 axis
binding antagonist
(e.g., an anti-PD-L1 antibody) may be administered to a human will be in the
range of about 0.01 to about
50 mg/kg of patient body weight whether by one or more administrations. In
some embodiments, for
example, the antagonist (e,g., anti-PD-L1 antibody) is administered in a dose
of about 0,01 to about 45
mg/kg, about 0,01 to about 40 mg/kg, about 0.01 to about 35 mg/kg, about 0.01
to about 30 mg/kg, about
0.01 to about 25 mg/kg, about 0.01 to about 20 mg/kg, about 0.01 to about 15
mg/kg, about 0.01 to about
10 mg/kg, about 0.01 to about 5 mg/kg, or about 0.01 to about 1 mg/kg
administered daily, for example.
In some embodiments, the antagonist (e.g., anti-PD-L1 antibody) is
administered at 15 mg/kg. However,
other dosage regimens may be useful. In one embodiment, a PD-1 axis binding
antagonist (e.g., anti-PD-
L1 antibody) is administered to a human at a dose of about 100 mg, about 200
mg, about 300 mg, about
400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg,
about 1000 mg,
about 1100 mg, about 1200 mg, about 1300 mg, about 1400 mg, or about 1500 mg.
In some
embodiments, a PD-1 axis binding antagonist (e.g., anti-PD-L1 antibody) is
administered at a dose of
98
Date Recue/Date Received 2021-04-08
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
about 800 mg to about 850 mg every two weeks. In some embodiments, a PD-1 axis
binding antagonist
(e.g., anti-PD-1.1 antibody) is administered at a dose of about 840 mg every
two weeks. The dose may
be administered as a single dose or as multiple doses (e.g., 2 or 3 doses),
such as infusions. The dose
of the antibody administered in a combination treatment may be reduced as
compared to a single
treatment. In some embodiments, for example, the method for treating or
delaying progression of locally
advanced or metastatic breast cancer in an individual comprises a dosing
regimen comprising treatment
cycles, wherein the individual is administered, on days 1 and 15 of each
cycle, a human PD-1 axis
binding antagonist (e.g., anti-PD-L1 antibody) at a dose of about 840 mg,
wherein each cycle is 28 days
(i.e., each cycle is repeated every 28 days). The progress of this therapy is
easily monitored by
conventional techniques
In some embodiments, the 0X40 binding agonist includes, for example, an 0X40
agonist
antibody (e.g., an anti-human 0X40 agonist antibody), an OX401_ agonist
fragment, an 0X40 oligomeric
receptor, and an 0X40 immunoadhesin.
In some embodiments, the 0X40 agonist antibody depletes cells that express
human 0X40 (e.g.,
CD4+ effector T cells, CD8+ T cells, and/or Treg cells), for example, by ADCC
and/or phagocytosis. In
some embodiments, the 0X40 agonist antibody binds human 0X40 with an affinity
of less than or equal
to about 1 nM (e.g., less than or equal to about 0.5 nM, e.g., less than or
equal to about 0.45 nM, e.g.,
less than or equal to about 0.4 nM, e.g., less than or equal to about 0.3 nM).
In some embodiments, the
binding affinity of the 0X40 agonist antibody is determined using
radioimmunoassay.
In some embodiments, the 0X40 agonist antibody binds human 0X40 and cynomolgus
0X40.
In further embodiments, binding to human 0X40 and cynomolgus 0X40 is
determined using a FACS
assay. In some embodiments, binding to human 0X40 has an EC50 of less than or
equal to about 1
pg/m1(e.g., less than or equal to about 0.7 pg/ml, e.g., less than or equal to
about 0.5 pg/ml, e.g., less
than or equal to about 0.4 pg/ml, e.g., less than or equal to about 0.3 pg/ml,
e.g., less than or equal to
about 0.2 pg/ml, e.g., less than or equal to about 0.1 pg/m1). In some
embodiments, binding to
cynomolgus 0X40 has an EC50 of less than or equal to 3 pg/m1(e.g., less than
or equal to about 2 pg/ml,
e.g., less than or equal to about 1.7 pg/ml, e.g., less than or equal to about
1.5 pg/ml, e.g., less than or
equal to about 1.4 pg/ml, e.g., less than or equal to about 1.3 pg/ml, e.g.,
less than or equal to about 1.2
pg/ml, e.g., less than or equal to about 1.1 pg/ml, e.g., less than or equal
to about 1.0 pg/ml).
In some embodiments, the 0X40 agonist antibody increases CD4+ effector T cell
proliferation
and/or increases cytokine production by the CD4+ effector T cell as compared
to proliferation and/or
cytokine production prior to treatment with the 0X40 agonist antibody. In some
embodiments, the
cytokine is IFN-y.
In some embodiments, the 0X40 agonist antibody increases memory T cell
proliferation and/or
increasing cytokine production by the memory cell. In some embodiments, the
cytokine is IFN-y.
In some embodiments, the 0X40 agonist antibody inhibits Treg suppression of
effector T cell
function. In some embodiments, effector T cell function is effector T cell
proliferation and/or cytokine
production. In some embodiments, the effector T cell is a CD4+ effector T
cell.
99
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
In some embodiments, the 0X40 agonist antibody increases 0X40 signal
transduction in a target
cell that expresses 0X40. In some embodiments, 0X40 signal transduction is
detected by monitoring
NFkB downstream signaling.
In some embodiments, the 0X40 agonist antibody is stable after treatment at 40
C for one to four
weeks, e.g., one week, two weeks, three weeks, or four weeks. In some
embodiments, the 0X40 agonist
antibody is stable after treatment at 40 C for two weeks.
In some embodiments, the 0X40 agonist antibody comprises a variant IgG1 Fe
polypeptide
comprising a mutation that eliminates binding to human effector cells has
diminished activity relative to
the 0X40 agonist antibody comprising a native sequence IgG1 Fc portion. In
some embodiments, the
0X40 agonist antibody comprises a variant Fe portion comprising a DANA
mutation.
In some embodiments, antibody cross-linking is required for anti-human 0X40
antagonist
antibody function.
In some embodiments, the 0X40 agonist antibody comprises (a) a VH domain
comprising (i) a
HVR-H1 comprising the amino acid sequence of SEQ ID NO: 278, 279, or 280, (ii)
a HVR-H2 comprising
the amino acid sequence of SEQ ID NO: 281, 282, 283, 284, 285, or 286, and
(iii) a HVR-H3 comprising
an amino acid sequence selected from SEQ ID NO: 287, 288, or 289; and (b) a VL
domain comprising (i)
a HVR-L1 comprising the amino acid sequence of SEQ ID NO: 290, (ii) a HVR-L2
comprising the amino
acid sequence of SEQ ID NO: 291, and (iii) a HVR-L3 comprising the amino acid
sequence of SEQ ID
NO: 292, 293, 294, 295, 296, 297, 298: or 299. For example, in some
embodiments, the 0X40 agonist
antibody comprises (a) HVR-Hl comprising the amino acid sequence of SEQ ID NO:
278; (b) HVR-H2
comprising the amino acid sequence of SEQ ID NO: 281; (c) HVR-H3 comprising
the amino acid
sequence of SEQ ID NO: 287; (d) HVR-Ll comprising the amino acid sequence of
SEQ ID NO: 290; (e)
HVR-L2 comprising the amino acid sequence of SEQ ID NO: 291; and (f) HVR-L3
comprising an amino
acid sequence selected from SEQ ID NO: 292. In some embodiments, the 0X40
agonist antibody
comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 278; (b)
HVR-H2 comprising
the amino acid sequence of SEQ ID NO: 281; (c) HVR-H3 comprising the amino
acid sequence of SEQ
ID NO: 287; (d) HVR-Ll comprising the amino acid sequence of SEQ ID NO: 290;
(e) HVR-L2 comprising
the amino acid sequence of SEQ ID NO: 291; and (f) HVR-L3 comprising an amino
acid sequence
selected from SEQ ID NO: 297. In some embodiments, the 0X40 agonist antibody
comprises (a) HVR-
H1 comprising the amino acid sequence of SEQ ID NO: 278; (b) HVR-H2 comprising
the amino acid
sequence of SEQ ID NO: 281; (c) HVR-H3 comprising the amino acid sequence of
SEQ ID NO: 287; (d)
HVR-Ll comprising the amino acid sequence of SEQ ID NO: 290; (e) HVR-L2
comprising the amino acid
sequence of SEQ ID NO: 291; and (f) HVR-L3 comprising an amino acid sequence
selected from SEQ ID
NO: 298.
In other embodiments, the OX40 agonist antibody comprises a VH sequence having
at least 90%
sequence identity to the amino acid sequence of any one of SEQ ID NOs: 300-
325. For example, the
0X40 agonist antibody comprises a VH sequence having at least 90% sequence
identity to the amino
acid sequence of SEQ ID NO: 300 (e.g., wherein a total of 1 to 10 amino acids
have been substituted,
inserted, and/or deleted in SEQ ID NO: 300). Thus, in some embodiments, the
0X40 agonist antibody
comprises a VH comprising one, two, or three HVRs selected from: (a) HVR-H1
comprising the amino
100
WO 2017/053748 PCT/US2016/053368
acid sequence of SEQ ID NO: 278, (b) HVR-H2 comprising the amino acid sequence
of SEQ ID NO: 281,
and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 287.
In other embodiments, the OX40 agonist antibody comprises a VL sequence having
at least 90%
sequence identity to the amino acid sequence of any one of SEQ ID NOs: 326-
351. For example, the
0X40 agonist antibody comprises a VL having at least 90% sequence identity to
the amino acid
sequence of SEQ ID NO: 326 (e.g., wherein a total of 1 to 10 amino acids have
been substituted,
inserted, and/or deleted in SEQ ID NO: 326), Thus, in some embodiments, the
0X40 agonist antibody
comprises a VL comprising one, two, or three HVRs selected from (a) HVR-L1
comprising the amino acid
sequence of SEQ ID NO: 290; (b) HVR-L2 comprising the amino acid sequence of
SEQ ID NO: 291; and
(c) HVR-L3 comprising the amino acid sequence of SEQ ID NO; 292.
In some embodiments, the 0X40 agonist antibody comprises (a) a VH sequence of
SEQ ID NO:
300; (b) a VL sequence of SEQ ID NO: 326; or (c) a VH sequence as in (a) and a
VL sequence as in (b).
In some embodiments, the 0X40 agonist antibody comprises (a) a VH sequence of
SEQ ID NO:
319; (b) a VL sequence of SEQ ID NO: 345; 01(c) a VH sequence as in (a) and a
VL sequence as in (b).
In some embodiments, the 0X40 agonist antibody comprises (a) a VH sequence of
SEQ ID NO:
320; (b) a VL sequence of SEQ ID NO: 346; or (c) a VH sequence as in (a) and a
VL sequence as in (b).
Also specifically contemplated are 0X40 agonist antibodies, such as an
antibody sharing the
same or substantially the same HVR sequences and/or VH and VL sequences of the
anti-OX40
antibodies disclosed in U.S. Patent No, 7,550,140 and International Pub. Nos,
WO 2014/148895 and WO
2013/038191.
In some embodiments, the 0X40 agonist antibody is L106 BD (Pharmingen Product
#340420).
In some embodiments, the antibody comprises at least one, two, three, four,
five, or six hypervariable
region (HVR) sequences of antibody L106 (BD Pharmingen Product # 340420). In
some embodiments,
the antibody comprises a heavy chain variable region sequence and/or a light
chain variable region
sequence of antibody L106 (BD Pharmingen Product #340420).
In some embodiments the 0X40 agonist antibody is ACT35 (Santa Cruz
Biotechnology, Catalog
# 20073). In some embodiments, the antibody comprises at least one, two,
three, four, five, or six
hypervariable region (HVR) sequences of antibody ACT35 (Santa Cruz
Biotechnology, Catalog #20073).
In some embodiments, the antibody comprises a heavy chain variable region
sequence and/or a light
chain variable region sequence of antibody ACT35 (Santa Cruz Biotechnology,
Catalog # 20073),
In some embodiments, the 0X40 agonist antibody is MEDI6469, In some
embodiments, the
antibody comprises at least one, two, three, four, five, or six hypervariable
region (HVR) sequences of
antibody MEDI6469. In some embodiments, the antibody comprises a heavy chain
variable region
sequence and/or a light chain variable region sequence of antibody MEDI6469,
In some embodiments, the 0X40 agonist antibody is MEDI0562. In some
embodiments, the
antibody comprises at least one, two, three, four, five, or six hypervariable
region (HVR) sequences of
antibody MEDI0562. In some embodiments, the antibody comprises a heavy chain
variable region
sequence and/or a light chain variable region sequence of antibody MEDI0562,
In some embodiments, the 0X40 agonist antibody is an agonist antibody that
binds to the same
epitope as any one of the 0X40 agonist antibodies set forth above.
101
Date Recue/Date Received 2021-04-08
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
In any of the above embodiments, the 0X40 agonist antibody can be a full-
length antibody (e.g.,
IgG1 antibody) or an antibody fragment.
0X40 agonists useful for the methods described herein are in no way intended
to be limited to
antibodies. Non-antibody 0X40 agonists are contemplated and well known in the
art.
As described above, OX4OL (also known as CD134L) serves as a ligand for 0X40.
As such,
agonists that present part or all of OX4OL. may serve as 0X40 agonists. In
some embodiments, an 0X40
agonist may include one or more extracellular domains of OX4OL. Examples of
extracellular domains of
OX401. may include 0X40-binding domains. In some embodiments, an 0X40 agonist
may be a soluble
form of OX40L. that includes one or more extracellular domains of OX4OL but
lacks other, insoluble
domains of the protein, e.g., transmembrane domains. In some embodiments, an
0X40 agonist is a
soluble protein that includes one or more extracellular domains of OX401. able
to bind OX4OL. In some
embodiments, an 0X40 agonist may be linked to another protein domain, e.g., to
increase its
effectiveness, half-life, or other desired characteristics. In some
embodiments, an 0X40 agonist may
include one or more extracellular domains of OX401.. linked to an
imrnunoglobulin Fc domain.
In some embodiments, an 0X40 agonist may be an oligomeric or multimeric
molecule. For
example, an 0X40 agonist may contain one or more domains (e.g., a leucine
zipper domain) that allows
proteins to oligomerize. In some embodiments, an 0X40 agonist may include one
or more extracellular
domains of OX401. linked to one or more leucine zipper domains.
In some embodiments, an 0X40 agonist may be any one of the 0X40 agonists
described in
European Patent No. EP0672141131.
In some embodiments, an 0X40 agonist may be a trimeric OX4OL fusion protein.
For example,
an 0X40 agonist may include one or more extracellular domains of OX401. linked
to an immunoglobulin
Fc domain and a trimerization domain (including without limitation an
isoleucine zipper domain).
In some embodiments, an 0X40 agonist may be any one of the 0X40 agonists
described in
International Publication No. W02006/121810, such as an 0X40 immunoadhesin. In
some
embodiments, the 0X40 immunoadhesin may be a trimeric 0X40-Fc protein. In some
embodiments, the
0X40 agonist is MEDI6383.
Such combination therapies noted above encompass combined administration,
whereby the anti-
TIGIT antibody and the one or more agents (e.g., PD-1 axis binding antagonist.
0X40 binding agonist,
agent that decreases or inhibits one or more additional immune co-inhibitory
receptors, and/or additional
therapeutic agent) are included in the same or separate formulations, and
separate administration,
whereby administration of the anti-TIGIT antibody of the invention can occur
prior to, simultaneously,
and/or following, administration of the one or more agents (e.g., PD-1 axis
binding antagonist, 0X40
binding agonist, agent that decreases or inhibits one or more additional
immune co-inhibitory receptors,
and/or additional therapeutic agent). In one embodiment, administration of the
anti-TIGIT antibody and
administration of one or more of the agents occur within about one month, or
within about one, two or
three weeks, or within about one, two, three, four, five, or six days, of each
other. Anti-TIGIT antibodies
of the invention (e.g., 4.1D3 or a variant thereof, e.g., 4.103.Q1E) can also
be used in combination with
radiation therapy.
102
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
An anti-TIGIT antibody of the invention (and/or any additional therapeutic
agent) can be
administered by any suitable means, including parenteral, intrapulmonary, and
intranasal, and, if desired
for local treatment, intraiesional administration. Parenteral infusions
include intramuscular, intravenous,
intraarterial, intraperitoneal, or subcutaneous administration. In some
embodiments, the antibody is
administered by subcutaneous administration. In some embodiments, an anti-
TIGIT antibody
administered by subcutaneous injection exhibits a less toxic response in a
patient than the same anti-
TIGIT antibody administered by intravenous injection. Dosing can be by any
suitable route, for example,
by injections, such as intravenous or subcutaneous injections, depending in
part on whether the
administration is brief or chronic. Various dosing schedules including but not
limited to single or multiple
administrations over various time-points, bolus administration, and pulse
infusion are contemplated
herein.
Anti-TIGIT antibodies of the invention would be formulated, dosed, and
administered in a fashion
consistent with good medical practice. Factors for consideration in this
context include the particular
disorder being treated, the particular mammal being treated, the clinical
condition of the individual patient,
the cause of the disorder, the site of delivery of the agent, the method of
administration, the scheduling of
administration, and other factors known to medical practitioners. The antibody
need not be, but is
optionally formulated with one or more agents currently used to prevent or
treat the disorder in question.
The effective amount of such other agents depends on the amount of antibody
present in the formulation,
the type of disorder or treatment, and other factors discussed above. These
are generally used in the
same dosages and with administration routes as described herein, or about from
1 to 99% of the dosages
described herein, or in any dosage and by any route that is
empirically/clinically determined to be
appropriate.
For the prevention or treatment of disease, the appropriate dosage of an anti-
TIGIT antibody of
the invention (e.g., 4.1D3 or a variant thereof, e.g., 4.1D3.01E), when used
alone or in combination with
one or more other additional agents (e.g., PD-1 axis binding antagonist, 0X40
binding agonist, agent that
decreases or inhibits one or more additional immune co-inhibitory receptors,
and/or additional therapeutic
agent), will depend on the type of disease to be treated, the type of antibody
used, the severity and
course of the disease, whether the antibody is administered for preventive or
therapeutic purposes,
previous therapy, the patient's clinical history and response to the antibody,
and the discretion of the
attending physician. The antibody is suitably administered to the patient at
one time or over a series of
treatments.
As a general proposition, the therapeutically effective amount of the anti-
TIGIT antibody
administered to human will be in the range of about 0.01 to about 100 mg/Kg of
patient body weight
whether by one or more administrations. In some embodiments, the antibody used
is about 0.01 to about
45 mg/kg, about 0.01 to about 40 mg/kg, about 0.01 to about 35 mg/kg, about
0.01 to about 30 mg/kg,
about 0.01 to about 25 mg/kg, about 0.01 to about 20 mg/kg, about 0.01 to
about 15 mg/kg, about 0.01 to
about 10 mg/kg, about 0.01 to about 5 mg/kg, or about 0.01 to about 1 mg/kg
administered daily, for
example. In one embodiment, an anti-TIGIT antibody described herein is
administered to a human at a
dose of about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg,
about 600 mg, about
700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200
mg, about 1300 mg or
103
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
about 1400 mg on day 1 of 21-day cycles. The dose may be administered as a
single dose or as multiple
doses (e.g., 2 or 3 doses), such as infusions. For repeated administrations
over several days or longer,
depending on the condition, the treatment would generally be sustained until a
desired suppression of
disease symptoms occurs. One exemplary dosage of the antibody would be in the
range from about 0.05
mg/kg to about 10 mg/kg. Thus, one or more doses of about 0.5 mg/kg, 2.0
mg/kg, 4.0 mg/kg, or 10
mg/kg (or any combination thereof) may be administered to the patient. Such
doses may be administered
intermittently, for example, every week or every three weeks (e.g., such that
the patient receives from
about two to about twenty, or, for example, about six doses of the anti-TIGIT
antibody). An initial higher
loading dose, followed by one or more lower doses may be administered. The
progress of this therapy is
.. easily monitored by conventional techniques and assays.
In some embodiments, the methods may further comprise an additional therapy.
The additional
therapy may be radiation therapy, surgery, chemotherapy, gene therapy, DNA
therapy, viral therapy, RNA
therapy, immunotherapy, bone marrow transplantation, nanotherapy, monoclonal
antibody therapy, or a
combination of the foregoing. The additional therapy may be in the form of
adjuvant or neoadjuvant
therapy. In some embodiments, the additional therapy is the administration of
small molecule enzymatic
inhibitor or anti-metastatic agent. In some embodiments, the additional
therapy is the administration of
side-effect limiting agents (e.g., agents intended to lessen the occurrence
and/or severity of side effects
of treatment, such as anti-nausea agents, etc.). In some embodiments, the
additional therapy is radiation
therapy. In some embodiments, the additional therapy is surgery. In some
embodiments, the additional
therapy is a combination of radiation therapy and surgery. In some
embodiments, the additional therapy
is gamma irradiation. In some embodiments, the additional therapy may be a
separate administration of
one or more of the therapeutic agents described above.
IX. Articles of Manufacture
In another aspect of the invention, an article of manufacture or a kit
containing materials useful for
the treatment, prevention and/or diagnosis of the disorders described above is
provided. The article of
manufacture comprises a container and a label or package insert on or
associated with the container.
Suitable containers include, for example, bottles, vials, syringes, IV
solution bags, etc. The containers
may be formed from a variety of materials such as glass or plastic. The
container holds a composition
which is by itself or combined with another composition effective for
treating, preventing and/or
diagnosing the condition and may have a sterile access port (for example the
container may be an
intravenous solution bag or a vial having a stopper pierceable by a hypodermic
injection needle). At least
one active agent in the composition is an anti-TIGIT antibody of the
invention. The label or package
insert indicates that the composition is used for treating the condition of
choice. Moreover, the article of
manufacture may comprise (a) a first container with a composition contained
therein, wherein the
composition comprises an antibody of the invention; and (b) a second container
with a composition
contained therein, wherein the composition comprises a further cytotoxic or
otherwise therapeutic agent.
The article of manufacture in this embodiment of the invention may further
comprise a package insert
indicating that the compositions can be used to treat a particular condition.
Alternatively, or additionally,
the article of manufacture may further comprise a second (or third) container
comprising a
104
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
pharmaceutically-acceptable buffer, such as bacteriostatic water for injection
(BWFI), phosphate-buffered
saline, Ringer's solution and dextrose solution. It may further include other
materials desirable from
a commercial and user standpoint, including other buffers, diluents, filters,
needles, and syringes.
In one embodiment, provided is a kit including an anti-TIGIT antibody of the
invention (e.g., 4.1D3
or a variant thereof, e.g., 4.1D3.01E) and a package insert comprising
instructions for using the anti-
TIGIT antibody for treating or delaying progression of cancer in a subject or
for treating or delaying
progression of an immune-related disease in a subject. In a related
embodiment, the invention features a
kit including an anti-TIGIT antibody of the invention (e.g., 4.1D3 or a
variant thereof, e.g., 4.1D3.Q1E), a
PD-1 axis binding antagonist (e.g., a PD-1 binding antagonist, a PD-1.1
binding antagonist, and a PD-L2
binding antagonist), and a package insert comprising instructions for using
the anti-TIGIT antibody for
treating or delaying progression of cancer in a subject or for treating or
delaying progression of an
immune-related disease in a subject. In a related embodiment, the invention
features a kit including an
anti-TIGIT antibody of the invention (e.g., 4.1D3 or a variant thereof, e.g.,
4.1D3.Q1 E), an 0X40 binding
agonist (e.g., an 0X40 agonist antibody, an 0X4OL agonist fragment, an 0X40
oligomeric receptor, and
an 0X40 immunoadhesin), and a package insert comprising instructions for using
the anti-TIGIT antibody
for treating or delaying progression of cancer in a subject or for treating or
delaying progression of an
immune-related disease in a subject. In a related embodiment, the invention
features a kit including an
anti-TIGIT antibody of the invention (e.g., 4.1D3 or a variant thereof, e.g.,
4.1D3.01E), a PD-1 axis
binding antagonist (e.g., a PD-1 binding antagonist, a PD-L1 binding
antagonist, and a PD-L2 binding
antagonist), an 0X40 binding agonist (e.g., an 0X40 agonist antibody, an
OX401. agonist fragment, an
0X40 oligomeric receptor, and an 0X40 immunoadhesin), and a package insert
comprising instructions
for using the anti-TIGIT antibody for treating or delaying progression of
cancer in a subject or for treating
or delaying progression of an immune-related disease in a subject. In any of
the above embodiments, the
subject may, for example, be a human. It is specifically contemplated that any
of the anti-TIGIT
.. antibodies, 0X40 binding agonists, and PD-1 axis binding antagonists
described herein may be included
in the kit.
In yet another embodiment, provided is a kit including an anti-TIGIT antibody
of the invention
(e.g., 4.1D3 or a variant thereof, e.g., 4.1D3.01E) and a package insert
comprising instructions for
increasing, enhancing, or stimulating an immune response or function in a
subject. In a related
embodiment, the invention features a kit including an anti-TIGIT antibody of
the invention (e.g., 4.1D3 or a
variant thereof. e.g., 4.1D3.Q1E), a PD-1 axis binding antagonist (e.g., a PD-
1 binding antagonist, a PD-
L1 binding antagonist, and a PD-L2 binding antagonist), and a package insert
comprising instructions for
increasing, enhancing, or stimulating an immune response or function in a
subject. In a related
embodiment, the invention features a kit including an anti-TIGIT antibody of
the invention (e.g., 4.1D3 or a
variant thereof, e.g., 4.1D3.Q1E), an 0X40 binding agonist (e.g., an 0X40
agonist antibody, an OX4OL
agonist fragment, an 0X40 oligomeric receptor, and an 0X40 immunoadhesin), and
a package insert
comprising instructions for using the anti-TIGIT antibody for increasing,
enhancing, or stimulating an
immune response or function in a subject. In a related embodiment, the
invention features a kit including
an anti-TIGIT antibody of the invention (e.g., 4.1D3 or a variant thereof,
e.g., 4.1D3.Q1E), a PD-1 axis
binding antagonist (e.g., a PD-1 binding antagonist, a PD-L1 binding
antagonist, and a PD-L2 binding
105
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
antagonist), an 0X40 binding agonist (e.g., an 0X40 agonist antibody, an OX4OL
agonist fragment, an
0X40 oligomeric receptor, and an 0X40 immunoadhesin), and a package insert
comprising instructions
for using the anti-TIGIT antibody for increasing, enhancing, or stimulating an
immune response or
function in a subject. In any of the above embodiments, the subject may, for
example, be a human. It is
specifically contemplated that any of the anti-TIGIT antibodies, 0X40 binding
agonists, and PD-1 axis
binding antagonists described herein may be included in the kit.
EXAMPLES
The invention can be further understood by reference to the following
examples, which are
provided by way of illustration and are not meant to be limiting.
Example 1. Generation of anti-TIGIT antibodies
Either Sprague Dawiey rats or OMT transgenic rats (Open Monoclonal Technology,
Palo Alto,
CA) were co-immunized with an initial dose subcutaneously of 50 pg human TIGIT
protein (Genentech,
Inc.) and 50 pg cynomolgus monkey (cyno) TIGIT protein (Genentech, Inc.) mixed
with Complete
Freund's Adjuvant (BD, Franklin Lakes, NJ), followed by 25 pg human TIGIT
protein and 25 pg cyno
TIGIT protein diluted in PBS in multiple sites subcutaneously and
intraperitoneally every two weeks.
Multiple lymph nodes were harvested three days after the last immunization. B
cells from these
rats were enriched using negative selection with biotinlyated antibodies
targeting rat non-B cells (BD;
eBioscience, San Diego, CA) and streptavidin-coated magnetic beads (Miltenyi,
San Diego, CA). The
resulting B cell population was fused with P3X63-Ag8U.1 mouse myeloma cells
(American Type Culture
Collection, Rockville, MD) via electrofusion (Harvard Apparatus, Holliston,
MA). Fused cells were
incubated at 37;.C, 7% CO2, overnight in Medium C (StemCell Technologies,
Vancouver, BC, Canada),
before resuspension in semi-solid Medium 0 (StemCell Technologies) with anti-
rat IgG-FITC (Sigma-
Aldrich, St. Louis, MO) and plating into Omniwell trays (Thermo Fisher
Scientific, Rochester, NY). Seven
days after plating, fluorescent colonies were selected and transferred into 96-
well culture plates (BD)
containing Medium E (StemCell Technologies) using a Clonepix FL (Molecular
Devices, Sunnyvale, CA).
Supernatants were screened by ELISA against human TIGIT protein seven days
after colony picking.
384-well plates (Greiner MicroIon, Greiner Bio-One, Monroe, NC) were coated
with 1 pg/m1 of protein
diluted in 0.05 M sodium carbonate buffer, pH 9.6, and incubated overnight at
4'C. Then wells were
blocked with 100 pi of PBS containing 0.5% BSA and 0.5% Tween-20 for one hour
at room temperature.
After washing, supernatants and/or sera were added at 50 pl and shaken for 30
minutes at room
temperature. For detection of specific antibodies, horseradish peroxidase-
conjugated anti-rat IgG
antibodies (Bethyl Laboratories, Montgomery, TX) were diluted to an optimized
concentration in PBS
containing 0.5% BSA and 0.5% Tween-20 and added at 50 pi per well alter
washing, and plates were
shaken for 30 minutes at room temperature. Plates were washed three times with
100 pl PBS containing
0.05% Tween-20. 50 pi TMB Substrate (BioFX, Owings Mills, MD) was added and
plates were incubated
for five minutes at room temperature, followed by the addition of 50 pi stop
solution (BioFX), then read at
630 nm. Human TIGIT-binding hybridoma cell lines were expanded and cultured
for two to four days,
then screened by ELISA against human TIGIT, cyno TIGIT, and mouse TIGIT
proteins (Genentech, Inc.).
106
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
Supernatant from human and cyno cross-reactive cell lines was harvested and
purified by protein G
(Protein G Sepharose 4 Fast Flow, GE Healthcare, Pittsburgh, PA).
Approximately 500 clones were
screened. From the screening, clones 4.1D3, 7.4A3, and 4.1A4 were identified
from the immunization of
OMT rats, and clones 1.6B2, 1.10A5, 1.7E7, and 1.15C8 were identified from the
immunization of
Sprague Dawley rats.
Example 2. Optimization of anti-TIGIT antibodies
A. OMT rat-derived anti-TIGIT human monoclonal antibody polishing
To prevent unwanted pymglutamate formation for clones 4.1A4, 4.103, and 7.4A3
(also referred
to as 1A4, 103, and 4A3, respectively) and to resolve the issue of unpaired
cysteine residues for clones
4.1A4 and 7.4A3, the following optimized anti-TIGIT antibody variants were
generated: 4.1A4.C96S.Q1E,
4.1A4.C96Y.Q1E, 4.103.01E, 7.4A3.C96S.Q1E, and 7.4A3.C96Y.Q1E (also referred
to as
1A4.C96S.Q1E, 1A4.C96Y.01E, 103.01E, 4A3.C96S.01E, and 4A3.C96Y.01E,
respectively). As
described below in Table 2, the affinities of these five optimized variants
for human and cynomolgus
monkey (cyno) TIGIT were then determined by Surface Plasmon Resonance (SRP)
(BIACORETM
analysis) and compared to that of their respective parental clones.
Briefly, a series S CM5 biosensor chip was activated with N-ethyl-N'-(3-
dimethylaminopropyI)-
carbodiimide hydrochloride (EDC) and N-hydroxysuc.cinimide (NHS) reagents
according to the supplier's
(GE Healthcare Biosciences, Piscataway, NJ) instructions, and a human antibody
capture kit was applied
to couple goat anti-human Fc IgGs in order to achieve approximately 10,000
response units (RU) on each
flow cell, followed by blocking un-reacted groups with 1M ethanolamine.
For kinetics measurements, each clone was captured to achieve approximately
250 RU and 5-
fold serial dilutions of TIGIT antigen (1.23 nM to 300 riM) were injected in
HBS-P buffer (0.01M HEPES
pH 7.4, 0.15M NaCl, 0.005% surfactant P20) at 25 C (flow rate: 3041/min) with
no regeneration between
injections. The sensorgrams were recorded and evaluated by BlAcoreTM T200
Evaluation Software
(version 2.0) after subtraction of reference cell signal. Association rates
(kon) and dissociation rates (korr)
were calculated using a simple one-to-one Langmuir binding model. The
equilibrium dissociation
constant (KO was calculated as the ratio korrikun.
Table 2. BIACORETM affinity measurements for OMT rat-derived 1A4, 1D3, and 4A3
antibody
variants against human and cyno TIGIT
Human TIGIT Cyno TIGIT
xTIGIT mAbs Kon (105M- Koff (10-4s. Kon (105M- Koff (10-4s-
KD (nM) KD (nM)
10) I) is-1) 1)
1A4 3.42 12.2 3.57 2.66 6.43 2.42
1A4.C966.01E 12.5 367.9 29.4 13.4 169.1 12.6
1A4.C96Y.01E - >100 >100
1D3 38.4 16.4 0.43 6.21 20.7 3.33
107
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
103.01E 17.2 9.7 0.56 4.78 15.4 3.22
4A3 3.02 10.4 3.44 3.34 6.99 2.09
4A3.C969.01E 2.88 8.56 2.97 2.76 5.56 2.01
4A3.C96Y.Q1E 3.72 364.7 98.0 3.95 140.5 35.6
The clones 4.1A4.C96S.Q1E, 7.4A3.C965.Q1E, and 4.1D3.Q1E were considered as
final
molecules with similar and acceptable binding affinity to both human and cyno
TIG1T by comparison with
the parental clones. Additional BIACORETN analyses revealed that the 4.1D3.Q1E
clone, in particular.
was able to cross-react and bind to rabbit TIGIT with low nanomolar affinity
(Table 3).
Table 3. 4.1D3.01E is capable of cross-reacting with human, cyno, and rabbit
TIGIT
BlAcore Kinetics Analysis
Human Cyno TIGIT Rabbit
Source Clone TIGIT
Monovalent Affinity (nM)
OMT 4.103.01E 0.56 3.2 4.9
7.4A3.01E.C966 2.97 2.01 >500
Mouse h1A5.L2H8 5.76 > 500 >500
B. Humanization of SD rat-derived anti-TIG1T monoclonal antibodies
Monoclonal antibodies 1.682, 1.10A5, 1.7E7, and 1.15C8 (as referred to herein
as 682, 10A5,
7E7, and 15C8, respectively) were humanized as described below. Residue
numbers are according to
Kabat et al. (Sequences of Proteins of Immunological Interest. 5th Ed.. Public
Health Service, National
Institutes of Health, Bethesda, MD (1991)).
For 6B2 antibody humanization, hypervariable regions from the rat 682 (rat682)
antibody were
engineered into its closest human acceptor frameworks to generate humanized
682 (h6B2.L1H1).
Specifically, from the rat6B2 VL domain, positions 24-34 (L1), 50-56 (L2), and
89-97 (L3) were grafted
into human germlineIGKV1-33*01. From the rat6B2 VH domain, positions 26-35
(H1), 50-65 (H2), and
95-102 (H3) were grafted into human germlineIGHV2-5*08. In addition, position
43 in framework II of VL
and positions 69, 73, 78 in framework III of VI-I were retained from the rat
sequence in h6B2.L1H1.
Those residues were found to be part of the framework residues acting as
"Vernier' zone, which may
adjust CDR/HVR structure and fine-tune the antigen fit. See, e.g., Foote and
Winter, J. Mot Biol. 224:
487-499 (1992). These CDRIHVR definitions include positions defined by their
sequence hypervariahility
(Wu. T. T. & Kabat, E. A. (1970)), their structural location (Chothia, C. &
Lesk, A. M. (1987)) and their
involvement in antigen-antibody contacts (MacCallum et al. J. Mot Biol. 262:
732-745 (1996)).
Additional humanized 6B2 variants were generated by engineering each rat
residue of
h6B2.L1H1 at Vernier zone back to human germline residue and these variants
are h6B2.L2H1 (VL:
S43A), h6B2.L1H2 (VH: V691), h6B2.1.1H3 (VH: A73T), h682.L1H4 (VH: A78V),
h6B2.1.1H5 (VH: V691,
A73T, A78V), and h682.L2H5 (VL: 843A, VH: V691, A73T, A78V; a fully humanized
version).
108
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
For 10A5 antibody humanization, hypetvariable regions from the rat 10A5 (rail
OM) antibody
were engineered into its closest human acceptor frameworks to generate
humanized 10A5
(h10A511H1). Specifically, from the ratl OAS VL domain, positions 24-34 (L1),
50-56 (L2), and 89-97
(L3) were grafted into human germline IGKV3-15*01. From the rail 0A5 VH
domain, positions 26-35
(H1), 50-65 (112) and 95-102 (113) were grafted into human germline IG11V2-5-
08. In addition, position 43
in framework II and position 58 in framework III of VL and positions 69 and 78
in framework III of VII were
retained from the rat sequence in h10A5.L1H1. Those residues were found to be
part of the framework
residues acting as "Vernier" zone as described above.
Additional humanized 10A5 variants were generated by engineering each rat
residue of
h10A51.1H1 at Vernier zone back to human germline residue and these variants
are h10A5.L2H1 (VL:
S43A), h10A5.L3H1 (VL: V581), h10A5.L4H1 (VL: S43A, V581), h10A5.L1H2 (VH:
V69I), h10A5.L1H3
(VH: A781/), h10A5.L1H4 (VH: V691, A78V), and h10A5.L4114 (VL: S43A, V581,
V11: V691, A78V; a fully
humanized version)
For 7E7 antibody humanization, hypervariable regions from the rat 7E7 (rat7E7)
antibody were
engineered into its closest human acceptor frameworks to generate humanized
7E7 (h7E7.L1H1).
Specifically, from the rat7E7 VL domain, positions 24-34 (Li), 50-56 (L2), and
89-97 (L3) were grafted
into human germlineIGKV1-9*01. From the rat7E7 VH domain, positions 26-35
(H1), 50-65 (H2), and
95-102 (H3) were grafted into human germlineIGHV1-3*01. In addition, positions
58, 71, and 87 in
framework III of VL, positions 47, 48 in framework II of VH and positions 67,
69, 71, 91, and 93 in
framework III of VH were retained from the rat sequence in h7E7.L1H1 . Those
residues were found to be
part of the framework residues acting as "Vernier zone as described above.
Additional humanized 7E7 variants were generated by engineering each rat
residue of
h7E7.L1H1 at Vernier zone back to human germline residue and these variants
are h7E7.L2H1 (VL:
158V), h7E7.L3H1 (VL: Y71F), h7E7.L4H1 (VL: F87Y), h7E7.L5H1 (VL: 158V, Y71F,
F87Y), h7E7.L1H2
(VH: I47W), h7E7.L1H3 (VII: 148M), h7E7.L1H4 (VII: A67V), h7E7.L1H5 (VH:
L691), h7E7.L1H6 (VH:
A71R), h7E7.L1H7 (VH: F91Y), h7E7.L1118 (VII: T93A), h7E7.L1H9 (VH: 147W,
148M, A67V, L691, A71R,
F91Y, T93A), and h7E7.L5H9 (VL: 158V, Y71F, F87Y, VH: I47W, I48M, A67V, L691,
A71R, F91Y, T93A; a
fully humanized version).
For 15C8 antibody humanization, hypervariable regions from the rat 15C8
(ratl5C8) antibody
were engineered into its closest human acceptor frameworks to generate
humanized 15C8
(h15C8.L1H1). Specifically, from the rat15C8 VL domain, positions 24-34 (L1),
50-56 (12), and 89-97
(L3) were grafted into human germline IGKV1-9*01. From the ratl 5C8 VH domain,
positions 26-35 (H1),
50-65 (112), and 95-102 (113) were grafted into human germline IGHV1-3*01. in
addition, positions 58, 71,
and 87 in framework III of VL, positions 37, 47. and 48 in framework II of
VII, and positions 67, 69, 71,
and 91 in framework III of VH were retained from the rat sequence in
hl5C8.L1H1. Those residues were
found to be part of the framework residues acting as "Vernier zone as
described above.
Additional humanized 15C8 variants were generated by engineering each rat
residue of
hi 5C8.L1H1 at Vernier zone back to human gemiline residue and these variants
are hi 5C8.1...2H1 (VL:
158V), hl5C8.L3H1 (VL: Y71F), hl5C8.L4H1 (VL: F87Y), h15C8.L5H1 (VL: I58V,
Y71F, F87Y),
h15C8.1.1112 (VH: L37V), h15C8.L1H3 (VH: 147W), h15C8.L1H4 (VH: I48M),
h15C8.L1115 (VII: A67V),
109
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
h15C8.L1H6 (VII: L691), hl5C8.L1H7 (VII: T71R), h15C8.L1H8
F91Y), hl5C8.L1H9 (VII: L37V,
147W, 148M, A67V, L691, T71R, F91Y), and h7E7.L5H9 (VL: 158V, Y71F, F87Y,
L37V, 147W, 148M,
A67V, L691, T71R, F91Y; a fully humanized version).
The first humanized versions, h6B2, L1 HI, h10A5.1.1H1, h7E7, Ll H1, and
h15C8.L1H1, which
contain both rat CDRs and framework residues at Vernier positions, and the
fully humanized versions,
h6B2.L2H5, h10A5.L4H4, h7E7.L5H9, and hi 5C815H9, which contain only rat CDRs
were subject to
BlAcore affinity measurement by comparison with original rat antibodies,
rat6B2, ratl 0A5. rat7E7 and rat
15C8. For binding affinity determinations of TIGIT antibodies against human
TIGIT, cynomolgus monkey
TIGIT and human alanine-scanned TIGIT mutants by single-cycle kinetics,
Surface Plasmon Resonance
(SRP) measurement with a BIACORETK-T200 instrument was used, as described
above. The
BIACORETM results in Table 4, below, indicate that all the humanized variants
exhibit a drop in binding
affinity (i.e., an increase in Ku) of about 5- to 10-fold against both human
and cyno TIGIT. The fully
humanized versions of h6B2.L2H5 and h10A5.L4H4 surprisingly show similar
binding affinity as the first
humanized versions of h6B2.L1H1 and h10A511H1, suggesting that ra1682 and
rat10A5 framework
residues at Vernier positions do not contribute to human and cyno 'MIT
binding. Therefore, both
h6B2.L2H5 and h10A5.L4H4 represent the final humanized version for rat6B2 and
rat10A5, respectively.
By contrast, the fully humanized versions of h7E7.L5H9 and hi 5C8.1.5H9 lost
the ability to bind human
and cyno TIGIT.
To further elucidate which rat framework residues at Vernier positions for the
first humanized
antibodies h7E7, L1 I-11 , and hl5C8.L1H1 are crucial for binding, all the
framework polishing variants were
subject to BlAcore affinity measurement. For 7E7 framework polishing, variants
of h7E7.1.1H2,
h7E7.L1H9, and h7E7.L5H9 containing VII: 147W substitution show human and cyno
TIGIT binding
affinity drop more than 100-fold, and variants of h7E7.L3H1 and h7E7.L5H1,
containing VL: Y71F
substitution, show cyno TIGIT binding affinity drop about 2-3 fold. Therefore,
both VII: 147 and VL: Y71
rat framework residues were kept in the final 7E7 humanized version, called
h7E7.L5aH9a, to retain
human and cyno TIGIT binding. For 15C8 framework polishing, variants of
h15C8.L1H3, h15C8.L1H9,
and h15C8.L5H9, containing VII: 147W, substitution show human and cyno TIGIT
binding affinity drop
more than 100-fold, and variants of hi 5C8.13H1 and hi 5C8.1.5H1 containing
VL: Y71F substitution show
human and cyno TIG1T binding affinity drop about 2-3 fold. Other variants,
h15C8.L1H2, h15C8.L1H5,
and h15C8.L1H7, contain VII: L37V, A67V, and T71R substitution, respectively,
also show human TIGIT
binding affinity drop about 2-3 fold. Therefore, all five VH:147, L37, A67,
T71 and VL: Y71 rat framework
residues were kept in the final 15C8 humanized version, called h15C8.L5aH9a,
to retain human and cyno
TIGIT binding.
Table 4. BIACORETM affinity measurements summary for humanized SD rat-derived
6B2, 10A6,
7E7, and 16C8 antibody variants against human and cyno TIGIT
Human TIGIT Cyno TIGIT
xT1GIT mAbs Kon (105M- Kon (105M
Koff (10-4s-1) KD (nM) Koff
(10-4s-1) KD (nM)
ls.1) 1s-1)
110
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
rat6B2 9.97 0.35 0.04 6.88 2.02 0.29
h6B2.1_1 H1 46.7 25.3 0.54 12.3 11.8 0.96
h6B2.L2H5 46.5 22.2 0.48 12.8 12.4 ' 0= .97
rail 0A5 9.05 0.84 0.09 6.78 2.81 0.41
hl 0A511H1 45.7 23.8 0.52 14.7 12.7 0.86
h 1 0A514H4 52.1 22.7 0.44 15.2 12.9 0.85
rat7E7 5.68 0.18 0.03 3.99 0.27 0.07
h7E711H1 20.6 4.76 0.23 4.18 1.52 0.36
h7E7.1..2H1 20.6 5.04 0.24 4.93 1.79 0.36
h7E7.1.3H1 9.2 2.18 0.24 12.8 12.2 0.95
h7E7.1.4H1 29.5 7.96 0.27 6.29 2.74 0.44
-T7E7.-04:1------3-21------1674 0.32 ------5.7-5----- ---72.4.--- ---67-6---
-----
h7E7.1..1H2 - - - >100 - >100
h7E711H3 28.2 10.7 0.38 9.08 3.81 0.42
h7E7.1.1H4 27.9 7.49 0.27 6.01 2.43 0.40
h7E7.1.1H5 32.4 12.9 0.40 8.98 3.59 0.40
h7E71.1 H6 18.5 6.48 0.35 6.41 2.84 0.44
h7E711H7 27.4 8.49 0.31 6.64 2.86 0.43
h7E7.1.1H8 27.8 10.1 0.36 8.45 3.31 0.39
h7E711H9 - - - >100 - >100
h7E7.1.5H9 - - - >100 - ' >= 100
h7E7.1.5aH9a 12.8 3.63 0.28 5.91 1.82 0.31
________________________________________________________________________ ,
rat15C8 5.22 0.18 0.03 3.81 0.96 0.25
h15C811H1 9.22 3.57 0.39 4.93 4.64 0.94
-ii-15-6-61:2171-1- - - 7.71 - - - - -576.6 - - - -676-6 - -----KoT ---- --76--
i---------71.-6-6-- - - - -
hi 5C813H1 6.31 5.33 0.84 3.36 5.88 1.75
h15C8.1.4H1 9.55 6.11 0.64 4.85 5.59 1.15
h15C8.1.5H1 6.74 5.62 0.83 2.81 7.52 2.68
hl 5C811H2 10.4 10.7 1.03 3.82 8.06 2.1
hi 5C81.1H3 - - - >100 - >100
-h-1-e-8-.[.-1-1-14--8:41----4T4-8--6.-59----5-I2------5-.58------1:05
h15C8.i..1H5 7.98 5.67 0.71 4.84 5.58 1.15
h15C811H6 13.8 7.56 0.55 6.63 5.56 0.84
--61 -5-C8-1-11:177- - - 6.1 - - 5.97 ------676-8-----2. ii-- - - 2.06 - - - -
- if 74-4- hi 5C811H8 6.2 3.81 0.61 2.91 1.19 0.41
h 1 5C811H9 - - - >100 - >100
--n71-5-o-8.I..-5i:i9---::--------7--------;100----:T----------------;1-00
h15C8.1..5a H9a 11.2 4.21 0.38 5.96 6.13 ' 1= .03
111
WO 2017/053748 PCT/US2016/053368
Example 3. In vitro binding and blocking studies of anti-TIGIT antibodies
A. In vitro binding characterization of anti-MIT antibodies
The OMT- and SD-derived anti-TIGIT antibodies were characterized in vitro for
their ability to bind
to TIGIT and to block poliovirus receptor (PVR) binding to TIGIT. Binding to
human and cyno TIGIT was
tested by BIACORE TM analysis, as described above, in the context of both
monovalent and bivalent
affinity, and compared to a mouse-derived anti-TIGIT antibody (1 A5) and a
chimeric hamster-derived
anti-TIGIT antibody (10A7; see, e.g., U.S. Pub. No. 2009/0258013). The results
of the BIACORETM
analysis, depicted in Table 5, indicate that numerous OMT-derived anti-TIGIT
clone variants, such as 4.1
03.Q1E and 7.4A3.C96S.Q1E, and SD-derived anti-TIGIT clone variants were
capable of binding to both
human and cyno TIGIT, each with a high and similar affinity. Such properties
are desirable for therapeutic
anti-TIGIT antibodies as they allow for facile toxicity testing using
cynomolgus monkey (Macaca
fascicularis) as a non-clinical toxicology species. Additional cross-
reactivity of the 4.1D3.01E clone with
rabbit may provide an additional toxicology species.
Table 5. BIACORETM analysis of optimized OMT- and SD-derived anti-TIGIT clones
Source Clone BlAcore Kinetics Analysis
Human Cyno TIGIT Human Cyno TIGIT
TIGIT TIGIT
Monovalent Affinity (nM) Bivalent
Affinity (nM)
OMT Rat 4.1A4.Q1.C96 4.9 2.6 0.31 0.035
4.1A4.Q1E.C96 3.6 2.4
4.1A4.01E.C965 29.4 12.6
4.1A4.01E.C96Y >100 >100
4.1D3.Q1 0.61 3.4 5 0.019 0.36
4.1D3.Q1E 0.57 3.2
7.4A3.01.C96 3.60 1.6 0.098 5. 0.05
7.4A3.Q1E.C96 3.45 2.09
7.4A3.01E.C96S 2.97 2.02
7.4A3.Q1E.C96Y 98.1 35.5
SD Rat Chimeric 1.662 0.035 0.29 5 0.027 0.091
h1.66211H1 0.54 0.96
Chimeric 1.10A5 0.093 0.41 s 0.003 0.013
h1.10A5111-11 0.52 0.86
Chimeric 1.7E7 5 0.018 0.067 5 0.004 5 0.009
h1.7E7.L1H1 0.33 0.51
Chimeric 1.15C8 0.034 0.25 50.007 5 0.013
112
Date Recue/Date Received 2021-04-08
WO 2017/053748 PCT/US2016/053368
hl ,15C8,L1H1 0,58 1.39
Mouse hl A512H8 5.76 > 500 0.26 7.77
Hamster c1 0A7 (to human) 24 0.54 8.22
c1 0A7 (to murine) s 0.24
Additional in vitro binding studies of the OMT- and SD-derived anti-TIGIT
antibody clones were
conducted. The OMT- and SD-derived anti-TIGIT clones were tested for binding
to human and cyno
TIGIT expressed on the surface of CHO cells by FACS analysis. CHO cells were
transfected with full-
length human TIGIT (CHO-hTIGIT) or cynomologous TIGIT (CHO-cyTIGIT). The TIGIT-
expressing CHO
cells were incubated with each anti-TIGIT antibody at the indicated
concentrations and then detected via
a FITC-labeled anti-higG antibody (see Figure 1A) using standard methods. The
results, shown in Table
6 and Figures 1B-1E, corroborate the results from the BIACORE TM analysis,
described above.
The OMT- and SD-derived anti-TIGIT clones were also tested for binding to
human primary T
cells by FACS analysis. Human PBMC were activated for with plate-bound anti-
CD3 (5 pg/m1) and
soluble anti-CD28 (2 pgiml) for 2 days as described in Yu et al. Nature
immunology. 10: 48-57, 2009,
Cells were then washed and incubated with incubated with each anti-TIGIT
antibody at the indicated
concentrations and then detected via a FTC-labeled anti-higG antibody. Cells
were also stained with
anti-CD4, anti-CD8, and anti-CD25 (BD bioscience). Human CD4+ (CD25+CD4+) and
human CD8+
(0D25+CD8+) T cells were assessed for binding by the anti-TIGIT clones by
FACS, All samples were
acquired on LSR-II or LSR-Fortessa instruments (BD Biosciences) and analyzed
using FlowJo software
(Treestar). As described in Table 6 and Figures 2A-2D, the clones exhibited
approximately equivalent
binding to their target TIGIT.
Table 6. Summary of CHO-TIGIT and human T cell binding of optimized OMT- and
SD-derived anti-
TIGIT clones
Assay 10A7 (mu TIGIT) & OMT clones (hu TIGIT) SD clones (hu
TIGIT)
1A5 (hu TIGIT)
CHO-TIGIT 10A7 0.54 nM 4.1A4.096S.Q1E 0_90 nM 1.662 0.52 nM
binding 1A5 0.14 nM 4.1D3.Q1E 1.04 nM 1.7E7 0.10 nM
(EC50) 7.4A3.096S.Q1E 3_04 nM
Human T cell 10A7 0.63 nM 4.1A4.096S.Q1E 0,38 nM 1,6B2 0.09 nM
binding 1A5 0.14 nM 4.1D3.Q1E 1,36 nM 1,7E7 0.11 nM
(EC50) 7.4A3.096S.Q1E 2,63 nM
B. In vitro blocking characterization of anti- PG/ T antibodies
The OMT- and SD-derived anti-TIGIT antibody clones were also tested for their
ability to block
TIGIT-PVR and TIGIT-CD226 interactions.
To test for the ability of the clones to block the TIGIT-PVR interaction, a
blocking ELISA assay
was used. Briefly, recombinant human PVR-Fc fusion protein, cynomolgus monkey
PVR-Fc fusion
protein, or mouse PVR-Fc fusion protein was coated at 4 pgirril at 25 iwell in
phosphate-buffered saline
113
Date Recue/Date Received 2021-04-08
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
(PBS, pH 7.0) onto 384-well Maxisorp microtiter plates (NUNC, Denmark) and
incubated overnight at
4 C. The coating solution was then discarded and the plate was blocked using
0.5% bovine serum
albumin (BSA) in PBS at 80 p1/well and incubated with gentle agitation for 1
hour. Titration curves of anti-
TIGIT and Fab isotype control antibodies were diluted in assay buffer (PBS,
0.5% BSA, 0.05% Tween 20)
using 12 serial 2.5-fold dilutions (40000-1.7 ng/mL). Equal volumes of either
human TIGIT-AviFlag-biotin
(1 pg/mL), cynomolgus TIGIT-AviFlag-biotin (150 ng/mL), or mouse TIGIT-His (1
jig/mL) were added to
these titration curves and incubated at room temperature for 1 hour with
gentle agitation. The blocked
plate was washed 3x with wash buffer (PBS, 0.05% Tween 20, pH 7.4) using an
ELx405 automated
microtiter plate washer (BioTek Instruments, Vermont) and the antibody/ligand-
biotin or ligand-His mixture
was added at 25 p1/well and incubated for 1 hour at room temperature with
gentle agitation. The plate
was then washed 6x with wash buffer and bound human TIGIT-AviFlag-biotin, cyno
TIGIT-AviFlag-biotin,
or mouse TIGIT-His was detected by adding 25 p1/well of horseradish peroxidase-
conjugated streptavidin
(1:10000, Amersham, UK) or horseradish peroxidase-conjugated mouse anti-His
(1:2500, Qiagen,
Germany) diluted in assay buffer. After a 30 minute or 1 hour incubation, the
plate was washed 6x with
wash buffer and 100 p1/well of 3,3',5,5'-tetramethyl benzidine (TMB) substrate
(KPL, Inc., Gaithersburg,
MD USA) was added to allow color to develop. The reaction was quenched by
addition oil M
phosphoric acid. Absorbance was read at 450 nm on a MULTISKAN ASCENTS
microtiter plate reader
(Thermo Labsystems, Helsinki, Finland). Fit curves were plotted from the
resulting optical density values
from the ELISA plates and 1050s were calculated using Genedata Screener
software (Genedata,
Switzerland). As shown below in Figures 3A-3D, these assays demonstrated the
cross-reactivity and
blocking ability of 4.1D3.Q1E for human TIGIT and cyno TIGIT, which
distinguishes 4.1D3.Q1E from the
hamster-derived anti-TIGIT antibody. 10A7, which cross-reacts with mouse
TIGIT, but not cyno TIGIT.
The data indicate that 4.1D3.01E strongly blocks the binding of cyno TIGIT to
cyno PVR. The data also
indicate that 4.1D3.Q1E is a stronger blocker of human TIGIT to human PVR than
the 10A7 hamster-
derived anti-TIGIT antibody clone.
These studies were further validated in CHO-TIGIT PVR blocking experiments in
which TIGIT-
expressing CHO cells were incubated with labeled PVR-Fc fusion protein in the
presence of anti-TIGIT
antibody or an human IgG1 control (Figure 4A). As shown in Table 7 and Figures
46-4E, incubation with
10 pg/m1 of OMT-derived anti-TIGIT antibody (Figures 48 and 4C) or SD-derived
anti-TIGIT antibody
(Figures 4D and 4E) resulted in blocking of TIGIT-PVR binding for both huTIGIT-
huPVR and cyTIGIT-
cyPVR, with IC50 values in the nanomolar and subnanomolar range.
To test for the ability of the clones to block the TIGIT-CD226 interaction, TR-
FRET (Time-
resolved Fluorescence Resonance Energy Transfer) was used. First, human SNAP-
tagged (ST) CD226
with non-permeant donor and acceptor fluorophores was expressed and labeled
using CHO cells. The
human ST-CD226 was co-expressed with HA-tagged TIGIT, in the presence or the
absence of the OMT-
and SD-derived anti-TIGIT antibody clones. The addition of each of the tested
clones to the cell cultures
significantly reduced the ability of TIGIT and CD226 to associate (Table 7).
These data suggested that
anti-TIGIT treatment with the identified anti-TIGIT antibodies can limit
TIGIT's interaction with CD226,
indicating that these antibodies may be favorable therapeutics based on their
ability to activate T cell
114
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
activity by releasing TIGIT-mediated suppression of CD226 activity and
preventing subsequent CD8+ T
cell exhaustion.
Table 7. Summary of TIGIT-PVR blocking and TIGIT-CD226 blocking of optimized
OMT- and SO-
derived anti-TIGIT clones
Assay 10A7 (mu TIGIT) & OMT clones (hu TIGIT) SD clones (hu
TIGIT)
1 AS (hu TIGIT)
TIGIT-PVR 10A7 0.07 nM 4.1A4.C96S.Q1E 0.14 nM 1.6B2 0.08 nM
blocking IA5 0.18 nM 4.1D3.01E 0.29 nM 1.7E7 0.04 nM
(IC50) 7.4A3.C96S.Q1E 0.38 nM
TIGIT-CD226 10A7 17.6 nM 4.1A4.C96S.Q1E 25.2 nM
FRET (IC50) 1A5 13.7 nM 4.1D3.Q1E 45.0 nM
7.4A3.C965.Q1E 19.3 nM
Example 4. Pharmacokinetic characterization of anti-TIGIT antibodies
Next, the pharmacokinetic (PK) properties of OMT- and SD-derived anti-TIGIT
antibody clones
were tested in cynomolgus monkeys as compared to the mouse-derived anti-TIGIT
antibody bearing an
.. N297G aglycosylation mutation (1A5 N297G) and an anti-gD control antibody.
In these experiments,
serum concentration of the antibodies was measured over the span of 28 days
following 10 mg/kg
intravenous administrations in cynomolgus monkeys. The PK studies revealed
that the SD-derived
h1.68.2 variant exhibited the fastest clearance, at approximately 20 ml/day/kg
(Figures 5A and 58). The
tested 1A5 variant also exhibited fast clearance, at approximately 15
ml/day/kg (Figures 5A and 5B). In
contrast to these anti-TIGIT variants, the tested OMT variants (4.103.Q1E.
7.4A3.C96S.Q1E, and
4.1A4.C96S.Q1E) exhibited a clearance of approximately 8-10 mi/day/kg (Figures
5A and 513), which is
on the high end of the historically accepted cyno range of approximately 4-8
ml/day/kg. The PK profiles
of the OMT variants were similar to the control anti-gD antibody through dl 0,
at which time target-
mediated drug disposition (TMDD) and/or anti-therapeutic antibody (ATA)
effects convolute the estimates.
The OMT-derived anti-TIGIT antibody 4.1D3, which exhibited favorable PK
properties, was also
compared to humanized 10A7 (ti 1 0A7.K4G3) in a 7-day PK study. In this
experiment, eight female
cynomolgus monkeys were binned into two groups of four monkeys, with the first
group receiving
hi 0A7.K4G3 and the second group receiving 4.1D3. Both anti-TIGIT antibodies
were administered at a
dose level of 10 mg/kg (dose volume of 5 milkg; dose concentration of 2 mg/m1)
by slow bolus
intravenous injection. Blood samples (0.5 ml) were collected at 0 hour (pre-
dose). 0.25 hour, 2 hours, 8
hours, 1 day, 3 days, and 7 days post-dose in accordance with the following
collection windows:
Postdose Time Point Collection Window
0 to 15 minutes +1- 1 minute
16 to 30 minutes +/- 2 minutes
31 to 45 minutes +/- 3 minutes
46 to 60 minutes +/- 4 minutes
61 minutes to 2 hours +/- 5 minutes
>2 to 8 hours +1-10 minutes
>8 to 24 hours +1- 20 minutes
115
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
using gel serum separator tubes. The blood was maintained at ambient
temperature and allowed to clot
for at least 20 minutes prior to centrifugation. Samples were centrifuged
(approximately 10 to 15 minutes
at approximately 1500 to 2000 x g [force], 2 C to 8 C) within 1 hour of
collection. Serum was harvested
within 30 minutes of the start of centrifugation and transferred into 0.5-mL
2D bar-coded screw top tubes
(Thermofisher Scientific catalog #3744 or equivalent). The serum sample was
labeled with the animal
number, species, dose group, day of collection, sample type (i.e., PK-serum),
and study numbers. The
serum samples were then analyzed for concentrations of hi 0A7.K4G3 or 4.1D3.
As shown in Figures 5C
and 5D, this PK study revealed that hi 0A7.K4G3 exhibited a faster clearance
(lower AUC) than 4.1D3,
and that the clearance of h10A7.K4G3 (>9 int/day/kg) is faster than
recommended for monoclonal
antibody selection in cynomolgus monkey. The estimated clearance was based on
data from day 0
through day 7 and calculated by Winnonlin using NCA.
Example 5. Molecular Analysis of anti-TIGIT antibodies
OMT-derived (4.1D3, 7.4A3.C96S, and 4.1A4.C96S) and SD-derived (h1.6B2.L1 H1,
h1.10A511H1 , h1.7E711H1, and hi .15C811 H1) anti-TIGIT antibody clones were
also tested in
molecular assessment (MA) analyses for stable cell line properties. Briefly,
the anti-TIGIT antibodies (1
mg/m1) were tested for stress under chemical conditions with AAPH (2,2-
azobis(2-amidinopropane)
dihydrochloride), a small molecule known to generate free radicals, as well as
under thermal conditions at
varying pH (a two-week thermal stress test at 40`C, at either pH 5.5 or pH
7.4). As shown in Tables 8
and 9, below, 4.1A4.C96S was determined to be unstable, showing unacceptable
main peak loss and
increased deamidation in the MA studies. Similarly, hi .7E7.1.1H1 and
h1.15C811H1 showed high initial
deamidation (>30%). On the other hand. the anti-TIGIT antibodies 4.1D3,
7.4A3.C96S, hi .6B211 H1,
and h1 .10A511 Hi were found to possess acceptable stability properties in the
MA studies.
Table 8. MA stability summary for OMT-derived anti-TIGIT antibody clones
4.1A4.C96S 4.1D3 7.4A3.C96S
W in CDR-Hi is stable
M in CDR-H1 is stable M In CDR-H1 is stable
MPH Stress W in CDR-H2 is stable W in CDR-H2 is stable W in CDR-H2 is
stable
W in CDR-L2 is stable
Thermal NY in CDR-H1 is stable
Stress N(52)T in CDR-H2 are
pH 5.5 stable DS in CDR-H1 is stable
(2 weeks) N( 54)T in CDR-H2 are NS in CDR-H1 is stable N(52)T in CDR-
H2 is stable
stable DY in CDR-H2 is stable N(54)T in CDR-H2
is stableNP in CDR-H2 is stable
Peptide map DY in CDR-H3 is stable DY in CDR-H3 is stable
DS in CDR-H3 is stable
analysis NS in CDR-L3 is unstable NN in CDR-L.1 is stable
¨ 15.7% increase in
deamidation
116
CA 02994858 2018-02-05
WO 2017/053748
PCT/US2016/053368
-------------------------------------------------------------------------------
-----------------------
Monomer loss (0.6%) is Monomer loss (0.6%) is Monomer loss (1.1%) is
Size acceptable acceptable acceptable
Charge Main peak loss (16.7%) is Main peak loss (11.1%) Main peak loss
(7.3%) is
LC/MS unacceptable is acceptable acceptable
Masses are as expected Masses are as expected Masses are as expected
Thermal DS CDR-H1 2.8%
Stress NY in CDR-H1 no change increase in isomerization N(62)T in CDR-H2
no
pH 7.4 N(62)T & N(64)T in CDR- NS CDR-H1 no change change
(2 weeks) H2 no change DV in CDR-H2 no N(54)T in CDR-H2 no
DY in CDR-H3 no change change change
Peptide map NS in CDR-L3 9.4% DV in CDR-H3 2.7% NP in CDR-1-12 no change
analysis increase in deamidation increase in isomerization DS in CDR-H3
no change
NN in CDR-L1 no change
Size Monomer loss (2.7%) Monomer loss (0.9%) Monomer loss (2.3%)
Charge Main peak loss (21.9%) Main peak loss (27.7%)
Main peak loss (16.7%)
LC/MS Masses are as expected Masses are as expected Masses are as
expected
Table 9-1. MA stability summary for SD-derived anti-TIGIT antibody clones
n7E71.1111 h16C8.L1H1
MPH Stress No oxidation hotspots No oxidation hotspots
Thermal DP in CDR-H2 is stable
Stress DP in CDR-H2 is stable NO in CDR-H2 is stable
pH 5.5 NO in CDR-H2 is stable DG in CDR-H3 is unstable
(2 weeks) NT in CDR-L2 is stable (14.7% increase in
Peptide map NL in CDR-L2 is stable isomerization (3.8% to
analysis N(92)N(93)G in CDR-L3 is 18.5%)
stable ¨ high initial N(92)N(93)G in CDR-L3 is
deamidation 31.5% stable ¨ high initial
deamidation 39.2%
Size Monomer loss (0.8%) is Monomer loss (0.9%) is
Charge acceptable acceptable
LC/MS Main peak loss (6.2%) is Main peak loss (10.3%) is
acceptable acceptable
Masses are as expected Masses are as expected
Thermal DP in CDR-H2 no change DP in CDR-H2 no change
Stress NO in CDR-H2 1.9% NO in CDR-H2 3.3%
pH 7.4 increase in deamidation increase in deamidation
(2 weeks) NT in CDR-L2 no change DG in CDR-H3 7.0%
NL in CDR-L2 no change increase in isomerization
Peptide map N(92)N(93)G in CDR-L3 ¨ N(92)N(93)G in CDR-1.3 ¨
analysis 24.3 /c. increase in 15.5 % increase in
deamidation deamidation
117
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
1-----------KZ;;;-1;;-(-0:ii)------MT;o¨r-n;r-I-Os;¨(-1-.6;i0-)-----
Size Main peak loss (16.7%) Main peak loss (25.2%)
Charge Masses are as expected Masses are as expected
LC/MS
Table 9-2. MA stability summary for SD-derived anti-TIGIT antibody clones
h6B2.L1H1 h10A5.L1H1
M in CDR-H1 is stable M in CDR-H1 is stable
W(52) and W(53) in CDR- W(52) and W(53) in CDR-
AAPH Stress 112 are stable 1-12 are stable
W in CDR-H3 is stable W in CDR-H3 is stable
Thermal
Stress
pH 5.5 (2 NO in CDR-H2 is stable NO in CDR-H2 is stable
weeks) NT in CDR-H2 is stable NT in CDR-H2 is stable
NP in CDR-H2 is stable NP in CDR-H2 is stable
Peptide map NS is CDR-L3 is stable NS is CDR-L3 is stable
analysis
Size Monomer loss (0.2%) is Monomer loss (0.1%) is
Charge acceptable acceptable
LC/MS Main peak loss (2.4%) is Main peak loss (6.3%) is
acceptable acceptable
Masses are as expected Masses are as expected
Thermal
Stress NG in CDR-H2 5.6% NG in CDR-H2 4.8%
pH 7.4 (2 increase in deamidation increase in deamidation
weeks) NT in CDR-H2 no change NT in CDR-H2 no change
NP in CDR-H2 no change NP in CDR-H2 no change
Peptide map NS is CDR-L3 no change NS is CDR-L3 no change
analysis
Size
Charge
LC/MS Monomer loss (0.0%) Monomer loss (0.2%)
Main peak loss (9.9%) Main peak loss (14.5%)
Masses are as expected Masses are as expected
Example 6. Structural and functional TIGIT epitope mapping
To better understand how the 4.1D3 anti-TIGIT antibody and its optimized
variants (e.g.,
4.103.Q1E), in particular, are capable of exemplary cross-reactivity (e.g.,
cross-reactivity between
human, cyno, and rabbit TIGIT), high affinity for TIGIT, and robust blocking
of TIGIT-PVR and TIGIT-
CD226 interaction/function while exhibiting pharmacokinetic and molecular
assessment properties, the
crystal structure of 4.1D3 in complex with TIGIT was determined and compared
to the crystal structures of
mouse-derived anti-TIGIT antibody 1A5 bound to TIGIT and a hamster-derived
anti-TIGIT antibody 10A7
bound to TIGIT, as described in detail below. Alanine scanning mutagenesis
experiments of the TIGIT
interface were also performed to identify functional epitopic residues.
118
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
A. 77G1T and Fab expression, purification, and crystallization
Human TIGIT residues 23-128 was expressed and purified as described (see,
e.g., Stengel et al.
PNAS. 109(14): 5399-5404, 2012). Fab fragments including heavy and light
chains were expressed and
purified as described (see, e.g., Carter et al. Nat. Biotech. 1992). Purified
TIGIT was mixed with an
excess of purified Fab fragment to generate the TIGIT/Fab complex. The complex
was then further
purified on a size exclusion column equilibrated in HEPES buffered saline (10
mM HEPES, pH 7.5 and
100 mM NaCl) to generate a sample containing only 1:1 complexes of TIGIT and
Fab. Each of the
TIGIT/Fab complexes were then concentrated for crystallization and subjected
to standard techniques of
high throughput vapor diffusion crystallization screening. For the TIGIT/10A7
complex, the sample was
concentrated to approximately 25 mg/mL and found to crystallize in 0.1 M HEPES
pH 7.5, 20% PEG
4000, and 10% isopropanol. For the TIGIT/1A5 complex, the sample was
concentrated to approximately
25 mg/mL and found to crystallize in 0.05 M HEPES pH 7.0, 12% PEG3350, and 1%
Tryptone. For the
TIGIT/4.1D3 complex, the sample was concentrated to approximately 25 mg/mL and
found to crystallize
in 0.1 M HEPES pH 7.5, 10% PEG 6000, and 5% MPD. Crystals were cryoprotected
with glycerol and
flash frozen in liquid nitrogen according to standard techniques for data
collection.
B. Data collection and structure solution
X-ray diffraction data was collected under cryo cooled conditions at 100
Kelvin using various
synchotron X-ray radiation at the Advanced Light Source (Berkeley, CA) or
Advanced Photon Source
(Argonne, IL) according to standard methods. Diffraction images were processed
and reduced using the
data processing software XDS (Kabsch W. Acta Cryst. D. Biol. CrystL 66: 125-
132, 2010). Models were
generated using the molecular replacement technique with the program PHASER.
The structure of
human TIGIT (Stengel et al PNAS 2012) and Fab antibody model (Nakamura et al
Cell Host Microbe
2013) were used as search models. The structures underwent iterative rounds of
model adjustment
using the program COOT and refinement using the Phenix.refine or BUSTER
programs. Models were
refined to acceptable R and R free values and Ramachandran statistics
(calculated by Molprobity). Data
processing and refinement statistics can be found in Table 10.
119
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
Table 10. Data Collection and Refinement Statistics
Data collection and refinement statistics
TIGIT/10A7 TIGIT/1A5 TIGIT/1D3
Data collection ALS 5Ø2 APS LS-CAT 211D-G APS 221D-D
Space group P21 PI 14
Cell dimensions
a. b. c (A) 53.02, 76.99, 136.91 74.60, 88.78, 101.10
212.39, 212.39,66.52
a, /3. yIII 90, 90.6,90 101.1, 101.5, 110.5 90, 90, 90
Resolution (A) 136.90-1.84 (1.94-1.84)* 81.11-2.77 (2.92-2.77)*
106.19-1.91 (2.01-1.91)*
Rõ,õ or /.?õ,9, 0.063 (0.512) 0.062 (0.558) 0.089 (0.973)
//a/ 12.7 (2.4) 12.1 (2.3) 12.8 (1.8)
Completeness (%) 96.4 (95.7) 97.8 (97.1) 93.8 (69.3)
Redundancy 3.8 (3.8) 2.2 (2.1) 7.4 (6.6)
Refinement
Resolution (A) 136.9-1.85 81.11-2.77 27.96-1.91
No. reflections 90418 58936 107910
Rwork Rirct 17.8/21.8% 19.9/27.1% 18.6/21.6%
r.m.s. deviations
Bond lengths (A) 0.00) 0.010 0.010
Bond angles (I) 1.16 1.26 1.13
Rarnachandran
Most favorable 97.0% 91.2% 97.4%
Disallowed 0.3% 1.4% 0.1%
*Values in parentheses are for highest-resolution shell.
C. The structure of 4.103 bound to human TIGIT
The 4.1D3 Fab in complex with TIGIT crystallized in the 14 space group, with
two complexes in
the asymmetric unit, and diffracted to 1.91A. Overlay of the two individual
complexes in the asymmetric
unit shows only minor changes in main chain positioning between the individual
copies. The structure of
4.1D3 bound to human TIGIT (Figure BA) shows that 4.1D3 sterically interferes
with PVR binding (Figures
6B and BC). The buried surface area between 4.1D3 and TIGIT is approximately
1630A2. 4.1D3 light
chain interactions are clustered around TIGIT residues 77-82, with CDR Ll
Tyr27d and CDR L3 Tyr92>
Sera, Thr94, and Phe96 contacting TIGIT residues 11e77, Pro79, Ser80, and
Lys82. CDR L2 does not
make any contact with TIGIT. 4.1D3 heavy chain interactions are primarily
mediated by CDR H2 and H3
and make more extensive contact with TIGIT. 4.1D3 CDR H1 Asn32 contacts TIGIT
Leu73. 4.1D3 CDR
H2 Tyr52, Arg52b, Phe53. Lys54, Tyr56, and Asp58 contact TIGIT residues Thr55,
Gin56, Asn58, Glu60,
Asp63, Gin64, Leu65, I1e68, Asn70, Ser80, and His111. 4.1Q3 CDR H3 residues
Tyr99, Aspl 00,
Leu100a Leu100b, and Ala100c contact TIGIT residues Leu65, Ala67,11e68, Leu73,
His76, 11e77, Ser78,
Pro79, and Lys82. 4.1D3 interacts with TIGIT using a combination of non-polar
and polar interactions.
Light chain residue CDR L3 Thr94 forms polar contacts with TIGIT Pro79 and
Ser80. Heavy chain CDR
H2 residues Arg52b and Tyr56 form hydrogen bonds with TIGIT residues Asn58 and
Glu60. Heavy chain
CDR H3 residue Leu100a forms a hydrogen bond with TIG1T His76. Heavy chain CDR
H2 residue Lys54
and CDR 113 residue Aspl 00 form salt bridges with TIGIT residues Glu60 and
Lys82, respectively. See
also Figures 6D and BE.
120
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
Based on the crystal structure of the 4.1D3fTIGIT complex, the residues of
TIGIT that are
contacted by 4.1D3 (i.e., the epitopic residues of TIGIT bound by 4.1D3) and
the residues of 4.1D3 that
are contacted by TIGIT (i.e., the paratopic residues of 4.1D3 contacted by
TIGIT) were determined.
Tables 11 and 12, below, show the residues of TIGIT and the light or heavy
chain residues of 4.1D3 to
which they contact, as assessed using a contact distance stringency of 3.7A, a
point at which van der
Waals (non-polar) interaction forces are highest.
Table 11. Epitopic residues of TIGIT and their corresponding paratopic
residues on the light chain
of 4.1D3
TIGIT _4.1D3 Light chain
Ile 77 T_yr 27d
Pro 79 Ty! __ 92
Ser 93
______________________ Thr 94
Ser 80 Thr 94
Lys 82 Tyr 27d
Table 12. Epitopic residues of TIGIT and their corresponding paratopic
residues on the heavy
chain of 4.1D3
TIGIT 4.1D3 Heavy chain
Thr 55 Phe 53
Gln 56 Phe 53
Asn 58 Arg 52b
Tyr 56
Glu 60 Lys 54
Tyr 56
Leu 65 Leu lOOb
Ile 68 Leu _____ 100a
Leu 73 Leu 100a
His 76________ T_ys 99 _
Asp_ 100
Leu 100a
Leu 100b
Ser 78 Leu 100b
Pro 79 Leu 100b
Ser 80 Asp 58
Lys 82 Asp 100
His 111 Phe 53
Alanine scanning of the human TIGIT interface was also performed, with alanine
mutations of
TIGIT residues made for GIn53, Gin56, Glu60, Leu65, I1e68, Asn70, Leu73,
His76, His111, Tyr113, and
121
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
Thr117. These mutants, along with wild-type, were tested for binding to the
4.1D3 Fab fragment. In this
experiment, mutation of TIGIT residues Glu60, Leu65, and I1e68 reduced 4.1D3
binding greater than 10
fold (Figures 7A, 713, and 7E). Mutation of TIGIT residues Gin56, Asn70,
Leu73, His111, and Tyr113
reduced 4.1D3 binding between 1 and 10 fold (Figures 7A, 7B, and 7E). Mutation
of TIGIT GIn53, His76,
and Thr117 did not affect 4.1D3 binding (Figures 7A, 78, and 7E). This
analysis agreed with the crystal
structure analysis, with the TIGIT residues that most affected 4.1D3 binding
found to interact with 4.1D3
in the structure.
D. The structure of 1A5 bound to human TIGIT
The 1A5 Fab complex with TIGIT crystallized in the P1 space group. with four
complexes in the
asymmetric unit, and diffracted to 2.77 A. Overlay of the four individual
complexes in the asymmetric unit
shows only minor changes in main chain positioning between the individual
copies. The structure of 1A5
bound to human TIGIT (Figure 8) shows that 1A5 sterically interferes with PVR
binding, but the epitope
on human TIGIT to which 1A5 binds is not identical to that of 4.1D3 (Figure
9). The buried surface area
.. between 1A5 and 'MIT is approximately 1715A2. 1A5 light chain interactions
with TIGIT are primarily
clustered between residues 109 and 119, with one outlying contact with Glu60.
1A5 light chain CDR Li
has a single contact residue, Trp32, that contacts TIGIT residues I1e109,
Thr117, and Thr119. 1A5 CDR
L2 residue Lys50 contacts TIGIT Glu60. 1A5 CDR L3 residues Gly91, GIn92,
Ser93, and Tyr94 contact
TIGIT residues Thr112, Tyr113, Pro114, Asp115, Gly116, and Thr117. For the
10A7 heavy chain, CDR
111 residues Thr30 and Asp31 make a contact with TIGIT residue Leu73. 10A7 CDR
112 residues Tyr52,
Va153, Ser54, Tyr58, and Tyr59 make contact with TIGIT residues Gin53, Thr55,
Asp72, Leu73, and
Tyr113. 10A7 CDR 113 residues Phe97, Arg98, Pro100. and Trpl 00a make contact
with TIGIT residues
Gin56, Asn58, Glu60, Asp63, Gln64, Leu65, I1e68, Leu73, His76, and His111.
Contacts between 1A5
and TIGIT are primarily non-polar in nature, with the two exceptions being a
hydrogen bond between 1A5
CDR 112 residue Ser54 and TIGIT residue Asp72, and a salt bridge between 1A5
CDR 113 residue Arg98
and TIGIT residue Glu60.
Based on the crystal structure of the 1A5/TIGIT complex, the residues of TIGIT
that are contacted
by 1A5 (i.e., the epitopic residues of TIGIT bound by 1A5) and the residues of
1A5 that are contacted by
TIGIT (i.e., the paratopic residues of 1A5 contacted by TIG1T) were
determined. Tables 13 and 14,
below, show the residues of TIGIT and the light or heavy chain residues of 1A5
to which they contact, as
assessed using a contact distance stringency of 3.7A, a point at which van der
Waals (non-polar)
interaction forces are highest.
Table 13. Epitopic residues of TIGIT and their corresponding paratopic
residues on the light chain
of 1A6
TIGIT ......... _ 1A5 Light chain
Thr 112 Tyr 94
Tyr 113 Tyr 94
Pro 114 Tyr 94
Gly 116 Gin 92
122
CA 02994858 2018-02-05
WO 2017/053748 PCT/U52016/053368
Thr 117 Tip 32
Gly 91
Gin 92
Table 14. Epitopic residues of TIGIT and their corresponding paratopic
residues on the heavy
chain of 1A5
TIGhT 1A5 Heavy chain
Gin 53 Tyr 58
Thr 55 Tyr 52
Tyr 58
Gin 58 Phe 97
Arg 98
Pro 100
Asn 58 Arg 98
Glu 60 Arg 98
Leu 65 Arg 98
Asp 72 Tyr 52
Val 53
Ser 54
Leu 73 Thr 30
Asp 31
Tyr 113 Tyr 58
Tyr 59
Alanine scanning of the TIGIT interface was also performed, with alanine
mutations of TIGIT
residues made for GIn53, Gin56, Glue , Leu65, 11e68, Asn70, Leu73, His76,
His111, Tyr113, and Thr117.
These mutants, along with wild-type, were tested for binding to the 1A5 Fab
fragment. In this experiment,
mutation of TIGIT residues Gln56, Giu60, Leu65, 11e68, and Tyr113 reduced 1A5
binding greater than 10
fold (Figures 7A, 78. and 7D). Mutation of TIGIT residues Leu73, His76, Asn70,
His111, and Thr117
reduced 1A5 binding between 1 and 10 fold (Figures 7A, 78, and 7D). Only
mutation of TIGIT Gln53 did
not affect 1A5 binding (Figures 7A, 7B, and 7D). This analysis agreed with the
crystal structure analysis,
with many of the TIGIT residues that most affected 1A5 binding found to
interact with 1A5 in the structure.
E. The structure of 10,47 bound to human TIGIT
The 10A7 Fab/TIGIT complex crystallized in the P21 space group, with two
10A7/TIGIT
complexes in the asymmetric unit, and diffracted to 1.85A. Overlay of the two
complexes shows only
minor differences in main chain positioning for both TIGIT and 10A7. The
structure of 10A7 bound to
human TIGIT (Figure 10A) shows that 10A7 stericaliy interferes with PVR
binding (Figure 10B), but the
epitope on human TIGIT to which 10A7 binds is not identical to that of 4.1D3
or 1A5 (Figure 9). The
buried surface area between 10A7 and TIGIT is approximately 1420 A2. TIGIT
contact residues cluster
between Leu65 and I1e77, with two outlying 10A7 CDR contacts with TIGIT Gin%
and Pro87. The light
123
CA 02994858 2018-02-05
WO 2017/053748 PCT/US2016/053368
chain CDR Ll has as six amino acid insertion and utilizes residues Tyr27d,
Gly27f, Va128, Lys29, and
Leu32 to make contacts with TIGIT residues Gin56, Leu65, I1e68, Asn70, Leu73,
His76, Ser78, I1e77, and
Pro79. CDR L2 only makes two contacts via Tyr50 and 11e53 with TIGIT His76,
11e77, and Pro79. CDR
L3 Gly9t I1e92, Asn93, and Asn94 contact TIGIT residues Asp72, Leu73, and
His76. For the heavy
chain CDRs, no H1 residues contact TIGIT. For CDR H2, Phe50 and Arg52 contact
Asn70, Ala71,
Asp72, Leu73, and Gly74. For CDR H3, residues Arg95, Leu97, Gly98, His99, and
Asn100 contact TIGIT
residues Leu73, Gly74, Trp75, His76, I1e77, and Pro87. Overall the
interactions between the 10A7 light
chain and TIGIT were primarily hydrophobic in nature, with one hydrogen bond
contact between CDR L2
Tyr50 hydroxyl group and the backbone carbonyl of I1e77. For the 10A7 heavy
chain, polar contacts are
found between Arg52 and the backbone carbonyl groups of TIGIT Ala71 and Asp72,
as well as between
Arg95 and the backbone carbonyl groups of Gly74 and Trp75.
Based on the crystal structure of the 10A7/TIGIT complex, the residues of
TIGIT that are
contacted by 10A7 (i.e., the epitopic residues of TIGIT bound by 10A7) and the
residues of 10A7 that are
contacted by TIGIT (i.e., the paratopic residues of 10A7 contacted by TIGIT)
were determined. Tables 15
.. and 16, below, show the residues of TIGIT and the light or heavy chain
residues of 10A7 to which they
contact, as assessed using a contact distance stringency of 3.7A, a point at
which van der Weals (non-
polar) interaction forces are highest.
Table 15. Epitopic residues of TIGIT and their corresponding paratopic
residues on the light chain
of 10A7
TIE 10A7 Licht chain_
Asp 72 Asn 94
Leu 73 Gly 91
Ile 92
His 76 Tyr 27d
Leu 32
Tyr 50
Ile 77 Tyr 50
Pro 79 Glu 30
Tyr 50
Ile 53
Table 16. Epitopic residues of TIGIT and their corresponding paratopic
residues on the heavy
chain of 10A7
TIGIT 10A7 Heavy chain
Ala 71 Arg 52
Phe 58
Asp 72 Ang 52
Leu 73 Arg 52
Arg 95
124
CA 02994858 2018-02-05
WO 2017/053748 PCT/U52016/053368
Asn 100
Gly 74 Arg 52
Tip 75 Apg 95
Leu 97
His 99
His 76 Giy 98
Asn 100
Ile 77 Gly 98
Pro 87 Leu 97
Alanine scanning of the TIGIT interface was also performed, with alanine
mutations of TIGIT
residues made for Gln53, Gln56. Glue , Leu65,11e68, Asn70, Leu73, His76,
His111, Tyr113, and Thr117.
These mutants, along with wild-type, were tested for binding to the 10A7 Fab
fragment. In this
experiment, only Leu73Ala and His76Ala mutations affected 10A7 binding greater
than 10 fold (Figures
7A-7C). Mutation of the other residues listed did not significantly affect
10A7 binding (Figures 7A-7C).
This agreed closely with the crystal structure of 10A7 bound to TIGIT, in
which Leu73 and His76 were
found directly in the epitope bound by 10A7.
F. The anti-TIGIT antibodies 4.103, 1A5, and 10A7 recognize TIGIT at unique
epitopes
The structural studies described above demonstrate that the three anti-TIGIT
antibodies 4.1D3,
1A5, and 10A7, recognize TIGIT at unique epitopes, which may explain their
distinct functional properties
and characteristics. As shown below in Table 17, for example, 4.1D3 binds to
TIGIT at residues Ser78,
Ser80, and Lys82, which are not bound by either the 1A5 or the 10A7
antibodies. Figure 11 is a
structural rendering, showing that residues Ser78, Ser80, and Lys82 of TIGIT
are intimately contacted by
4.1D3, but not by 1A5 or 10A7.
Table 17. Epitopic residues of TIGIT within 3.7A for the 4.1D3, lAS, and 10A7
anti-TIGIT antibodies
4.1D3 1A6 10A7
53
55 55
56 56
58 58
60 60
65 65
68
71
72 ____________________________________ 72
73 73 73
74
75
125
WO 2017/053748 PCT/US2016/053368
76 76
77 77
78
79 79
82
87
111
112
114
111111111111011.1 116
117
Example 7. Characterization of TIGIT, PD-1, and CD226 Expression on Immune
Cells
Next, we characterized the expression of TIGIT, PD-1, and CD226 on CD4+ and
CD8+ T cells
from bone marrow specimens of multiple myeloma (MM) pateints using multi-color
flow cytometry. Cells
5 were isolated from frozen bone marrow procured from MM patients (n=10).
Two of the MM patients
tested had samples collected at diagnosis and again upon remission. Frozen
bone marrow from healthy
donors was used as a control (n=8). In these experiments, the bone marrow
samples were stained with
the following fluorescently conjugated monoclonal antibodies: 8V605 (PD-1),
Alexa Fluor 488 (FoxP3),
PE-DNAM-1 (CD226), PE-Cy7 (CD45), BUV737 (CD8), PerCP-eF710 (CD4), APC
(TIGIT), Brilliant Violet
10 421 (NKp46), Brilliant Violet 421 (CD56), Brilliant Violet 510 (CD3),
Brilliant Violet 510 (CD38), PE-Cy7
(CD319), PE (CD19), and LIVE/DEAD FixabieNear-IR Dead Cell Stain (Life
Technologies,
ThermoFisher).
TIGIT, PD-i, and CD226 were shown to be highly expressed on CD4+ and CD8+ T
cells
obtained from the bone marrow of MM patients compared to CD4+ and CD8+ T cells
obtained from the
15 peripheral blood of healthy patients (Figure 12). CD4+ and CD8+ T cells
obtained from the bone marrow
of MM patients were also determined to co-express both TIGIT and PD-1 (Figure
13). Given this
expression pattern, the anti-TIGIT antibodies of the invention are useful for
treating patients having an
immune-related disease or cancer (e.g., a myeloma, e.g., MM), either as a
monotherapy or in
combination with an additional therapeutic agent, such as a PD-1 axis binding
antagonist (e.g., a PD-L1
20 binding antagonist, e.g., an anti-PD-L1 antibody, e.g., MPDL3280A
(atezolizumab)).
Other Embodiments
Although the foregoing invention has been described in some detail by way of
illustration and
example for purposes of clarity of understanding, the descriptions and
examples should not be construed
25 as limiting the scope of the invention. It is understood that various
other embodiments may be practiced,
given the general description provided above.
126
CA 2994858 2019-05-06
